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Dose-banding studies on oxaliplatin 
Xiaoqing Liu 
Abstract 
Oxaliplatin is an anticancer drug widely used in cancer chemotherapy. This 
thesis evaluates whether a specific dose-banding scheme for oxaliplatin could 
replace the individual dosing method that is currently used in the oxaliplatin 
administration.  Dose-banding was introduced into UK clinical practice in 2001, 
as it reduces delays in patients receiving their treatment and, through quality 
control and end-product testing, safeguards the infusion quality and patient 
safety.  
A range of studies were included in this thesis: an extended stability study on 
oxaliplatin infusions using a sequential temperature cycling design; studies on 
oxalate, a potential degradation product and metabolite of oxaliplatin which has 
been linked to oxaliplatin neurotoxicity and the development of an ex vivo 
pharmacokinetic (PK) simulation model to compare the effect of different 
oxaliplatin dosing methods on its therapeutic outcomes. 
The shelf-life of oxaliplatin infusions over a concentration range of 0.2 mg/mL – 
0.7 mg/mL is extended to 84 days when stored at 2 – 8℃ plus a further 7 days 
after being left at room temperature (25℃) for 24 hours. This ensures the 
unused oxaliplatin infusions are safe to be re-issued to patients, which could 
reduce drug wastage. The oxalate study suggests that the dose-limiting 
neurotoxicity of oxaliplatin is unlikely to be directly related to the oxalate 
produced from oxaliplatin degradation in infusions or from the non-enzymic 
transformation of oxaliplatin in vivo because the oxalate levels from these 
routes are minor compared to the endogenous level. The safety and efficacy of 
vii 
 
dose-banding schemes was demonstrated by comparing the simulated PK 
characteristics gained from the ex vivo model. Dose-banding with the +10% 
maximum deviation was selected as the most promising dosing scheme for 
oxaliplatin.  
Finally, recommendations are made concerning the introduction of oxaliplatin 
dose-banding scheme into clinical practice, and on the benefits of harmonised 
dose-banding schemes. 
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Chapter 1: Literature review and general introduction to 
this thesis 
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1.1 General introduction 
1.1.1 Background 
Oxaliplatin is a relatively new cytotoxic drug from the platinum group, which was 
approved in 1999 for clinical use in European countries and in 2002 for use in 
the United States. (1) Compared with other drugs in platinum group, such as 
cisplatin and carboplatin, oxaliplatin is more active against a wider range of 
tumours, especially the cisplatin-sensitive and cisplatin-/carboplatin-resistant 
cancers, such as colon cancer. (2) (3) Furthermore, oxaliplatin has a favourable 
toxicity profile with less side-effects to patients during the treatment. (4) The 
dose-limiting side effect of oxaliplatin is neurotoxicity, which occurs in around 
48% of patients studied receiving oxaliplatin treatment with 5-FU/LV (5-
fluorouracil and leucovorin). (5) Oxaliplatin is currently used in chemotherapies 
for metastatic colorectal cancers as the first-line treatment with the combination 
of 5-fluorouracil (5-FU) and leucovorin (LV). (6) Oxaliplatin is also used in a 
variety of adjuvant treatments for other cancers without licencing approval, such 
as advanced breast cancer, non-small cell lung cancer, ovarian cancer, 
hepatocellular carcinoma and non-Hodgkin’s lymphoma. (7) Due to its broad 
panel of anti-tumour activity, oxaliplatin certainly has significant potential in 
treatments for different diseases in clinical practice. (4) 
At present, oxaliplatin is normally administered by the individualized dosing 
method, with which the drug dose is calculated individually for each patient 
based on their BSA (Body Surface Area) and the recommended oxaliplatin dose 
(usually 85 mg/m2) from the SPC (Summary of Product Characteristics). (5) 
However, the individual preparation of oxaliplatin infusions with timely provision 
has increased the demand on pharmacy cytotoxic compounding services, which 
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brings a challenge for the hospital pharmacy aseptic unit. (8) (9) Problems 
associated with the individual dosing  method include: increasing the workload 
and stress for pharmacy and nursing staff involved; greater risk of errors in the 
calculation of doses and volumes during the preparation of drug infusions; 
delays for patients awaiting treatment and disruption of outpatient scheduling. 
(8) (9) To improve the chemotherapy service for patients, the implementation of 
a dose-banding scheme could be considered as an alternative dosing method 
for oxaliplatin administration. 
Dose-banding is a new approach for chemotherapy administration which was 
introduced by R J Plumridge and G J Sewell in 2001. (8) With dose-banding 
schemes, doses of the cytotoxic drug are divided into a series of dose bands 
and a standard dose is selected for each band (normally the middle point of the 
band). The prescribed dose for an individual patient is calculated from his/her 
BSA as usual, which is then fitted into one of these dose bands in the dose-
banding scheme. Subsequently, the standard dose from that band will be 
administered to the patient. Without the need for preparing individualized dose 
for each patient before every treatment course, the application of standard 
doses in the dose-banding schemes allows the advanced preparation of drug 
infusions within the hospital or by outsourced manufacturers, which can also 
permit streamlined preparation and rigorous quality control. (8) (10) To ensure 
the pharmacological effectiveness and safety of the drug during the advanced  
preparation and storage time before administration to patients, long-term 
stability must be demonstrated for  the cytotoxic drug infusion. (9) Furthermore, 
the pharmacokinetic (PK) behaviour of the drug in terms of the amount of drug 
available to the tissues, identified as the area under the drug plasma-
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concentration versus time curve (AUC) should also be confirmed to ensure the 
therapeutic efficacy and an acceptable safety profile. (11) 
Therefore, to develop a specific dose-banding scheme for oxaliplatin 
administration, more data is required in two aspects: 1) the extended physical 
and chemical stability period of oxaliplatin infusions; 2) confirmation of an 
acceptable therapeutic efficacy and toxicity using the pharmacokinetic profile of 
oxaliplatin as a surrogate for the clinical effect of implementing the dose-
banding scheme. Thus, a stability study of oxaliplatin infusions and a PK 
simulation study with different dosing methods were both conducted and 
presented in this thesis. In addition, to improve the understanding of oxaliplatin 
side-effects, especially neurotoxicity, more studies on oxalate in human plasma 
were included since the oxalate has been anecdotally implicated in oxaliplatin-
associated neurotoxicity. (12)  
1.1.2 Studies and experiments 
The organisation of this thesis is set out below: 
Chapter 1 (Literature review): The relevant literature on cancer, 
chemotherapeutic drugs and oxaliplatin was reviewed in this chapter. In order to 
fully understand the development of oxaliplatin, different cancers and anticancer 
drugs were discussed and drugs from the three generations of the platinum 
group were compared. Recent research on oxaliplatin was reviewed in this 
chapter including studies on the mechanism of anti-tumour activity; 
pharmacokinetics/pharmacodynamics in preclinical and clinical studies; cancers 
which can be treated with oxaliplatin chemotherapies and the related 
therapeutic issues; comparisons of oxaliplatin to cisplatin and/or carboplatin; 
toxicities with oxaliplatin treatment. 
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Chapter 2: The extended stability study on oxaliplatin infusions in 5% glucose is 
reported in this chapter. The long-term stability data of oxaliplatin infusions is 
required to support the development of a specific dose-banding scheme for 
oxaliplatin administration in clinical practice. However, the SPC (Summary of 
Product Characteristics) from the manufacturer and previous stability studies on 
oxaliplatin infusions were limited by various conditions and issues. Therefore 
this study, which employed a novel sequential temperature cycling design, 
explored the long-tern stability of standard oxaliplatin infusions under both 
storage and in-use conditions. The development and validation of the required 
analytical methodology is also described in this chapter. 
Chapter 3: A series of oxalate studies are described in this chapter. The 
peripheral neuropathy side-effects associated with oxaliplatin chemotherapy 
have been attributed to oxalate, which is both a potential degradation product 
from oxaliplatin breakdown in infusions, and also a “metabolite” which occurs 
non-enzymically in the blood following oxaliplatin administration. The purpose of 
these studies was to determine the concentrations of oxalate that can arise from 
long-term storage of oxaliplatin infusions (studied in Chapter 2), and the oxalate 
produced non-enzymically in blood after oxaliplatin administration to patients. 
Thus, oxaliplatin in human plasma was prepared and stored at 37℃ to simulate 
the body temperature. The concentration of oxalate was then measured using a 
validated assay. The amount of oxalate produced from oxaliplatin by both of 
these routes was then compared to the endogenous level of oxalate from 
dietary intake to establish if the oxaliplatin administration could produce a 
significant increase in oxalate levels. 
Chapter 4: This chapter describes the development and application of an ex 
vivo simulation model on oxaliplatin pharmacokinetic (PK) studies. Previous 
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studies (13) on comparisons between individualised treatments and dose-
banding have used key PK parameters (e.g. AUC, Cmax) as a surrogate for 
clinical outcomes such as tumour response and toxicity, where small 
differences would be difficult to measure and very large numbers of patients 
would be required. In addition, the clinical PK studies are invasive (blood 
sampling) and inconvenience for patients, and so an ex vivo PK model was 
developed to simulate drug clearance and test the different dosing options. Five 
different dosing methods were compared with simulations on 10 assumed 
patients using this PK model. These studied dosing methods included: 
individual dosing, dose-banding scheme with 5% maximum deviation from 
prescribed dose, dose-banding scheme with 10% maximum deviation from 
prescribed dose, logarithmic dose-banding scheme and flat-fixed dosing. 
Although it was necessary to scale-down the ex vivo model for practical 
reasons, the model was able to replicate the technical challenges of infusion 
administration posed by different dosing schemes. Key pharmacokinetic 
parameters (AUC, Cmax and Tmax) were compared to establish if the dosing 
methods influenced the availability of oxaliplatin to the tissues, which would in 
turn influence both toxicity and therapeutic outcomes. 
Chapter 5: This chapter presents concluding remarks and recommendations for 
further work. 
1.1.3 Contributions to knowledge 
The results from studies described in this thesis broadened the current 
knowledge of oxaliplatin and indicated the feasibility of dose-banding 
implementation for oxaliplatin administration in clinical practice.  
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The new extended shelf-life of oxaliplatin infusions (in the concentration of 0.2 
mg/mL – 0.7 mg/mL) was demonstrated, which also enabled the unused 
oxaliplatin infusions to be returned to stock and re-issued later with safety. This 
extended stability study with the sequential temperature cycling design has also 
set a benchmark for stability studies required to support dose-banding 
application.  
The oxalate study in Chapter 3 proved that the amount of oxalate in both 
oxaliplatin infusions and human plasma are relatively small and unlikely to 
cause any toxic effects on patients. This result enhanced the knowledge on 
potential contribution of oxalate to oxaliplatin-related neurotoxicity implied in 
previous literature, and also brought alternative hypotheses surrounding the role 
of oxalate in neurotoxicity for further research.  
From simulation results with the ex vivo PK model described in Chapter 4, 
dose-banding schemes with 5% and 10% maximum deviation from the 
prescribed dose both demonstrated an acceptable inter-individual variability of 
PK characteristics. In addition, the mean values of AUC and Cmax and their 
standard deviation (SD) for the dose-banding schemes were comparable to the 
individualized dosing. As a result, dose-banding schemes simulated in this 
study should be able to provide the acceptable and comparable therapeutic 
efficacy and toxicity for oxaliplatin administration in clinical practice. Among 
different dose-banding schemes, the 10% deviation scheme required less 
standard infusions was highly recommended for chemotherapy administration. 
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1.2 Literature review 
1.2.1 Introduction to cancer 
1.2.1.1 Cancer definition 
There are approximately 50 trillion (50 × 1013) cells in a human body which can 
make up bones, tissues and organs. (14) Cells can be differentiated and 
specialized to perform individual tasks in different groups, and a cell life-cycle 
includes growth, division, differentiation, senescence and apoptosis. Normally, 
cell proliferation can be controlled with cell process and only occur when 
required, which shows the fine balance between growth-promoting and growth-
restraining systems. However, sometimes this balance can be disrupted and the 
regulation control of cell growth can be lost. These abnormal cells then have the 
potential to develop into cancer. (14) 
Cancer is defined as a disease which is caused by the failure of the process 
controlling cell growth. There are over one hundred different kinds of cancer 
and almost all of these cancers have different tumour locations, types and 
treatments. (14) Even in the same tumour type, significant differences in tumour 
growth and response to chemotherapy may be observed. (15) 
Compared with normal cells, tumour cells exhibit continued cell proliferation, 
loss of differentiation and failure to undergo apoptosis. (14) Generally, cancer 
starts with a single cell that has undergone mutations; it can not only increase 
the cell’s growth but also result in the loss of normal controls of cell proliferation. 
The initial mutation would lead cells to form a genetically homogeneous clone. 
Additional mutations occur to encourage cell growth further and raise sub-
clones in the tumour with different properties, which result in heterogeneous 
cells. (14) Tumours are classified into two main groups, benign and malignant 
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tumours. Benign tumours are relatively mild because the cells are growing 
within a well-defined capsule and usually maintain the original characteristics of 
cells with well differentiated functions. On the other hand, malignant tumours 
are life-threatening and always invade surrounding tissues and metastasize to 
different areas of the body. (14) 
Tumour cells exhibit a number of features which distinguish them from normal 
cells: (14) 
1) The tumour cells are not dependent on growth factors which are 
necessary in normal cells.  
2) Normal cells need to be in contact with the cell surface in the 
extracellular environment which is not required in tumour cells.  
3) The tumour cell growth is not restricted by the presence of other cells.  
4) Tumour cells are less adhesive than normal cells.  
5) Finally, tumour cell proliferation is not responsive to tissue density.  
1.2.1.2 Cancer causes 
Carcinogenesis is a multistep process which involves a series of mutations 
resulting in the increased cellular proliferative capacity, invasiveness and 
metastatic potential of the cell. (15) Normally it is inaccurate to consider single 
agent as the cause of cancer. (15) There are a number of different factors, 
called risk factors which affect the likelihood of cancer developing including host 
factors and exogenous agents. (16) Host factors include hormonal patterns and 
immunological capacities, which are more important in the development stage 
of cancer than in genetic influence. (16) Even if cancer is caused by mutations, 
this does not mean the disease is heritable. (16)  It has been found that in most 
patients who have a so-called heritable cancer the carcinogenesis requires 
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particular environmental factors. (16) Although the role of genetics should not 
be overstated, genetics can still play an important role in the control of cancer, 
such as 1) identification of individuals who are at risk of a specific cancer to help 
build preventive or screening strategies for the individual or family; 2) 
identification of cancer subtype to tailor the treatment for targeting specific 
disease. (16) 
Current knowledge of cancer and carcinogenesis indicates that environmental 
factors play a significant role in the development of most of the common 
cancers associated with fatality. (17) These external risk factors can be 
categorized into 3 main groups: physical agents (e.g. asbestos, ultraviolet light), 
chemical agents (e.g. tobacco) and biological agents (e.g. Aflatoxins). (18) 
Generally, physical factors include ionizing and non-ionizing radiation as well as 
certain materials with significant physical properties such as asbestos. (16) 
Most common causes, for example tobacco and alcohol, are normally 
considered as chemical factors. Biological factors include various viruses, such 
as hepatitis B virus leading to liver cancer, human papilloma virus leading to 
cervical cancer. (16) In addition, there is increasing recognition of cancers 
potentially caused by lifestyle factors like diet, physical activity and alcohol 
consumption. (16)  
Tobacco is as known the main cause of cancer-related death and the most 
common cause of lung cancer. (19) The risk of lung cancer is related to the 
dose of carcinogen (tobacco daily consumption), the duration of smoking and 
the intensity of exposure (smoking device used, such as cigarette, cigar, pipe, 
hookah, etc.). (18)  
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Heavy alcohol drinking is another main cause of cancers in different sites 
including the oral cavity, pharynx, larynx, oesophagus and liver, and probably 
breast and colorectal. (20) These cancers are linearly related to the mean daily 
alcohol consumption. (18) 
Many carcinogenic factors are also associated with occupation, including 
exposure to asbestos. (18) Occupational exposure to asbestos under domestic 
circumstances leads to the risk of mesothelioma while the non-occupational 
exposure to asbestos may cause lung cancer. (18) (21) In addition to asbestos 
exposure, many other occupational factors often result in various cancers of 
lung, skin, urinary tract, nasal cavity and pleura. (21) The industries with 
evidence of carcinogenic risk include agriculture, construction, demolition, 
shipbuilding, shipbreaking, petroleum, metal and rubber. (16) (22) 
Diet has an important role in the cause of cancer, and more than 30% of human 
cancers are considered to be related to diet and nutrition. (18) Obesity 
increases the risk of several common cancers such as colorectal and breast 
cancer. (23) Some studies show that certain substances contained in 
vegetables and fruits can protect against cancers; while it has also been 
indicated that the excess amount of some animal products could increase the 
risk of colorectal and probably breast cancer as well as other diseases. (23)  
Furthermore cancers could also be caused by other factors, such as 
environmental pollution, medical interventions including drugs used and 
infections. (15)  
1.2.1.3 Cancer classification 
Tumours from one organ always show apparently different behaviour from 
those originating from another organ. (17) As a result, classifying cancers into 
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various types would help with diagnoses and treatment. Generally, cancers can 
be divided into two groups, benign cancer and malignant cancer on the basis of 
behavioural characteristic. (17) There are over 100 different types of cancers 
arising from different cells, among which the most common types are 
carcinomas, sarcomas, lymphomas and leukaemia. (15) For histological 
classification, those cancers are usually sub-classified by the types of organs or 
tissues that they originate from but not the ones they metastasize to. (24) 
Carcinomas are the most common type of cancer which constitutes 
approximate 90% of cancers occurring in a year. (15) Carcinomas can originate 
from several different organs including skin; lining of the internal organs such as 
lungs, stomach and intestine; form glands such as breast and prostate. (15) 
Carcinomas can be further classified by the appearance of the cells they 
originate from, for example squamous carcinomas (arise from skin, lung, mouth, 
throat and oesophagus), adenocarcinomas (arise from breast, bowel, lower 
oesophagus, stomach and ovary), transitional cell carcinomas (arise from 
bladder) and small cell carcinomas (arise from lung). (24) 
Sarcomas derive from the connective tissues and are rarely found in humans. 
(15) The cells of these supportive tissues are called “fibroblasts” and these 
tissues include bone, fat and muscle, which are also named as fibrous tissues, 
ligaments and tendons. (25) Carcinomas and sarcomas are both solid tumours 
that affect discrete organs. (26) Three main available treatment options for solid 
tumours are surgery, radiotherapy and chemotherapy. These modalities can be 
used either alone or as combinations depending on the disease. (26) 
Lymphomas are malignant tumours of lymphoid tissues which spread via the 
lymph nodes. (27) Lymphomas originate from lymphocyte cells, a particular type 
of white blood cells, which metastasize throughout the body via the lymph 
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glands and blood. (24) According to the affected cell types, the lymphomas can 
be divided into two major groups called Hodgkin’s disease (HD) and non-
Hodgkin’s lymphomas (NHLs). (24) HD always presents as a painless 
enlargement of lymphnodes which is often observed in the neck. (27) NHLs are 
a different malignancy group which change from indolent, slow growing tumours 
to an aggressive, rapidly fatal disease. The prognostic important “B symptoms” 
include fever, night sweats and weight loss and also malaise, itching or pain in 
enlarged nodes after drinking alcohol. With fatigue and weakness of the 
patient’s body, “B symptoms” may appear with the NHLs. (24) The treatments of 
patients with HD and NHLs are different. In general, HD is sensitive to 
radiotherapy and chemotherapy. However, 50 – 60% NHLs has to be treated 
with combination chemotherapy. (27) 
Leukaemia is not a common type of cancers, which arises from bone marrow 
cells that are responsible for making the white blood cells to build up the 
immune system. (24) With leukaemia, the number of abnormal white cells 
increases which would damage the patient body in two main ways: reduction of 
the normal function of white blood cells and restriction of the space for new 
normal white cells. (24) Unlike other cancers, Leukaemia can be originally 
defined as acute or chronic based on the condition of the patient. (28) For acute 
leukaemia, infection, anaemia and bleeding are common symptoms but life 
threatening. For chronic leukaemia, the main symptoms are not always specific, 
such as malaise, “B symptoms”, abdominal discomfort and sometimes 
hepatomegaly. The treatment of leukaemia, which is generally based on 
combination chemotherapy, is still improving with more focused therapy and 
supportive care. Bone marrow transplantation is also increasingly used in the 
treatment for all kinds of leukaemia. (28) 
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1.2.1.4 Cancer diagnosis 
Diagnosis of cancer requires both careful clinical assessment and detailed 
diagnostic investigations including endoscopy, histopathology, imaging, 
cytology and laboratory studies. (16) An early diagnosis can increase the 
possibility of cure in many kinds of cancers (but not all of them) and reduce the 
morbidity that results from both disease and treatment. (16) 
Many symptoms may alert the patient or their physician to the possibility of 
cancer, but normally no specific symptoms could be found. (29) The cancer 
symptoms are various and depend on the site of tumour, the size of tumour, 
which tissue has been invaded and whether the tumour has metastasized to 
other parts of the body. (29) In addition to more severe symptoms (e.g. 
coughing up blood, chest pain and persistent profound diarrhoea), there may be 
other lighter symptoms such as slight shortness of breath, general feelings of 
fatigue and loss of appetite. (29) All these symptoms may have different causes 
unrelated to cancer, and therefore an expert diagnosis is necessary. (29) 
The definitive way to diagnose cancer is to use the histological examination of a 
biopsy sample from the tissue suspected to contain cancer cells. (29) Different 
techniques are also required for correcting the cancer diagnosis, including 
aspiration biopsy, needle biopsy, incisional biopsy and excisional biopsy. (16) 
Other tests could also be undertaken to assist with the diagnosis, such as blood 
and urine tests, X-rays, CT (Computerized Tomography) scans, MRI (Magnetic 
Resonance Imager) scans and scanning of different tissues. (30) 
Blood and urine tests can give the information about anaemia, bone marrow, 
liver and kidneys function, and can also estimate the cancer-specific biomarkers 
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(29) such as prostate specific antigen (PSA) levels, which can be elevated in 
both malignant and benign prostatic disease. (31) 
Tumour markers are the molecules produced by tumours, which can 
characterize various cancers and be properly employed to identify them. (31) As 
a result, tumour biomarkers sometimes can be used to support the diagnosis of 
the specific cancers. However, some biomarkers are not sufficiently specific or 
sensitive enough to contribute to a definitive diagnosis. (25) For example, 
carcinoembryonic antigen (CEA) is a protein secreted by colon and rectal 
carcinomas as well as cancers of breast, lung and pancreas, which can be used 
as a biomarker for cancer diagnosis. However, the CEA is not only expressed 
on the surface of cancer cells, but also some embryonic cells types. (25) 
Therefore, the determination of CEA could not directly lead to the definite 
diagnosis of cancer. Furthermore, since the CEA can be only detected with 
advanced tumours, it is thereby not used frequently in early diagnostic testing of 
cancers. (25) There are some other examples of tumour biomarkers, such as 
human chorionic gonadotropin (HCG) produced by choriocarcinoma, 
adrenocorticotrophic hormone (ACTH) coming from pituitary gland by 
squamous cancer of lungs and alpha-fetoprotein (AFP). (31) All these 
biomarkers can be used to assist diagnosis and also to monitor the programme 
of treatment. (31) However, caution must be exercised as the elevated bio-
marker levels may arise from non-neoplastic conditions. (31) 
X-ray and computerised – tomography (CT) are imaging techniques which could 
give the visualization of any suspected tumour. (15) There are two different 
kinds of X- rays: plain X-rays and contrast X-rays. Compared with the plain X-
ray, the contrast X-ray is more useful for cancer diagnosis since the tumour 
outline can be shown on the X-ray with an injection or a drink of the certain 
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substance. (29) Moreover, CT and MRI can provide more details about the 
structure of vital organs. (29) The only way to give a conclusive diagnosis of 
cancer and confirmation of malignancy is the histological examination of a 
biopsy sample obtained from the abnormal cells. (29) This requires the 
expertise of an experienced pathologist to confirm the diagnosis. (30) For 
leukaemia, blood samples and bone marrow biopsies are taken for the 
examination in place of the tissue samples biopsy used for solid tumour 
diagnosis. (15)  
Some cancers can be diagnosed without biopsy. For example, abnormal cells in 
the sputum can be seen and tested for lung cancer; for the cancers related to 
intestines, a few drops of fluid gathered in the intestine cavity can be removed 
by needles and tested in the laboratory. (29) The diagnosis for breast cancer is 
based on laboratory assessment of Fine-Needle Aspiration (FNA) biopsy, which 
has been used since 1930’s. (32) These tests can not only facilitate the 
diagnosis of cancers but also assist with the choice of various treatments. (30) 
1.2.1.5 Cancer staging 
Before selecting the treatment strategy, some key pieces of information on the 
extent of disease are required from the reported results in cancer patients, such 
as presenting sites, histological type and the anatomic extent of the disease. 
(33) This identification of cancer extension has been termed “cancer staging”. 
(33) Staging is the fundamental assessment of tumour burden and its 
anatomical dissemination, and can be sub-divided by clinical, radiological and 
pathological staging. (34) 
Staging at presentation is significant for both patients and clinicians who could 
use cancer staging systems to make an accurate prediction of prognosis and 
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plan the next treatment modalities. (34) Recently, the TNM classification system 
became the global benchmark for reporting the extent of malignant disease, and 
a main factor of prognosis for predicting the result of cancer treatment. (33) The 
TNM system was invented in 1940s by Pierre Denoix (35)  and has evolved into 
a comprehensive and broadly applicable system, which is now generally 
accepted by most cancer research groups. (35) 
In TNM system, malignancy can be described with three scales: T, the extent of 
the primary tumour; N, absence or presence and extent of regional lymph nodes 
metastases; M, absence or presence of distant metastases. (34) Following that, 
numerical values are added to indicate the extent of local and distant spread of 
tumour. (35) 
The different meanings for symbols in this system are shown below: (34) 
For T 
Tx: primary tumour cannot be assessed; 
T0: no evidence of primary tumour; 
Tis: carcinoma in situ; 
T1, T2, T3, and T4: increasing size and/or local extent of primary tumour. 
For N  
Nx: regional lymph node metastases; 
N0: no regional lymph node metastases; 
N1, N2, N3: increasing involvement of regional lymph nodes 
For M  
Mx: presence of distant metastases; 
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M0: no distant metastases; 
M1: distant metastases.  
The distant metastases mentioned above are different from the lymph node 
metastases. (34) Lymph node involvement is a direct extension of primary 
tumour into lymph nodes and the involvement of distant nodes is referred to as 
the “distant metastases which are other than regional”. (34) 
There are also some other systems used for assessing the likelihood of 
recurrence of disease around the tissue part where the surgery was applied to. 
In the meantime, the high-risk tumour groups can be identified and treated more 
appropriately with the assistant of using these staging systems. (24) 
For example, according to the TNM classification system, lung cancer can be 
staged based on an assessment of the presence of distant metastases and the 
condition of chest and mediastinum. (18) For colon cancer, ‘Dukes’ 
classification’ has been used successfully as an indicator of prognosis. (17) 
Cancers of major organ systems including bowel, however, mostly use more 
than one staging classification. (17) The ‘Jass classification’ is used as one of 
the supportive systems of staging rectal carcinoma. (17) For different cancers, 
the same feature in clinical outcomes could be inspected with a broadly looking 
by using combined systems. (17) 
1.2.1.6 Treatment options of cancer 
The basic principles of cancer treatment are similar all over the world, while the 
management depends on local patterns such as the commonest cancer types 
and the relative proportions presenting at early or late stages of cancer. (16) 
These proportions come from not only the prevailing circumstances but also the 
results of early detection and screening. (16) The successful treatment for 
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neoplastic diseases is to inflict the maximum damage on the tumour stem cells 
and the minimum toxicity on normal tissue cells. (17) In different countries, 
however, the specific treatments are adopted based on the availability of 
human, physical and financial resources, as well as political considerations. (16) 
Even though there are some differences in treatment principles between 
individual countries, the primary goals of cancer treatment are the same, which 
are aimed at cure, life prolongation and improvement of quality of life. (16) 
Generally, the cure rate for many types of cancers is relatively low, and if the 
cancer cannot be cured the paramount goal is to maintain the highest possible 
quality of life. (18) It means curative and palliative treatment is not mutually 
exclusive but supportive to each other. (16) 
The principle methods of cancer treatment are surgery, radiotherapy and 
chemotherapy, which also include hormonal manipulation and psychosocial 
support. (16) These therapies can be used alone or in combinations (18), and 
the main management of cancer treatment is usually the surgical resection 
assisted with systemic chemotherapy or localized irradiation. (17) The 
effectiveness of all cancer treatments varies greatly and depends on the site of 
disease and a number of social factors. (16)  
Surgery is based on physical removal of the tumour mass while radiotherapy 
and chemotherapy expose tumour to toxic ionizing radiation and cytotoxic 
chemicals, respectively, to destroy cancer cells without isolating and removing 
them. (31) The practical experience suggests that the multidisciplinary 
management model is more effective than the sequential independent 
modalities to patients with various cancers. (16) For example, the combination 
therapy of surgery and radiotherapy is suitable for both local and regional 
tumours with curative effect in early stages. (16) 
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1.2.1.6.1 Surgery 
Surgery is the first line attack for most cancers (15) and also the most effective 
modality for local diseases. (31) It contributes essentially to diagnosis, staging 
and treatment of local tumours through removal of tumour masses, which could 
also provide palliation and reduction of some complications. (16) 
The role of surgery in the cancer management depends on whether the tumour 
is benign or malignant. Benign tumours could normally be cured completely by 
the surgical therapy. (15) However, there are some life-threatening benign 
tumours, which are either inoperable (mainly because of the difficult anatomical 
location) or untreatable (because of infection or compression of vital structures 
when they increase in size). (15) For malignant tumours, the success of surgery 
mainly depends on the complete removal of tumour cells, because any 
remaining tumour cells will remain viable and are capable for metastasis. (15)  
Surgery can cure the early-stage tumours which have not invaded normal 
tissues. (15) Once the invasion starts, it becomes difficult to guarantee that the 
entire tumour cell population can be removed completely. (15) Over 50% of 
cancers have metastasized already by the time they are diagnosed. (15) As a 
result, it requires not only surgery but also radiotherapy and/or chemotherapy to 
build up a combined therapeutic modality. (15) Even in a combined therapy 
model, the removal of specimens by surgery is important to: 1) determine the 
extent of tumour progress and designing the further treatment; 2) sometimes 
eliminate the isolated metastatic tumours; 3) reduce pain and disease 
symptoms in advanced cases. (15)  
Some cancers can be cured by the surgery alone, such as cancers of 
oesophagus, lung, liver and stomach. On the other hand, for some cancers 
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surgery could only influence the course of treatment, for examples, the early 
stage solid tumours (e.g. Dukes A or T1 colon tumours), early prostate, breast 
cancer and oral cavity cancers, and early skin tumours. (16) 
However, the ‘un-resectionable tumour’ cannot be separated by surgery, which 
are either from the inaccessible anatomic sites or the extensive intermingling of 
tumour and critical normal tissue. (31) The need for anaesthesia, loss of 
haemostasis and infection are the general risks in the surgery. (31) Another 
serious issue of surgery found in the clinical experience is that any remaining 
cancer cells are provoked to spread to other tissues faster than before. (31) 
1.2.1.6.2 Radiation therapy 
As one of the main treatments for localized tumours, radiotherapy can increase 
mutations by damaging DNA and sometimes kill cells completely to create more 
extensive damage. (15) The damage caused by radiation is based on disruption 
of genetic material and is lethal to most cells which are rapidly dividing including 
both cancer cells and normal cells. (15) The proliferating cells are very sensitive 
to radiation and the cells that are capable for proliferation but not actively 
dividing at the exposure time can still be destroyed by radiation with higher 
doses. (31) There are several different types of radiation, such as X-rays, 
radiation from the decay of radioactive elements (cobalt) and particles or 
electrons beams produced by linear accelerators. (15) 
Generally, radical radiotherapy can influence the cure of cancers of head, neck, 
cervix and prostate and early stage Hodgkin’s disease (HD) as well as various 
un-resectable brain tumours in young people. (16) Sometimes the radiotherapy 
is a preferred alternate to surgery for curative treatment in localized tumours, 
but in other cases radiotherapy is more suitable in the treatment for tumours 
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with special locations where the operation is not possible. (15) For example, in 
laryngeal cancer, radiation is usually used for the treatment instead of surgery 
since it does not affect the ability of speech while the surgery may damage the 
vocal cords and cause the loss of speech. (15) In addition, skin cancers at sites 
like the eyelid or nose tip are often treated by radiation. (15) In clinical practice, 
cancer treatment is based on the combinations of surgery and radiation, surgery 
and chemotherapy and sometimes chemotherapy and radiation. Radiation is 
used to kill remaining cells around the surgical sites when the combination 
treatment is chosen for certain cancers. (15) For instance, the combination 
treatment of surgery and radiation is usually used in the early stage of breast 
cancer. During the treatment, surgery is used to remove only primary tumour 
and affected lymph nodes while radiation is used to destroy the remaining 
tumour cells at the surgical margin. (15) Furthermore, for some cancers 
occurred in certain tissues that are sensitive to radiation, such as testicular 
cancers, the treatment is limited to surgery combined with radiotherapy in 
regional lymph nodes. (15) 
Meanwhile, radiotherapy in the palliative treatment is of great value in life-
threatening situations such as profuse bleeding from tumours or superior vena 
cava syndrome. (16) It is also valuable in cases of secondary pain under bone 
metastasis and bleeding, and of compressive syndromes caused by tumours 
including spinal cord compression and cerebral metastatic disease. (16) 
Two main methods used for radiotherapy are tele-therapy and brachytherapy, 
which provide the quality assurance to meet the requirements of imaging and 
medical physics services. (16) For tele-therapy, cobalt machines and 
accelerators are used. For brachytherapy, the choice of equipment depends on 
the dose rate, and normally caesium is used under low dose rate (LDR) and 
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iridium or cobalt is used in high dose rate (HDR). (16) With all these equipment, 
the radiotherapy staffs are required to work in accordance with a registerable 
qualification and clearly defined protocols. (16) 
There are, however, still a number of side effects and limitations with 
radiotherapy resulting from the high sensitivity of rapidly dividing normal cells. 
(31) The blood-forming cells in the bone marrow, the cells that line the intestine, 
skin cells, the hair forming cells and the cells of reproductive organs are 
included. (15) Damage of these normal cells causes various side effects such 
as anaemia, nausea, vomiting, mucositis, diarrhoea, skin damage, hair loss, 
infection and haemorrhage as well as sterility. (31) The extent of the side effects 
from radiotherapy relates to the amount of radiation delivered and the area of 
body that is irradiated. (15) Therefore, the dose of radiotherapy must be limited, 
which can also facilitate the control of the chronic side effects in non-
proliferative tissues and/or in slowly renewing tissues like liver and kidney. (31) 
Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) can be referred 
to limit the radiation exposure in the dose-limiting tissue to ensure that patients 
receive the safe amount of radiation without life-threatening toxicity. (31) 
1.2.1.6.3 Chemotherapy 
The surgery and/or radiotherapy could be used effectively in treatments for 
localized cancers, but are usually limited by the metastasis of cancer cells to 
other distant sites of the body. (15) These metastatic growths are too small to 
be detected at first diagnosis, which means a systematic treatment is necessary 
to kill cancer cells throughout the body. (15) As a result, chemotherapy is 
required in the effective cancer treatments. Chemotherapy can lead to cure of 
some disseminated diseases, such as Hodgkin’s disease (HD) and high grade 
non-Hodgkin lymphomas including Burkitt lymphomas, germ cell tumours, 
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leukaemia and small cell lung cancer in the limited stage. (16) In addition, 
chemotherapy is an important part of palliative treatment of cancer and can also 
assist in the control of symptoms in some cancers such as metastatic breast 
cancer, prostate cancer and low-grade non-Hodgkin disease. (16) For instance, 
anti-androgens and anti-oestrogens do not kill cancer cells but occupy the 
respective cytosolic receptors and block the action of trophic hormones. (17) 
The primary goal of chemotherapy is to kill cancer cells while conserving normal 
tissues and consequently achieve a balance between cancer cell death and 
normal cell survival in the cancer treatment. (15) 
The target of chemotherapy, like radiotherapy, is rapidly proliferating cells in 
tissues, which means chemotherapy is another type of cytoreductive therapy. 
(31) Most anticancer drugs increase apoptosis rather than cell necrosis, and on 
scale this is the most significant cell death mode in the antineoplastic therapy. 
(17) Chemotherapeutic drugs are generally classified according to the different 
mechanisms of their anticancer activity. (30) Three of the main anticancer 
mechanisms are inhibition DNA synthesis, induction DNA damage and blocking 
cell division. (15) The principle of antimetabolites is interfering with one or more 
steps during the synthesis of DNA by incorporating a false substrate into the 
DNA as the biological base materials in an active tumour cell. (30) In this way, 
DNA cannot replicate in tumour cells which leads to the block of cell division 
and/or the death of dividing cells. (15) The antimetabolites include 
methotrexate, 5-fluorouracil, cytosine arabinoside, mercaptopurine, thioguanine 
and hydroxyurea. (15) By chemically reacting with DNA molecules directly these 
agents can cause several types of damage in the tumour cell and block further 
DNA replication. (15) However, some chemotherapeutic agents which can 
directly damage the DNA may sometimes encourage the development of 
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secondary cancers, particularly leukaemia. (15) Alkylating agents are a major 
group of DNA-damaging drugs, including cyclophosphamide, ifosphamide, 
melphalan, bischloroethylnitrosourea (BCNU), cyclohexyl chloroethyl 
nitrosourea (CCNU), thiotepa, chlorambucil and procarbazine. (15) Other drugs 
that damage the DNA molecules in different ways include bleomycin, cisplatin, 
mitomycin C, daunomycin, etoposide (VP-16) and teniposide. (15) In addition to 
having direct effects on DNA, there are also some other ways to inhibit cellular 
processes in tumour cells. For example, actinomycin D can interfere with cell 
division by blocking gene expression rather than replication. (15) Paclitaxel, 
vincristine and vinblastine usually inhibit the movement of chromosomes. (15) 
Furthermore, in acute leukaemia, leukemic cells cannot synthesize their own 
asparagine and have to depend on endogenous supply; the enzyme 
asparaginase can block the growth of leukaemia cells by degrading the amino 
acid asparagine in the blood. (15) 
Chemotherapeutic agents can also be classified according to whether they are 
cell cycle-specific or cell cycle phase-specific. (17) Cell cycle phase-specific 
drugs include antimetabolites and antimitotic drugs, and cell cycle-specific 
drugs include anti-tumour antibiotics, alkylating agents and platinum-related 
compounds. (17) 
However, chemotherapeutic drugs are not specific for cancer cells, which 
eradicate dividing cells in renewing tissues including both tumour and normal 
tissues. (31) The toxicity and side effects of chemotherapy depends on the 
relative sensitivities of cancer and normal cells. (15) Several common side 
effects (e.g. nausea and vomiting) could occur during the chemotherapy, but 
only a small proportion of chemotherapeutic drugs can cause really severe 
adverse effects. (30) Some widely used chemotherapeutic agents can cause 
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hair loss while the hair can grow out again after stopping the treatment. (30) 
The bone marrow suppression (myelosuppression) may cause various adverse 
effects, such as anaemia, various infections resulted from the lower white cell 
count and bleeding tendency caused by the loss of the platelet cells. (30) The 
vincristine and vinblastine drug group can cause peripheral neuropathy giving 
pins-and-needles or numbness symptoms by affecting the nerves in hands and 
feet. (30) Cisplatin can damage the kidneys and cause deafness. (30) Although 
chemotherapy is associated with significant adverse effects, it is the only 
modality which can potentially treat all kind of malignant metastatic cancer 
including micro-metastatic disease with unknown locations of tumour. (31) 
A major obstacle to the ultimate success of cancer chemotherapy is the ability 
of malignant cells developing drug resistance. (17) After the chemotherapy, 
some tumour cells may remain and develop new tumour tissues which would be 
resistant to the drug that the tumour is exposed to. (15) A number of different 
kinds of mutation can confer resistance of tumour cells to chemotherapeutic 
drugs. (15) These cells sometimes are resistant to a single agent, like the 
DHFR gene to methotrexate, but in other cases the tumour cell can become 
resistant to multiple drugs. (17) Single-drug resistance is often attributed to the 
development of alternate bio-synthetic pathway in the cell, and to alternation or 
over-expression of the drug targets. (17) Multi-drug resistance is related to the 
over-expression of a membrane-bound energy-dependent drug efflux pump. 
(17) 
However there are some solutions for the drug resistance problem and the use 
of combinations of chemotherapy agents in the treatment is one of them. The 
administration that combines several different chemotherapeutic agents can 
reduce the possibility of tumour resistance, as it is generally unlikely that the 
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tumour cells can be resistant to all of the used drugs. (15) To avoid multi-drug 
resistance, a spectrum of drugs should be selected, ideally without overlapping 
side-effects. (15) For practical administration, the combination chemotherapy is 
superior to a single agent, and its schedule usually aims at using drugs from 
different categories to gain the maximum tumour cell killing and the minimum 
side effects. (30)  
The clinical use of chemotherapy also requires highly trained physicians, 
expensive drugs, close monitoring of laboratory tests and skilful nursing 
support. (16) 
1.2.2 Anticancer drugs 
1.2.2.1 Alkylating agents 
Alkylating agents are one of the earliest classes of chemotherapeutic drugs, 
which were introduced into clinical practice since 1940s. (36) The first attention 
for alkylating agents came from mustard gas, a chemical weapon used in the 
First World War. (36) Nitrogen mustard was then introduced into clinical use as 
the first alkylating agent after several studies of the mustard gas, which started 
the modern evolution of cancer chemotherapy. (37) 
Alkylating compounds contain alkyl groups (CnH2n+1) and are capable of forming 
covalent linkages with other molecules. (36) The general formula of an 
alkylating reaction (alkylation) can be expressed as R-CH2-X + Y = R-CH2-Y + 
X. (36) Moreover, the alkylating reaction can be divided into two types due to 
different agents, which are those that can directly react with biological 
molecules and other agents forming into the reactive intermediate first. These 
two types are named SN1 and SN2 (SN denotes ‘Substitution Nucleophilic’), and 
their reaction formulas are illustrated in Figure 1-1 below. (38) 
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𝑅𝑋 → 𝑅+ + 𝑋−  
𝑌−
→  𝑅𝑌 + 𝑋−
𝑆𝑁 1 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛
 
𝛿−          𝛿−
𝑅𝑋 +  𝑌− → [𝑌⋯𝑅⋯𝑋]    → 𝑅𝑌 + 𝑋−
𝑆𝑁 2 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛
 
Figure 1-1, SN1 and SN2 reactions of alkylating agents through different routes.  
For the therapeutic alkylating agents, five major structural classes are 
considered as common agents: nitrogen mustards, aziridines, alkyl sulphonates, 
nitrosoureas and the mechanistically distinct platinum-containing drugs. (39) 
There are two main anticancer mechanisms for the alkylating agents reacting 
with biological molecules in vivo at physiological temperature and pH. (36) One 
of them is combining with biologically active molecules by covalent bonds, such 
as nucleic acid, proteins, amino acid and nucleotides. These alkylating agents 
also have the potential of damaging cell membranes, depleting amino acid 
stores and inactivating enzymes which are necessary for supporting the protein 
synthesis and the construction of new DNA strands. (36) However, the most 
important action of alkylating agents to damage the DNA of tumour cells is to 
form a cross-linkage between DNA chains. (36) Alkylating agents are divided 
into two different groups according to the number of alkyl groups in the drug, 
which are mono-functional and bi-functional. (40) The most effective drugs used 
in cancer treatment are the bi-functional alkylating agents, which have two alkyl 
groups to form covalent bonds at two nucleophilic sites, usually the N-7 and 
sometimes O-6 position on the purine base guanine. (36) It means that these 
alkyl groups can bind to a guanine base on the two opposite strands (inter-
strand) and/or on the same strand (intra-strand). (41) For mono-functional 
alkylating agents with only one alkyl group, one site of guanine bases can be 
alkylated. Guanine bases with the alkyl bridge are prevented from acting as 
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templates for the formation of new DNAs. (39) Figure 1-2 below shows different 
alkylating situations resulted from the various reactions between alkylating 
agents and the DNA. (39) Adducts generated from these reactions inhibit DNA 
replication and cell division. 
A number of drugs from different alkylating agent groups are currently used in 
cancer chemotherapy. From the nitrogen mustard group there are 
mechlorethamine, chlorambucil, melphalan, cyclophosphamide and ifosfamide. 
From aziridines group, there are triethylenemelamine, thio-tepa, mitomycin C 
and altretamine. For alkyl sulphonates which have reactive methyl sulfonate 
groups, busulphan is the most common agent. From nitrosoureas group, 2-
chloroethylnitrosoures (CENUs), carmustine (BCNU), lomustine (CCNU), 
methyl-CCNU (semustine) and chlorozotocin are used in the clinic. (39) 
Platinum-based agents will be discussed in following chapters. 
 
Figure 1-2, Mono-functional adduct, 1, 2- and 1, 3- inter-strand, and 1, 2- intra-strand 
cross-links induced by the DNA interactive agents. X = alkylating agent. (41) 
[Permission to reproduce this figure has been granted by John Wiley and Sons.] 
Cyclophosphamide (CP), for instance, is one of the most valuable nitrogen 
mustards, which is widely used in treatments of various kinds of cancer. (36) 
The molecular formula of cyclophosphamide is C7H15C12N2O2P·H2O with the 
molecule weight of 279.1. The chemical name of cyclophosphamide (CP) is 
known as 2-[bis(2-chloroethyl) amino] tetrahydro-2H-1,3,2-oxazaphosphorine 2-
oxide monohydrate and the structure formula is shown below (Figure 1-3). 
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Figure 1-3, The chemical structure formula of cyclophosphamide (CP). 
Cyclophosphamide is an inactive pro-drug with high stability, which needs to be 
activated into 4-hydroxycyclophosphamide by the hepatic mixed function 
oxidase system. (39) (42) This metabolite is most significant for the function of 
cyclophosphamide since its degradation process forms into effective nor-
nitrogen mustard after distributing throughout the body. (39) Following the 
activation of cyclophosphamide, DNA alkylation is effected by reactive nitrogen 
mustard molecules. This mechanism is also representative of most drugs with 
chloroethyl groups as shown in Figure 1-4. (39) 
 
Figure 1-4, Mechanism of DNA alkylation by a reactive nor-nitrogen mustard molecule 
and formations of inter-strand cross-link and mono-functional adduct. (39) [Permission 
to reproduce this figure has been granted by John Wiley and Sons.] 
Cyclophosphamide has been incorporated into the treatment of most paediatric 
and adult malignancies, such as sarcoma, leukaemia, lymphomas and breast 
cancer. (43) Cyclophosphamide has also played a major role in the 
improvement of treatment to bone and soft tissue sarcoma both in children and 
adults. (44) In addition, cyclophosphamide is used in patients with responsive 
47 
 
chronic lymphocytic leukaemia (CLL) in the combination with fludarabine and 
rituximab (known as FCR). (45) (46) For lymphoma, the combination 
chemotherapy regimen of cyclophosphamide, doxorubin, vincristine and 
prednisone (CHOP) has been used as a standard treatment for a long time. (47) 
The role of cyclophosphamide in the treatment of breast cancer is complex. On 
one hand, cyclophosphamide is commonly used with concurrent docetaxel and 
doxorubicin as the neoadjuvant chemotherapy for patients who have locally 
advanced breast cancer. (48) On the other hand, metronomic low-dose 
cyclophosphamide can improve the clinical outcome in advanced-stage breast 
cancer patients, as a result of the induction of stable tumour-specific T-cell 
responses. (49) 
Cyclophosphamide has a number of adverse effects including cardio-toxicity, 
nephrotoxicity, neurotoxicity, infertility, bladder toxicity, myelosuppression and 
leukaemogenesis. (43) To prevent serious bladder toxicities, the use of mesna 
(2-mercaptoethanesulfonic acid) has been considered and frequently 
recommended from textbooks and clinical guidelines. Mesna works by forming 
a complex with acrolein which is the toxic metabolite of cyclophosphamide. (50) 
But there is no direct evidence for its effectiveness in preventing bladder cancer 
in humans. Compared with other drugs in the nitrogen mustard group, 
cyclophosphamide has less risk of gastrointestinal toxicity, thrombocytopenia 
and alopecia which mostly depends on the dosage of cyclophosphamide. (36) 
Not all alkylating agents are used frequently in clinical practice in the UK, but 
bendamustine, as an alkylating drug, is unique with both alkylating and 
antimetabolite properties. (51) Bendamustine, 4-{5-[bis (2-chloroethyl) amino]-1-
methyl-2-benzimidazolyl} butyric acid hydrochloride, is a bifunctional alkylating 
agent and the chemical structure is shown in Figure 1-5. (52)  As one of the 
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licensed approval nitrogen mustard, bendamustine is also known as Treanda® 
and Ribomustin®. (53) Its empirical molecular formula is C16H21Cl2N3O2· HCl 
and its molecular weight is 394.7. (52) 
 
Figure 1-5, Chemical structure formula of bendamustine with HCl.  
The anticancer activity of bendamustine is structurally related to three elements: 
2-chloroethylamine alkylating group, benzimidazole ring and butyric acid side 
chain. (54) The action mechanism of bendamustine is similar to the other 
nitrogen mustard agents which is using the 2-chloroethylamine alkylating group 
to react with N7-Gua or O6-Gua in the DNA in order to crosslink DNA strands 
and subsequently break them. (39) However, bandamustine appears to provide 
more extensive and durable DNA strand breaks compared with other 2-
chlorothylamine alkylates. (51) Bendamustine has been proven with the 
distinctive preclinical activity in cell lines, and also shows the clinical activity in 
patients with cancers that are resistant to alkylating agents. (55) The clinical 
indications of bandamustine include a range of diseases, such as non-
Hodgkin’s lymphoma, chronic lymphocytic leukaemia, multiple myeloma, breast 
cancer and small-cell lung cancer. (54) 
1.2.2.2 Antimetabolites 
Antimetabolite chemotherapeutic agents have a long history in cancer treatment 
for almost 50 years and are continued using today. (56) (57) As the second 
family of cytotoxic drugs to be discovered, antimetabolites could interfere some 
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essential metabolic processes by using their structurally similarity to the 
biochemical materials within tumour cells. (36) (58) 
The general mechanism of antimetabolite drug activity is related to the 
metabolites which contribute to the formation of nucleic acid and protein needed 
for cell division. (36) There are two important ways that antimetabolites can 
prevent cell division by replacing the normal metabolites: incorporation into new 
nuclear material (inhibit purine and pyrimidine metabolism); combination with 
vital enzymes in an irreversible reaction. (36) (59) The major classes of 
antimetabolites are antifolates, cytidine analogues, pyrimidine analogues, 
adenosine analogues and purine analogues. (57) According to the Food and 
Drug Administration (FDA, US), there are 14 purine and pyrimidine 
antimetabolites in total which account for nearly 20% of all the drugs used for 
cancer treatment. (60) Methotrexate (MTX), N-(phosphonacetyl)-L aspartate 
(PALA), 5-fluorouracil (5-FU) and the new thymidylate synthesis (TS) inhibitions 
all work on key steps in the principal pathways of pyrimidine and also purine 
biosynthesis. (61) Another significant antimetabolite target is to bind with the 
dihydrofolate reductase (DHFR) which is a key enzyme in DNA synthesis. (56) 
Folate bio-synthetises pathways are shown in Figure 1-6 below, according to 
which the inhibitors are aiming at the vital enzymes such as dihydrofolate 
reductase (DHFR), thymidylate synthase (TS) and glycinamide ribonucleotide 
formyltransferase (GARFT). (62) Dihydrofolate reductase (DHFR) is normally 
inactivated by methotrexate (MTX), which leads to the inhibition of 
tetrahydrofolates (FH4) synthesis and arresting the formation of purine and 
pyrimidine. (36)  On the other hand, thymidylate synthase (TS) can be blocked 
by 5-fluorouracil (5-FU) to prevent the formation of thymine and cytosine, and 
subsequently arrest the production of new DNAs. (36) Similar to 5-FU, another 
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more efficient drug, capecitabine (Xeloda), is developed as a pro-drug of 5-FU, 
which improves the drug tolerability and intra-tumour drug concentrations due to 
its conversion into 5-FU. (63) 
 
Figure 1-6, Folate bio-synthetises pathways and inhibitors. mFBP, membrane-
associated folate binding protein; RFC, reduced folate carrier; FPGS, 
folylpolyglutamate synthase; dUMP, deoxyuridine monophosphate; FH4, 
tetrahydrofolate; GAR, glycinamide ribonucleotide; TMP, thymidine monophosphate; 
FH2, dihydrofolate; TS, thymidylate synthase; DHFR, dihydrofolate reductase; Glun, 
polyglutamate; dAMP, deoxyadenosine monophosphate; dGMP, deoxyguanosine 
monophosphate; TTP, thymidine triphosphate. (62) [Permission to reproduce this figure 
has been granted by Nature Publishing Group.] 
Methotrexate (MTX) is a principal example for antimetabolites as a folic acid 
antagonist. (35) (57) The systematic name of MTX is 4-Amino-4-deoxy-10-met 
hylpteroyl-L-glutamic acid and the molecule formula is C20H22N8O5 with a 
molecule weight of 454.44. (64) MTX is a structural analogue of dihydrofolic 
acid (Figure 1-7) which can replace the dihydrofolate and react with the enzyme 
dihydrofolate reductase (DHFR) since that MTX has 100,000 times greater 
affinity for dihydrofolate reductase (DHFR) than dihydrofolate. (35) (61) 
In simple terms, the mechanism of MTX starts from the inhibition of the 
conversion of dihydrofolate to tetrahydrofolate, and subsequently restricts the 
supply of deoxythymidine triphosphate and purine nucleotide. (57) (64) As a 
result, pyrimidine nucleotide synthesis and purine biosynthesis are inhibited, 
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and the formation of DNA, RNA and protein are interfered. (59) (61) In addition, 
MTX could also inhibits folate-dependent enzymes such as thymidylate 
synthesis (TS) and other enzymes involved in purine synthesis leading to the 
depletion of three nucleotide pools: guanine nucleotide triphosphate (GTP), 
adenine nucleotide triphosphate (ATP) and thymidine triphosphate (TTP). (57) 
(61) 
 
 
Figure 1-7, Chemical structure formulas of dihydrofolic acid (above) and methotrexate 
(bottom). (65) [Permission to reproduce this figure has been granted by Elsevier.] 
Several purine-based and pyrimidine-based drugs exhibit anticancer activity 
against various solid tumours, leukaemia and lymphomas. (66) As one of them, 
MTX is used in the chemotherapy of different human malignancies, such as 
lymphoblastic leukaemia, lymphoma, breast cancer, head and neck cancer, and 
osteosarcoma. (59) For children with acute lymphoblastic leukaemia (ALL), in 
particular, MTX acts as a key agent in the treatment. The high-dose regimen 
contributes to the increased cure rate and improves patients’ prognosis. (67) 
Even though the determinants of MTX in the treatment of ALL are not clear, 
MTX effects on prophylaxis of the central nervous system (CNS) damage 
involve the MTX in the intensification regimen and the maintenance therapy. 
(67) (68) High-dose methotrexate has been reported as the most active drug for 
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newly diagnosed primary CNS lymphoma. (69) MTX, as a single or combined 
modelling, expresses considerable activity in different kinds of lymphoma, and 
those drug combinations include MTX and irradiation (IR) for NK/T-cell 
lymphoma, high-dose MTX and temozdomide (HD-MTX-TMZ) for the primary 
central nervous system lymphoma (PCNSL). (70) (71) In addition, MTX is also 
used in the treatment of inflammatory diseases. (64) Recently, MTX has been 
used as an immunosuppressive agent in the organ transplantation and 
additionally in the treatment of some autoimmune diseases, such as rheumatoid 
arthritis (RA), and severe asthma. (64) Furthermore low MTX doses can be 
administered through oral or parental routes for the treatment of rheumatoid 
arthritis and psoriasis. (72) (73) 
As usual, the balance between the clinical efficacy and side effects of MTX is 
important and has been the subject of continued research. (74) It can be 
discussed in two aspects: the low dose and the high dose of MTX. The low MTX 
dose used for benign disorders or continuation therapy of ALL and NHL rarely 
cause any significant and uncontrollable toxicity other than bone-marrow 
suppression and mild hepatotoxicity, which never leads to severe liver fibrosis. 
(74) For high-dose MTX (HD-MTX), more significant side-effects are observed, 
including reversible myelosuppression, mucositis, hepatotoxicity, and reduced 
kidney function, as well as both transient and persistent neurotoxicity. (74) With 
the long period use of MTX, several side effects can also occur during the 
treatment including mucosal, ulceration, stomatitis, bone marrow suppression, 
loss of appetite with drug induced hepatic fibrosis and cirrhosis. (73) Among all 
these toxicities, the intestinal damage or enterocolitis is one of the major toxic 
effects, which results in malabsorption syndrome and could disrupt the 
chemotherapy regimen in the meantime. (64) To reduce the adverse effects of 
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MTX, new approaches directing to the target cells (e.g. Leukocytes) have been 
evaluated. (64) (73) As an activated form of folic acid, leucovorin can terminate 
the metabolic pathway blocked by MTX to reverse most of its side-effects, apart 
from the nephrotoxicity. (74) 
Another issue limiting the use of MTX in cancer chemotherapies is the drug 
resistance of tumour cells. (61) The mechanism of the MTX resistance is still 
not clearly known nowadays, but there are some hypothesises including cellular 
deletion of the folate transporter, loss of the ability of polyglutamate folates, and 
amplification of genes encoding for dihydrofolate reductase. (57) As a result, 
MTX is often used in combination treatments with other drugs to prevent the 
development of its resistance, which could modulate the expression of genes 
involved in MTX resistance. (75) 
Another typical antimetabolite drug, 5-Fluorouracil (5-FU), is one of the first 
examples of the series of fluoropyrimidine. (36) (60) In addition, 5-FU is also the 
most important and simplest among these fluoropyrimidine compounds, which 
consists of a uracil molecule with a fluorine atom substituted for the number five 
hydrogen atom as shown in Figure 1-8. (36) (76) 
 
Figure 1-8, Chemical structure formula of 5-fluoroucil (5-FU).  
The mechanism of 5-FU reaction is not fully acknowledged but it is believed to 
be related with the interference of DNA synthesis and mRNA translation. (36) 
(77) Division of tumour cells can be inhibited by 5-FU in two different ways: 1) 
blocking the enzyme thymidylate synthesis to arrest the production of new DNA; 
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2) incorporation into RNA in place of uracil or thymine to inhibit RNA synthesis. 
(36) 
5-Fluorouracil has been used in daily clinical oncology practice for almost 50 
years and continues to be widely used in the management of several common 
malignancies, such as cancers of the colon, breast and skin. (78) (79) However, 
treatments containing 5-FU are observed with several side effects as a result of 
its nonspecific cytotoxicity. (77) These include hematologic toxicity (leukopenia 
including neutropenic fever and anaemia, and thrombocytopenia), 
gastrointestinal toxicity (oral and intestinal mucositis, stomatitis, diarrhoea, 
nausea and vomiting), and less frequent dermatologic toxicity (hand-foot 
syndrome and hair loss). (80)  
1.2.2.3 Antitumor antibiotics 
Antitumor antibiotics are a group of important anti-cancer drugs which were 
originally derived from microorganisms by fermentation. (34) (81) Unlike other 
antibiotics used for infections, antitumor antibiotics have cytotoxicity which limits 
the value of antimicrobial agents but ensures its efficacy in malignant 
conditions. (82) These antibiotic agents can interfere with the proliferation of 
malignant cells through several different mechanisms. Most of antitumor 
antibiotics are cell-cycle non-specific while a few of them are cell-cycle specific, 
and some could be considered with both properties. (81) (83) 
There is controversy concerning the mechanisms of the anticancer activity of 
antitumor antibiotics. (83) However, some evidences were found for the 
following modes:  
Ⅰ. Intercalation: antitumor antibiotics can bind to the double helical structure of 
DNA molecule and cause strand breakage. (82) (83) 
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Ⅱ. Disrupting RNA synthesis: RNA synthesis can be inhibited by several 
different ways such as inhibiting the DNA-dependent RNA synthesis, directly 
inhibiting RNA synthesis, altering DNA to block transcription by forming tight 
adducts with it. (17) (34) (82) (83)  
Ⅲ. Antimitotic effects: the free radical formation provided by antitumor 
antibiotics can disrupt the DNA chain and prevent mitosis. (81)  
Ⅳ. Membrane binding: antibiotics agents alter the cellular membranes by 
increasing their permeability to various ions.  
Ⅴ. Alkylation: some antibiotics are even demonstrated with their activity that 
resembles alkylating agents or antimetabolites to block DNA replication. (83)  
Ⅵ. Others: some other models are considered to contribute to the antitumor 
effect, for instance metal ion chelating with antibiotics can produce cytotoxic 
compounds and then inhibit topoisomerase enzymes. (81) 
Antitumor antibiotics can be classed into two groups: anthracyclines and non-
anthracyclines, among which anthracyclines are more important while the other 
group are also of value in cancer treatments. (36) Several anthracycline agents 
are used widely in the treatment of haematological and solid tumours, such as 
daunorubicin, doxorubicin and epirubicin. (36) (84) The first antitumor 
anthracycline was daunorubicin isolated in 1963, and doxorubicin was 
introduced around the 1970s and then became into the best known and the 
most widely used anthraquinone anticancer agent for treatments of malignant 
cancers. (85) (86) 
Doxorubicin is commonly prescribed as a small molecular chemotherapeutic 
drug for the treatment of an extensive range of solid tumours due to its broad 
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antitumor activity. (87) (88) (89) The molecular formula of doxorubicin is 
C27H29NO11 and the chemical structure is shown in Figure 1-9, with the 
comparison to the structure of daunorubicin. (86) 
 
Figure 1-9, Chemical structure formulas of doxorubicin (A) and daunorubicin (B). 
[Permission to reproduce this figure has been granted by John Wiley and Sons.] 
The mechanism of the anticancer action of doxorubicin is partly attributed to its 
complexation with DNA. (89) The data from the UV-resonance Raman spectra 
shows that doxorubicin can interact with the elements on positions of adenine 
and guanine. N7 positions of purines are the proton-acceptor sites of adenine 
and guanine rings, which could be connected with the portion of doxorubicin 
hydroxyl group via a hydrogen bond formation. (89) This interaction causes a 
partial deformation of the hydrogen bonds between the adenine and thymine as 
well as the cytosine and guanine bases as shown in Figure 1-10. (89) 
 
Figure 1-10, Diagram of the interaction site of doxorubicin on adenine and guanine 
rings of DNA. [Permission to reproduce this figure has been granted by Korean 
Chemical Society.] 
With the most effective activity against cancers, doxorubicin can be prescribed 
for a broad range of solid tumours such as breast carcinoma, bronchogenic 
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carcinoma, gastric cancers and soft tissue sarcomas. (36) However, for both 
daunorubicin and doxorubicin, various side effects can occur with their 
treatments including severe myelosuppression, development of drug resistance 
and considerable nausea and vomiting. (36) (86)  
Doxorubicin is associated with a dose-related cardio-toxicity which limits the use 
of doxorubicin in clinical chemotherapies. (84) (85) Cardiotoxicity, as a further 
adverse effect, is proved to be a fatal factor depending on if it is acute or, more 
commonly, chronic. (88) (90) The acute or late-stage cardiotoxicity may 
manifest itself as congestive heart failure (CHF), arrhythmias or conductivity 
dysfunction, associated with electrocardiographic (ECG) abnormalities, a 
pericarditis-myocarditis syndrome, and occasionally myocardial infarction and 
sudden death. (84) (85) (90) Because that the development of cardiomyopathy 
is related to the cumulative drug dose, the cardiotoxicity can be minimized by 
limiting the dosage of doxorubicin. (36) (88) In the doxorubicin treatments, the 
incidence of cardiotoxicity is 3% at 400 mg/m2, 7% at 500 mg/m2 and 18% at 
700 mg/m2. As a result, the total drug dose has been recommended to be better 
below 550 mg/m2. (36) (84) As a small-molecule chemotherapeutic agent, 
doxorubicin is commonly limited by a lack of specificity in targeting, which could 
potentially cause those  dose-limiting toxicities via the drug exposure to non-
target tissues in patient’s body. (91) Therefore the adverse effect of 
cardiotoxicity from doxorubicin could be caused by its release to the 
cardiovascular system when the drug is trying to accurately target the cancer 
sites in vivo. (91)  
On the other hand, the major drawback of doxorubicin is the onset of 
resistance. (92) As an anthracycline, doxorubicin is a substrate for several ATP-
binding cassette (ABC) membrane transporters including P-glycoprotein (Pgp), 
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multidrug-resistance related protein-1 and -2, and breast cancer resistance 
protein. (92) (93) As a result, doxorubicin is actively extruded from cells by over-
expression these pumps, which reduces the intracellular retention of the drug. 
(92) To reduce the drug resistance, several inhibitors of Pgp (P-glycoprotein) 
have been designed and tested which turned out to have poor specificity and 
high toxicity in clinical trials. (92) In recent years, to improve the antitumor 
efficacy and ameliorate dose-related toxicity, various drug delivery technologies 
have been developed to increase the specificity of drug targeting including lipid-
based (liposome), micelles and conjugated to a polylysine dendrimer. (85) (86) 
(91) Meanwhile, the nanoparticle-mediated drug delivery has been proven with 
effectiveness to overcome the MDR (multidrug resistance). (93) Liposomes can 
passively target the drug and reduce the drug toxicity to normal tissues by 
utilising the increased permeability of the tumour vascular system, which leads 
to the drug accumulation in tumour tissues. (86) Micelle-encapsulated 
doxorubicin (M-DOX) can improve the drug penetration and accumulation in 
tumour sites leading to a higher antitumor activity. (86) According to preclinical 
and clinical studies, the liposome-encapsulated doxorubicin formulation has 
also improved the pharmacokinetics distribution of doxorubicin especially the 
accumulation in tumour tissues and provided a greater antitumor efficacy than 
free doxorubicin. (85) (86)  
Additionally, another way to improve the anticancer activity and reduce the 
toxicity of chemotherapeutic agents is to develop new analogues for cancer 
treatments. (36) For example, epirubicin, a stereoisomer of doxorubicin, is now 
commonly used in the treatment of breast cancer. (84) Epirubicin has less 
cardio-toxicity on an mg/m2 unit basis than doxorubicin. However, epirubicin is 
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tended to be prescribed at 25-50% higher dosage than doxorubicin to achieve 
the similar antitumor benefit. (84) 
1.2.2.4 Vinca alkaloids 
Some plants have been found to have anticancer activity, which encouraged a 
great deal of effort to screen the suspect plants for potential cytotoxic drugs. 
Even though only few relative agents have clinical impact, a number of plant 
extracts have been screened for their cytotoxicity against mammalian cells. (17) 
Plant alkaloids are nitrogenous bases, and a majority of them have medicinal 
properties, for example, cocaine, morphine, quinine and atropine. (36) The 
group of plant alkaloids called vinca alkaloids have been isolated from the 
common periwinkle plant Vinca rosea for more than 60 years. (82) As one of the 
most useful cytotoxic agents, this vinca alkaloid group supports the traditional 
belief of the strong healing powers from the periwinkle. (82) In clinical practice, 
three vinca alkaloids have been demonstrated with good therapeutic effect in 
cancer treatments, named vincristine, vinblastin and vindesine. (24) (36) 
Tubulin is the key point in the anticancer mechanism of vinca alkaloids which 
are lethal to mitotic cells. (24) In the mitotic process, tubulin is an intracellular 
protein that polymerises into microtubules. Microtubule has many functions 
such as the mitosis transport of solutes, cell movement and maintaining the 
structural integrity of the cell. (36) The most important function of the micro-
tubular proteins is to form the cell mitotic spindle and to arrange the chromatid 
pairs during metaphase. (24) (82)  The mechanisms of the anticancer activity of 
these three drugs are similar and all related to the binding of tubulin. The major 
antineoplastic effects of vinca alkaloids are exerted during the metaphase of the 
mitotic process starting with binding tightly to tubulin. (17) (82) By preventing 
the polymerisation of tubulin subunits into microtubules, the vinca alkaloids can 
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block the cell spindle formation. (24) (36) The mitosis is arrested in metaphase, 
and the death of cells ensues since they are unable to divide. (17) (82) For this 
reason, vinca alkaloids are known as ‘spindle poisons’. Other relevant 
properties of the antitumor effect of vinca alkaloids include inhibition of 
thymidine incorporated into DNA; inhibition of uridine incorporated into RNA; 
disrupting synthesis of both RNA and intracellular proteins at high doses. (17) 
(82) 
Vincristine (VCR) is one of the most widely used chemotherapeutic agents in 
clinical practice, which has been known for its medicinal properties since the 
17th century. (94) (95) It was first used in adults and children successfully as a 
cytotoxic agent in 1962 and then remains a key component of chemotherapy 
regimens for many paediatric cancers. (94) (95) The molecular formula of 
vincristine is C46H58N4O10, and the chemical structure is shown in Figure 1-11 
along with another analogue vinblastine (VLB). (96) (97) 
 
Figure 1-11, Chemical structure formulas of vincristine (R=CHO) and vinblastine 
(R=CH3). [Permission to reproduce this figure has been granted by Elsevier.] 
The mechanism of the action of vincristine is as described above about the 
interaction with tubulin which causes interference with microtubules and mitotic 
spindle dynamics, the disruption of intracellular transport, and thereby arresting 
cell division in metaphase. (94) (98) The tumour blood flow would reduce and 
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cell apoptosis would arise as the ultimate result from the vincristine-mediated 
cellular disruption. (94) 
In medicinal folklore, vincristine has been described as being effective for the 
treatment of haemorrhage, scurvy, toothache, wound healing, diabetic ulcers 
and hyperglycaemia. (94) Vincristine is also extensively used in combinations 
with the other agents for treatments of a number of human carcinomas, such as 
acute lymphoblastic leukaemia (ALL), malignant lymphoma and solid tumours 
like breast cancer. (98) (99) (100) 
The main dose-limiting side effect of vinca alkaloids is the dose-dependent 
cumulative peripheral neuropathy. (98) For different vinca alkaloids, the related 
neurotoxicity is qualitatively similar but quantitatively different following the 
order: vincristine > vindesine > vinblastine > vinorelbine. (99) In terms of 
neuropathy, the limitations of the therapeutic potential of vincristine are the lack 
of proven neuroprotective measures and the incomplete understanding of 
pharmacokinetics and pharmacogenetics mechanisms of the drug. (94) The 
neurotoxicity associated with vincristine is related to the drug dosage, frequency 
of drug administration and patients’ age, but can be generally reversible with 
slow recovery. (94) (99) (101) Vincristine-induced neuropathy is normally mild 
but sometimes with severe consequences including an autonomic and 
peripheral sensory-motor polyneuropathy and, reported only rarely, the severe 
partial or total paralysis. (94) (99) The most common clinical symptoms of 
neurotoxicity, appearing in 2 to 19 weeks after the commencement of vincristine 
administration, include loss of deep tendon reflexes (may be associated with 
foot drop and gait disturbance), jaw pain, constipation and ileus. (94) (99) Some 
circumstances can enhance the vincristine neurotoxicity, such as: 1) if the 
recommended dose of 12 mg is exceeded; 2) if the patient is hypersensitive to 
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the drug; 3) if there is a pre-existing liver dysfunction or a hereditary 
neuropathy; 4)  if other drugs are concomitantly used, such as allopurinol, 
erythromycin, isoniazid, mitomycin C, phenytoin and itraconazole. (99) (100) 
These drugs can prolong the exposure to VCR through inhibiting the enzymes 
of cytochrome P-450 in the liver or blocking P-glycoprotein pumps and interfere 
with the metabolism of vincristine. (102)  
Thereby, the neurotoxicity of vincristine can be increased by drug interactions 
when the drug is applied in a combination treatment course. (102) A careful 
neurological examination and detailed family history record should be 
accomplished before initiating the vincristine treatment. It is necessary to keep 
vincristine neuropathy as a differential diagnosis in patients with ALL (Acute 
Lymphoblastic Leukaemia) who may develop neurological symptoms. (99)  
Other non-neural side effects of vinca alkaloids are markedly less common, 
including alopecia and myelosuppression. (94) 
1.2.3 Platinum drugs 
1.2.3.1 Development 
Platinum-based compounds have been used worldwide in treatments of 
different types of cancer since cisplatin was introduced into clinical use in the 
1970s. (103) (104) As the first platinum drug used for cancer patients, cisplatin 
(Figure 1-12) is one of the most active agents in chemotherapies for treatments 
of a variety of malignancies, such as head and neck, bladder, cervical and 
lymphomas cancers, especially testicular and ovarian carcinoma. (103) (104) 
(105)  However, the clinical utility of cisplatin has been restricted by two major 
limitations: severe toxicity and tumour resistance. (104) (106) (107) (108) 
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Figure 1-12, Chemical structure formulas of cisplatin, cis-diamminedichloro platinum 
(Ⅱ). 
The dose-limiting toxic effects of cisplatin include nephrotoxicity, high 
emetogenic potential (e.g. nausea and vomiting), ototoxicity and neurotoxicity 
(e.g. peripheral neuropathy). (107) (109) (110) The renal toxicity can be 
circumvented by adequate intravenous hydration, slow cisplatin infusion rates 
and simultaneous administration of mannitol, and the emesis can be effectively 
controlled by the combination treatment with dopamine agonists, corticosteroids 
and/or serotonin antagonists. (109) However, these support measures are not 
effective for all patients and besides the ototoxicity and neurotoxicity remain 
difficult to control. (109) The sensory neuropathy becomes evident after having 
received a cumulative dose of cisplatin higher than 300 mg/m2, and has been 
reported occurring in 90% of patients receiving the cisplatin-based 
chemotherapy. (111) (112) Another severe toxicity of cisplatin, ototoxicity, 
occurs in up to 93% of patients after the administration of cisplatin. (113) This 
progressive hearing loss is often irreversible, which leads to lower quality lives 
for survivors from cancer. (113) (114) In attempt to overcome the renal and 
gastrointestinal side effects of cisplatin, the second-generation platinum Ⅱ 
compound, carboplatin (Figure 1-13) was developed as a cisplatin analogue to 
conserve the therapeutic effectiveness and meanwhile provide a more 
acceptable side-effect profile. (106) (109) Carboplatin substantially diminishes 
the major toxicities caused by cisplatin (e.g. emesis) and also avoids ototoxicity 
and nephrotoxicity. (107) (110) As a result, carboplatin has replaced cisplatin in 
many chemotherapeutic regimens and emerged as the first-line treatment of 
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choice for patients with advanced ovarian cancer. (104) (109) However, the 
clinical use of carboplatin is also limited by its primary toxic effect of 
myelosuppression (bone marrow suppression) which could possibly cause the 
thrombocytopenia. (103) (104) (107) (110) Since the renal excretion is the main 
pathway of carboplatin elimination (65% of the administered dose excreted into 
urine within the first 24 hours (115)), the clearance of carboplatin in patient’s 
body mostly depends on the individual renal function. (116) In addition, the 
major adverse effect of carboplatin, thrombocytopenia, is highly correlated with 
its pharmacokinetic characteristic of AUC (Area Under the concentration-time 
Curve). (117) Thereby, unlike other cytotoxic drugs whose doses are calculated 
with the patient’s body surface area (BSA), carboplatin dosing is generally 
calculated using the Calvert formula: (116) (117) (118) 
Dose (mg) = Target AUC (mg ∙ min/mL) ×  [GFR (mL/min)  + 25] 
(AUC = area under the concentration-time curve; GFR = glomerular filtration rate) 
This Calvert formula related with AUC and GFR is the most widely used formula 
for dose calculation and prescription of carboplatin in clinical practice. (115) 
(118) (119)  
 
Figure 1-13, Chemical structure formula of carboplatin, cis-diammine (1,1- cyclobutane 
dicarboxylate) platinum (II).  
Tumours that are resistant to both cisplatin and carboplatin cover some of the 
most frequent human tumour types, and their resistance can be classed into 
intrinsic resistance and acquired resistance. (105) (107) Cisplatin is inactive 
against some cancers related to the intrinsic resistance, such as colon cancer 
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and non-small cell lung cancers. (107) Some tumours show well responding to 
cisplatin at previous stage of the therapy, while cisplatin cannot produce long-
lasting remissions afterwards. The resistances that normally emerge during the 
course of therapy are known as acquired resistance. (107) The mechanisms of 
tumour resistance are with multifactor, but can be discussed in two broad 
categories: before and after the drug binds to DNA. (104) (106) 
First, the tumour resistance occurs before the binding of platinum to DNA, which 
is mediated by inadequate levels of platinum to reach target DNA. (106) The 
relevant mechanisms of this type resistance are shown below: (Figure 1-14) 
1) Reduce the influx of the drug by losing the main copper transporters 
(CTR1) which can facilitate the platinum transport across the cell 
membrane. (106) 
2) Increase the cellular detoxification due to raising the levels of glutathione 
and metallothionein. (104) In the cytoplasm, the chemically reactive aqua 
species from cisplatin and water preferentially react with tripeptide 
glutathione or metallothioneins. Therefore, the increase of glutathione 
and metallothionein can effectively bind to the activated platinum in the 
cytoplasm before it can reach the nucleus. (104) (106) 
3) Enhance the efflux of the drug by activating the exporters of platinum. 
Generally, platinum exports from cells through the copper exporters 
ATP7A and ATP7B as well as the glutathione S-conjugate export GS-X 
pump (MRP2 or ABCC2). (106) 
Second, the tumour resistance is mediated after DNA binding. (111) After 
entering the nucleus, the activated aqua platinum species would bind with 
the target DNA on position N7 of guanine (intra-strand and/or inter-strand 
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crosslink) and produce the platinum-DNA adducts. (111) To contribute to the 
platinum drug resistance, nucleotide-excision repair (NER), as the main 
removal pathway of these DNA adducts, could be increased to remove the 
platinum-DNA adducts before the apoptotic signalling pathways are 
triggered. (109) (111) Additionally, the increased tolerance to platinum-DNA 
adducts can lead to tumour resistance either through the loss of DNA 
mismatch repair (NMR), bypassing of DNA adducts by polymerase β and η, 
or through down-regulation of apoptotic pathways. (109) (111) 
 
Figure 1-14, Tumour resistance to cisplatin and carboplatin mediated by inadequate 
levels of platinum reaching the target DNA. GSTs: glutathione S-transferases; CTR1: 
copper transporter; ATP7A, ATP7B: copper exporter. (106) [Permission to reproduce 
this figure has been granted by Nature Publishing Group.] 
To circumvent the tumour resistance and broaden the clinical utility of platinum-
based agents, new platinum analogues, such as oxaliplatin, have been 
developed. (106) Oxaliplatin shows more benefits than cisplatin and carboplatin 
with less toxic effects, and it is the only third generation of platinum agent 
currently used in clinical practice of cancer chemotherapy. (105) (109) It has 
been proposed that oxaliplatin has no inheritance cross resistance with both 
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cisplatin and carboplatin, and thereby oxaliplatin can be used in the treatment of 
colorectal cancer which is extremely insensitive to the earlier platinum 
analogues. (109) Furthermore, the toxicity profile of oxaliplatin is favourable, 
with the incidences of just 1% and 3% respectively for oto- and renal toxicity. 
(109) 
Cisplatin, carboplatin and oxaliplatin have been approved with varied licenced 
indications by different regulatory authorities in countries and areas, such as 
MHRA (Medicines and Healthcare products Regulatory Agency, UK) and FDA 
(Food and Drug Administration, US). (106) (120) (121) (122)  
From MHRA, cisplatin has the broadest therapeutic indications including the 
advanced or metastasised testicular cancer, ovarian cancer, bladder carcinoma, 
squamous cell carcinoma of the head and neck, non-small cell and small cell 
lung carcinoma, as well as cervical carcinoma (in the combination with other 
chemotherapeutic drugs or with radiotherapy). (120) Carboplatin is only 
indicated for the treatment of small cell lung carcinoma and advanced ovarian 
carcinoma of epithelial origin either as the first line therapy or the second line 
therapy after other treatments have failed. (121) Oxaliplatin, in combination with 
5-fluorouracil (5-FU) and folinic acid (FA), can be used for treatment of 
metastatic colorectal cancer and adjuvant treatment of stage Ⅲ (Duke’ C) colon 
cancer after complete resection of the primary tumour. (122) 
From FDA, licenced indications of cisplatin are limited with metastatic testicular, 
metastatic ovarian and transitional bladder cancer. (106) Carboplatin can only 
be used for the treatment of advanced ovarian cancer as the first line treatment 
or the second line with palliative treatment. (106) Furthermore, oxaliplatin has 
been approved for the second line and previously untreated or adjuvant 
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treatment of metastatic colorectal cancer with 5-FU with leucovorin (LV) by 
FDA. (106) 
 
Figure 1-15, The current ‘family tree’ of platinum drugs and the generalized rationales 
underlying their development. Dates after drug names indicate when each drug was 
first given to patients. DACH: diamino-cyclohexane, contained in oxaliplatin and 
aroplatin. (106) [Permission to reproduce this figure has been granted by Nature 
Publishing Group.] 
In recent years, studies of platinum have been increased, which focus on 
different aspects of the possible developments on platinum. For examples, the 
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elucidation of mechanisms of tumour resistance to platinum drugs, the 
introduction of new platinum-based agents (oxaliplatin, satraplatin and 
picoplatin) and clinical combination studies using platinum drugs with resistance 
modulators or new molecularly targeting drugs. (106) The current developments 
of platinum agents are briefly shown in Figure 1-15. (106) 
1.2.3.2 Oxaliplatin 
1.2.3.2.1 Biotransformation and mechanism of action 
The chemical structure of oxaliplatin (trans-[(1R,2R)-1,2-cyclohexanedi- amine-
N,N0]oxalato(2-)-O,O0 platinum) is shown in Figure 1-16, which contains a 1,2-
diaminocyclohexane group (DACH) and a bidentate oxalate ligand. Compared 
with other stereochemical isomers of the oxalate-Pt-DACH, the trans-1-(R,R)-
DACH-Pt isomer has been shown with the most cytotoxicity and subsequently 
been selected for  developing oxaliplatin. The development of platinum drugs 
and oxaliplatin was discussed in the above section, which has indicated that the 
primary advantage of oxaliplatin is the anticancer efficacy against some 
tumours that are resistant to cisplatin and carboplatin. However, the specific 
mechanism of oxaliplatin anticancer activity in tumour cells is difficult to 
ascertain. 
 
Figure 1-16, Chemical structure of oxaliplatin. 
Generally, the principle anticancer mechanism of oxaliplatin is believed to be 
similar to cisplatin, in that the formation of platinum-DNA adducts results in the 
cell death. (123) (124) The most preferable site on DNA strand for both cisplatin 
and oxaliplatin to bind to is the same, which is the N-7 positions of guanine and 
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adenine. (109)  Oxaliplatin could react with both nuclear and cellular DNA and 
form in three kind of adducts: intra-strand, inter-strand and DNA protein cross-
links adducts. (4) (123) The intra-strand adduct is formed by the cross-link 
between oxaliplatin and NDA through adjacent guanines and occasionally 
adenines, which is the most abundant among all three adducts. (123) Among 
those intra-strand DNA-platinum adducts, 60% are bound between two guanine 
bases and between an adenine and a guanine is 30% of the intra-strand 
adducts. (109) The other kind of platinum-DNA binds are only about 1% 
compared to all platinum adducts, including inter-strand and DNA-protein cross-
links. (109) Moreover, oxaliplatin can break more DNA strand compared to 
cisplatin. (109) With these DNA lesions and damages, oxaliplatin could inhibit 
both DNA replication and transcription and sequentially cause the apoptosis of 
tumour cells. (4) However, with equal or frequently more cytotoxicity compared 
to cisplatin, oxaliplatin has surprisingly lower reactivity to crosslink with the 
DNA. (4) (125) Furthermore, oxaliplatin degrades in a high rate in vivo with the 
half-life about 15 minutes, while the reaction between oxaliplatin and DNA is 
proved very slow. Therefore, except for the intact oxaliplatin, one or more 
biotransformation products from oxaliplatin might also be able to cause the fatal 
DNA adducts. (124) (125) 
After administration to patients, about one third of oxaliplatin irreversibly binds 
to erythrocytes and another one third reacts with various albumins and plasma 
proteins. (124) The remaining free oxaliplatin degrades with an extensive non-
enzymatically biotransformation, and subsequently produces different 
complexes under different conditions. (124) The biotransformation of oxaliplatin 
in vivo is shown in Figure 1-17, which could be divided into two phases with 
different half-life time for the degradation of oxaliplatin. According to some 
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previous studies, before reacting into Pt(DACH) complexes, oxaliplatin rapidly 
dehydrates into the monodentate intermediate with the oxalate ring open which 
could then form into other platinum complexes. (125) It has been indicated that 
the half-life for the Phase I was only 16 minutes, while the half-life for oxalate 
ligand lost was up to 92 minutes which could represent Phase II. (126)  
 
Figure 1-17, Non-enzymatic biotransformation of oxaliplatin in vivo, with the oxalate 
monodentate intermediate which is produced rapidly in Phase I of oxaliplatin 
degradation. The reactions are slightly slower in Phase II compared to Phase I. The 
oxaliplatin complexes included in this figure are produced under different conditions: 
C1 = Alkaline hydrolysis by nucleophiles; C2 = Acid hydrolysis by chloride. The 
intermediates are oxaliplatin with the oxalate ring open, which are respectively 
protonated and deprotonated.  
However, nucleophiles causing the alkaline hydrolysis in human bodies, such 
as endogenous bicarbonate and dihydrogen phosphate, present very low 
reactivity to oxaliplatin under the physiological conditions. (125) (126) 
Therefore, the dihydrated oxaliplatin could not be produced much in plasma, 
even though the DOC (dihydrate oxaliplatin complex) is more cytotoxic than 
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oxaliplatin. (125) Pt(DACH)Cl2 could be produced by both the intact oxaliplatin 
and the intermediate with oxalate which can be formed due to the high 
concentration of extracellular chloride. (127) Additionally, Pt(DACH)Cl2 is also 
more cytotoxic to tumour cells than oxaliplatin, but its contribution to the total 
cytotoxicity of oxaliplatin in vivo is unclearly acknowledged. (125) Consequently, 
considering those studies on oxaliplatin, Elin Jerremalm (125) has suggested in 
his review that the intact oxaliplatin is acting as the main cytotoxic component in 
blood. (125) 
If the cytotoxicity is only related to the intact oxaliplatin, with increased 
lipophilicity oxaliplatin is supposed to be more readily taken up by cells and 
reacted with the nuclear DNA. (124) On the other hand, the sulphur-containing 
compounds in blood are very reactive to oxaliplatin, including glutathione, 
methionine and cysteine. (124) But the sulphur-platinum species are most likely 
inactive, which could influence the cellular effects of the drug. (124) (125) From 
all these studies, it was shown that the intact oxaliplatin degrades rapidly and 
forms with a wide range of blood components in. As a result, oxaliplatin could 
not produce as many DNA adducts as cisplatin. However, the measurable 
cytotoxicity of oxaliplatin is frequently higher to tumour cells than cisplatin. (4) 
Therefore, the mechanism of anticancer activity of oxaliplatin might also involve 
other cellular effects through other components in the blood rather than the 
DNA itself. (124) (125) It has been indicated that RNA and proteins can also 
interfere with the anticancer activity mechanism of oxaliplatin. (109) In a study 
with mouse leukaemia cell cultures, oxaliplatin inhibited RNA synthesis while no 
positive result was observed with cisplatin. (109) In addition, with conjugating to 
different cellular proteins, oxaliplatin can inactivate those proteins and 
subsequently interfere with the cell functions to cause more cell deaths. (109) 
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Other potential mechanism of oxaliplatin cytotoxicity is also suggested from 
different studies. For example, the inhibition of the thioredoxin system, an 
important cellular redox system, causes the cell apoptosis. It has been proved 
that the cisplatin–glutathione complex could inhibit the thioredoxin reductase by 
binding to a selenocysteine-containing active site on thioredoxin reductase and 
subsequently induce cell death. (128) Therefore it might also be triggered by 
oxaliplatin-sulphur compound, which is similar in chemical structure to cisplatin. 
(124) (125) Furthermore, the possibility has also been suggested that platinum-
sulphur complex could act as a potential drug reservoir and be activated for the 
subsequent DNA bindings. (124) 
1.2.3.2.2 Pharmacokinetics (PK) 
Pharmacokinetics (PK) studies are very important for the clinical development 
of drugs. To evaluate the therapeutic efficacy and safety of oxaliplatin, various 
clinical and preclinical studies have been conducted under different conditions, 
and a wide range of PK characteristics were achieved. Oxaliplatin is normally 
administrated by intravenous infusions within 5% glucose, in which case the 
absorption of oxaliplatin would be 100% in a patient’s blood circulation. 
Therefore, PK studies of oxaliplatin mostly aimed at the representative PK 
parameters involved in the processes of drug distribution and elimination, which 
are reviewed in the following paragraphs. 
After administration to patients, oxaliplatin immediately transfers through the 
blood circulation and distributes widely among various tissues/organs in the 
body within a short distribution time. (3) From previous studies, the estimated 
distribution volume for oxaliplatin was different for total (protein-bound and 
intact fractions) and intact (free) oxaliplatin, but with high values for both. (11) 
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(109) For the total amount of oxaliplatin (including protein-bound and un-bound 
oxaliplatin) in plasma, the distribution volume was around 35 L, while for the un-
bound oxaliplatin in PUF (plasma ultra-filtrate) the value ranged from 349 – 812 
L. (11) (109) This large distribution volume for oxaliplatin could be explained by 
its nature of lipophillicity from the DACH ligand. (11) In addition, the irreversible 
bindings to proteins, DNA and other cellular macromolecules could potentially 
overestimate the distribution volume of oxaliplatin. (11) With a 2-hour infusion of 
oxaliplatin, the Cmax (the maximum drug concentration in plasma after 
administration) normally appears at the very end of the infusion, of which value 
depends on the dosage of administered oxaliplatin. (11) (129) With the standard 
dose of oxaliplatin suggested in SPC (Summary of product characteristics), the 
Cmax value after 2-hour infusion of 85 mg/m
2 oxaliplatin was observed as 3.6 µM 
in PUF. (125) The previous study conducted with oxaliplatin in different infusion 
duration presented that prolonging the infusion time (from 2 – 6 hours) reduced 
the mean plasma Cmax by approximately 32%. (11) In order to obtain the full 
profile of oxaliplatin PK process, various simulation models for oxaliplatin PK 
analysis have been applied in previous studies. (130) Information about the 
pharmacokinetics characteristics of oxaliplatin and their modelling systems are 
described in detail in Chapter 4 (refer to Section 4.1.1).  
Among those previous studies, the most suitable PK models for oxaliplatin were 
selected with 2-compartment, 3-compartment and non-compartment models. (3) 
(131) AUC (area under the drug concentration-time curve) is an important PK 
parameter representing the drug exposure in the human body, which can be 
calculated from the simulation models. (3) The mean AUC0-inf values for 85 
mg/m2 oxaliplatin were presented differently in different studies after the 2-hour 
infusion, which were 4.25, 118 and 252 µg-hr/mL respectively for PUF, plasma 
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and blood cells. (11) Within 48 hours after oxaliplatin administration, more than 
50% of the platinum complexes were eliminated through the kidney by urine. 
(129) Consequently, the glomerular filtration is proven to be the principal 
mechanism of oxaliplatin elimination by the kidney. Therefore renal clearance 
could be roughly considered as the total clearance for oxaliplatin elimination 
from plasma/PUF. (3) The value of oxaliplatin clearance from PUF was 
indicated as 18.5 L/h at 85 mg/m2 dosage, which was higher than the average 
human glomerular filtration (≈7.5 L/h). (11) To investigate the PK variations for 
patients with renal impairment, a PK study of oxaliplatin on cancer patients with 
normal renal function and renal impairment was conducted by Chris 
H.Takimoto. (129) Results from different groups of patients with different renal 
functions has shown that patients with renal impairment had lower clearance for 
PUF platinum and subsequently the platinum exposure was higher in those 
patients. (129) However, the corresponding increase of the clinical toxicity 
related to oxaliplatin was not observed. (129) According to those results, a 
hypothesis about oxaliplatin elimination was proposed, which suggested that 
the clearance mechanism for cytotoxic platinum complexes eliminated within 
the initial phase was not related to renal function. (129) However, the particular 
mechanism of the effect of renal impairment on platinum clearance still has not 
been proven. (11) (129) 
Time course of the PK process for oxaliplatin could be characterized by three 
phases, including the short initial α-phase, the longer β-phase and the 
prolonged terminal γ-phase. (11) (129) The distributions phase of oxaliplatin 
comprises the α-phase and β-phase, of which the average half-lives were 
indicated respectively as 0.28 hour and 16.3 hour from previous studies. (11) 
During this time, the intact oxaliplatin and anti-tumour reactive platinum 
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complexes were distributed in two ways: 1) rapid removal and binding to 
tissues; 2) clearance from the systematic circulation through glomerular 
filtration. (11) The prolonged γ-phase is actually the terminal elimination phase 
of oxaliplatin and the value of its half-life largely varies in different studies with 
the rough range from 240 hour to more than 600 hour. (129) The big T1/2 
variation for γ-phase was generally caused by variation in the experiment 
conditions in different studies, such as the sampling time design and the 
detection limits from different determination methods. (11) For example, 
oxaliplatin results detected with FAAS and ICO-MS were significantly different 
with the respective accuracy of each assay. Even, after comparison between 
results from studies using the same detection technic, the terminal elimination 
phase for oxaliplatin was proven to be long and the average T1/2 could be 
considered as about 250 hours. (131) This terminal phase could represent the 
slow release of the platinum bound reversibly to some cellular macromolecules, 
such as amino acid and plasma proteins. (11) Meanwhile, platinum change 
occurred during the terminal γ-phase only comprise the inactive platinum 
conjugates. (11) Therefore, the shorter distribution phase is more clinically 
relevant as its T1/2 could represent the change of pharmacologically reactive 
platinum complexes.  
Detailed PK parameters of oxaliplatin collected from previous literature are 
presented in Table 4-1 (refer to Chapter 4), with different experimental 
conditions and data analysis. To understand the big variability among those PK 
data from different studies, more effective factors to experiment results should 
be concerned, including the experiment design, detection sample types, method 
selection, patient number and conditions.  
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In different studies, different matrices were applied on oxaliplatin determination, 
including blood, plasma and plasma ultra-filtrate (PUF). (11) As discussed 
above, after administration, most oxaliplatin binds irreversibly to erythrocytes 
and various albumins in blood and plasma. These products of oxaliplatin are 
pharmacologically inactive and without cytotoxicity, while the free intact 
oxaliplatin is capable of being ultra-filtered from plasma. (125) Therefore, the 
determination of oxaliplatin in plasma ultra-filtrate is considered as the most 
acceptable approach to investigate the platinum PK processes. (11) (109) In 
early PK studies, oxaliplatin was only tested with blood and plasma samples. 
(11) After more was discovered about the oxaliplatin cytotoxicity mechanisms, 
the important role of free intact oxaliplatin in its anti-tumour activity has been 
confirmed. As a result, most of the recent PK studies on oxaliplatin started to 
include the platinum determination in PUF samples together with plasma and 
occasionally full blood samples. (11) (125) However, it has been indicated that 
the free platinum concentration is probably overestimated by the amount of 
platinum in PUF which could also include the inactive oxaliplatin bound to amino 
acids and other small biomolecules from blood. (109) Although, the 
overestimated result from PUF samples can still be analysed with the total 
oxaliplatin concentration in plasma/blood samples, in order to observe the 
relationship between active and inactive platinum and subsequently learn about 
the pharmacological behaviour of active platinum complexes. (109) 
As discussed above, determination assays for oxaliplatin used in its PK studies 
are required with good precision and accuracy on samples of blood, plasma and 
PUF. According to previous PK studies, different techniques were applied to 
detect oxaliplatin in those samples, among which FAAS (Flameless Atomic 
Absorption Spectrometry) and ICP-MS (Inductively Coupled Plasma - Mass 
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Spectrometry) were the most commonly selected. (11) FAAS and ICP-MS could 
be both applied to several different types of samples, such as full blood, 
plasma, PUF and urine samples. (129) (132) (133) Assays validated from these 
two methods were all with good accuracy and precisions, and with FAAS the 
assay for oxaliplatin samples (including blood, plasma and PUF) could test 
within the concentration range of 4 ng/mL – 400 ng/mL. (132) Various assays 
using ICP-MS were validated and applied in previous studies, while one of 
those studies on cancer patients with different renal functions has indicated 
different detection range of oxaliplatin in different samples. (129) The test 
concentration ranges were 1 – 250 ng/mL for PUF samples and 0.1 – 10 µg/mL 
for plasma, and the lowest platinum concentration that can be tested was 0.1 
µg/mL in urine samples. (129) The HPLC system with an UV detector was also 
used for oxaliplatin determinations in some PK studies. (11) With further 
development, a HPLC-MS (High Performance Liquid Chromatography tandem 
with mass spectrometry) method was validated for the quantification of intact 
oxaliplatin in human plasma, which could test the oxaliplatin concentration as 
small as 20 ng/mL within the range of 20 ng/mL – 1000 ng/mL. (125) (134)  
Compared with cisplatin and carboplatin, oxaliplatin has a similar drug exposure 
in patient bodies after administration, which indicates that the therapeutic effect 
from these three drugs should be without significant difference. (11) The main 
difference between oxaliplatin and cisplatin/carboplatin is caused by the carrier 
ligands. The DACH-platinum complexes produced from oxaliplatin are more 
lipophilic, which is easier to distribute into tissues and subsequently increases 
the volume of oxaliplatin distribution in PUF. (11)  While no platinum 
accumulation was observed in PUF after the oxaliplatin administration of 85 
mg/m2 every 2 weeks. (135) (136) Furthermore, in studies with chemotherapy 
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combination of oxaliplatin and 5-Fluorouracil (5-FU), the significant PK 
interactions were not found between these two drugs in patients. (11) This 
result could indicate that the additive anti-tumour activity obtained from the 
combination chemotherapy is not caused by the major alterations in drug 
exposure, and the potential mechanism for the enhanced efficacy of oxaliplatin 
is still unknown. (11)  
1.2.3.2.3 Clinical use and toxicities 
The development of platinum drugs was presented above in Section 1.3.1, 
according to which oxaliplatin is probably the most successful compound from 
the newest generation and widely applied in chemotherapies for various 
cancers at present. In fact, after cisplatin and carboplatin, a range of platinum 
compounds with the DACH ligand were studied, some of which were even 
tested and evaluated in preclinical and/or early clinical trials. (4) Because those 
DACH-platinum compounds have shown good anti-tumour activity in cell lines 
that are cisplatin-sensitive and/or carboplatin-resistant. (4) As one of the DACH-
platinum compounds that passed the initial tests and selected for preclinical 
studies, oxaliplatin has competed the others with its auspicious characteristics, 
such as stability, formulation, solubility and safety issues. (4) Furthermore, it 
has been indicated from previous studies that the activity of oxaliplatin could be 
remained without the cross-resistance in cisplatin-resistant cell lines, as well as 
a 5-FU-resistant and a doxorubicin-resistant cell line. (4) The DACH-platinum 
complex as oxaliplatin could exist in three isomeric conformations which could 
express their anti-tumour activities by interacting with DNA in different ways. (4)  
However, according to a previous study published in 1978, the trans-1-(R,R)-
DACH-Pt isomer was indicated as the most effective agent against the tumour 
cells that are resistant to other platinum drugs. (137) Therefore, the 
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stereochemical isomeric conformation of oxaliplatin was confirmed and after 
approved with valid preclinical and clinical results oxaliplatin is currently applied 
in clinical practice in many countries around the world, including Europe, Asia 
and America. (11) 
In clinical chemotherapies, oxaliplatin was approved for the treatment of 
metastatic colorectal cancer generally with 5-FU (5-fluorouracil) and leucovorin. 
(5) (6) Colon cancers have shown with the primary resistance to both cisplatin 
and carboplatin treatments either as single agents or in combinations. (123) 
However, the cytotoxic activity of oxaliplatin was observed against colorectal 
cancer, which is the first platinum-based drug that shows convincing clinical 
activity on colorectal cancers. (1) (4) Oxaliplatin was first launched in France in 
1996 and subsequently accepted in the rest of Europe since 1999, while in the 
United States oxaliplatin was approved by the FDA (Food and Drug 
Administration, US) a few years later in 2002. (1) Moreover, the clinical 
application of oxaliplatin is indicated differently in Europe and US as presented 
below: 
 In the US, oxaliplatin was approved for the initial treatment of advanced 
colorectal cancer in combination with infusions of 5-FU and LV 
(leucovorin) in 2004. (138) But initially in 2002, it was recommended to 
be used as the second-line treatment for patients with metastatic 
carcinoma of the colon or rectum when the disease had recurred and 
progressed after the first-line therapy (bolus 5-FU/LV and irinotecan) 
failed. (1) 
 In Europe, oxaliplatin in combination with 5-FU/LV was initially indicated 
as a first-line treatment for patients with metastatic colorectal cancer. (1) 
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In 2004, an extended indication of oxaliplatin was approved through the 
Mutual Recognition Procedure, which included the ‘Adjuvant treatment of 
stage III (Dukes’ C) colon cancer after complete resection of the primary 
tumour’. (139) 
Colorectal cancer was initially treated by the antimetabolite 5-FU (5-fluorouracil) 
with its biomodulator (LV, leucovorin) before new active medicines were 
discovered. (1) After approval in 1995, irinotecan started to be used as the main 
agent for the first-line treatment of colorectal cancers associated with 5-FU. (1) 
However, after oxaliplatin was introduced into clinical chemotherapies, the 
treatment combinations with oxaliplatin have competed with irinotecan, because 
the oxaliplatin treatment has a favourable toxicity profile and therapeutic 
efficacy variability. (1) (6)  
Even though, oxaliplatin are only approved for the treatment of colon cancers so 
far, the cytotoxic activity of oxaliplatin in various tumour cell lines and cancer 
types was investigated and presented in a range of preclinical and clinical 
studies. (4) (123) Oxaliplatin is cytotoxic to a broad range of cell lines some of 
which are cisplatin-resistant, including colon, ovarian, cervix, lung cancer cells 
and leukemia cell lines. (4) In previous in vivo and in vitro studies, oxaliplatin 
has shown activity against a number of tumours, including breast cancer, 
gastric cancer, renal cell carcinoma and sarcoma. (4) As a platinum drug, the 
possible use of oxaliplatin in treatments for those cancers that response to 
cisplatin and/or carboplatin are also considered. Recently, more clinical studies 
were conducted on some cancers that are occasionally treated with 
chemotherapeutic combinations containing oxaliplatin as the second-line 
treatment, such as advanced breast cancer, ovarian cancer, hepatocellular 
carcinoma and non-Hodgkin’s lymphoma. (7) Studied on 23 patients with 
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metastatic breast cancer, oxaliplatin in off-label use was indicated with little 
value to the combination chemotherapy. (140) While for the platinum-resistant 
ovarian cancer, the combination of gemcitabine and oxaliplatin (GEMOX) 
showed encouraging activity and manageable toxicity, which indicated the 
potential of this combination treatment for patients with ovarian cancer, 
especially for those who have been pre-treated with other chemotherapeutic 
agents. (141) As a result, the GEMOX has been tested in a large number of 
patients (n=204) with advanced hepatocellular carcinoma (HCC), and the result 
of acceptable tumour responses has demonstrated the therapeutic efficacy and 
safety of GEMOX for the treatment of advanced HCC. (142) In addition, 
GEMOX (gemcitabine and oxaliplatin) could also be applied to the treatment of 
advanced non-small cell lung cancer, which was indicated with good activity 
and toleration in studied patients. (143) For other chemotherapy combinations, 
the significant activity of OFAR2 (including oxaliplatin, fludarabine, cytarabine 
and rituximab) regimens was found in the treatment for non-Hodgkin’s 
lymphoma. (144) Furthermore, the potential of oxaliplatin in chemotherapies 
against pancreatic cancer and gastrointestinal cancer was also in development 
in clinical studies. (1) (139) 
Compared with cisplatin and carboplatin, oxaliplatin has a preferable toxicity 
profile with mild myeloid-suppression and moderate gastrointestinal side effects 
to patients. (1) (129) The gastrointestinal toxicity presented by nausea and 
vomiting are common with platinum drugs, which could be systematically 
prevented by the antiemetic of 5-HT3 antagonists which could significantly 
reduce the severity of this toxicity. (123) (129) Severe toxicity effects associated 
with cisplatin, otoxicity and nephrotoxicity were not observed in clinical studies 
of oxaliplatin. (123) (129) However, the dosing administration of oxaliplatin is 
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limited by the major toxicity of the transient peripheral neuropathy, which is 
characterized by paresthesia, dysesthesia and hypoesthesia in hands, feet, 
perioral area or throat in patients. (5) (123) (129) The neurotoxicity of oxaliplatin 
expresses differently during the chemotherapy treatment, which was classified 
in two types as following: 
I. An acute sensory neuropathy occurred rapidly during the infusion and 
lasted for hours to a few days. (5) (123) These symptoms can be fully 
reversed within 14 days after the completion of oxaliplatin treatment. (5) 
However, the acute neuropathy frequently recurs with the accumulative 
oxaliplatin from further dosing schedules. (5) In addition, acute 
neurological symptoms are proven to be triggered and exacerbated by 
contact with cold temperature, in which case ice from food or drink 
should be avoided during the infusion administration of oxaliplatin. (5) 
(145)  
II. A persistent (> 14 days) chronic sensory neuropathy normally occurs 
with oxaliplatin treatment following the acute neuropathy events but it 
could also appear without prior symptoms. (5) The chronic neuropathy is 
also one of the severe side effects for cisplatin, which mechanism is 
believed to be related to the platinum-DNA bindings in neuron cells. (12) 
(146) Compared to the acute neuropathy, deficits in proprioception might 
be developed in persistent neurotoxicity, which can interfere with daily 
activities for a number of patients. (5) Furthermore, these symptoms of 
persistent neuropathy may be reduced in some patients upon the 
discontinuation of oxaliplatin treatment. (5) 
Mechanisms of these two types of neurotoxicity associated with oxaliplatin are 
not clearly acknowledged at the moment. Several hypotheses were proposed 
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and investigated in previous studies, which lead to a few options after the 
exclusion of irrelative factors: 1) interference with voltage-gated ion channels 
either by the oxalate produced from oxaliplatin degradation which can chelate 
with the extracellular calcium ions, or directly by oxaliplatin or oxaliplatin 
intermediates (such as [Pt(DACH)oxCl]-); 2) the apoptosis of sensory neurons 
could be caused by the DNA damage from oxaliplatin/cisplatin bindings. (145) 
(146) In a previous study on dorsal root ganglion (DRG) neurons, which has 
been proven to be the major damage site in chronic neurotoxicity, the results of 
oxalate treatment on those neurons indicated that oxalate did not cause 
significant cell damage and is consequently not involved in chronic neurotoxicity 
of oxaliplatin. (146) However, the potential of oxalate related to the acute 
neurotoxicity occurred with oxaliplatin treatment was not excluded, which was 
believed with great values in the relative researches for oxaliplatin. (12) (146) 
(147) To prevent the neurotoxicity from oxaliplatin, different clinical approaches 
were tested, and the calcium-magnesium infusions have shown good efficacy 
as an adjuvant agent in clinical practice. (147) Detailed information reviewed 
from previous studies on the relationship between oxalate and neurotoxicity of 
oxaliplatin was discussed in Chapter 3, please refer to Section 3.1.1. 
In addition to neurotoxicity, thrombocytopenia is also a frequent side effect 
observed with oxaliplatin treatment, which normally appears in up to 70% 
patients as a mild or moderate toxicity but occasionally becomes the major 
issue that could delay or discontinue the chemotherapy treatment. (7) (123) The 
mechanism of thrombocytopenia has been indicated with mild to moderate bone 
marrow suppression in previous studies. New mechanisms were also 
demonstrated from recent studies, including splenic sequestration of platelets, 
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the relevant liver damage induced from oxaliplatin and immune 
chrombocytopenia. (7)  
In summary, oxaliplatin is currently used as the first-line treatment of metastatic 
colon cancers and adjuvant treatments for various cancers. Although oxaliplatin 
has a favourable toxicity profile compared with other platinum drugs, 
mechanisms of those major side effects (such as neurotoxicity and 
thrombocytopenia) are still in need of further studies in order to discover 
effective preventions and for the improvement of clinical use with oxaliplatin. 
From previous in vivo and ex vivo studies, the value of oxaliplatin in clinical 
chemotherapies was indicated, and oxaliplatin could be applied to a wider range 
of clinical use with appropriate development. 
1.2.4 Dose-banding 
Drug dosing is always a key issue in chemotherapy with the ‘dose-effect’ 
relationship of cytotoxic drugs. (13) Doses of most anticancer drugs have 
currently been calculated on the basis of BSA (Body Surface Area) in clinical 
practice since 1958. (8) (13) The only exception is carboplatin, for which the 
dose is calculated on the basis of patient renal function and pre-defined 
pharmacokinetic targeted AUC (area under the plasma concentration-time 
curve). (8) (9) The use of BSA can provide individualized dose of cytotoxic 
drugs for each patient in accordance with the evaluation of haematology test 
results and renal and hepatic function as well as other indicators of the patient’s 
clinical status. (8) (9) Chemotherapy, in now, is mostly administered in the 
outpatient setting, which means that drug infusions, with bespoke dose 
calculated according to BSA, are required immediately after the patients’ 
assessment and the authorization of their prescription by the oncologist during 
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their visit to the outpatient department. (8) (9) As a result, this individual 
preparation of chemotherapeutic drug infusions, with timely provision, increases 
the demand on pharmacy intravenous admixture and anticancer drug 
compounding service bringing a challenge for hospital pharmacy aseptic units. 
(8) (9) This situation could cause several problems, such as delays for patients 
awaiting treatment and disrupting scheduling; limiting the number of patients 
that hospital clinics can treat in the same time; increasing the stress for 
oncology outpatients, pharmacy and nursing staff involved; the lack of specialist 
nursing resources in or beyond the normal working hours. (8) (9) In this case, 
new approaches for chemotherapy administration are required among which the 
pre-preparation of batch-scale aseptic infusions is attractive since it can permit 
streamlined preparation and rigorous quality control. (10) However, this would 
introduce a limitation of using standard doses, when in practice it is necessary 
to calculate bespoke, individual patient doses using BSA. To overcome this 
difficulty, the dose-banding approach has been developed for chemotherapy 
preparation, since it allows standard batch-prepared infusion bags or syringes 
to be used for individual patients where doses are based on BSA. (10) (13)  
Dose-banding has been defined as “a system whereby through agreement 
between prescribers and pharmacists, doses of intravenous cytotoxic drugs 
calculated on an individualized basis that are within defined ranges or bands 
are rounded up or down to predetermined standard doses.” (8) The maximum 
variation of the adjustment between the standard dose and the doses 
constituting each band is not more than 5%. (8) (10) Therefore, a range of 
prefilled syringes or infusions, manufactured by pharmacy staff or purchased 
from commercial sources, can then be used to administer the prescribed drug 
dose for chemotherapy. (8) (10) 
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These ranges (or bands) of doses based on BSA are predefined and a pre-
determined standard dose is applied to each band usually as the midpoint of the 
band which means the standard dose should be used for the patients whose 
prescribed doses are included in the same dose band. (13) (148) Dose-banding 
schemes are constructed individually for each drug to make sure the variation 
should not be more than 5% from the prescribed dose. (8) (148) Moreover, the 
standard dose applied for patients are prepared from the combinations of pre-
filled syringes or pre-prepared infusion bags, which are the only drug solutions 
stored and used directly in the clinical administration of chemotherapy with 
dose-banding scheme. (8) (148) An example of a part of a dose-banding 
scheme is shown in Figure 1-18, which presents some dose bands of 
methotrexate in the chemotherapy of CMF (Cyclophosphamide; Methotrexate; 
5-Flourouracil).  
 
Figure 1-18, Examples of a part of the dose-banding scheme of methotrexate in CMF 
(Cyclophosphamide; Methotrexate; 5-Flourouracil) chemotherapy, inside which the 
dose of methotrexate is 40 mg/m
2
 based on BSA. Two lower dose ranges are shown 
above: 38 mg – 42 mg and 43 mg – 47 mg. The standard doses of 40 mg and 45 mg can 
be provided within these two bands and the maximum variance is 2 mg which is not 
more than 5% from the prescribed dose. The pre-produced syringes of methotrexate are 
made in 5 different sizes to be combined into several different standard doses of each 
band, which are 10 mg, 15 mg, 20 mg, 30 mg and 60 mg. Rx dose: prescription dose. 
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With more than 10 years use in the UK, dose-banding has shown various 
benefits in clinical practice. (9) The main advantages of dose-banding are 
described in three aspects below:  
1, Safety and quality: By improving workload planning of the pharmacy 
production, dose-banding can reduce errors related to the cytotoxic drugs 
preparation and the stress from pharmacists and nurses. (148) In addition, 
dose-banding simplifies the process of dose calculation and provides the 
possibility of the end-product testing of batches, such as drug assay, drug 
identification and infusion sterility. (8) (148) Therefore, dose-banding enables 
the prospective quality control for validated batches and pre-filled syringes, and 
thus increases the accuracy and safety of chemotherapy administrations.  
2, Good for pharmacy staff: dose-banding reduces the stress on pharmacists 
and nursing staff to decrease the risk of errors in the preparation and 
administration of chemotherapy. (8) (148) Using the ‘ready-to-use’ batches or 
pre-filled syringes, the occupational exposure risk to the staff that is responsible 
for handling cytotoxic chemotherapy is also reduced. Furthermore, providing 
good quality data on the drug infusion stability is available, and the shelf-life of 
the drug infusions could be prolonged to minimise/eliminate the drug wastage. 
(8) (9) (148) 
3, Good for patients: dose-banding has been shown to decrease patients’ 
waiting time since their infusions are pre-prepared and readily available, 
avoiding the delay of up to several hours while bespoke chemotherapy infusions 
are prepared. In addition, dose-banding can also provide the possibility to give 
treatments to patients nearer their homes, in GP clinics and on any weekday. 
(10) (148) 
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However, there are still some potential disadvantages, such as the dose 
variance from dose-banding might result in an unacceptable total variance from 
the intended dose when combined with errors incurred in the estimation of 
BSA ; the need to combine different syringes/infusions (two or three) giving to a 
standard dose may add some errors in practice. (8) (148) Furthermore, not all 
patients are suitable for dose-banding approach. Patients with extreme 
conditions, such as children, cachexic patients and obese patients, might 
require more accurate drug dosage for the treatment. (10) 
Several anticancer drugs have been successfully administered with dose 
banding schemes in clinical practice in the UK, including cyclophosphamide, 
methotrexate, doxorubicin, epirubicin, vincristine, 5-FU (Fluorouracil) and folinic 
acid. (148) Two main conditions are required for the cytotoxic drugs to be dose 
banded, which are clinical acceptability of 5% variation from the prescribed 
dose and longer stability duration (ideally at least 3 months) to provide a 
reasonable shelf-life for pre-preparation of standard infusions. (8) (148)  
In summary, pre-filled syringes and infusion bags for dose-banding can be 
manufactured from a licensed pharmacy facility or the pharmaceutical industry, 
and then used in clinical practice associated with trained pharmacy staff, 
especially pharmacists, nurses and oncologists. (8) (148) (149) As a result, the 
implementation of dose-banding in clinical chemotherapy practice requires well-
designed infusion stability studies and clinical evidence that dose banding is 
acceptable in the oncology practice with no adverse effect on patient outcomes. 
(149) Determination of stability of the drug infusions is necessary to ensure that 
the drug potency is not reduced and that harmful degradation products or drug 
precipitates are not produced during prolonged storage. (8) Thereby the safe 
use of drug infusions for dose-banding scheme can be supported by long-term 
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stability data of pre-prepared syringes and infusions. (148) There are few 
clinical studies using key pharmacokinetic measures as a surrogate to research 
on the implementation of dose-banding. (13) (149) These studies indicate that 
there is no significant difference between the pharmacokinetic profiles obtained 
with dose-banding and individual dosing based on BSA. (10) (13) Thus, dose-
banding is currently considered to be acceptable in clinical practice. (8) 
Furthermore, the administration of dose-banding not only facilitates the quality 
control of cytotoxic drug infusions but also improves the services to patients 
compared with the traditional (individual) dose preparation. (8) (10) (13) 
1.2.5 Summary of the literature review 
Cancer is a type of disease caused by abnormal cell growth with the potential to 
expand and/or metastasize to normal tissues/organs of the body.  The causes 
of cancers are generally considered as the host factors and the 
exogenous/environmental factors, among which the environmental factors are 
the key issue to prevent the development of cancer. There are more than 100 
types of cancer, which can be classified into four main kinds, which are 
carcinoma, sarcoma, lymphoma and leukaemia. For different types of cancer, 
different treatment will be selected and applied to patients, including surgery, 
radiation therapy and chemotherapy, which can be used independently or within 
combinations. Compared with other treatments, chemotherapy can provide 
systematic effects against metastatic and disseminated cancers with various 
anticancer drugs, such as alkylating agents, antimetabolites, anti-tumour 
antibiotics and vinca alkaloids. The anticancer activity of those drugs used for 
chemotherapies aims at different cancers with different mechanisms. Alkylating 
agents are based on the mechanism of damaging the DNA by cross-link DNA 
strands and subsequently causing cell apoptosis. Platinum group is one of the 
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major alkylating agents that are currently used for various cancers in clinical 
chemotherapies. In platinum group, cisplatin, carboplatin and oxaliplatin are 
three main drugs with outstanding cytotoxicity to a number of cancer cell lines. 
Oxaliplatin is the third generation of platinum drugs, which can be used for 
cisplatin- and/or carboplatin-resistant cancers with different activities and 
mechanisms. Since approached in France in 1996, oxaliplatin has been used 
for metastatic colorectal cancers as the first-line treatment. Meanwhile, 
increasing preclinical and clinical studies have shown the wider range of 
tumours that oxaliplatin is reactive to, which has improved the clinical use of 
oxaliplatin. However, the dose-limiting side effect of oxaliplatin is neurotoxicity, 
which mechanism has not been clearly defined. As a result, the search for 
suitable adjuvant agents for the effective prevention of neurotoxicity associated 
with oxaliplatin treatment requires further study. 
Furthermore, dose-banding has been introduced as an alternative drug 
administration method to improve the clinical administration of anticancer drugs, 
which are normally prepared by the individual dosing scheme based on 
patient’s BSA (Body Surface Area). With more advantages for patients, 
pharmacists and manufacturers, dose-banding is currently applied to many 
chemotherapeutic drugs in the UK. However, the application of dose-banding in 
clinical practice requires further investigations of the specific drug to ensure the 
therapeutic efficacy and safety for its chemotherapies. 
As a regular chemotherapeutic drug used frequently in clinical practice, the 
administration of oxaliplatin can be improved with dose-banding schemes. 
Therefore, a well-designed infusion stability study is required to indicate that 
oxaliplatin infusions are suitable for preparation in advance and safe to use after 
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a long-term storage (at least 3 months). In addition, the dose-banding schedule 
for oxaliplatin must be proven with appropriate pharmacological efficacy and 
acceptable toxicity to patients, which could be demonstrated from a 
pharmacokinetic study with clinical or laboratory-based experiments. 
Furthermore, studies on side effects produced from oxaliplatin would be useful 
and supportive to improve the clinical chemotherapies with oxaliplatin. 
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Chapter 2: Sequential-temperature stability study on 
oxaliplatin infusions 
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2.1 Introduction 
2.1.1 Oxaliplatin background 
Oxaliplatin is a third-generation platinum Ⅱcompound which has been 
developed by replacing the diamino ligand attached to Pt with 1, 2 – diamino-
cyclohexane (DACH) and adding an oxalate ligand as a ‘leaving group’. (134) 
As a novel platinum drug, the use of oxaliplatin could increase the number of 
cancer types which can be treated by platinum, and overcome some of the 
present limitations of platinum-based chemotherapy such as the resistance 
tumour cells have developed against cisplatin and carboplatin. (150) In clinical 
practice, oxaliplatin is currently used in the treatment of many types of tumours 
such as colorectal cancer, refractory breast cancers, non–small-cell lung 
cancer, and non-Hodgkin’s lymphoma. (151) The mechanism of anti-tumour 
activity of oxaliplatin is based on activation of oxaliplatin derivatives following: 
displacement of the labile oxalate ligand leaving groups, and the active platinum 
species form both inter- and intra- standard platinum-DNA crosslinks. (127) As 
a result, replication and transcription of DNA are inhibited, and moreover the 
drug has cell - cycle nonspecific cytotoxicity. (109) 
In clinical practice, oxaliplatin is normally administered to patients by individual 
dosing method. Oxaliplatin doses for each patient are calculated according to 
patient BSA values. Like other frequently-prepared chemotherapy infusions, the 
preparation and administration of oxaliplatin individual doses has added stress 
to pharmacy aseptic compounding units. Furthermore, the waiting time for 
patients is prolonged because of the labour-intensive preparation of individual 
infusions and the associated large workloads. (8) (9) In order to reduce the 
preparation workload for pharmacy compounding units and improve the 
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timeliness and safety of drug administration to patients, dose-banding schemes 
offer many advantages for oxaliplatin infusions, including: 1) improved quality 
control on oxaliplatin infusions because dose-banding facilitates end-product 
testing; 2) ease of preparation for pharmacy compounding units by use of 
batch-scale preparation; 3) reduce waiting time for patients because their  
banded-dose of chemotherapy is available immediately after the prescription 
has been authorised. (152) The benefits of dose-banding are well documented 
for a range of chemotherapy infusions used in clinical practice in the UK. (9) To 
develop a specific dose-banding scheme for oxaliplatin administration, the 
stability of oxaliplatin infusions must be sufficient to permit the preparation of 
infusions in advance. The validation of extended shelf-life requires appropriate 
stability studies to be conducted on oxaliplatin infusions at relevant 
concentrations and storage conditions.  
Oxaliplatin is normally prepared with 5% glucose to gain the individual dose for 
each patient in clinical administration. According to previous studies on 
oxaliplatin degradation, it has been proven that oxidative degradation is the 
major route of oxaliplatin degradation within aqueous solutions, such as glucose 
solution. (153) In 5% glucose, oxaliplatin is considered to be fairly stable and 
slowly degrades into oxalate and diaquated DACH-platinum complexes, such 
as [Pt(DACH)(OH)2]. (154) (See Figure 2-1) As discussed in Chapter 1, the 
degradation process of oxaliplatin could be significantly influenced by the 
presence of chloride ion and the pH of the solution. (127) For example, in 
human blood, where the chloride concentration is relatively high (97 – 107 
mmol/L), oxaliplatin can rapidly degrade into [Pt(DACH)Cl2] and/or 
[Pt(DACH)Cl(OH)] by non-enzymatic biotransformation. (154) (127) For this 
reason, oxaliplatin infusions are normally prepared in 5% glucose infusions as 
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opposed to sodium chloride diluent. In recent years, polyolefin infusion bags 
have replaced those made of PVC to avoid the requirement for plasticisers 
(typically phthalates) that can leach into the drug infusion. (155) Therefore, 
polyolefin bags of 5% glucose were used in this stability study on oxaliplatin 
infusions. (127) (156) 
 
Figure 2-1, The hydrolytic degradation of oxaliplatin in aqueous solutions, resulting in 
the production of [Pt(DACH)(OH)] and oxalate ions. 
The stability information of oxaliplatin is generally indicated within the SPC 
(Summary of Product Characteristics) produced from the manufacturer. 
However, the shelf-life stated in SPC is very short for oxaliplatin infusions after 
dilution from the stock vial (5 mg/mL), and is given as 6 hours at room 
temperature (25℃) and only 24 hours at 2 - 8℃. (122) To extend the shelf-life of 
oxaliplatin infusions, several stability studies have been conducted under 
different conditions. In a previous study in 2007, oxaliplatin infusions of 0.7 
mg/mL concentration were prepared with 5% glucose in PVC-free bags, and 
stored separately at 3 - 7℃ and 20 - 24℃ for 30 days. (154) The chemical 
stability of oxaliplatin in those infusions was determined by an HPLC assay, 
while the physical stability was only examined visually with the evaluation of 
colour change and visible particle formations in the infusion. (154) With over 
90% remaining concentrations of oxaliplatin in all infusions, the study results 
supported the extended 30 day stability of oxaliplatin infusions (0.7 mg/mL) 
under the storage at both temperatures. (154) Furthermore, a more recent study 
in 2009 demonstrated longer stability period for oxaliplatin infusions. (151) In 
this study, oxaliplatin infusions at a concentration of 0.25 mg/mL were prepared 
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with 5% glucose. After storage for 90 days separately at 4℃ and 25℃, 97.8% 
and 96.4% of the oxaliplatin was retained, respectively, compared with the initial 
concentrations. (151) Although the recommended shelf-life of oxaliplatin was 
increased to 90 days as a result of this study, the data obtained were limited in 
several ways: 
 The concentration range of oxaliplatin infusions in previous stability 
studies could not fully cover the range required in clinical practice. The 
average BSA (body surface area) range of cancer patients in UK can be 
considered as 0.59 m2 to 2.06 m2. (157) With the licenced oxaliplatin 
dosage of 85 mg/m2 (122) this give a required dose range of 
approximately 50 mg – 175 mg. Assuming that 5% glucose bags in 250 
mL are used for oxaliplatin dilutions, the concentration of oxaliplatin in 
those infusions should then be within the range of 0.2 mg/mL – 0.7 
mg/mL. The results from the two previous stability studies described 
above were limited with a single test concentration, which could not 
represent the concentration range of oxaliplatin infusions used in clinical 
practice. 
 The physical stability of oxaliplatin infusions was only assessed by visual 
examination in both studies, including colour change and visible particle 
precipitation. In this case, the formation of sub-visual particles was not 
tested, which could significantly influence the physical stability of 
infusions. (158) 
 The acceptance criteria used for appraising the oxaliplatin concentration 
change in both studies was the same: ± 10%. For cytotoxic drugs with a 
narrow therapeutic window, the criteria for the concentration variation 
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should be more restricted to improve patient safety and a limit of ± 5% 
has been proposed in stability studies on cytotoxic drugs. (149) This is 
particularly important when the identity, pharmacology and toxicology of 
any breakdown products are not known. However, it is notable that in the 
second study the actual variation of oxaliplatin concentration was within 
5% of the original concentration. This suggests that the extended 90 day 
shelf-life for 0.25 mg/mL oxaliplatin infusions from this study would have 
been achieved even if stricter acceptance criteria had been applied. 
 The parallel temperature design was applied in all previous stability 
studies on oxaliplatin infusions. This limits the interpretation of extended 
shelf-lives to single temperature conditions and does not account for the 
variable temperatures encountered by infusions during storage and 
administration to the patient. (159) 
Given the limitations of pre-existing stability data for oxaliplatin infusions, and 
the need for rigorous data to support extended shelf-lives of batch-
manufactured infusions at a range of standard concentrations required for dose-
banding, an appropriately designed stability study reflecting these needs was 
required. 
2.1.2 Experiment design 
In order to improve the stability data for oxaliplatin infusions, a sequential 
temperature design was applied in this study. (160) Compared to the studies 
conducted with a parallel temperature design, the sequential temperature 
approach provides the stability data with different and/or mixed temperature 
conditions, including temperature cycling, which simulates expected situations 
in clinical practice. With valid stability data, drug wastage could be significantly 
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reduced in situations where staff forgets to return an infusion bag to the fridge 
immediately after receipt, or where a patient’s treatment has been delayed for 
clinical reasons after the infusion was prepared or taken out of refrigerated 
storage. (159) The sequential temperature schedule was designed by the 
addition of two regular storage temperatures: the refrigerated storage 
temperature of 2 – 8℃ and the room temperature of 25℃ at which the infusions 
are administered to the patient. For instance, the infusion bags can be stored in 
the fridge at 2 – 8℃ for a defined period and then incubated at 25℃ for another 
24 hours afterwards to simulate long-term refrigerated storage followed by a 
period of time at room temperature consistent with transport of the infusion 
around the hospital and administration to the patient in the day-case clinic. The 
specific schedule of the sequential temperature cycling designed for this 
stability study is described in detail in Section 2.3.1.1. 
As discussed above, the concentration of oxaliplatin infusions is normally 
prepared within the range of 0.2 mg/mL – 0.7 mg/mL in clinical practice. To 
ensure the stability data from this study is practically applicable, oxaliplatin 
infusions were prepared in two different concentrations of 0.2 mg/mL and 0.7 
mg/mL. Thus, results from this study should be able to cover all oxaliplatin 
infusions administered to patients within the expected BSA range. 
It was important to evaluate both chemical and physical stability of oxaliplatin 
infusions in this study. Chemical stability was determined by monitoring the 
drug-degradation using High Performance Liquid Chromatography (HPLC) with 
a fully validated stability-indicating method, which was also validated for 
precision, linearity of response and stability indication. (161) (162) Oxaliplatin 
concentrations were determined at different time-points for each infusion group, 
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and the concentrations at each time were compared to oxaliplatin 
concentrations obtained at time zero.   
Previous stability studies on oxaliplatin infusions were limited in their 
assessment of physical stability, but in this study a systematic multi-parameter 
analysis was adopted including visual appearance, sub-visual particulate 
counting and pH measurement as well as weight changes monitoring. (158) 
Sub-visual particulate counts were used to monitor the aggregation of micro-
precipitates which can affect the physical stability of infusions and remain 
undetected by the visual examination. (149) (163) Meanwhile, infusion weight 
changes were monitored to examine the loss of water through the infusion 
container membrane, which can change the oxaliplatin concentration of infusion 
and may even mask drug loss through degradation. (149) 
2.1.3 Aims and objectives 
This stability study aims to support a dose-banding scheme, which is based on 
batch-preparation of a range of standard infusions, for oxaliplatin administration 
by investigating and validating the extended stability of oxaliplatin infusions in 
5% glucose. 
The objectives of this stability study also include: 
 To develop and validate the methodology to rigorously evaluate the 
physical and chemical stability of oxaliplatin infusions; 
 To design a robust sequential-temperature cycling schedule for this study 
in order to determine the stability of oxaliplatin infusions under ‘real-life’ 
conditions encountered in clinical practice; 
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 To identify the optimum shelf-life of oxaliplatin infusions within the 
constraints of laboratory-based study, which could be referred and 
applied to clinical and pharmaceutical practice. 
2.2 Materials and methods 
2.2.1 Materials 
2.2.1.1 Chemical and reagents 
Oxaliplatin concentrate solution 5 mg/ mL, batch 871SD008/2, expiry 11/2013 
(Fresenius Kabi Oncology Plc., UK) 
Glucose 5% w/v Freeflex 250 mL polyolefin bags, batch 14DL7107, expiry 
08/11/2013 (Fresenius Kabi, UK) 
Sodium phosphate monobasic monohydrate (ACS reagent, 98.0 - 102.0%) 
(Sigma-Aldrich, Japan) 
Sodium phosphate dibasic (HPLC grade) (Sigma, USA) 
Sodium hydroxide 1M (HPLC grade) (Fisher Scientific, UK) 
Acid ortho-phosphoric (HPLC grade) (Fisher Scientific, UK) 
Methanol (HPLC grade) (Fisher Scientific, UK) 
Hydrochloric acid 1M (Fisher Scientific, UK) 
Multifunction peroxide solution 3% (Specsavers, UK) 
Screen washing liquid (Halfords, UK) 
pH electrode storage solution; pH 4.01 Buffer solution;  pH 7.00 Buffer solution 
(Thermo Fisher Scientific, USA) 
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Sterile water for irrigation and dilution, batch 12E22B28, expiry 04/2015 
(distilled and de-ionised) (Baxter, UK) 
2.2.1.2 Consumables 
10 mL Luer-lock syringes (Codan Medical ApS, UK) 
50 mL Luer-lock syringes (BD Plastipak, UK) 
0.8mm × 40mm needles, 21G × 11/2’’, LOT 120507, expiry 04-2017; 1.1mm × 
40mm needles, 19G × 11/2’’, LOT 120411, expiry 03-2017 (BD Microlance, UK) 
Screw-cap polypropylene tubes 7 mL (Fisher Scientific, UK) 
Screw-cap polypropylene tubes 20 mL (Gosselin SAS, UK) 
HPLC autosampler crew-cap vials 2 mL and caps (Chromacol Ltd., UK) 
Cellulose acetate filters (pore size 0.45 μm) (Sartorius Stedium Biotech, 
Germany) 
Disposable polypropylene pipettes 3 mL (Fisher Scientific, UK) 
Micropipette tips 1000 μl (Gilson SAS, France) 
Prep Pad, 70% Isopropyl Alcohol BP (A CliniMed Group Company, UK) 
2.2.1.3 Equipment and instrumentation 
Analytical balance: Sartorius Basic 100g - 0.0001g, 4-figure balance (Sartorious 
Ltd., UK) 
Balance: SG-601(600g ×0.1g) 2-figure (Fisher Scientific, UK) 
Refrigerator at 2 – 8℃ (Fisher Scientific, UK) 
Incubator at 25℃  (Gallenkamp, Japan) 
Digital thermometers (Fisher Scientific, UK) 
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Micropipette: Proline Plus 100 – 1000 μL (Biohit Limited, UK) 
pH meter : Orion 5 Star Benchtop (Thermo Scientific, UK) 
Magnetic stirrer : HI 190M (Hanna Instruments, UK) 
Glass filter holder and flask (Emil company, UK) 
Filter vacuum pump: FB 70155 (Fisher Scientific, UK) 
Static water bath: Clifton Range (Nickel-Electro Ltd., UK) 
Class Ⅱsafety cabinet: Biological Class Ⅱ containment (Bigneat Ltd., UK) 
Particle counter: LiQuilaz LS200, attached with software PSS-view (Particle 
Measuring Technique GB Ltd., UK) 
Glassware: Grade A, flasks, measuring cylinders and beakers (Fisher Scientific, 
UK) 
HPLC Column: Water Spherisorb® (CNRP) 4.6 mm×250 mm stainless steel, 
packed with 5.0 μm bonded phase cyano CNRP Column (Waters Limited, UK) 
HPLC System: (Jasco UK, Essex UK) 
Intelligent Column Thermostat, CO-2060 plus 
Intelligent Auto-sampler, AS 2057 plus 
Quaternary Gradient Pump, PU-2089 plus 
Multiwavelength Detector, FP 2020 
LE-Net Ⅱ/ADC 
Chrompass Software version 1.8.6.1  
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2.2.2 HPLC assay 
2.2.2.1 Conditions 
A bonded-phase cyano column of Water Spherisorb® (CNRP), 5.0 μm particle 
size and 4.6 mm×250 mm, was used to detect and separate oxaliplatin in a 
validated HPLC method. The HPLC assay for the quantification of oxaliplatin in 
infusions was adapted and developed from the European Pharmacopoeia (EP) 
by optimizing the detection conditions within the Jasco system of HPLC, 
including mobile phase composition, column temperature, flow rate and UV 
wavelength for detection. (164)  
Compared with the phosphate mobile phase with 1% acetonitrile described in 
EP, larger fraction of organic phase has shown better peak shape and effective 
separation of oxaliplatin from interference peaks in chromatograms under 
isocratic conditions. A range of mobile phase containing 5% - 10% methanol 
was tested with the standard solution of oxaliplatin under isocratic conditions. 
According to those tests, the effective chromatogram with good separation of 
oxaliplatin was obtained using the mobile phase with 5% methanol. As a result, 
the mobile phase prepared with 5 mM phosphate buffer at pH 6.5 and 5% 
methanol was selected and used in this assay.  
To optimize the peak shape and separation of oxaliplatin in chromatogram, 
temperature of the column oven was adjusted into 35℃, which provided sharper 
peaks of oxaliplatin with appropriate peak heights and good separation between 
different peaks. In order to short the retention time and modify the peak shape, 
the flow rate in this assay was adjusted into 1.0 mL/min from 1.2 mL/min that 
stated in the method from EP. In addition, oxaliplatin showed maximum 
absorbance at 210 nm after testing the standard solution of oxaliplatin in the UV 
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wave length ranging from 200 nm to 250 nm. Therefore, the wave length 210 
nm was applied in the UV diode-array detector in this HPLC assay. The 
software of Jasco ChromPass version 1.8.6.1 was used to collect and analyse 
the chromatographic data. HPLC conditions are shown below: 
Flow rate = 1.0 mL/min; Injection volume = 20 μL; Run time = 12 mins; 
Detection wave length = 210 nm; Temperature of column oven = 35℃. 
Column maintenance: The HPLC column was conditioned at the flowrate of 1.0 
mL/min every 14 days with: HPLC grade water for 20 minutes; methanol and 
water with 50:50 (v/v) for 20 minutes; 100% methanol for 20 minutes; methanol 
and water 50:50 (v/v) for 20 minutes; HPLC grade water for 20 minutes. In 
addition, daily storage of the column required flushing with HPLC grade water 
for 20 minutes followed by 50:50 methanol : water (v/v) for 20 minutes prior to 
shut down. 
The column and system performance data were calculated with the equations 
referring to EP (European Pharmacopoeia). (162) 
N = 5.54 (
tR
Wh
)
2
 
(N = the number of theoretical plates; tR = retention time; Wh = width of the peak at half-height.) 
As =
W0.05
2d
 
(As = symmetry factor; W0.05 = width of the peak at one twentieth of the peak height; d = 
distance between the perpendicular dropped from the peak maximum and the leading edge of 
the peak at one-twentieth of the peak height.) 
For this HPLC assay, the initial number of theoretical plates was N = 2628, and 
the peak is symmetrical with the As = 1.48. Variation from those performance 
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parameters of ＞10% triggered column re-conditioning in advance of the normal 
2 week schedule. (165) 
2.2.2.2 HPLC method validation 
The HPLC method described in Section 2.2.2.1 was validated monthly over the 
duration of the stability study. Such validations comprised intra- and inter-day 
precision, linearity of response and specificity (stability-indication). All the 
acceptance criteria, except for stability-indication, in this section are referred 
from British Pharmacopoeia (BP) and European Pharmacopoeia (EP). (162) 
(166) 
2.2.2.2.1 Intra-day precision 
Vials of oxaliplatin solution (5 mg/mL) were used to prepare all the samples for 
intra-day precision including one standard solution and six test solutions which 
were diluted volumetrically to the concentration of 20μg/mL. Six test dilutions 
were transferred to sample vials and analysed in triplicate using a HPLC 
method sequence created especially for intra-day precision. The process was 
completed within the same day. Mean values of peak heights and standard 
deviation (RSD) were calculated: 
RSD = (
SD
x
) × 100% 
(SD = standard deviation; x = mean concentration) 
Acceptance criteria: RSD ＜ 2.0%  
2.2.2.2.2 Inter-day precision 
A standard solution of 20 μg/mL was prepared in the first day of the inter-day 
precision from the initial 5 mg/mL oxaliplatin vial. This standard solution was 
stored at 4℃ and used for the whole term of this precision test in 6 consecutive 
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days when 6 test solutions (20 μg/mL) were prepared on each day. Replicated 
test solutions were injected in triplicate each day for 6 days, and from the mean 
peak heights the RSD value was calculated using the equation referred in 
section 2.2.2.2.1. 
Acceptance criteria: RSD ＜ 2.0% 
2.2.2.2.3 Linearity of response 
1 mL of 5 mg/mL oxaliplatin solution was diluted volumetrically with HPLC grade 
water in a grade A volumetric flask (50 mL) to give a 0.1 mg/mL solution. Then 
a series of calibration solutions were prepared by diluting the 0.1 mg/mL 
solution from 0.25, 1.25, 2.5, 5 mL into 25 mL and 8, 12, 18 mL, measured with 
an automatic pipette, into 20 mL separately with HPLC grade water in grade A 
volumetric flasks to give a calibration plot with the oxaliplatin concentrations of 
1.0, 5.0, 10.0, 20.0, 40.0, 60.0 and 90.0 μg/mL. 
This concentration range included the concentrations of samples expected to be 
analysed in this stability study. 
Data of 7 mean peak heights from 3 replicate injections for each solution were 
plotted against concentration and were fitted to a linear relationship using the 
least-squares regression analysis. 
Acceptance criteria: R2 ≥ 0.995; and even distribution of data on regression line 
by visual inspection. 
2.2.2.2.4 Stability-indicating capability validation 
The degradation of oxaliplatin is mainly affected by acid or base catalysed 
nucleophilic substitution or aquation reactions. (126) (127) These mechanisms 
were used in forced degradation studies to demonstrate the stability-indicating 
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attributes of the HPLC assay, in which 5 individual oxaliplatin solutions were 
subjected to different treatments to accelerate oxaliplatin degradation prior to 
HPLC assay. Considering the concentration of the control solution is 20 μg/ mL, 
10 times more concentrated solutions of 200 μg/mL were prepared to be diluted 
10 times later. Five of 10 mL grade A volumetric flasks were used and labelled 
A, B, C, D, E. 1 mL of oxaliplatin solution (200 μg/mL) was pipetted into each 
flask followed with 1 mL 0.1 HCl added in flask B, 1 mL 0.1 NaOH added in 
flask C, 1 mL 3% H2O2 added in flask D and 1 mL HPLC grade water added in 
flask E. Flask A (control) was kept in the fridge at the temperature of 2 - 8℃ and 
all the other flasks were stoppered and incubated in water bath at 50℃ for 30 
minutes. After all the flasks equilibrated to room temperature, 1 mL 0.1 NaOH 
was added into flask B and 1 mL 0.1 HCl into flask C to neutralise the acid and 
alkaline treatments, respectively, and then all 5 flasks were adjusted to volume 
with HPLC grade water. The solutions were then diluted to give a nominal drug 
concentration of 20 μg/mL and analysed in duplicate by the HPLC assay. 
The peak heights of solutions from flasks B – E were then compared against 
those of the control solution (flask A). 
2.2.3 Physical stability tests 
2.2.3.1 Visual appearance 
To examine the physical change in infusion bags, for instance the infusion 
colour and particulate contamination, the infusion bags were viewed against 
both dark and white backgrounds under the normal laboratory lighting 
conditions. In addition, a 5% glucose bag with no added drug was used as a 
comparison against test infusion bags. 
Acceptance criteria: clear, colourless and free from visible particles. 
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2.2.3.2 Sub-visual particle counting 
A LiQuilaz LS200 Particle counter, working with the light-blockage principle, 
was used to quantify 10μm and 25μm diameter particles in samples to provide 
an indication on whether particulate aggregation was occurring during the 
storage of oxaliplatin infusions. (158) Before sampling, the fluid pathway was 
flushed with screen washing liquid for 3 times and another 3 times with distilled 
water. Samples were filled into 7 mL screw-cap polypropylene tubes which had 
been pre-rinsed with water for irrigation (BP) for 5 times in advance. Each 
sample in 5 mL was measured twice and the mean value was recorded. 
Between sampling, the system was flushed 3 times with distilled water for 
irrigation (BP). 
Pharmacopoeia Acceptance criteria: the count of 10 μm particle ≤ 25 units per 
millilitre; the count of 25 μm particle ≤ 3 units per millilitre. However, this test 
was used semi-quantitatively to identify any trends in particulate aggregation at 
each sample point. 
2.2.3.3 pH 
pH variation may indicate significant chemical and physical changes in 
oxaliplatin  infusions. An Orion 5 Star GLP pH meter with combination glass 
electrode was used to measure the pH of samples at each time point. For 
calibrating the pH meter, the reference buffer solutions at pH 4.01 and pH 7.00 
were used each time before sampling. Between samples, distilled water was 
used to rinse the glass electrode, and automatic temperature compensation 
was deployed. 
Acceptance criteria: ± 1.0 pH unit. 
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2.2.3.4 Weight change 
The infusion bags were weighed to assess moisture loss or gain across the 
container wall at each test point using a 4-figure analytical balance. Calculations 
were based on the weight of after sampling from the previous test point and the 
weight recorded immediately prior to the next sampling, and the weight 
differences were recorded. 
Acceptance criteria: ＜ 0.2% variation from the weight of last sample time. 
2.3 Experimental 
2.3.1 Study design 
2.3.1.1 Sequential temperature cycling 
The sequential temperature study design was selected to closely simulate the 
temperatures and conditions experienced by oxaliplatin infusions in 
pharmaceutical storage and clinical practice.  
The infusion bags were divided into 7 groups each containing 3 infusions 
following the time schedule of 1, 3, 7, 14, 28, 56, 84 days which are durations 
for infusion bag storage under refrigerated condition (2 – 8℃). The scheme is 
shown below, where x is the number of days of refrigerated storage. 
Step A: Storage at 2 – 8℃ (refrigerated temperature) for x days and sample 
analysis. 
Step B: Incubation at 25℃  (room temperature) for 24 hours and sample 
analysis (a). 
Step C: Storage at 2 – 8℃ (refrigerated temperature) for 7 days and sample 
analysis (b). 
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If x = 1, 3, 7, 14 days, the process includes Step A and Step B. 
If x = 28, 56, 84 days, the process includes Step A, Step B and Step C.  
This design allows information to be obtained about temperature cycling effects 
with this infusion in the first 2 weeks of the study. If the infusion remains within 
specification during this study phase, it is then possible to proceed to the more 
rigorous cycling which replicates an infusion bag being removed from the 
refrigerator, taken to the clinical treatment area (room temperature) and then 
returned to refrigerated storage to simulate situations such as treatment delays. 
2.3.1.2 Selection of infusion concentrations 
The two concentrations used in this study were 0.2 mg/mL (the lowest) and 0.7 
mg/mL (the highest). As recommended in the SPC, the dosage of oxaliplatin 
should be 85 mg/m2 based on BSA (Body Surface Area). (122) The 
concentration range used in this study was commonly prepared in clinical 
practice to meet typical patients’ BSA ranging from 0.59 m2 to 2.06 m2. (157) In 
addition, higher dosage of oxaliplatin for patients with larger BSA could also be 
covered in this concentration range by preparing oxaliplatin infusions in different 
volume of glucose. 
2.3.2 Preparation of oxaliplatin infusion bags 
All of the oxaliplatin infusions were prepared, sampled and diluted in a Biomat 
AC Class Ⅱ safety cabinet to insure maintenance of asepsis and safe handling 
of cytotoxic drugs. The principles of ‘Good Pharmaceutical Manufacturing 
Practice’ were followed throughout the whole study. 
There were 8 groups of bags in total which comprise the 7 sample groups of 
group A, B, C, D, E, F, G and a spare group H to cover any leaking or damaged 
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infusion bags. For each group, 6 bags were prepared, comprising 3 bags at the 
lowest concentration of 0.2 mg/mL and 3 bags at the higher concentration of 0.7 
mg/mL. 
For 0.2 mg/mL bags, 10 mL oxaliplatin solution concentrate (5 mg/mL) was 
diluted into 250 mL, 5% glucose in a polyolefin bag after 10 mL of the 5% 
glucose solution had been withdrawn from the bag. The bag was then gently 
mixed. For 0.7 mg/mL bags, 35 mL oxaliplatin was diluted into 250 mL, 5% 
glucose in a polyolefin bag following the withdrawal of 35 mL of 5% glucose 
solution. 
After preparation of each group of infusion bags, the infusions were left to stand 
for 30 minutes before sampling (time zero) in order to provide time for complete 
mixing. 
All bags were labelled clearly with the drug name, concentration, group number, 
infusion volume and date of preparation.  
The ‘spare’ group could be used to replace infusions from any group if required. 
Because oxaliplatin is light sensitive (122), each infusion bag was placed in 
light-protecting plastic bags to ensure protection from light throughout the entire 
study.  
2.3.3 Stability determination 
2.3.3.1 Chemical stability  
The HPLC method used for oxaliplatin assay to assess chemical stability was 
validated monthly, which equated to 4 times in total during the whole study. At 
each sample point, 1 mL infusion sample was withdrawn from each infusion bag 
(triplicate bags for each group and concentration) and diluted to the test 
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concentration. Using a previously calibrated automatic pipette, samples were 
transferred into grade A volumetric flasks and adjusted to volume with HPLC 
grade water: 
For 0.2 mg/mL infusions, 1 mL sample was diluted in a 10 mL volumetric flask 
to provide a nominal concentration of 0.02 mg/mL.  
For 0.7 mg/mL infusions, 1 mL sample was diluted in a 20 mL volumetric flask 
to provide a nominal concentration of 0.035 mg/mL. 
The external standard method of HPLC assay was used and the concentration 
of the external standard solution was 0.02 mg/mL. The standard solution of 
oxaliplatin at 0.02 mg/mL was prepared by diluting 0.04 mL, 5 mg/mL oxaliplatin 
concentrate with deionized water into a 10 mL grade A volumetric flask. 
Oxaliplatin concentrate vial used for standard solution preparation was from the 
same batch that was used for preparing oxaliplatin infusion bags for each group. 
Duplicate injections of each test dilution were bracketed with duplicate injections 
of the standard solution. 
Quantification of oxaliplatin in samples: 
The mean peak heights of duplicate sample solutions and the two ‘bracketing’ 
standard chromatograms were recorded for each sample point. The calculation 
equation for the concentration of oxaliplatin in samples is: 
Ct = (
Ht
Hs
) × D × Cs 
(Ht = mean peak height of test sample solution; Hs = mean peak height of standard solution; D = 
dilution factor of test sample solution; Cs = concentration of oxaliplatin in standard solution.) 
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2.3.3.2 Physical stability 
For physical stability tests, two samples of 3 mL and 5 mL volume were 
transferred to sterile polypropylene vials. All of the physical tests were 
processed at each sample point, e.g. t = 0, t = x, t = a and/or t = b (refer to 
Study Design section 2.3.1.1). 
Visual examination was conducted using the method described in Section 
2.2.3.1, and the calculations of weight differences followed the method 
described in Section 2.2.3.4. The pH variation was measured using the method 
in Section 2.2.3.3 and calculated with respect to the initial pH-value from time 
point zero. Sub-visual particle counts were measured with the method 
discussed in Section 2.2.3.2 and the differences were recorded to establish any 
trends in the variation of 10 μm and 25 μm particle counts. 
2.4 Results 
2.4.1 Development and validation of HPLC method for 
oxaliplatin 
A simple, effective HPLC assay was developed and validated for the analysis of 
oxaliplatin in 5% glucose infusions. A low concentration of phosphate buffer 
salts was used in the mobile phase of this method to minimise nucleophilic 
substitution reactions of oxaliplatin when samples were diluted for assay in the 
mobile phase. (109) In addition, the mobile phase was adjusted for a pH of 6.5 
to reduce the possibility of oxaliplatin degradation. (126) (156)  
The method was re-validated monthly in terms of specificity (stability-indication), 
intra-day precision, inter-day precision and linearity of analytical response, 
referred to by the International Conference of Harmonisation (ICH) Harmonised 
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Tripartite Guideline, ‘Validation of analytical Procedures: TEXT AND 
METHODOLOGY Q2(R1). (161)  
During these validations, precision of the method was analysed with the 
calculation of the RSD (relative standard deviation) using the equation stated in 
Section 2.2.2.2.1. As shown in Table 2-1, the RSD of Inter-day precision and 
Intra-day precision were respectively  within the limits of ＜ 2.0%, which means 
the method is repeatable according to British Pharmacopoeia (BP). (161) (166) 
In addition, the calibration plot was shown to be linear over the concentration 
range 1.0 – 90.0 μg/mL (n=7), with the equation of y = 1.0076x + 0.0969 (R2 = 
0.9999) derived from the least-squares regression analysis, and an even 
distribution of the data on the regression line can be inspected visually (Figure 
2-2). Results of the stability-indicating capability validation of the developed 
method are presented in Table 2-2. These results demonstrate that oxaliplatin 
can degrade in the presence of HCl, NaOH or H2O2, and additional peaks 
arising from degradation products were separated from the oxaliplatin analytic 
peak. This HPLC assay for oxaliplatin was therefore considered to be stability 
indicating. 
In summary, all validations of the HPLC assay based on linearity of analytical 
response, intra- and inter- day precision and stability-indicating ability confirmed 
the assay as being suitable for oxaliplatin drug stability studies in 
pharmaceutical infusions. 
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Table 2-1, Inter-day precision data for the HPLC assay of oxaliplatin during 6 
continuous days and intra-day precision data of oxaliplatin assay with 6 triplicate assays  
within one day. 
RSD = Relative Standard Deviation; concentrations are calculated from mean peak heights of triplicate 
injections. Inter-day study: 06/12/12-11/12/12     Intra-day study:  06/12/12 
 
 
Figure 2-2, Oxaliplatin linearity of response plot with analytic concentrations and peak 
heights obtained with the HPLC assay.  
y = 1.0076x + 0.0969 
R² = 0.9999 
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Oxaliplatin Concentration (μg/mL) 
Precision Type 
Injection 
Identifier 
Oxaliplatin 
Concentration 
(μg/mL) 
RSD  
(%, n=6) 
Inter-day 
Precision 
Day1 20.0396 
0.3228 
Day2 20.1009 
Day3 20.1026 
Day4 20.1593 
Day5 19.9728 
Day6 20.0450 
Intra-day 
Precision 
Test1 19.8609 
0.3246 
Test2 19.9851 
Test3 19.9004 
Test4 19.9683 
Test5 20.0396 
Test6 19.9854 
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Table 2-2, Oxaliplatin degradation and the presence/absence of additional peaks in 
stability-indicating validation of the HPLC assay. 
 Flask 
Oxaliplatin 
Conc. 
(μg/mL) 
Treatment 
1 
Treatment 
2 
Treatment 
3 
Oxaliplatin 
Remaining 
Conc. (as % of 
the control) 
Number of 
Additional 
Peak 
Oxaliplatin 
Peak 
Resolution 
A  20 None 
2-8℃, 
control 
None 100 0 N/A 
B 20 
0.1 mL, 
0.1M HCl 
50℃, 30 
min 
1  mL,0.1M 
NaOH 
N/A 1 resolved 
C 20 
1 mL, 0.1M 
NaOH 
50℃, 30 
min 
1  mL, 
0.1M HCl 
28.72 1 resolved 
D 20 
1 mL, 
3%H2O2 
50℃, 30 
min 
None N/A 2 resolved 
E 20 
1 mL, 
Water 
50℃, 30 
min 
None 96.61 0 N/A 
Flask A is the control solution in this validation and the results from other flasks were compared with 
flask A. N/A = not applicable. 
2.4.2 Results from stability studies of oxaliplatin infusions 
Chemical Stability data for oxaliplatin infusions (0.2 mg/mL and 0.7 mg/mL) in 
250 mL 5% glucose bags under the sequential-temperature cycling storage 
condition have been calculated based on peak heights, and are presented in 
Table 2-3.  
Results of sub-visual particle counts measured at 10μm and 25μm diameter by 
per millilitre are shown in Table 2-4.  
The changes of pH-value and bag weight are both recorded in Table 2-5, where 
the data are compared to the initial values from T0. 
Each table contains data from 7 groups of Group A – G, and all infusions 
remained clear and colourless and free from visible particles throughout the 
whole course of this study. 
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Table 2-3, Chemical stability of oxaliplatin infusions (0.2 mg/mL and 0.7 mg/mL) under the sequential-temperature storage conditions (Group A – G), 
showing the percentages of the remaining oxaliplatin with respect to the initial concentrations at T0. 
Infusion Group 
Nominal 
oxaliplatin  
Conc. (mg/mL) 
Conc. T0 
(mg/mL) 
Conc. Tx Relative 
to T0 [(SD)%] 
Conc. Tx+a Relative to 
T0 [(SD)%] 
Conc. Tx+a+b Relative to 
T0 [(SD)%] 
Group A (x=1) 
0.2 0.1840 98.57 (1.0) 98.38 (0.3) 101.80 (0.5) 
0.7 0.6490 98.92 (0.2) 97.97 (0.5) 102.04 (0.04) 
Group B (x=3) 
0.2 0.1888 100.06 (1.3) 99.17 (0.6) 99.64 (0.9) 
0.7 0.6666 100.02 (0.7) 99.61 (0.7) 100.08 (1.1) 
Group C (x=7) 
0.2 0.1902 98.58 (0.3) 98.09 (0.9) 99.48 (0.5) 
0.7 0.6642 98.63 (0.2) 98.80 (0.4) 100.15 (0.4) 
Group D (x=14) 
0.2 0.1892 100.55 (0.4) 99.30 (0.2) 97.61 (0.5) 
0.7 0.6642 100.04 (0.3) 99.65 (1.0) 98.32 (0.5) 
Group E (x=28) 
0.2 0.1914 102.12 (1.7) 97.89 (0.7) 100.21 (0.4) 
0.7 0.6745 101.46 (0.07) 97.35 (0.05) 101.38 (0.3) 
Group F (x=56) 
0.2 0.1922 96.58 (0.2) 98.98 (0.6) 98.39 (0.8) 
0.7 0.6637 97.23 (0.9) 99.31 (0.4) 100.13 (1.2) 
Group G (x=84) 
0.2 0.1868 103.03 (0.9) 99.73 (0.9) 99.93 (0.8) 
0.7 0.6566 99.80 (1.6) 99.65 (1.7) 98.64 (0.9) 
Conc. = concentration; SD = Standard deviation; T0 = Time zero; all the values are average value. Sequential-temperature cycling conditions for each group:  x = days for storage 
at 2 – 8℃; a = 24 hours at room temperature; b = 7 days storage at 2 – 8℃. 
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Table 2-4, Sub-visual particle counts (per mL) of oxaliplatin infusions (0.2 mg/mL and 0.7 mg/mL) at 10 μm and 25 μm under the sequential-
temperature storage conditions (Group A – G). 
Infusion Group 
Nominal 
oxaliplatin  
Conc. 
(mg/mL) 
Particle Counts T0 
(per mL) 
Particle Counts Tx 
(per mL) 
Particle Counts  Tx+a 
(per mL) 
Particle Counts  Tx+a+b 
(per mL) 
10 μm 25 μm 10 μm 25 μm 10 μm 25 μm 10 μm 25 μm 
Group A (x=1) 
0.2 3.7 0.0 2.2 0.0 15.5 0.0 1.8 0.0 
0.7 9.3 0.0 3.0 0.0 1.2 0.0 1.2 0.0 
Group B (x=3) 
0.2 4.5 0.0 3.2 0.2 2.2 0.0 2.3 0.0 
0.7 5.7 0.0 1.0 0.0 3.5 0.0 1.2 0.0 
Group C (x=7) 
0.2 2.2 0.0 2.3 0.0 1.7 0.0 2.7 0.0 
0.7 6.2 0.0 2.5 0.2 1.7 0.0 3.2 0.0 
Group D (x=14) 
0.2 2.5 0.2 2.2 0.0 2.5 0.2 3.8 0.0 
0.7 15.5 0.0 1.0 0.0 2.7 0.0 3.3 0.0 
Group E (x=28) 
0.2 4.8 0.0 4.2 0.2 5.2 0.2 6.7 0.0 
0.7 5.2 0.0 6.2 0.5 5.2 0.3 10.0 0.2 
Group F (x=56) 
0.2 3.2 0.0 6.5 0.2 4.8 0.0 5.3 0.2 
0.7 3.0 0.2 3.2 0.0 4.0 0.2 3.5 0.0 
Group G (x=84) 
0.2 3.5 0.0 3.8 0.0 4.3 0.0 8.0 0.5 
0.7 7.5 0.0 3.3 0.0 4.8 0.0 5.0 0.0 
Conc. = concentration; SD = Standard deviation; T0 = Time zero; all the values are mean values, n=3. Sequential-temperature cycling conditions for each group:  x = days for 
storage at 2 – 8℃; a = 24 hours at room temperature; b = 7 days storage at 2 – 8℃. 
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Table 2-5, The pH-value and weight of oxaliplatin infusions (0.2 mg/mL and 0.7 mg/mL) and the percentage variations in pH compared to the initial 
value (T0) under the sequential-temperature storage conditions (Group A – G). 
Infusion 
Group 
Nominal 
oxaliplatin  
Conc. 
(mg/mL) 
T0 Tx Tx+a Tx+a+b 
Weight 
Change 
in Tx (g) 
Weight 
Change 
in Tx+a (g) 
Weight 
Change in 
Tx+a+b (g) 
pH 
pH 
Difference 
Relative to 
Initial T0 (%) 
pH 
pH 
Difference 
Relative to 
Initial T0 (%) 
pH 
pH 
Difference 
Relative to 
Initial T0 (%) 
pH 
pH 
Difference 
Relative to 
Initial T0 (%) 
Group A 
(x=1) 
0.2 4.38 0.0000 4.42 0.9130 4.39 0.2280 4.41 0.6850 0.0000 0.0000 0.0667 
0.7 4.41 0.0000 4.47 1.3610 4.43 0.4540 4.47 1.3610 0.0333 0.0333 0.0000 
Group B 
(x=3) 
0.2 4.28 0.0000 4.36 1.8690 4.39 2.5700 4.38 2.3360 0.0333 0.1000 0.0670 
0.7 4.36 0.0000 4.45 2.0640 4.46 2.2940 4.46 2.2940 0.1000 0.0667 0.0000 
Group C 
(x=7) 
0.2 4.27 0.0000 4.41 3.2790 4.43 3.7470 4.42 3.5130 0.0667 0.0000 0.0667 
0.7 4.33 0.0000 4.47 3.2333 4.48 3.4642 4.46 3.0020 0.0667 0.0000 0.0667 
Group D 
(x=14) 
0.2 4.38 0.0000 4.36 0.4566 4.36 0.4566 4.39 0.2283 0.0000 0.0333 0.1000 
0.7 4.44 0.0000 4.43 0.2252 4.43 0.3352 4.46 0.4505 0.0333 0.0000 0.0333 
Group E 
(x=28) 
0.2 4.40 0.0000 4.43 0.6818 4.45 1.1364 4.42 0.4545 0.1000 0.0667 0.1000 
0.7 4.45 0.0000 4.48 0.6742 4.50 1.1236 4.47 0.4494 0.1000 0.1000 0.1000 
Group F 
(x=56) 
0.2 4.40 0.0000 4.39 0.2273 4.42 0.4545 4.39 0.2273 0.1667 0.0667 0.1000 
0.7 4.44 0.0000 4.42 0.4505 4.45 0.2252 4.43 0.2252 0.1333 0.0000 0.0333 
Group G 
(x=84) 
0.2 4.40 0.0000 4.38 0.4550 4.40 0.0000 4.40 0.0000 0.2000 0.0000 0.0333 
0.7 4.44 0.0000 4.39 1.1260 4.43 0.2250 4.43 0.2250 0.1667 0.0333 0.1000 
Conc. = concentration; SD = Standard deviation; T0 = Time zero; all the values are average value. Sequential-temperature cycling conditions for each group: x = days for storage 
at 2 – 8℃; a = 24 hours at room temperature; b = 7 days storage at 2 – 8℃. 
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2.5 Discussion 
2.5.1 Analysis of results on chemical stability 
Specific monographs for oxaliplatin infusions are not included in official 
documents, such as European Pharmacopoeia (EP) or British Pharmacopoeia 
(BP). However, in the Revision Bulletin of The United States Pharmacopoeia 
the oxaliplatin injection is referred to and it is required that these injections 
should contain NLT (not less than) 90.0% and NMT (not more than) 110.0% of 
the labelled dosage of oxaliplatin. (167) The ± 10% acceptance criterion has 
also been widely used in a majority of stability studies of cytotoxic drugs in 
Europe. (154) (168) Recently, however, there has been a growing consensus 
that the practical stability limits should be defined by taking into account certain 
factors such as the therapeutic index of the drug, its clinical use, safety and 
potency and its pharmacodynamics/pharmacokinetic variability. (149) By this 
criteria it has been recommended that the stability limit for anticancer drugs with 
low therapeutic indices should be restricted to ± 5%, (149) and for this reason 
the acceptance criteria of 95% - 105% was adopted for oxaliplatin concentration 
in this study. 
Table 2-3, which shows the experimentally derived chemical stability data of 
oxaliplatin infusions from this study, demonstrates that the drug concentrations 
did not vary by more than ± 4% of the initial concentrations at any of the sample 
points, which meets the ± 5% acceptance limit. On the other hand, these 
accepted concentration changes suggest no significant absorption of oxaliplatin 
onto the container walls, which is another main potential cause of drug loss 
occurring independently and/or in addition to the drug degradation. 
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In addition to the stability of oxaliplatin itself, the degradation products and 
metabolites of oxaliplatin must be considered in order to ensure the safe use of 
drug infusions. For instance, oxalate is one of the main degradation products of 
oxaliplatin, and is also a calcium chelator which may partly contribute to the 
neurotoxicity of oxaliplatin. (147) From Figure 2-1 showing the degradation of 
oxaliplatin, it could be deduced that 1 mol oxaliplatin can liberate 1 mol oxalate 
if fully degraded. Oxalate generally exists in several different forms such as 
oxalic acid (Figure 2-3), and as oxalate salts such as sodium and calcium 
oxalate. Because the oxalic acid is the most basic form among this group, it can 
be used as an example in this study. (126) (127) (147) Hypothesis of the worst 
case permitted by the ± 5% degradation limits imposed above means 5% of 
oxaliplatin totally degrade into oxalic acid, and the equation below can be used 
to calculate the content mass of oxalic acid. (162) (166) 
M =
m
n
 
(M = the molar mass; m = the mass; n = the number of moles) 
For the infusion bags in high concentration of 0.7 mg/mL and low concentration 
of 0.2 mg/mL, a 5% loss of oxaliplatin by degradation would produce oxalic acid 
of 1.9825 mg and 0.5663 mg respectively in each dose. Acute toxicity studies 
indicate that oxalic acid is of moderate to high toxicity by the oral route in 
mammalian species, and the LD50 (lethal dose to kill 50% of test population) 
orally in rats is reported as 375 mg/kg of body weight. (169) (170) The data for 
oxalic acid toxicity to human beings are insufficient, but the LDL0 (minimal dose 
found to be lethal) orally in human has been documented as 71 mg/kg. (170) 
The overall average BSA of patients in UK is 1.79 m2 which requires an 
oxaliplatin dose of 152.15 mg based on 85 mg/m2 standard dose, and the 
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degradation of 5% of this dosage would give at most 2.0 mg oxalic acid. This is 
well within the limit range of LDL0 mentioned above, although the limits refer to 
the oral route whereas oxaliplatin is administered by the IV route. (122) (157) 
With the reservation that the bioavailability of oral oxalate will be lower than the 
IV route, the acceptance criteria of oxaliplatin stability studies of ± 5% can be 
justified. Moreover no additional HPLC peaks contributed by other degradation 
species were apparent in this study. However, the possibility of other oxaliplatin 
degradation products cannot be ruled out as some species may not be detected 
by the UV detection system in this HPLC assay. (162) (166)   
 
Figure 2-3, Chemical structure formula of oxalic acid (ethanedioic acid).  
The current lack of data provided by pharmaceutical companies and difficulties 
in retrieving the experimental data from industry are a critical issue for stability 
forecasting of cytotoxic drug preparations in current practice. (171) For 
oxaliplatin, there are only few published studies available in the public domain 
concern with chemical and physical stability, and SPCs (Summary of Product 
Characteristics) provided by different companies show a high variation in shelf 
life statements. (172) The most recent SPC available gives a shelf-life for 
oxaliplatin infusions in 5% glucose of 48 hours at 2 – 8℃ and 24 hours at 25℃. 
(122) It is likely however, that the short shelf-lives supported by the 
pharmaceutical industry are associated more with concerns about sterility of 
aseptically manipulated infusions than physical and chemical stability. Of the 
reports currently available (see Section 2.1.1 of Introduction), the longest period 
of oxaliplatin infusion stability reported was 90 days at temperature of 4℃ or 
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25℃ with a drug concentration of 0.25 mg/mL. (151) All these studies explored 
exposure to light and it was demonstrated that exposure to light did not 
significantly affect the stability of oxaliplatin infusions. (151) (154) (168) (173) 
Several limitations have been found with these previous stability studies on 
oxaliplatin infusions. For example, only one study considered the oxaliplatin 
dosage based on the recommended BSA calculation of 85 mg/m2, while the 
concentrations or concentration ranges selected by other studies were not 
evidence-based. (154) (173) The acceptance criteria for oxaliplatin 
concentrations applied in previous studies were all 90% - 110%, which is not 
appropriate for a cytotoxic drug with narrow therapeutic index, as discussed 
previously.  
Additionally, the various temperatures experienced by oxaliplatin infusions in 
clinical practice and pharmaceutical storage, and the transfer of infusions 
between these different conditions were not considered in these studies. (151) 
(154) (168) (173) Unlike this study (Refer to Table 2-3) previous stability studies 
of oxaliplatin infusions fail to meet the current requirements of clinical practice 
and dose-banding. (8) (149) This study, on the other hand, included a rigorously 
derived concentration range of 0.2 mg/mL to 0.7 mg/mL based on the licenced 
BSA dose (122), an acceptance criteria of 95 – 105% for oxaliplatin 
concentration concordant with current thinking on cytotoxic drug stability, and 
finally the use of a sequential temperature design which is distinct from the 
other studies on the stability of oxaliplatin infusions. 
This study is also distinct from others in that it provides evidence that infusion 
bags can remain stable when exposed to room temperature (25℃) for 24 hours 
and returned to a refrigerator of 2 – 8℃ for further 7 days. (159) Because the 
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sequential-temperature design provides definitive physical and chemical 
stability data under the additive storage conditions at 2 – 8℃ and 25℃, and also 
accounts for the effects of temperature cycling, it is possible to assign shelf-
lives that have the potential to reduce drug wastage. The study design, which 
incorporates triplicate infusion evaluation at each temperature/concentration 
combination, improves rigour over previous studies. 
2.5.2 Analysis of results on physical stability 
2.5.2.1 pH change 
pH is one of the most important characteristics that could influence the stability 
of oxaliplatin infusions in several ways as shown below. 
Firstly, the ionisation, and hence solubility, of most substances is affected by 
the pH of the solution, which means not only could the physical stability of 
oxaliplatin be affected, but the pH change could also affect other components of 
the infusion. (162) (174) A pH change may therefore affect the efficacy and 
safety of infusions as well as its suitability for intravenous injection. (122) (175)  
Extremes of pH are associated with vascular pain and phlebitis, although other 
factors are also implicated including osmotic pressure of the infusion, size of the 
vein used, size and material of the catheter and infusion periods. (176) 
According to a previous study, the optimal infusion pH for the peripheral vein is 
about 6.5 units. (177) The pH of oxaliplatin infusions in the range of 4.27 – 4.50 
are shown in the results section (Table 2-5), it is considered that this low pH 
partly causes the negative side effect on patients reported in clinical practice. 
(176) (177) Therefore any further decrease in pH is not desirable. 
In addition, pH is one of the factors contributing to the degradation rate of 
oxaliplatin in aqueous media. (127) It has been established that oxaliplatin is 
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normally transformed by water and nucleophiles such as Cl
－
 and HCO3
－
, while 
the main source for the pH variation is CO2 diffusion through the wall of the 
plastic bag and subsequent acidification producing HCO3
－
. (127) (149) 
Therefore, the pH variation caused by CO2 contamination would increase the 
rate of oxaliplatin degradation and potentially influence the stability of the 
infusions. 
Therefore the pH of oxaliplatin infusions should be monitored carefully and 
reported throughout the study period, and its variations must be properly 
interpreted. (149) 
As shown in Table 2-3, pH-values in this study varied slightly at each time point, 
while the maximum pH deviations of the infusions of 0.2 mg/mL and 0.7 mg/mL 
were 0.16 and 0.15 units, respectively, from the initial values. Because these 
differences are much lower than the pre-defined acceptance criteria of ± 1.0 
unit, the pH variations observed in this study were considered to be of no 
pharmaceutical or clinical significance. (162) (166) 
Furthermore, there could be several reasons for such minor changes in pH, 
such as the initial pH of oxaliplatin concentrate (normal pH range is 4.0 – 7.0) 
(122) and 5% glucose infusions (pH range is 3.5 – 6.5, BP) (166); and finally 
dissolved CO2 from air in the infusion bag could also have a small effect on pH. 
In previous stability studies on oxaliplatin infusions physical stability, physical 
stability tests were limited to only visual appearance and pH measurement. 
(154) (168) However, sub-visual particulate counts and weight change 
monitoring should also be applied in stability studies to ensure physical stability 
and water-transfer across the container walls are monitored effectively. (149) 
(161) Without this, it would be possible to miss particulate aggregation at the 
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sub-visual level and to overlook water loss from the infusion that could mask 
drug loss due to chemical degradation. 
2.5.2.2 Weight change 
Variations in the concentration of oxaliplatin could also occur as a result of 
weight changes due to the diffusion of water through the plastic bag wall. (149) 
Weight changes observed in this study, shown in Table 2-5, did not exceeded 
0.0750%, which implies that the oxaliplatin concentration was not significantly 
influenced by the loss or gain of water. (149) It is important to test for the 
moisture loss from infusion bags, since significant permeation (e.g. ≥ 2%) and 
water loss from the infusion could mask the loss of oxaliplatin occurring as a 
result of drug degradation. 
2.5.2.3 Visible appearance and particulate counts 
Both visual and sub-visual particle characterisation always has significance in 
stability studies, which should be well defined and standardized. (149) (163) 
Such particulate examinations are crucial to prevent potential adverse effects 
from particle contamination. (149) (163) For example, particles can cause 
toxicity to specific tissues or organs; or distribute via blood and block the blood 
flow causing an embolism if they reach a certain size. (163) Another severe 
effect is that particles could be identified by the immune system as foreign 
materials, which could result in an immune reaction causing secondary effects. 
(163) Furthermore, the particulate nature of the drug can affect its 
bioavailability, solubility, filterability, all of which may result in an unfavourable 
clinical outcome. (163) 
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In this study, the particle examination was divided into two sections, visual 
particle inspection and sub-visual particle evaluation, each of which was 
determined by a different technique. (158) (178) 
The visual test can detect formation of visual particles and also any change to 
the initial colour of solutions. (149) (178) In this study, the infusion bags were 
examined against both black and white backgrounds under normal laboratory 
lighting, enabling a visual qualitative assessment to be achieved. (162) (178) 
Any colour changes would be easily observed because of the colourless and 
transparent characteristics of oxaliplatin infusions. (162) As shown in the result 
section (Section 2.4.2), all the infusion solutions remained clear and colourless 
with no visible particles throughout this study period. 
With no visible changes apparent, micro-precipitates can still appear, and by 
increasing in size with time could eventually induce the formation of visible 
precipitates. (149) Therefore, a sub-visual particulate evaluation is required for 
stability studies. Using the method from pharmacopoeia, a sub-visual particle 
counter based on light obscuration was used to count sub-visual particles of 10 
µm and 25 µm diameter in this study. (162) (178) In accordance with the 
International Pharmacopoeia requirements, the sub-visual particulate count 
(Table 4) was expressed as counts per millilitre for oxaliplatin infusion bags with 
nominal volume of 250  mL, and remained well below the criteria of ≤ 25 units 
per millilitre for 10 μm particles and ≤ 3 units per millilitre for 25 μm particles. 
(162) (178) These results indicated that there is no significant sub-visual particle 
contamination in oxaliplatin infusions with time. Because there was no marked 
increase in the counts for the larger 25 µm particles over time, there was no 
pharmaceutically significant particle aggregation. (149) This was important to 
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establish as the temperature cycling used in this sequential-temperature design 
could have induced particulate growth. (179) 
2.6 Limitations, further work and clinical application 
2.6.1 Limitations  
The range of oxaliplatin concentrations used in this study was 0.2 mg/mL to 0.7 
mg/mL which has been calculated from the average patients’ BSA in the range 
of 0.59 – 2.06 m2 and the oxaliplatin dose of 85 mg/m2 provided on SPC. (122) 
(157) This range of oxaliplatin concentrations will cover the majority of patients 
but the requirements of patients with extreme BSA values were not considered 
in this study. (157) In clinical practice, such extreme cases are normally 
excluded from dose-banding schemes and doses are provided on a patient-
specific basis. 
The stability duration of oxaliplatin infusions was limited to 92 days through all 
the temperature cycles in this study with the design of sequential-temperature 
cycling. There is the possibility that longer stability duration of oxaliplatin 
infusions might be required, while the result of this study is limited to satisfy the 
demand. Nevertheless, this 92 days shelf-life of oxaliplatin infusion is sufficient 
for clinical application, and it also could facilitate a ‘dose-banding’ scheme 
which ideally requires 3 months of infusion stability in storage. (8) Therefore, the 
design and duration of this study could be considered reasonable. In the UK, 
the MHRA regulatory inspectorate are reluctant to approve infusion shelf-lives 
for aseptic products beyond 3 months because of microbiological and container 
integrity concerns. (180)  
According to EP (European Pharmacopeia), plastic containers for parenteral 
infusions are manufactured from polymers, and the most commonly used 
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polymers are polyethylene, polypropylene and polyvinyl chloride (PVC). (162)  
Considering the limited experimental conditions (e.g. limited storage space), 
there was only one type of infusion container used in this study, which was 
polyolefin, a newer plastic from Fresenius Kabi, UK, which does not leach 
plasticisers into the infusion. (181) However, this modern material is now widely 
adopted into clinical practice and polyolefin is seen as the ‘gold-standard’ for 
infusion containers. The data reported in this study could not be extrapolated to 
containers constructed of other materials without additional experimental work 
to certify that there is no effect on either chemical or physical stability of the 
infusion. 
Additionally, oxaliplatin concentrate of 5 mg/mL from Fresenius Kabi Oncology 
Plc. was the only formulation and brand used in this study. There are two 
different formulations of oxaliplatin manufactured from different suppliers, which 
are lyophilised powder and concentrate injection. (122) (182) Considering 
oxaliplatin concentrate is widely used to be diluted with glucose in clinical 
practice, this formulation was selected in this study while the other brands and 
formulations of oxaliplatin were not included. The use of cytotoxic drug 
formulations presented as lyophilised powders is declining on the basis of the 
additional reconstitutions required and perceived additional risks of cytotoxic 
exposure to pharmacy staff. 
2.6.2 Potential avenues for further investigation  
This study has not involved the validation of long-term storage of oxaliplatin 
infusions at ambient temperature of 25 ℃ . Considering pharmaceutically 
practical conditions with limited refrigerated storage space, drug infusions could 
be prepared and stored at room temperature, therefore the duration of infusion 
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stability under this condition might be useful. (182) (173) However, for most 
aseptically-prepared infusions refrigerated storage is preferred to limit the 
proliferation of any inadvertent microbiological contamination. To realistically 
replicate the various practical situations, additional experimental stressed-
conditions studies could be included, such as exposure to light for a short time 
period, accidental freezing, or exceeding temperature limits for a few hours. 
(149) Moreover, it has been shown in this study that ‘in-use’ infusion bags could 
be returned to the refrigerated temperature (2 – 8℃) and stored for a further 7 
days while maintaining stability. This period could potentially be extended within 
the experiment design to offer more information for hospitals or clinical 
departments on stability in cases where treatment delays are longer than 7 days, 
and further increase the flexibility of oxaliplatin infusions use. (36) 
2.6.3 Clinical application  
In addition to extending the shelf-life of oxaliplatin infusions in 5% w/v glucose 
to 84 days, this study also demonstrated that it is safe to use these infusions 
which have been placed at 25℃ and returned in refrigerator for another 7 days. 
The conclusion from the sequential-temperature cycling included in this study 
could avoid unnecessary wastage of re-issued drugs in some situations, such 
as the unexpected failure of a refrigerator, bags stored at room temperature or 
the return of unused bags from the clinic because of treatment delays. (149) 
(159) The range of concentrations in this study (Section 3.1.2) was selected 
carefully based on the BSA dose of 85 mg/m2, which would include virtually all 
requirements for cancer patients. (122) In this case, the data from this study 
could facilitate a ‘dose-banding’ scheme. This approach is predicated on long 
term chemical and physical infusion stability to allow anticancer drug infusions 
to be prepared in advance. (13)  
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However, as the microbiological quality depends on the individual working and 
handling practice, the application of the extended shelf-lives requires rigorously 
controlled and validated pharmacy aseptic units accredited for the preparation 
of oxaliplatin infusions. (162) (173) Thus, with the secure knowledge of the 
production environment and appropriate storage conditions, all the results from 
this study could be applied for clinical practice by adopting rigorous preparation 
procedures and using appropriately trained staff in the preparation process. 
(149) 
2.7 Conclusion 
Oxaliplatin infusions at 0.2 mg/mL and 0.7 mg/mL concentrations in 250 mL 5% 
glucose contained in polyolefin bags were chemically and physically stable for 
at least 84 days at 2 – 8℃. For the temperature sequential section, oxaliplatin 
infusions were also stable under the further storage at 25℃ for 24 hours and the 
following 7 days at 2 – 8℃ in a refrigerator. All the bags were stored with 
protection from light. This result indicated a long-term stability period for 
oxaliplatin infusions of concentrations between 0.2 and 0.7 mg/ mL, which 
allows the pre-preparation of oxaliplatin infusions for dose-banding schemes. 
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Chapter 3: Studies of oxalate formation in oxaliplatin 
solutions  
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3.1 Introduction 
3.1.1 Background 
3.1.1.1 Oxalate and neurotoxicity from oxaliplatin 
As a third generation of platinum compound, oxaliplatin can be used for 
treatment against some tumours which exhibit primary resistance to cisplatin 
and carboplatin, which are from the same cytotoxic drug group. (123) Even 
though oxaliplatin has a more tolerable side-effect profile compared with 
cisplatin and carboplatin, sensory neurotoxicity is the main dose-limiting toxicity 
in oxaliplatin chemotherapies. (3) (146)  
About 85 – 95% patients with oxaliplatin treatment suffer from the sensory 
neuropathy during and/or shortly after the infusion, which might be triggered 
and aggravated by exposure to low temperatures. (12) (109) The particular 
neurosensory toxicity caused by oxaliplatin is acute and rapidly reversible, 
which can be characterized by paraesthesia and dysesthesia of hands, feet and 
perioral area, and jaw tightness. (12) (109) The chronic neuropathy from 
oxaliplatin (which also occurs with cisplatin) is believed to be a cumulative effect, 
which may increase in both duration and severity with repeated administration 
of oxaliplatin infusions. (12) (109) (183) These symptoms can be reversed 
within 4 – 6 months following completion or discontinuation of treatment, without 
any permanent impairment of sensory functions in patients. (109) (146) Thereby 
the circadian-guided dosing of oxaliplatin is potentially effective in limiting the 
neurological toxicities. (109) (146) Compared to the continuous infusion 
treatment, the dosing schedule based on circadian rhythm could also increase 
the anti-tumour activity of oxaliplatin. (109)  
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Mechanisms for both types of neurotoxicity of oxaliplatin are still not clear, but 
previous studies have been conducted on the basis of various hypotheses in 
the literature. (109) (147) (183) Those hypotheses were all based on the 
degradation process of oxaliplatin in blood circulation of patient bodies. 
After administration to patients, one third of the oxaliplatin dose binds 
irreversibly to erythrocytes and one third can form complexes with albumin and 
other plasma proteins. (124) The remaining free fraction of oxaliplatin normally 
undergoes non-enzymatic biotransformation and the oxalate ligand of oxaliplatin 
can be displaced by non-enzymatic hydrolysis. (109) (Shown in Figure 3-1) 
Degradation products of oxaliplatin, Pt-DACH (R-diamino-
cyclohexane platinum) and oxalate, subsequently react with endogenous 
chloride and water to form monochloro, dichloro and diaquo complexes with 
chloride glutathione, methionine and cysteine. (109) (124) As a result, oxalate 
complexes are the main degradation products from the initial non-enzymic 
transformation of oxaliplatin in vivo. 
Two hypotheses aimed at chronic neuropathy and transient acute neurotoxicity 
have been widely considered for oxaliplatin neurotoxicity, which focus on 
platinum-DNA interactions and ion-channel involvement. (147) (183) In both 
cases, the major damage sites of the neurotoxicity from oxaliplatin are 
peripheral sensory neurons and dorsal root ganglia (DRG) cells. (146) 
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Figure 3-1, The initial non-enzymatic hydrolysis biotransformation of oxaliplatin in vivo. 
[A: oxaliplatin; B: the protonated oxalate monodentate intermediate; C: the de-
protonated oxalate monodentate intermediate; D: dehydrated oxaliplatin complex; E: 
oxalate.] 
The cumulative chronic neurotoxicity of oxaliplatin also appears with other 
platinum drugs, such as cisplatin, and might be correlated with the Pt-DNA 
binding. (146) A previous study showed that compared with cisplatin oxaliplatin 
produced fewer Pt–DNA adducts and was less neurotoxic to DRG neurons in 
vitro. (146) The inhibition to rRNA synthesis by oxaliplatin was indicated as a 
mechanism of damage of sensory nerve nucleoli, which was recognised by 
measuring the nucleolar shrinkage and disintegration. (183) Another hypothesis 
arising from previous cisplatin studies indicated that the accumulation of heavy 
metal (Pt) in neurons could influence on their torpidity. (147)    
The acute, but rapidly reversible neuropathy is specifically associated with 
oxaliplatin therapies rather than other cytotoxic drugs in the platinum group, and 
it is believed to be related to ion-channels located in cellular membrane. (12) 
(147) The acute neurosensory symptoms caused by oxaliplatin are similar to 
the side-effect of some drugs/toxins that react with neuronal or muscular ion-
channels. (12) (147) In this case, it is suspected that the neurotoxicity is caused 
by the interaction of oxaliplatin and one or more channel subtypes. (12) The 
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acute neurological symptoms might also reflect the hyper-excitability of 
peripheral nerves resulted from the transient channelopathy induced by 
oxaliplatin. (12) According to the degradation process of oxaliplatin (refer to 
Figure 3-1), the voltage-gated ion channels could be interfered with by its 
degradation products, such as oxalate and the charged chloride complex. (145) 
It has been proven that the monochloro- complex of oxaliplatin has no general 
surface-charge effect on those ion channels, which means oxalate, as the main 
degradation product of oxaliplatin, could be the most significant cause of the 
neurotoxicity. (145)  
Oxalate produced from oxaliplatin might accumulate and interfere with 
intracellular divalent cation, such as calcium (Ca2+) and/or magnesium (Mg2+), 
and break the intracellular homeostasis within the neuronal systems. (147) 
Oxalate is a well-known calcium chelator, which could disrupt the voltage-gated 
sodium ion (Na+) channels, especially Ca2+-dependant Na+ channels, via Ca2+ 
chelation in sensory neurons. (12) (109) Then the disordered Na+ channel might 
induce the acute toxicity to neuron cells and subsequently result in neuropathy. 
(109)  
If it could be verified that the intracellular Ca2+/Mg2+ reduces in neuro systems of 
the patient who suffers neurotoxicity from oxaliplatin chemotherapy, then the 
possibility of oxalate being the main cause of neurotoxicity should be 
considered. A previous study demonstrated that during the oxaliplatin 
chemotherapy for colorectal cancer, the use of additional infusions containing 
calcium (Ca2+) and magnesium (Mg2+) ions could reduce the incidence of 
sensory neurotoxicity without any adverse influence on tumour response. (109) 
Therefore, oxalate might be involved in the neurotoxicity of oxaliplatin through 
interference with the voltage-gated sodium channel.  
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The hypotheses mentioned above are all subject to a lack of evidence to 
indicate the clear mechanism of neurotoxicity associated with oxaliplatin 
treatment. However, the association between oxalate and neurotoxicity is one of 
the more plausible theories, and so this study examined the prevalence of 
oxalate derived from oxaliplatin in both, oxaliplatin infusions and human plasma.  
3.1.1.2 Oxalate toxicity to human body 
Oxalate, as shown in Figure 3-2, is a dianion with formula of C2O4
2- , which has 
been found in a wide range of plants and high consumption foods. (184)  
Oxalate is also an important metabolite in the human body. (185) For humans, 
the intake of oxalate in regular daily diet is within the average range of 130 mg – 
152 mg per day. However it is thought that only about 50 mg oxalate can be 
absorbed by the human body. (186) The amount of oxalate in animals and 
humans originates from two sources: i) metabolic end-product produced largely 
in the liver; ii) absorbed directly from food in the gastrointestinal tract (GIT). 
(186) As shown in Figure 3-3, oxalate in blood circulation is mainly produced 
metabolically in the liver (85% - 90%), whereas food provides only 2% - 10% of 
total oxalate in blood. Most oxalate from food turns into an energy source by the 
intestinal bacterial or be eliminated in faeces. (186) The main pathway for 
oxalate elimination is through the kidney, where 90% - 95% of blood oxalate is 
removed from organism and excrete in urine. (186) The remaining 5% - 10% 
oxalate is secreted in the intestine. (186)  
 
Figure 3-2, Chemical structure of oxalate anion. 
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Figure 3-3, Pathways of oxalate in animal/human body. Oxalate in blood circulation is 
generated from two sources: internal metabolism and food absorption. The excretion of 
blood oxalate is mainly through kidney, while the un-absorbed oxalate in food is mostly 
used to provide energy for the body. 
As a regular compound in general diet, overdosed oxalate could cause kidney 
stones by chelation with calcium ions (Ca2+). (187) In human/animal body, 
oxalate can rapidly form crystals with calcium ions and produce calcium oxalate 
(CaOx), which is the most abundant compound in the formation of kidney 
stones. (186) (188) Kidney stones are the combination of protein complexes 
and crystal formations, including calcium oxalate (CaOx), calcium phosphate 
(CaP), purines and other uncommon stones. (186) (187) In more than 80% 
cases of urolithiasis, calcium oxalate is the predominant compound in kidney 
stones. (186) (188) In kidney, crystallisation occurs in several stages including 
solid phase precipitations, growth, aggregation and stone formation. (186) 
However, these kidney stones could only happen under the abnormal 
conditions in human body, such as damage to the integrity of tubular epithelium 
or higher tubular oxalate concentration. (186) (188) Furthermore, oxalate also 
has proven  toxicity to renal tubular cells at high concentrations of ≥ 5 mmol/L. 
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(188) Therefore, the physiological concentration of oxalate in the body (plasma 
and urine samples) is a key factor to indicate and prevent renal toxicity and 
kidney stones. 
For a healthy human person, the physiological concentration of oxalate from 
urine samples is within the range of ≤ 1mmol/L (188) (189) and the plasma 
oxalate is normally lower at concentrations of 1 – 3 µmol/L. (190) (191) 
However, after oxaliplatin administration, the plasma oxalate in patients could 
be increased by the oxalate derived from oxaliplatin degradation.  
In this study, the amount of oxalate produced in oxaliplatin infusions was 
determined, together with a simulation of the non-enzymic transformation of 
oxaliplatin in vivo in which oxaliplatin was incubated with blood plasma at 
physiological temperature (37℃). 
3.1.2 Method selection for oxalate assay 
3.1.2.1 Oxalate assays with HPLC methods 
As a normal constituent of food, oxalate is commonly monitored in water, 
agriculture, plants and food quality control since its potential toxicity to human 
bodies. (184) In previous studies on oxalate, various assay methods were 
applied with the most common detection methods of: HPLC, Gas 
Chromatography (GC) and Spectrophotometric/Colorimetric (590 nm) in 
conjunction with soluble oxalate oxidase and peroxidase.  
In this study, oxalate concentration was required to be detected in samples that 
contain various components including oxaliplatin. Compared with 
spectrophotometric method, HPLC offers a separation process to gain more 
accurate result of oxalate concentrations in different samples. Furthermore, 
unlike GC, no solvent extraction process was required with aqueous samples in 
141 
 
HPLC methods. Table 3-1 shows various HPLC assays for oxalate 
determination, from which a specific assay was developed and validated for 
oxalate determination in this study. 
A HPLC assay with C18 column modified from the literature was tested with 
samples of oxaliplatin infusions to separate oxalate in chromatography. But 
oxalate could not be completely separated from oxaliplatin and the shape of 
oxalate peak was undesirable. In general, ODS columns (Silica-based C18 
column) were often used for analysis of oxalate. However, oxalate is highly 
hydrophilic and poorly retained on ODS columns, which raised the difficulty to 
achieve the adequate oxalate separation in the chromatogram. (192) To 
overcome this problem, an amide column was used in this study, the Inertsil 
Amide column (4.6 mm × 250 mm and with 5.0 µm particle size from GL 
Science). The porous silica gel, packed in this amide column, has been 
chemically bonded with carbamoyl group and the polar interaction increases 
retention of oxalate on the stationary phase. (192) As a polar solute, oxalate 
would be better resolved by this assay in the HILIC mode (hydrophilic 
interaction chromatography) with a more polar mobile phase containing 65% 
acetonitrile. (193) 
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Table 3-1, Summary of published Liquid Chromatography methods for oxalate determination in biological samples. 
Literature EP 2012 (164) 
Rajendra B. 
Kakde 2012 
(194) 
Vinay B 
Patel 2012 
(195) 
Tarkatti 
Kaleemullah 
2011 (196) 
T. Machold 2009 (197) 
Substance Oxalic acid 
Escitalopram 
oxalate & 
Clonazepam 
Escitalopram 
oxalate (ESC) 
& Etizolam 
(ETI) 
DPTTA in 
Escitalopram 
oxalate 
Low-molecular-weight 
carboxylates 
Column 
C18; 5 μm; 
4.6×250 mm 
C18; 5 μm; 
4.6×250 mm 
C18; 5 μm; 
4.6×150 mm 
C8; 5 μm; 
4.6×150mm 
C18; 5 μm; 4.6×150 mm 
Flow Rate 2.0 mL/min 1.5 mL/min 1.0 mL/min 1.0 mL/min 1.0 mL/min 
Temperature 40 ℃ 40 ℃ 30 ℃ 25 ℃ 25 ℃ 
Injection 
Volume 
20 μL 20 μL 10 μL 20 μL 20 μL 
Wavelength 205 nm 268 nm 254 nm 240 nm 215 nm 
Run Time 10 min 10 min 10 min 15 min 10 min 
Mobile Phase 
acetonitrile & 
phosphate 
acetonitrile & 50 
mM phosphate 
acetonitrile & 
0.005 M 
Hexane 
Sulfonic Acid 
acetonitrile & 
0.02% (v/v) of 
Orthophosphoric 
acid 
25 mM KH2PO4 & H3PO4 
Retention 
Time 
2.7 min 
6.6 min & 9.4 
min 
3.66 min & 
8.07 min 
4.0 min 1.7 min (Oxalic acid) 
Continued       
Literature 
C. Murphy 
2009 (198) 
Joseph E. 
Zerwekh 1983 
(199) 
Evelyn A. 
Havir 1982 
(200) 
Hua-Wei Xu 2006 
(185) 
Warren D. 
Holloway 
1989 (201) 
Alastair B. 
Ross 1999 
(202) 
Substance Oxalic acid Urinary oxalate 
Separation of 
organic acids 
oxalate, citrate, 
and malate 
Organic Acids Oxalate 
Column 
C18; 4 μm; 
4.6×250 mm 
High Pressure 
Liquid 
Chromatograph 
(Water Corasil II 
Column) 
Aminex HP-
87H column 
(9μm; 
7.8×300mm) 
C18; 5μm; 
4.6×250mm 
ion-exclusion 
column(HPX-
87H); 300 mm 
X 7.8 mm 
ion exclusion 
column (HPX- 
87H); 300×7.8 
mm 
Flow Rate 4.0 mL/min 2.0 mL/min 0.6 mL/min 1.0 mL/min 0.5 mL/min 0.6 mL/min 
Temperature 37 ℃ N/A 25℃ N/A N/A N/A 
Injection 
Volume 
20 μL 5.0 μL N/A N/A N/A N/A 
Wavelength 210nm 211 nm 210 nm 220 nm 214 nm 210 nm 
Run Time 35min 
     
Mobile Phase 
0.25% KH2PO4 
& 2.5 mM 
C16H36N•HSO4 
120 mmol/L 
phosphate buffer 
0.03 M H2SO4 
0.5% KH2PO4 & 
0.5 mM TBA 
0.125 M 
H2SO4 
0.0125 M 
H2SO4 
Retention 
Time 
N/A 35 s N/A N/A 9.8min 7.0min 
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3.1.2.2 Oxalate assay kit 
The validated HPLC assay with an amide column mentioned above was 
sufficient for oxalate determination in oxaliplatin infusions (in 5% glucose). 
However, for plasma/PUF (plasma ultra-filtrate) samples, it was envisaged that 
this HPLC assay might not be capable of resolving the oxalate peak from the 
interference of various constituents in plasma samples. Furthermore, this HPLC 
assay was not expected to be sensitive enough to examine the low 
concentrations of oxalate in plasma/PUF samples. In plasma/PUF samples, the 
concentration of oxalate would be expected to be around 5 µmol/L. (191) 
Therefore, an alternate oxalate assay with better specificity and sensitivity was 
considered for oxalate determinations in plasma/PUF samples. 
Enzymatic methods with spectrophotometer/colorimeter were used in previous 
studies in literature, which were generally applied with oxalate oxidase and 
peroxidase. (191) (190) Compared to HPLC assays, spectrophotometric 
methods for oxalate determination were capable of higher sensitivity with a 
working concentration range of 0.6 µmol/L – 20 µmol/L. (191) 
As a result, an oxalate kit, from Trinity Biotech, specific for oxalate 
determination was selected to test plasma/PUF samples, since this method met 
both specificity and selectivity criteria required in this study. The enzymatic 
method with this oxalate kit was based on the oxidation of oxalate (by oxalate 
oxidase), which can produce hydrogen peroxide (H2O2). The quantity of H2O2, 
measured by a peroxidase-catalysed reaction, could reflect the concentration of 
oxalate in samples. 
The assay with this oxalate kit was originally designed for quantifying oxalate in 
urine samples. However, a study carried out by Ladwig (191) has suggested 
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that this assay was applicable  for plasma oxalate with a good linearity over a 
concentration range of 1 – 50 µmol/L. (191) In addition, more validation tests 
were conducted before the experiment to confirm the accuracy and precision for 
oxalate determination in this study. The mechanism and validation of this assay 
were described in details in Section 3.2.4 (page 160) below. 
3.1.3 Experiment design 
As mentioned above, oxalate was postulated to be the main cause of the 
neurotoxicity associated with oxaliplatin treatment. However, the mechanism of 
this neuropathy side effect was not clearly understood. According to the 
published literature oxalate was only proved to be associated with neuropathy. 
Because oxalate was a common metabolite in the human body, it was 
reasonable to expect that the oxalate in the human body would need to reach a 
critical concentration to cause any toxic effect in organs. After the administration 
of oxaliplatin, oxalate produced from oxaliplatin degradation would accumulate 
with the endogenous oxalate in human plasma. The total amount of oxalate in 
plasma might then reach the toxic concentration and consequently trigger the 
neurotoxicity in patients. Studies on oxalate production and accumulation at 
each stage of oxaliplatin degradation (before and after administration to 
patients) were conducted to investigate the relationship between oxalate and 
the neurotoxicity from oxaliplatin.  
3.1.3.1 Preliminary experiment with oxaliplatin infusions 
The ‘Stability study of oxaliplatin infusions’ was included in Chapter 2 (page 97) 
in this thesis. That stability study indicated that the stability period for oxaliplatin 
could be extended to at least 84 days when infusions were stored at 2 - 8℃ 
following a sequential temperature conditioning. During the experiment, those 
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oxaliplatin infusion bags were stored at 2 - 8℃ for most times, and also 
incubated at room temperature of 25℃ for 24 hours. Oxaliplatin infusions 
remained stable and drug concentration remained within the acceptance criteria 
of ± 5% of original concentration.  
After the stability study, samples (10 mL) of those oxaliplatin infusions were 
retained and stored at 2 - 8℃ within well labelled containers for the potential use 
in the oxalate study. In order to investigate the amount of oxalate produced in 
oxaliplatin infusions, these samples of oxaliplatin infusions (in 5% glucose) were 
then tested in a preliminary experiment before the main oxalate study. Results 
of this preliminary study would inform the design of the following study by 
indicating the concentration of oxalate that might be expected in oxaliplatin 
infusions, and also give an estimate of the time course of oxalate production in 
oxaliplatin infusions.  
In this preliminary study, concentrations of oxaliplatin and oxalate were detected 
from those infusions which have been stored at 2 - 8℃ for different time periods. 
The experiment procedure of this preliminary study was described in Section 
3.3.1 (page 168), and the result was also discussed in Section 3.4.2 (page 181) 
below. 
3.1.3.2 Experiment with plasma samples 
To simulate the degradation process of oxaliplatin in blood circulation of human 
bodies, 0.2 mg/mL samples of oxaliplatin were diluted with human plasma and 
incubated at 37℃ throughout the experiment. Oxaliplatin and oxalate 
concentrations were periodically tested in this experiment to determine the 
oxaliplatin degradation dynamics.  
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Since plasma proteins could potentially bond with oxaliplatin/oxalate, the total 
amount of oxaliplatin/oxalate in human plasma included the quantity of bound 
(with proteins) and un-bound (free) fractions of oxaliplatin/oxalate. To 
investigate the concentration dynamics of both bound (with proteins) and un-
bound (free) oxaliplatin/oxalate within plasma samples, 4 groups of oxaliplatin 
solutions were prepared and sampled in different ways as described below:  
Group A (The control group): Oxaliplatin infusions in this group were prepared 
with 5% glucose and stored under the same conditions with all other groups. 
Within this group, changes of oxaliplatin/oxalate concentration in glucose were 
monitored throughout the experiment. This result can be used as the 
benchmark comparison reference for other plasma/PUF groups. 
Group B: The total amount of oxaliplatin/oxalate (including bound and un-
bound fractions) in plasma was determined in this group. For this group, 
oxaliplatin were prepared with human plasma, and samples were treated with 
acetonitrile to precipitate proteins and break the bond between proteins and 
oxaliplatin/oxalate in plasma. (203) 
Group C: Concentrations of un-bound (free) oxaliplatin/oxalate in plasma were 
determined in Group C. The un-bound (free) oxaliplatin is normally considered 
as the therapeutic effective substance in bodies after the oxaliplatin 
administration to patients. Oxaliplatin solutions in this group were also prepared 
in human plasma and samples were prepared without any special treatment, 
from which only concentrations of un-bound oxaliplatin/oxalate were detected.  
Group D: In order to detect the concentration change of oxaliplatin/oxalate 
without interference from plasma proteins, Group D was prepared by diluting 
oxaliplatin with plasma ultra-filtrate (PUF). (204)  
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The concentration dynamics of oxalate in plasma and PUF samples was 
observed and compared with the referred average level in plasma of human 
bodies presented in published literature. The potential relationship between the 
neurotoxicity associated with oxaliplatin treatment and oxalate can be 
investigated in this study.  
Before the main experiment with those 4 groups mentioned above, a trial test 
was conducted in order to optimize test parameters for the main study. The 
experimental design described above was fully applied in this trial study using 
the HPLC assay validated for oxalate determination. However, oxalate results 
from this trial test showed significant variation and randomness, which indicated 
that the HPLC assay was not suitable and applicable for oxalate determination 
in plasma/PUF samples. Based on this trial test, some operational and 
experimental details were modified for the main experiment, such as sample 
preparations, the acetonitrile treatment process and the ultra-filter centrifuge 
procedure. 
3.1.4 Purpose and objectives 
The main purpose of this oxalate study can be divided into two parts: 1) to 
simulate the oxaliplatin degradation process in blood circulation in human 
bodies; 2) to investigate the potential relationship between oxalate and 
neurotoxicity associated with oxaliplatin chemotherapy. 
Additional objectives for those experiments also include: 
 To detect the concentration of oxalate in oxaliplatin infusions that are 
prepared for chemotherapy administration; 
 To investigate the possibility of potential toxicity to human bodies caused 
by oxalate increasing from oxaliplatin degradation in plasma; 
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 To investigate the degradation process of oxaliplatin in PUF (plasma 
ultra-filtrate) and indicate the difference between oxaliplatin degrading in 
plasma and PUF; 
 To estimate the concentration dynamics of un-bound (free) oxaliplatin in 
human plasma, and indicate the influence of oxaliplatin degradation to 
the drug therapeutic efficacy. 
3.2 Materials and methodology 
3.2.1 Materials 
3.2.1.1 Chemicals 
Oxaliplatin concentrate solution, 5 mg/mL; batch no. PP02066; expiry 10/2015 
(Accord Healthcare Limited, UK)  
Oxalic acid powder, 99.999%; batch no. #MKBC3170V (Sigma-aldrich, USA) 
Human plasma, Grade A, 2 × 250 mL plasma bag (Derriford Hospital, UK)  
Glucose 5% w/v Macoflex, Lot. 899914122H, expiry 09/2016 (Macopharma, UK) 
Sodium phosphate monobasic monohydrate (ACS reagent, 98.0 - 102.0%) 
(Sigma-Aldrich, Japan) 
Sodium phosphate dibasic (HPLC grade) (Sigma, USA) 
Sodium hydroxide 1 M (HPLC grade) (Fisher Scientific, UK) 
Acid ortho-phosphoric (HPLC grade) (Fisher Scientific, UK) 
Methanol (HPLC grade) (Fisher Scientific, UK) 
Hydrochloric acid 1 M (Fisher Scientific, UK) 
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pH electrode storage solution, 4.01 Buffer solution and 7.00 Buffer solution 
(Thermo Fisher Scientific, USA) 
Sterile water for irrigation and dilution, batch 12E22B28, expiry 04/2015 
(distilled and de-ionised) (Baxter, UK) 
Reagents in oxalate assay Kit: (Lot: D035002, expiry 05/06/2016, Trinity 
Biotech, Ireland) 
Oxalate reagent A: DMAB 3.2 mmol/L; MBTH 0.22 mmol/L; Buffer pH 3.1 ± 0.1. 
Oxalate reagent B: oxalate oxidase (Barley) 3000 u/L; Peroxidase (Horseradish) 
100.000 u/L. 
Sample diluent: EDTA 10 mmol/L; Buffer pH 7.6 ± 0.1. 
Sample purifier tubes: Activated charcoal. 
3.2.1.2 Consumables 
20 mL Luer-lock syringes (Codan Medical ApS, UK) 
0.8 mm × 40 mm needles, 21G × 11/2’’, LOT 120507, expiry 04-2017 (BD 
Microlence, UK) 
1.1 mm × 40 mm needles, 19G × 11/2’’, LOT 120411, expiry 03-2017 (BD 
Microlance, UK) 
Plus blood collection tubes, 10 Ml, LOT 380202, expiry 03/2015 (BD Vacutainer, 
UK) 
Centrifugal tubes with filter, 4 mL and 15 mL (Amicon, UK) 
Screw-cap sterile polypropylene tubes in 5 mL and 20 mL (Gosselin SAS, UK) 
HPLC auto-sampler crew-cap vials 2 mL and caps (Chromacol Ltd., UK) 
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Cellulose acetate filters, pore size 0.45 μm (Sartorius Stedium Biotech, 
Germany) 
Disposable polypropylene pipettes 3 mL (Fisher Scientific, UK) 
Micropipette tip 200 µL and 1000 μL (Gilson SAS, France) 
Prep Pad, 70% Isopropyl Alcohol BP (A CliniMed Group Company, UK) 
Cellulose acetate filter paper: pore size: 0.45; Lot: 0114111061305763 
(Sartorius Stedim Biotech GmbH, Germany) 
RC-Vliesver starkt filter paper: pore size: 0.45; Lot: 0314184061305223 
(Sartorius Stedim Biotech GmbH, Germany) 
3.2.1.3 Equipment 
Spectrophotometer with cuvettes, CE 1010; Serial No. 90506 (Cecil 
Instruments, Cambridge England) 
Centrifuge, Serial No. 30002493; Catolog No. 11175603 (Jouan, UK) 
Analytical balance: Sartorius Basic 100 g - 0.0001 g 4-figure balance 
(Sartorious Ltd., UK) 
Refrigerator at 2 – 8℃ (Fisher Scientific, UK) 
Incubator at 37℃  (Gallenkamp, Japan) 
Digital thermometers (Fisher Scientific, UK) 
Micropipette: Proline Plus 100 – 1000 μL (Biohit Limited, UK) 
Micropipette: Proline Plus 10 – 100 µL (Biohit Limited, UK) 
Orion 5 Star Benchtop with glass electrode (Thermo Scientific, UK) 
Magnetic stirrer : HI 190M (Hanna Instruments, UK) 
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Glass filter holder and flask (Emil company, UK) 
Filter vacuum pump: FB 70155 (Fisher Scientific, UK) 
Class Ⅱsafety cabinet: Biological Class Ⅱ containment (Bigneat Ltd., UK) 
Grade A, flasks, measuring cylinders and beakers (Fisher Scientific, UK) 
HPLC Column: Water Spherisorb® (CNRP) 4.6 mm×250 mm stainless steel, 
packed with 5.0 μm bonded phase cyano CNRP Column (Waters Limited, UK) 
HPLC Column: Inertsil Amide column, 5.0 µm particle size and 4.6 mm × 250 
mm, serial no. 4BI41544. (GL Science, Japan) 
HPLC System 1: (Jasco UK, Essex UK) 
Intelligent Column Thermostat, CO-2060 
Intelligent Auto-sampler, AS 2057 
Quaternary Gradient Pump, PU-2089 
Multiwavelength Detector, MD 2010 
LE-Net Ⅱ/ADC 
Chrompass Software version 1.8.6.1 
HPLC System 2: (Jasco UK, Essex UK) 
Intelligent Column Thermostat, CO-2067 
Intelligent Auto-sampler, AS 2057 plus 
Quaternary Gradient Pump, PU-2080 
Multiwavelength Detector, MD 2010 
LE-Net Ⅱ/ADC 
Chrompass Software version 1.8.6.1 
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3.2.2 HPLC assay for oxaliplatin 
The HPLC assay for oxaliplatin concentration detection was the same assay 
used in the stability study of oxaliplatin infusions described in Chapter 2 (page 
108). Detailed validation of this assay was shown in Section 2.2.2.2 in Chapter 
2 (page 110), although the setting conditions were slightly different as listed 
below: 
Column: bonded-phase cyano column of Water Spherisorb (CNRP), 5.0 µm 
particle size and 4.6 mm × 250 mm, serial no. 0159311311. 
Mobile phase: 5 mM phosphate buffer in pH 6.5 and 5% methanol. 
System: Jasco 1 system with Jasco ChromPass version 1.8.6.1. 
Method: Flow rate = 1.0 mL/min; 
Injection volume = 20 μL; 
Run time = 10 minutes; 
Detection wave length = 210 nm; 
Temperature of column oven = 35℃. 
The standard solution of oxaliplatin used in this study was in the concentration 
of 20 µg/mL in order to match up with the expected oxaliplatin concentration in 
samples. 
3.2.3 HPLC assay for oxalate determination in oxaliplatin 
infusions 
3.2.3.1 Method conditions 
Various oxalate assay techniques were discussed in the introduction section 
above (Section 3.1.2), the HPLC assay with an amide column was selected in 
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this study for oxalate determination. This assay was used to detect 
concentrations of oxalate in oxaliplatin infusion samples (diluted in 5% glucose), 
with method conditions shown below: 
Column: Inertsil Amide column from GL Science, 5.0 µm particle size and 4.6 
mm × 250 mm, serial no. 4BI41544. 
Mobile phase: 30 mM Na2HPO4 buffer in pH 6.5 with 65% acetonitrile. 
System: Jasco 2 system with Jasco ChromPass version 1.8.6.1. 
Method: Flow rate = 1.0 mL/min;  
Injection volume = 5 µL;  
Run time = 10 minutes; 
Detection wave length = UV 210 nm;  
Temperature of column oven = 50℃. 
Standard oxalate solution (10 µg/mL) was used in this external standard 
method. The amide column used in this study was chemically bonded with 
carbamoyl groups, on which oxalate was well retained unlike the regular ODS 
columns. The column was not suitable for the regular conditioning with 100% 
water; therefore 100% acetonitrile and 50% acetonitrile (in water) were used to 
condition this column every 2 days. 
3.2.3.2 Method validation 
The HPLC assay for oxalate determination was validated with intra- and inter-
day precision and linearity of response. The acceptance criterion in this section 
was taken from the British Pharmacopoeia (BP) and European Pharmacopoeia 
(EP), which requires relative standard deviation (RSD) ≤ 2% for precisions. 
(166) (205) Oxalate stock solution of 1 mg/mL was prepared in advance from 
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the Oxalic acid powder (99.999%), in order to prepare all oxalate solutions in 
different concentrations required by those validation tests. 
Intra-day precision: On the same day, one standard solution and one test 
solution were prepared in the same concentration of 10 μg/mL by diluting the 
oxalate stock solution (1 mg/mL) with water. The test solution was replicated 
from 5 individual vials in a HPLC method sequence created especially for intra-
day precision. Mean values of oxalate concentrations calculated from 
chromatogram peak heights were compared and the relative standard deviation 
(RSD) were calculated with the equation,  
RSD = (
SD
x
) × 100% 
[SD = Standard deviation; x = Mean concentration of oxalate.] 
Inter-day precision: A standard oxalate solution of 10 μg/mL was prepared in 
the first day of the inter-day precision from the 1 mg/mL oxalate stock. This 
standard solution was used for the whole term of this precision test in 6 
continuous days when 5 test solutions (10 μg/mL) were prepared on each 
sample day. Replicated test solutions were injected each day for 6 days, and 
from the mean oxalate concentrations calculated from peak heights the RSD 
value was calculated using the equation referred above. 
Linearity of response: Oxalate stock solution (1 mg/mL) was diluted 
volumetrically with HPLC grade water in a grade A volumetric flask, to give 10 
mL oxalate solution in 0.1 mg/mL. Then a series of calibration solutions was 
prepared by diluting the 0.1 mg/mL solution from 0.01, 0.05 mL into 10 mL and 
0.05, 0.15, 0.25, 0.5, 1.0 mL into 5 mL separately with HPLC grade water in 
grade A volumetric flasks, to give a calibration plot with the oxalate 
concentrations of 0.1, 0.5, 1.0, 3.0, 5.0, 10.0, 20.0 and 100.0 μg/mL. 
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Concentrations of these 8 test solutions ranged from 0.1 – 100.0 μg/mL, which 
covers all oxalate concentrations expected to be tested in this study. 
Eight mean peak heights from 3 replicate injections for each solution were 
plotted against concentration and were fitted to a linear relationship using the 
least-squares regression analysis. 
The acceptance criterion for linearity validation was R2 ≥ 0.995 and even 
distribution of data on regression line by visual inspection. 
During validation tests, it was found that the oxalate peak could be better 
separated from other interfering peaks when diluting oxalate samples with the 
mobile phase. Therefore, to obtain better chromatogram data, all samples 
tested with this HPLC assay for oxalate were prepared in the mobile phase 
instead of deionized water. 
Result tables of validation tests for the HPLC assay of oxalate are shown below 
in result section, Section 3.4.1.1 (page 178). 
3.2.3.3 Quantification of oxalate concentrations 
The values of peak heights of oxalate in samples were recorded with the two 
‘bracketing’ standard chromatograms at each sample point. Oxalate 
concentrations were calculated by using the equation below:  
Ctest =
Htest
HSTD
× CSTD  × D 
[Ctest = Concentration of oxalate in samples; Htest = Peak height of oxalate in test sample 
solution; HSTD = Mean peak height of standard solution; CSTD = Concentration of standard 
solution; D = Dilution factor]. 
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The standard solution (STD) involved in the above equation was the oxalate 
solution in concentration of 10 µg/mL. Additionally, the dilution factor of oxalate 
samples was the same in this study, as D = 10. 
3.2.4 Oxalate assay kit for oxalate determination in human 
plasma 
3.2.4.1 Assay mechanism 
The selected assay for oxalate was an enzymatic method based on the 
oxidation of oxalate with oxalate oxidase. Hydrogen peroxide (H2O2) was 
produced in oxalate oxidation, which can be measured by a peroxidase-
catalyzed reaction. Two enzymatic reactions involved in this assay were shown 
below: 
Oxalate + O2
Oxalate Oxidase
→            2CO2  + H2O2 
H2O2 +MBTH + DMAB 
Peroxidase
→        Indamine Dye + H2O 
[MBTH: 3-methyl-2-benzothiazolinone hydrazine; DMAB: 3-(dimethylamino) benzoic acid] 
Indamine dye yielded by the peroxidation of H2O2 had an absorbance maximum 
at 590 nm wavelength in spectrophotometer. Due to these reactions, the 
intensity of Indamine dye colour directly reflected the amount of H2O2, and 
consequently correlates with the concentration of oxalate in samples. 
The enzymes and reactants required for these reactions were provided within 
the oxalate kit, as well as sample diluent and purifier tubes. Separate vials were 
used to seal different reagents, which are described in details below. 
 Oxalate Reagent A: DMAB 3.2 mmol/L; MBTH 0.22 mmol/L; Buffer pH 3.1 
± 0.1 
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 Oxalate Reagent B: oxalate Oxidase (Barley) 3000 µ/L; Peroxidase 
(Horseradish) 100.000 µ/L 
 Sample diluent: EDTA 10 mmol/L; Buffer pH 7.6 ± 0.1 
The reagents in the oxalate kit were for ‘ex vivo diagnostic use’, which only 
required normal precautions exercised in handling regular laboratory reagents. 
These reagents were provided in light proof vials as dry powder, which can be 
stored for long period at refrigerated temperature of 2 – 8℃. However, after 
dilution in deionized water for oxalate determination, the reconstituted reagents 
had various stability periods in different environments. Reconstituted oxalate 
Reagent A and Reagent B were only stable for 1 day at ambient temperature of 
18 – 26℃, but at 2 – 8℃ they can be stored for 1 month (30 days). 
Reconstituted oxalate Reagent B also can be frozen at -20 ℃ for up to 30 days 
and unfrozen at room temperature before use. For sample diluent, the 
reconstituted solution can be stored for 1 week at ambient temperature 18 – 
26℃ and 3 months at refrigerated temperature 2 – 8℃. All dissolved reagents 
needed to be warm up to approximately 37 ℃ before each assay. As the 
crystalline material might be formed in reagent vials during the storage in the 
refrigerator, warming the reagents up to room temperature can dissolve those 
precipitates and prevent associated errors in oxalate concentration results. 
Sample purifier tubes provided in the kit contained activated charcoal, which 
could be stored at room temperature (18 – 26℃) without any specific storage 
requirements.  
The reagents should not be used if there was any moisture penetration in the 
dry reagent powder. The reconstituted reagents should be clear and free of 
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particulate matter. If the reagents developed haziness due to bacterial 
contamination, they should be discarded. 
3.2.4.2 Sample preparation 
The assay with the oxalate kit was originally designed for oxalate determination 
in urine samples, but it was also capable of testing oxalate in human plasma 
samples because: 1) the EDTA contained in sample diluent could prevent 
plasma clotting in samples; 2) sample purifier tubes can be used to purify 
human plasma; 3) plasma samples can be ultra-filtered in centrifuge to avoid 
the effect of various compounds in plasma to the oxalate detection.  
In this oxalate assay, samples have to be prepared following the operation 
steps below: 
1. Prepare sample diluent from the initial vial of dry reagent powder, which 
was described in details in the following section of oxalate determination 
(Section 3.2.4.3); 
2. Pipette 2 mL or any suitable volume of samples and plasma control into a 
series of appropriately labelled sterile tubes; 
3. Add equal volume (sample volume mentioned in Step 2) of sample diluent 
into each tube and mix them properly; 
4. Adjust pH of these mixture in each tube into the pH range of 5.0 – 7.0 using 
1 M hydrochloric acid or 1 M sodium hydroxide; 
5. Pipette a proper volume of diluted samples and plasma control into labelled 
sample purifier tubes and intermittently mix for 5 minutes (A rotator mixer is 
recommended for mixing.); 
6. Transfer these mixture into labelled ultra-filter tubes and centrifuged for 20 
minutes at 4100 rpm; 
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7. The supernatants of ultra-filtrate samples and plasma control are ready to 
be detected. 
Before sample preparation, all sterile vials, sample purifier tubes and ultra-filter 
tubes were prepared and labelled with proper information including group 
number, sample type and experiment date. For pH adjustment of diluted 
samples and plasma control, the pH meter was validated every day and the 
glass electrode was washed with deionized water before and between each 
sample. Oxalate Reagent A and Reagent B didn’t need to be prepared and 
used during sample preparation, while Sample diluent was prepared in advance 
to dilute samples and plasma control. 
3.2.4.3 Oxalate determination schedule 
In this assay, some equipment was required but not provided within the kit, 
including spectrophotometer (with cuvettes), pipettes and centrifuge with fitted 
ultra-filter tubes. The spectrophotometer used in this assay was able to 
accurately measure various samples that have the absorbance at 590 nm. The 
selected pipette devices were within the correct working range to accurately 
transfer the liquid volumes required. Ultra-filter tubes used for purifying samples 
and plasma control were in the size of 4 mL in order to handle the required 
sample volume. Additionally small ultra-filter tubes could ensure more samples 
can be loaded in the centrifuge at any one time, which can shorten the 
experiment time and consequently reduce the detection errors in oxalate results 
caused by temporal difference. 
Before the determination of oxalate in samples, reagents in the oxalate kit were 
prepared with deionized water and underwent the detailed preparation shown 
below. 
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Reagent A was reconstituted with the volume of deionized water as indicated 
on the vial label (10 mL). Then stoppered the vial and inversely mixed the 
reagent until it is completely dissolved. 
Reagent B required different volume of water to dissolve in, which should be in 
accordance with the instruction on the vial label (2 mL). The reconstituted 
Reagent B cannot be mixed by shaking the vial; instead it was mixed 
immediately by gentle inversion. 
Sample Diluent was prepared at the very beginning prior to sample preparation 
as mentioned in the above section (Section 3.2.4.2). According to the vial label 
of sample diluent, it was dissolved in 100 mL deionized water using a separated 
container in appropriate size. The entire powder from the vial was transferred 
into a labelled container (100 mL flask) and mixed with 100 mL deionized water. 
Since the dissolution procedure took round 0.5 – 1.0 hour, the preparation of 
sample diluent was conducted in advance of the whole experiment. 
In addition, standard oxalate of 45 µg/mL was required in this assay as the 
reference value for the calculation of oxalate concentration in samples and 
plasma control. Standard oxalate was prepared by diluting 0.225 mL, 1 mg/mL 
oxalate stock in 5 mL flask to obtain the concentration of 45 µg/mL.  
Oxalate concentrations of the treated samples and plasma control were 
determined as described below: 
I. Warm oxalate reagents (Reagent A and Reagent B) to assay temperature 
(18 – 37℃); 
II. Label sterile tubes for various solutions tested in this assay, including 
Reagent Blank, Standard oxalate, Plasma Control and Samples;  
III. Pipette 1 mL oxalate Reagent A in each sterile tube; 
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IV. Pipette 50 µL Water / Standard oxalate (45 µg/mL) / Plasma Control / 
Samples in the tubes with matching labels respectively; (water is for the 
tube of Reagent Blank; Plasma control and Samples have all been treated 
as mentioned above) 
V. Pipette 0.1 mL oxalate reagent B into each tube and mix immediately by 
gentle inversion; 
VI. Incubate the tubes at room temperature for 5 minutes; (to accurate the 
time, samples are better tested in a small number each time) 
VII. Calibrate the spectrophotometer at 590 nm wavelength and record the 
absorbance of pure water as a correction reference for samples; 
VIII. Record the readings of absorbance (A) for Water, Reagent Blank, 
Standard oxalate, Plasma Control and Samples at 590 nm in the 
spectrophotometer as the mean value of triplicate tests; 
Calculation of oxalate concentrations in plasma control and samples is referred 
to the calculation section below (Section 3.2.4.4). 
3.2.4.4 Calculation of oxalate Concentration 
In this assay, the absorbance (A) of Water and Reagent Blank were used to 
obtain the corrected absorbance (∆A) of Standard oxalate, Plasma control and 
oxalate samples. The corrected absorbance (∆A) can be calculated following 
Equation 1 – 4 as shown below.      
∆A Blank = A Blank − A Water Equation 1 
∆A Standard = (A Standard − A Water) − ∆A Blank Equation 2 
∆A Plasma control = (A Plasma control − A Water) − ∆A Blank Equation 3 
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∆A Sample = (A Sample − A Water) − ∆A Blank Equation 4 
Calibrated with ∆A value of Standard oxalate, oxalate concentrations in 
Samples were calculated following Equation 5 and Equation 6 in different unit. 
∆A Sample in these two equations can be replaced by ∆A Plasma control to 
calculate the oxalate concentration in Plasma control. The dilution factor of 2 in 
the equation represented the 1 : 1 dilution of samples/plasma control in Sample 
diluent as described in sample preparation section above. 
Oxalate concentration (µg mL⁄ ) =
∆A Sample
∆A Standard
× 45 × 2 Equation 5 
Oxalate concentration (mmol L⁄ ) =  
∆A Sample
∆A Standard
 × 0.5 × 2 Equation 6 
[45=Concentration (µg/mL) of oxalate in standard; 0.5=Concentration (mmol/L) of oxalate in 
standard; 2=Dilution factor] 
3.2.4.5 Method Validation 
The performance characteristics of this assay were provided in the method 
instruction with the oxalate assay kit with the validation results including 
linearity, sensitivity, precision and recovery studies. (189)  
A total of 30 urine specimens with oxalate concentrations ranging from 0.1 - 1.2 
mmol/L were assayed. The linearity of oxalate within this range turned out with 
a correlation coefficient of 0.99 and the regression equation was y = 0.94x + 
0.008. The sensitivity validation of this assay indicated an absorbance change 
of 0.150 corresponding to oxalate concentration of 0.1 mmol/L, when a 
spectrophotometer is used for the measurement under the stated conditions. 
Within-run and run-to-run precision studies showed that coefficient variations 
with 3 different urine samples were both lower than 2.18%. Known amounts of 
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oxalate were added to 59 urine specimens and the oxalate concentration was 
determined using this assay to obtain percentage of oxalate recovery. The 
recovery of added oxalate ranged from 93 - 107%, with the mean value of 
100.5%. 
All these validation tests were operated with urine samples, which was the 
sample subject that this assay originally focused on. To ensure that the plasma 
samples could be tested with this oxalate assay kit, additional validation tests 
were conducted with oxalate in the plasma samples. 
A series of calibration oxalate samples were prepared within human plasma by 
diluting the oxalate stock solution (1 mg/mL) into concentrations of 1 µg/mL, 10 
µg/mL, 20 µg/mL, 40 µg/mL, 60 µg/mL, 80 µg/mL and 100 µg/mL. This range 
was sufficient to cover the oxalate concentration of all samples expected in this 
study. Each sample was tested in triplicate with the spectrophotometer and the 
mean value of absorbance (A) was used for the calculation. The absorbance 
values of tested oxalate were plotted against the nominal concentrations and 
fitted to a linear relationship using the least-squares regression analysis. 
Furthermore, oxaliplatin to a concentration of 20 µg/mL was added to each 
plasma sample in this test, in order to investigate the effect of oxaliplatin on 
oxalate determination within this assay. Results of this oxalate assay validation 
was discussed in the result section below (Section 3.4.1.2). 
3.2.5 pH measurement 
pH variation may indicate significant chemical and physical changes in plasma 
samples with oxaliplatin. An Orion 5 Star pH meter with combination glass 
electrode was used to measure the pH of samples at each time point. For 
calibrating the pH meter, the reference buffer solutions at pH 4.01 and pH 7.00 
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were used every time before sampling. Between samples, distilled water was 
used to rinse the glass electrode, and the automatic temperature compensation 
was deployed. 
3.3 Experimental 
Two experiments were conducted to investigate the oxalate production from the 
oxaliplatin degradation process. The preliminary study was conducted with 
oxaliplatin infusions prepared with 5% glucose, in order to determine the 
amount of oxalate produced in oxaliplatin infusions before administration to 
patients for chemotherapy. The main experiment was designed with human 
plasma samples to simulate the oxaliplatin degradation in blood circulation in 
patients. In this experiment oxalate’s growth associated with oxaliplatin 
degradation was also examined in plasma samples. 
3.3.1 Preliminary study with oxaliplatin infusions (with 5% 
glucose) 
3.3.1.1 Infusion groups 
Oxaliplatin infusions used in this preliminary study were those infusions (in 5% 
glucose) stored from the stability study presented in Chapter 2 (page 97). As 
mentioned in Chapter 2 (Section 2.3.1), 7 groups of oxaliplatin infusions were 
prepared in two different concentrations, 0.2 mg/mL and 0.7 mg/mL, in order to 
test the stability period of oxaliplatin infusions within the working concentration 
range. Each group was stored following the sequential temperature design for 
different time period at refrigerated and room temperature. (Refer to Chapter 2, 
page 114) According to results of the stability study, oxaliplatin infusion bags in 
all groups were found to be stable at the end of the experiment period and 
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oxaliplatin concentration variations were within the criteria of ± 5%. Those 
infusion bags were stored at 2 – 8℃ in light proof bags since the finish of the 
stability study, which were capable of being used for the investigation of oxalate 
produced in oxaliplatin infusions. Those infusion bags were prepared on 
different dates and stored for various time periods during and after the stability 
study. As a result, a series of oxalate concentrations produced in oxaliplatin 
infusions can be obtained for 7 different time periods in a range of 24 days, 
which were 553, 560, 567, 570, 571, 572 and 577 days. Details of storage time 
for each oxaliplatin group are shown in Table 3-2 below.  
Table 3-2, Storage time period of oxaliplatin infusion bags with 5% glucose in each 
group during and after the previous stability study described in Chapter 2. 
 Group 
Storage time during the stability study of oxaliplatin 
infusions 
Storage time 
after Stability 
Study 
Storage 
time in 
total 
(days) Stored at 2-8℃ 
(days) 
Stored at 25℃ 
(days) 
Stored at 2-8℃ 
(days) 
Stored at 2-8℃ 
(days) 
Group A 1 1 7 568 577 
Group B 3 1 7 561 572 
Group C 7 1 7 556 571 
Group D 14 1 7 548 570 
Group E 28 1 7 531 567 
Group F 56 1 7 496 560 
Group G 84 1 7 461 553 
During the stability study of oxaliplatin infusions, the storage conditions of each group were following 
the sequential temperature design at different temperatures of 2-8℃ or 25℃. 
Samples from each group tested in this preliminary study were compared with 
the data from T0 and the last sampling point of the stability study. These 
oxaliplatin variations would represent the change of oxaliplatin during the 
additional storage time period after the stability study.  
Oxalate might exist in oxaliplatin infusions as a related substance from the 
original oxaliplatin vials. Reference to EP (European Pharmacopeia), within 
oxaliplatin infusions the concentration of oxalate impurity should not be more 
than 0.1% of oxaliplatin concentration. (164) Therefore, oxalate concentrations 
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detected from the oxaliplatin infusions in this study would indicate the total 
amount of oxalate in oxaliplatin infusions, which contained 1) the oxalate 
impurity originally existing in oxaliplatin vials; 2) the oxalate produced from 
oxaliplatin degradation through the entire storage period for each group. 
3.3.1.2 Oxaliplatin and oxalate determination 
Standard solutions of oxaliplatin and oxalate were both prepared on the same 
day before testing the samples from selected groups. Oxaliplatin standard 
solution (STD) was in 20 µg/mL, which was prepared in HPLC grade water 
following 0.04 mL, 5 mg mL⁄  → 5 mL, 20 µg mL⁄  to obtain 5 mL STD solution. 
Oxalate standard solution (STD) was at concentration of 10 µg/mL, and was 
prepared in mobile phase used in oxalate assay following 0.05 mL, 1 mg mL⁄  →
5 mL, 10 µg mL⁄  to obtain 5 mL STD solution. 
From each group, infusion samples were selected in each concentration (0.2 
mg/mL and 0.7 mg/mL) and tested in this preliminary study. Infusion samples 
were labelled as: 0.2A3, 0.7A2, 0.2B1, 0.7B3, 0.2C2, 0.7C1, 0.2D2, 0.7D3, 
0.2E3, 0.7E2, 0.2F3, 0.7F1, 0.2G3, 0.7G2.  
10 mL of samples were withdrawn from oxaliplatin infusions in each group by 20 
mL syringes with luer-lock. For each sample, 1 mL was used for oxaliplatin 
assay, 1 mL was for the determination of oxalate with the HPLC method and the 
remaining sample solution was for pH measurement. For pH measurement, 
samples were tested immediately without any preparation. But for 
determinations of oxaliplatin and oxalate, samples were prepared and diluted in 
the following ways: 
With the oxaliplatin assay, oxaliplatin infusion samples in concentrations of 0.2 
mg/mL and 0.7 mg/mL were diluted with deionized water respectively by 10 and 
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20 times. For the oxalate assay, samples were prepared in the mobile phase 
used in the HPLC method, and diluted in the same factors as for the oxaliplatin 
assay. 
Due to the amount of samples from those 7 groups, Group A, B, C and D were 
tested in the same day while other groups were tested together in the next day. 
During the sample time, two HPLC systems were used respectively for 
oxaliplatin and oxalate assays at the same time to gain the concentration result 
of both oxaliplatin and oxalate with less timing errors. 
3.3.2 Main study of oxalate formation in human plasma after 
oxaliplatin administration 
This experiment was to investigate the oxalate change in human plasma after 
administered oxaliplatin to give a concentration of 0.2 mg/mL. The degradation 
process of oxaliplatin in human plasma was simulated by incubating plasma 
sample groups at body temperature of 37℃. For oxalate determination, the 
HPLC assay used for the preliminary study described above was also tested 
with plasma samples in this experiment. Results showed that this HPLC assay 
was not suitable for testing human plasma samples. Therefore, an enzymatic 
method for oxalate determination in plasma samples was selected instead, 
since this assay could meet both specificity and selectivity criteria required in 
this study.  
3.3.2.1 Group design 
As mentioned in Section 3.1.3.2, 4 groups of oxaliplatin (0.2 mg/mL) solutions 
were prepared respectively in 5% glucose (Group A), human plasma (Group B, 
C) and PUF (Group D) in this study. In order to simulate the oxaliplatin 
degradation in blood circulation after administration to patients, oxaliplatin 
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concentration (0.2 mg/mL) prepared in those sample groups was carefully 
selected as approximately 100 times the oxaliplatin Cmax (the peak platinum 
concentration) in plasma and PUF (plasma ultra-filtrate) referring to the 
literature of PK studies on oxaliplatin. (129) In addition, all sample groups were 
incubated at 37℃ within light-proof bags to simulate the human body 
temperature. The Control group, Group A, of oxaliplatin in 5% glucose solutions 
was prepared and stored under the same condition as other groups to ensure 
its comparability.  
Details of each oxaliplatin group were described in Table 3-3 below. 
Table 3-3, Preparation and sampling information for Group A, Group B, Group C and 
Group D examined in this study. 
Groups Group A Group B Group C Group D 
Diluent 5% Glucose Human Plasma Human Plasma PUF 
Prepared 
oxaliplatin 
concentration 
0.2 mg/mL 0.2 mg/mL 0.2 mg/mL 0.2 mg/mL 
Number & 
Size of 
oxaliplatin 
solutions* 
3 × 50 mL 3 × 50 mL 3 × 50 mL 3 × 50 mL 
Sample 
treatment 
before assays 
None Acetonitrile None None 
Detected 
substances in 
samples 
All 
oxaliplatin/oxalate 
Protein-Bound 
and un-bound 
(free) 
oxaliplatin/oxalate  
Un-bound (free) 
oxaliplatin/oxalate 
All 
oxaliplatin/oxalate 
* Oxaliplatin solutions for each group were prepared in triplicate and stored in 10 mL blood tubes with 
EDTA. 
3.3.2.2 Study procedure 
These 4 groups of 0.2 mg/mL oxaliplatin solutions in different diluents were 
stored at 37℃ in the incubator for 5 days to simulate the body temperature. To 
investigate the oxaliplatin degradation process, samples were withdrawn and 
tested at each day including 6 tests at sample points of Day 0 (T0), Day 1, Day 
2, Day 3, Day 4 and Day 5. The initial (T0) oxaliplatin and oxalate 
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concentrations were the reference values for subsequent time-points. Samples 
taken from each solution in the group were divided into three portions 
respectively for oxaliplatin HPLC assay, oxalate assay with enzymatic method 
and pH measurement. The HPLC assay for oxaliplatin determination was 
described in details in the methodology section (Section 3.2.2). While for 
oxalate determination, an enzymatic method with oxalate assay kit was used to 
detect oxalate concentration in each sample. As a result, samples were 
prepared in two different ways respectively for oxaliplatin (by HPLC method) 
and oxalate (by enzymatic method) determinations, which are described in 
detail below (Section 3.3.2.3.2). 
Furthermore, a group of blank plasma was also tested under the same condition 
to investigate the endogenous oxalate in human plasma and its concentration 
change without the interference from oxaliplatin. Within this group, 3 samples 
(of 15 mL volume each) of blank plasma were incubated at 37 ℃ while 15 mL 
blank plasma was stored at 2 – 8 ℃ as control. The blank plasma samples were 
kept in blood container tubes with EDTA for 5 days and tested for oxalate 
concentration each day using the same oxalate assay kit. Additionally, the pH of 
blank plasma samples was also measured every day. Results from this group 
were used as references for the analysis of those results from oxaliplatin 
sample groups.  
3.3.2.3 Study preparation 
3.3.2.3.1 Group preparation  
Three sample solutions were included in each group and prepared following the 
operating process as described below. 
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Group A: 2 mL of the oxaliplatin concentrate stock solution (5 mg/mL) was 
diluted with 48 mL 5% glucose to prepare 0.2 mg/mL oxaliplatin solutions in 50 
mL flask. These solutions were mixed in inversion and left to stand for 30 
minutes before being transferred into the storage container in order to give them 
enough time for complete mixing. Then sample solutions of oxaliplatin in 5% 
glucose were stored separately in 5 × 10 mL labelled blood tubes with EDTA 
anti-coagulant. 
Group B & C: 50 mL human plasma was withdrawn from 250 mL plasma bag 
by luer-lock syringes and kept in a clean container before the preparation of 
sample solutions. Diluted 2 mL of oxaliplatin concentrate stock (5 mg/mL) with 
48 mL human plasma to gain the oxaliplatin concentration of 0.2 mg/mL. This 
50 mL solution was prepared and mixed completely in 50 mL flask and 
immediately transferred into 5 × 10 mL blood tubes with EDTA for storage to 
prevent the potential plasma clotting. 
Group D: To prepare 50 mL PUF, 60 – 70 mL human plasma was ultra-filtrated 
centrifuged with Amicon Ultra-15 centrifugal filter devices (up to 15 mL) spinning 
at 4100 rpm × g for approximately 3 hours. Then 48 mL of PUF was mixed with 
2 mL, 5 mg/mL oxaliplatin stock solution to obtain 0.2 mg/mL oxaliplatin solution 
in PUF. The solution was then completely mixed in 50 mL flask and stored in 5 
× 10 mL blood tubes with EDTA. 
All solutions with oxaliplatin were prepared, sampled and diluted in a Biomat AC 
Class II safety cabinet and labelled clearly with the drug name, concentration, 
group number, solution name and date of preparation. After first samples were 
withdrawn from each group, all oxaliplatin solutions were then covered by light-
proof bags and immediately put into the incubator at 37℃. 
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The blank plasma group only required human plasma without any additional 
substances, which included 3 × 15 mL test plasma stored in blood tubes with 
EDTA at 37℃ in the incubator. 
3.3.2.3.2 Sample preparation 
Samples from different group were prepared following the schedule as shown 
below: 
Group A (Control group):  
 8 mL sample was withdrawn from each sample solution; 
 4.5 mL sample was used for pH measurement; 
 0.5 mL sample was diluted into 5 mL with deionized water for oxaliplatin 
assay in the HPLC system; 
 3 mL sample was prepared for oxalate assay following the procedure of 
oxalate assay kit: 
1) 3 mL sample was pipetted and mixed with 3 mL of sample diluent in the 
labelled tube; 
2) Adjusted the pH to range of 5.0 to 7.0 with 1 N hydrochloric acid (HCl); 
3) The diluted sample was transferred to a sample purifier tube and mixed 
for 5 minutes;  
4) Then the sample was transferred from purifier tube into ultra-filter tubes 
(10 kDa MWCO) and centrifuged at 4000 rpm for 20 minutes. 
 1 mL of the centrifuged sample was diluted into 5 mL with deionized water, 
from which 50 µL of the dilution was used to test the oxalate concentration 
with reagents in the oxalate assay kit following the determination procedure 
described in methodology above (refer to Section 3.2.4.3). 
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Group B:  
 8 mL sample was withdrawn from each sample solution; 
 5 mL sample was used for pH measurement; 
 3 mL sample was mixed with 3 mL Acetonitrile in an ultrasonic machine for 
15 minutes to gain a 6 mL mixture;  
 3 mL of this mixture was ultra-filter centrifuged and 1 mL filtrate was then 
diluted into 5 mL with deionized water for oxaliplatin assay in HPLC system; 
 The remaining 3 mL mixture was prepared for the oxalate determination 
following the procedure of oxalate assay kit, which was same with Group A 
as described above. 
 2 mL of the centrifuged sample was diluted into 5 mL with deionized water, 
and 50 µL of the dilution was used for determination of oxalate with oxalate 
assay kit. 
Group C:  
 8 mL sample was withdrawn from each sample solution; 
 4 mL sample was used for pH measurement; 
 1 mL sample was centrifuged to gain 0.5 mL filtrate to prepare 5 mL testing 
sample with deionized water for oxaliplatin determination with the HPLC 
method; 
 3 mL sample was prepared for oxalate assay in the same way with Group A 
described above following the procedure of oxalate assay kit; 
 1 mL of the centrifuged sample was diluted into 5 mL with deionized water, 
from which 50 µL of the dilution will be used for determination of oxalate 
with oxalate assay kit. 
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Group D:  
 8 mL sample was withdrawn from each sample solution; 
 4.5 mL sample was used for pH measurement; 
 0.5 mL sample was diluted into 5 mL with deionized water for oxaliplatin 
assay in HPLC system; 
 3 mL sample was prepared for oxalate assay following the procedure of 
oxalate assay kit, which was same to Group A; 
 1 mL of the centrifuged sample was diluted into 5 mL with water, from which 
50 µL of the dilution was used for oxalate determination by oxalate assay 
kit. 
The plasma control required in the oxalate assay was prepared as it was 
described in the methodology section in Section 3.2.4.2. Oxalate concentrations 
were detected and quantified in a spectrophotometer following the 
determination procedure of the oxalate assay kit described in Section 3.2.4.3 
above. 
In the blank plasma group, all samples were only tested for oxalate 
concentrations by an enzymatic method with the oxalate assay kit. At each time 
point, 2 mL samples were taken and detected following the preparation and 
determination schedule described in the oxalate assay in Section 3.2.4. 
3.3.2.3.3 Preparation of other solutions 
Standard solutions of oxaliplatin and oxalate used in their assays were both 
prepared in deionized water from stock solutions following the schedule below: 
Oxaliplatin Standard solution (STD):  
0.02 mL, 5 mg mL⁄  → 10 mL, 10 µg mL⁄  
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Oxalate Standard solution (STD):  
0.45 mL, 1 mg mL⁄  → 10 mL, 45 µg mL⁄  
The oxalate stock solution of 1 mg/mL used above was freshly prepared by 
dissolving the Oxalic acid powder (99.999%) in deionized water. The 
preparation of other solutions and reagents required for oxalate assay was 
presented in Section 3.2.4.3 above.  
3.4 Results 
3.4.1 Validation results for oxalate assays 
3.4.1.1 Validations of the HPLC assay for oxalate determination 
The HPLC method for oxalate determination in oxaliplatin infusion samples was 
validated in terms of intra- and inter-day precisions and linearity of analytical 
response, with reference to the International Conference of Harmonisation 
(ICH) Harmonised Tripartite Guideline, ‘Validation of analytical Procedures: Text 
and Methodology Q2 (R1)’. (161) Precision of the method was analysed with 
the calculation of RSD (relative standard deviation) using equation stated in 
above section (Section 3.2.3.2).  
As shown in Table 3-4, the RSD of Inter-day precision and Intra-day precision 
were both  within the limits of 2.0%, which demonstrated that this method was 
repeatable by standards set in British Pharmacopoeia (BP). (166) (161) In 
addition, the calibration plot was shown to be linear over the concentration 
range of 0.1 – 20.0 μg/mL (n=7), with the equation y = 0.006x + 7E-05 (R2 = 
0.9999) from the least-squares regression analysis, and an even distribution of 
the data on the regression line was observed by visual inspection (as shown in 
Figure 3-4).  
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Table 3-4, Inter-day precision data for the oxalate HPLC assay during 5 continuous days 
and intra-day precision data of 5 injections within one day. 
Precision Type Injection Identifier 
Oxalate Concentration 
(μg/mL) 
RSD (%, n = 5) 
Inter-day 
Precision 
Oxalate Day1 10.6792 
1.61 
Oxalate Day2 10.3206 
Oxalate Day3 10.7386 
Oxalate Day4 10.6380 
Oxalate Day5 10.4776 
Intra-day 
Precision 
Oxalate Test1 11.9984 
0.89 
Oxalate Test2 12.0462 
Oxalate Test3 11.9639 
Oxalate Test4 12.2110 
Oxalate Test5 12.1658 
RSD = Relative Standard Deviation; concentrations were calculated from mean peak heights of two 
continuous injections in HPLC system. 
Inter-day study: 04/06/14-10/06/14     Intra-day study:  29/05/14 
 
Figure 3-4, Oxalate linearity plot with analytic concentrations and peak heights obtained 
with the HPLC assay in oxaliplatin infusion samples. 
In summary, all validation results of this HPLC assay based on intra- and inter- 
day precisions and linearity of analytical response confirmed the assay as being 
suitable for oxalate determination in oxaliplatin infusions in 5% glucose solution. 
3.4.1.2 Oxalate assay kit validations 
To ensure the oxalate assay kit was applicable for oxalate determination in 
human plasma samples, the linearity validation of assay response for oxalate in 
plasma was conducted with the resulting plot shown in Figure 3-5 below. A 
series of oxalate samples were prepared from the dilution of oxalate stock 
y = 0.006x + 7E-05 
R² = 0.9999 
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0 5 10 15 20 25
P
e
ak
 h
e
ig
h
t 
(m
A
U
) 
Oxalate concentration (µg/mL) 
176 
 
solution (1 mg/mL) with human plasma, including 7 oxalate samples in 
concentrations of 1 µg/mL, 10 µg/mL, 20 µg/mL, 40 µg/mL, 60 µg/mL, 80 µg/mL 
and 100 µg/mL. Furthermore, 20 µg/mL oxaliplatin was added to each plasma 
sample in this test in order to investigate the interference of oxaliplatin on 
oxalate determination in plasma samples with this assay. 
According to Figure 3-5, the regression equation from the least-squares 
regression analysis was y = 0.008 + 0.0691 (R2 = 0.9998), which indicated the 
good linearity of this oxalate assay in plasma samples. Moreover, the added 
oxaliplatin (20 µg/mL) might have slightly increased the concentration of oxalate 
but did not influence the linear plot in the result. 
Therefore, the oxalate assay kit could be applied in this study to quantify 
oxalate concentrations in plasma samples without the interference of oxaliplatin. 
 
Figure 3-5, Linearity result of oxalate determination in human plasma by using the 
oxalate assay kit. All samples were prepared with added oxaliplatin at 20 µg/mL. 
3.4.2 Preliminary study results on oxaliplatin infusions 
3.4.2.1 Determination of oxaliplatin and oxalate concentrations 
Oxaliplatin and oxalate concentrations tested in oxaliplatin infusion samples 
from each group were shown in Table 3-5 below, in which the oxaliplatin data 
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given at time zero was from the previous stability study presented in Chapter 2 
(page 121). Compared with the initial value at T0, oxaliplatin concentrations 
slightly increased after storage for  long periods of time and the concentration 
differences were within the range of 0.05% - 8.49%. The oxaliplatin 
concentration difference compared to T0 was calculated from the equation,  
Concentration Difference (%) =  
(Cs − CT0)
CT0
 × 100% 
[Cs: oxaliplatin concentration at sample time; CT0: oxaliplatin concentrations at time zero.]. 
Even though samples tested in this preliminary study were from oxaliplatin 
infusions in different concentrations. The variation percentage of oxaliplatin did 
not appear to be concentration dependent over the oxaliplatin concentration 
range of 0.2 mg/mL to 0.7 mg/mL. There was no obvious relationship between 
oxaliplatin concentration and storage time period for each group. 
Table 3-5, Oxaliplatin and oxalate concentrations in oxaliplatin infusions from Group A 
– G, and the oxaliplatin concentration difference between sample time and time zero. 
Group 
Total 
Storage 
Duration 
Nominal 
Concentration 
of Oxaliplatin 
Oxaliplatin 
Concentration 
at T0 (mg/mL) 
Oxaliplatin 
Concentration 
at Sample 
Time (mg/mL) 
Oxaliplatin 
Concentration 
Difference 
Between Sample 
Time and T0 (%) 
Oxalate 
Concentration 
at Sample 
Time (µg/mL) 
A 577 days 
0.2 mg/mL 0.1817 0.1914 + 5.34 1.8660 
0.7 mg/mL 0.6499 0.7051 + 8.49 3.1653 
B 572 days 
0.2 mg/mL 0.1893 0.1926 + 1.74 2.1580 
0.7 mg/mL 0.6609 0.6923 + 1.59 3.6257 
C 571 days 
0.2 mg/mL 0.1893 0.1923 + 1.59 2.1841 
0.7 mg/mL 0.6609 0.6806 + 2.98 4.3933 
D 570 days 
0.2 mg/mL 0.1880 0.1980 + 5.32 1.5800 
0.7 mg/mL 0.6624 0.6927 + 4.57 3.9401 
E 567 days 
0.2 mg/mL 0.1907 0.1958 + 2.67 2.0932 
0.7 mg/mL 0.6731 0.6872 + 2.10 4.0847 
F 560 days 
0.2 mg/mL 0.1911 0.1912 + 0.05 2.6425 
0.7 mg/mL 0.6634 0.6713 + 1.29 4.9521 
G 553 days 
0.2 mg/mL 0.1868 0.1906 + 2.03 2.2496 
0.7 mg/mL 0.6561 0.6855 + 4.48 4.6857 
T0: Time zero in the stability study; Sample time: The date that samples from different group were tested 
in this study; Storage Duration included storage time during and after the stability study. 
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As shown in Table 3-5 above, more oxalate was produced in those infusions 
with higher oxaliplatin concentration (0.7 mg/mL). In 0.7 mg/mL oxaliplatin 
infusions, the concentration of oxalate was within the range of 3.1653 – 4.9521 
µg/mL; while in 0.2 mg/mL oxaliplatin infusions, oxalate concentrations was 
shown in the range of  1.5800 – 2.6425 µg/mL. Relationships between the 
concentration of oxalate produced in oxaliplatin infusions and the storage time 
period were illustrated in Figure 3-6. As shown in this figure, oxalate 
concentrations slightly reduced along with the extension of storage time for 
oxaliplatin infusions in both concentrations of 0.2 mg/mL and 0.7 mg/mL. While 
for 0.7 mg/mL oxaliplatin infusions, concentrations of oxalate were higher and 
with larger temporal variation. 
 
Figure 3-6, Oxalate concentration change in oxaliplatin infusions at different 
concentrations of 0.2 mg/mL and 0.7mg/mL during the long-term storage period. 
3.4.2.2 pH variations 
pH measurements for each oxaliplatin infusion at sample times were shown in 
Table 3-6, which also included pH variations compared to the initial values from 
Time zero (T0). pH values for all oxaliplatin infusions were within the range of 
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4.32 – 4.56. The largest pH change over the entire storage time among different 
oxaliplatin groups was only + 0.19.  
Table 3-6, pH measurements for oxaliplatin infusions in Group A – G and the pH 
difference between sample time and time zero. 
Group 
Total Storage 
Duration 
pH at T0 
pH at sample 
time 
pH difference 
A 577 days 
4.36 4.48 +0.12 
4.41 4.52 +0.11 
B 572 days 
4.28 4.44 +0.16 
4.36 4.53 +0.17 
C 571 days 
4.28 4.47 +0.19 
4.33 4.52 +0.19 
D 570 days 
4.37 4.32 -0.05 
4.43 4.48 +0.05 
E 567 days 
4.38 4.45 +0.07 
4.48 4.56 +0.08 
F 560 days 
4.36 4.42 +0.06 
4.45 4.52 +0.07 
G 553 days 
4.36 4.43 +0.07 
4.42 4.50 +0.08 
T0: Time zero in the stability study; Sample time: the date that samples from different group were tested 
in this study; Storage Duration included storage time during and after the stability study. 
3.4.3 Results of the oxalate study with human plasma 
As mentioned above in Section 3.3.2, four groups of oxaliplatin sample 
solutions were prepared respectively in 5% glucose, human plasma and PUF, 
and then incubated at 37 ℃ for 5 days throughout the entire study of oxalate 
formation in human plasma with added oxaliplatin. 
3.4.3.1 Oxaliplatin concentration change in human plasma 
Table 3-7 shows oxaliplatin concentration results for Group A – D. Differences 
between oxaliplatin concentrations tested at sample time and at time zero (T0) 
are also presented in Table 3-7, which could show the oxaliplatin degradation 
process in different solvents (5% glucose, plasma and PUF) in this study.  
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For Group A, oxaliplatin degraded slowly at a constant rate in 5% glucose when 
incubated at 37℃. However, the degradation of oxaliplatin in human plasma at 
37℃ was different as shown in results from Group B and Group C. In human 
plasma, oxaliplatin concentrations were reduced significantly within the first day, 
and then maintained this concentration for the duration of the experiment. 
Group D showed the change of oxaliplatin in PUF (plasma ultra-filtrate), in 
which the concentration of oxaliplatin reduced to about 30% of the initial value 
(at T0) after the first day stored at 37℃ and then it remained constant. 
For all four sample groups (Group A – D), Figure 3-7 showed the change of 
oxaliplatin concentrations along with the study time period when stored at 37℃. 
Oxaliplatin concentrations plotted were the mean values from triple sample 
solutions in each group, and the standard deviations are shown as error bars in 
the figure. For Group A, the regression equation of this plot was y = - 16.789x + 
155.2 (R2 = 0.9811), according to which it could be indicated that the 
degradation of oxaliplatin in glucose was approximately linear following the 
time. (Refer to Figure 3-7) For Group B, C and D, changes of oxaliplatin 
concentrations in these groups were similar over the incubation time at 37℃ as 
shown in Figure 3-7. 
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Table 3-7, Oxaliplatin concentrations at each sample time for Group A – D during incubation at 37℃, and the variations of oxaliplatin concentrations 
with respect to the initial values at T0. 
Group 
Identifier 
Day 0 (T0) Day 1 Day 2 Day 3 Day 4 Day5 
Conc. 
(µg/mL) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
A 
(Control) 
157.8290 140.6313 89.11 114.0717 72.29 106.5970 67.54 85.1450 53.95 75.0930 47.58 
B 66.8428 15.8087 23.77 18.3373 27.57 16.3587 24.61 14.3910 21.64 18.1713 27.31 
C 61.8797 4.3623 7.05 4.5027 7.07 6.0293 9.75 6.2580 10.10 6.2480 10.11 
D 116.2983 34.0350 29.25 9.5550 8.22 5.9377 5.10 5.8173 5.01 6.1470 5.30 
Conc.: mean values of oxaliplatin concentration from triplicate samples in each group; Day 0: the start day of the 5 day storage period as Time zero for sample tests; Conc. Relative 
to T0: the proportion of oxaliplatin concentration at sample time compared to the concentration at T0. 
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Figure 3-7, Changes of oxaliplatin concentrations in different samples from Group A - 
D during incubation at 37℃. 
3.4.3.2 Oxalate variations in human plasma with/without added oxaliplatin 
The oxalate result for Group A – D is shown in Table 3-8 with the concentration 
change between each sample time and the initial values tested at T0. In contrast 
to the reduction of oxaliplatin, oxalate concentrations have increased in different 
rates for different groups during the experiment time when incubating at 37℃. 
Results from the blank plasma group were also presented in Table 3-8. The 
initial concentration of oxalate in blank plasma samples was detected as lower 
than 1 µg/mL at T0. The control plasma was also tested every day along with 
other tests but stored at 2 - 8℃ during the experiment. Oxalate concentration 
changes of the control plasma and test samples from the blank plasma group 
are shown in Figure 3-8 below. 
  
y = -16.789x + 155.2 
R² = 0.9811 
0
20
40
60
80
100
120
140
160
180
0 1 2 3 4 5 6
O
xa
lip
la
ti
n
 C
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
L)
 
Time (day) 
Group A
Group B
Group C
Group D
183 
 
Table 3-8, Oxalate concentrations at each sample time for Group A – D and the blank plasma group during incubation at 37℃, and the variations of 
oxalate concentrations with respect to the initial values at T0. 
Group 
Identifier 
Day 0 
(T0) 
Day 1 Day 2 Day 3 Day 4 Day 5 
Conc. 
(µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative 
to T0 
(µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative 
to T0 
(µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative 
to T0 
(µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative 
to T0 
(µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative 
to T0 
(µg/mL) 
A 
(Control) 
-1.8417 6.6532 8.4950 12.6188 14.4605 13.5263 15.3680 16.1943 18.0361 24.5566 26.3983 
B 9.8226 42.1371 32.3145 41.1126 31.2900 37.5505 27.7279 39.2712 29.4486 46.8622 37.0396 
C 9.0041 41.7339 32.7298 42.9444 33.9403 45.8277 36.8236 49.5952 40.5911 51.9782 42.9741 
D 4.5020 36.4919 31.9899 40.0950 35.5929 50.6729 46.1709 43.7247 39.2227 45.8390 41.3370 
Blank 
Plasma 
Group 
0.4487 1.5000 -0.0205 1.7100 0.1895 2.3100 1.8613 3.1177 2.6690 2.4466 1.9979 
Conc.: mean values of oxalate concentration from triplicate samples in each group; Day 0: the start day of groups storage as Time zero for sample tests. 
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Figure 3-8, Oxalate concentration changes in the control plasma and samples from the 
blank plasma group, which were stored separately at 2 – 8 ℃ and at 37℃. [The 
concentration used in the blank plasma sample plot was the average value calculated from triple tests.] 
Oxalate changes of Group A – D are shown in Figure 3-9, and for each group 
oxalate concentrations on these plots were mean values from triplicate samples 
with the standard deviations as error bars in the figure. As shown in Figure 3-9, 
the increasing of oxalate concentrations in Group A was not quite linear but the 
trend was obvious during 5 days storage at 37℃. Concentration changes of 
oxalate in Group B, C and D throughout the incubation (37℃) time period were 
also presented in Figure 3-9. For these three groups, oxalate was produced 
largely within the first storage day and the concentrations of oxalate increased 
at a low rate for remaining days of the experiment. 
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Figure 3-9, Changes of oxalate concentrations in different samples from Group A, B, C 
and D during incubation at 37℃. 
3.4.3.3 pH variation trend 
pH measurements for Group A – D at each sample time point was shown in 
Table 3-9 with the pH variation compared to the initial value at T0. 
In Group B, C and D, the largest pH variation was only 0.29 among all samples 
which was too small to indicate any significant change in those solutions. 
Although the pH variations in Group A were also quite small (within the range of 
0.28 – 0.71), there was a reducing trend of pH values in this group as shown in 
Figure 3-10. There were few potential reasons for this pH change which are 
explored later in the discussion section (Section 3.5.3.4) of this chapter. 
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Table 3-9, pH measurements at each sample time for Group A – D with the variation 
compared to the initial value at T0. 
Group 
Identifier 
Day 
0 
(T0) 
Day 1 Day 2 Day 3 Day 4 Day 5 
pH pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
A 
(Control) 
5.25 4.92 -0.33 4.84 -0.42 4.74 -0.51 4.63 -0.62 4.60 -0.65 
B 7.11 6.94 -0.17 7.23 0.11 7.1 -0.02 7.2 0.09 7.18 0.07 
C 7.06 7.02 -0.03 7.19 0.14 7.23 0.17 7.33 0.27 7.06 0.00 
D 7.09 7.11 0.01 7.14 0.05 7.28 0.18 7.25 0.15 7.34 0.25 
pH measurements presented in this table were mean values from triplicate samples in each group; Day 0: 
the start day of groups storage as Time zero for sample tests; pH difference to T0: difference between the 
pH of each sample and the initial value at T0. 
 
Figure 3-10, pH variation of oxaliplatin infusion samples in Group A during the 
incubation at 37℃. 
3.5 Discussion 
3.5.1 Preliminary study on oxaliplatin infusions 
The preliminary experiment utilised oxaliplatin infusions from the previous 
stability study (refer to Chapter 2, page 97) were stored at 2 - 8℃ for more than 
550 days, with different storage periods for each group. The determination of 
oxaliplatin and oxalate concentrations from those samples, provide useful 
benchmark information of the production and growth of oxalate in oxaliplatin 
infusions (including 0.2 mg/mL and 0.7 mg/mL oxaliplatin infusions) after 
prolonged storage. 
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Results of oxaliplatin and oxalate concentrations from those infusions were 
presented in Table 3-5 above. Variations of oxaliplatin concentrations over the 
storage time were shown in Figure 3-11 below, in which oxaliplatin 
concentrations were presented  as % variation with respect to the initial values 
at T0 (referring to the results of the previous stability study in Chapter 2, page 
121).  
Two separate data series were included in Figure 3-11, which presented the 
concentration variation of oxaliplatin in the infusion bags prepared respectively 
in 0.2 mg/mL and 0.7 mg/mL. Oxaliplatin concentrations from all infusions have 
increased compared with the initial value from time zero. However variations 
detected in 0.7 mg/mL oxaliplatin infusions were slightly higher than the other 
ones in 0.2 mg/mL infusions at most sample times. Before 575 days, variations 
of oxaliplatin concentrations in both infusions were within the strict criteria range 
of ± 5%, while after stored for 577 days the variation of oxaliplatin in 0.7 mg/ml 
infusions was up to 8.49%.  
 
Figure 3-11, Oxaliplatin variations over storage time in infusions that prepared in 
different oxaliplatin concentrations, 0.2 mg/mL and 0.7 mg/mL. [T0 = Time zero; oxaliplatin 
variation = the proportion of oxaliplatin concentration difference between sample and time zero 
compared to the initial value from time zero; the oxaliplatin variations shown in this figure are all 
positive values.] 
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Concentrations of oxalate were also determined in those oxaliplatin infusions 
with a validated HPLC assay. Oxalate results in this preliminary study showed 
the existence of oxalate in oxaliplatin infusions after storage for a prolonged 
period. In addition, the amount of oxalate produced from oxaliplatin degradation 
was detected in those infusions, which could be used to estimate the quantity of 
oxalate given to patients through oxaliplatin infusions in clinical practice. 
Consequently, the potential for oxaliplatin infusions to cause oxalate-mediated 
toxicity was demonstrated. 
As shown in Table 3-10, measured oxalate concentrations in all samples from 
those infusions stored for a long period were very low. When compared with 
oxaliplatin infusions of 0.2 mg/mL, slightly more oxalate was produced from the 
oxaliplatin degradation in 0.7 mg/mL infusions during the storage time. This may 
suggest that, oxaliplatin infusions prepared in higher concentrations might 
produce more oxalate before drug administration, which could increase the 
potential risk of oxalate-mediated toxicity for patients. 
Table 3-10, Oxalate concentrations (mmol/L) in samples from different infusions 
(prepared with 0.2 mg/mL and 0.7 mg/mL oxaliplatin) after stored at 2 - 8℃ for a 
period of time. 
Group 
Identifier 
Storage 
period 
(day) 
Oxalate concentrations in samples (mmol/L) 
0.2 mg/mL oxaliplatin 
Infusions 
0.7 mg/mL oxaliplatin 
Infusions 
A 577 0.02119 0.03596 
B 572 0.02452 0.04119 
C 571 0.02481 0.04991 
D 570 0.01795 0.04476 
E 567 0.02378 0.04641 
F 560 0.03002 0.05626 
G 553 0.02556 0.05324 
 
189 
 
 
Figure 3-12, Oxalate concentrations (mmol/L) in infusions prepared with 0.2 mg/mL 
and 0.7 mg/mL oxaliplatin during long-term storage at 2 - 8℃. 
As shown in Figure 3-12, oxalate concentrations in 0.2 mg/mL oxaliplatin 
infusions slightly decreased over the storage period. While for 0.7 mg/mL 
infusions, the reducing trend of oxalate concentrations was more obvious with a 
larger slope. It can be assumed that before 560 days oxalate concentrations 
were higher than 0.03002 mmol/mL and 0.05626 mmol/mL respectively for 
oxaliplatin infusions of 0.2 mg/mL and 0.7 mg/mL. 
From previous literature, concentrations of plasma oxalate in humans were 
determined by various methods. (206) From methods with different accuracy 
and precision, different results were presented for oxalate concentrations in 
human plasma and blood samples. (191) (206) In healthy human body, oxalate 
concentration in blood could range from less than 1 µmol/L to more than 400 
µmol/L according to the previous published studies. (206) However, the general 
consensus of the concentration range for plasma oxalate in healthy humans is 1 
– 3 µmol/L, (191) (206) (207) and this range was adopted as a reference for this 
study. 
As shown in Table 3-10, oxalate in 0.2 mg/mL oxaliplatin infusions were within 
the range of 0.01795 mmol/L – 0.03002 mmol/L, while for 0.7 mg/mL infusions 
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the concentrations were higher from 0.03596 mmol/L to 0.05626 mmol/L. 
Obviously, all infusions tested in this study were with higher concentration of 
oxalate than likely to be found in human plasma (1 – 3 µmol/L). (191) However, 
the maximum amount of oxalate in those infusions of 250 mL was only 0.66 mg 
and 1.24 mg respectively for 0.2 mg/mL and 0.7 mg/mL oxaliplatin infusions. 
Compared with the amount of oxalate (at most 50 mg) taken by people through 
regular diet, the amount of oxalate detected in oxaliplatin infusions was much 
lower. (186) According to the maximum amount of oxalate (1.24 mg) in 0.7 
mg/mL oxaliplatin infusions, the expected plasma concentration of oxalate was 
2.8062 µmol/L (calculated with the average blood volume of 5 L (208)), which 
was within the reference range of oxalate concentration in healthy human 
bodies. Furthermore, it has been indicated that oxalate was only toxic to renal 
tubular cells when its concentration reached as high as 5 mmol/L. (188)  
3.5.2 Oxalate assay selection for plasma samples 
In order to select a sufficient assay for oxalate determination in plasma 
samples, the validated HPLC assay used in the preliminary study (refer to 
Section 3.3.1.2) was also tested to determine oxalate in plasma samples. Two 
groups of plasma samples with added oxaliplatin and one group of oxaliplatin in 
PUF were included in this trial test. In contrast to the preliminary study with 
oxaliplatin infusions (prepared in 5% glucose), results from the plasma sample 
groups displayed huge variations of oxalate concentrations in each sample. 
Additionally, the blank PUF tested by the same HPLC assay has shown much 
higher concentrations of oxalate compared to other sample groups with added 
oxaliplatin. These results potentially indicated the endogenous oxalate existing 
in plasma and PUF, and also brought the negation of the precision and 
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accuracy of the oxalate HPLC assay for plasma/PUF samples applied in this 
trial. 
The HPLC assay for oxalate determination selected for the preliminary study 
(Section 3.3.1.2) was in Hydrophilic Interaction Chromatography (HILIC) mode 
with an improved amide column from GL science. As discussed above, the 
HILIC was a preferable technique for polar and/or basic solute, which could 
provide much higher solute diffusivity and highly symmetrical peak shapes. 
(193) For polar solute such as oxalate, the HILIC should be better than the 
regular reversed-phase chromatography. One of the major disadvantages for 
HILIC was the heavy reliance on the aprotic solvent (such as acetonitrile), and 
consequently the mobile phase applied in this assay was prepared with 65% 
acetonitrile. (193) This assay has been improved and validated for oxalate 
determination in samples of oxaliplatin infusions with 5% glucose in the 
preliminary study (Section 3.2.3.2). During those validations, it was found that 
sample dilution in the mobile phase with higher aprotic solvent could improve 
the chromatogram result for oxalate separation in the HPLC system. Thus, 
samples tested in this HPLC assay were all diluted within the mobile phase 
(containing 65% acetonitrile) before being injected into the HPLC system. 
However, for plasma/PUF samples, dilution in the solvent with high percentage 
of acetonitrile might not be suitable considering the deproteinisation effect of 
acetonitrile on plasma samples. Although plasma samples were ultra-filtered in 
advance following the preparation schedule, the oxalate determination results in 
HPLC system could still be influenced by various components in human 
plasma/PUF. With the diluted samples, the HPLC system can be potentially 
affected in several ways, such as damage or blockage in the HPLC column; 
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flowrate change in the system; interference on target substance separation in 
determination. 
Therefore, the HPLC assay with amide column was excluded for oxalate 
determination in plasma samples, and an alternative enzymatic method with an 
oxalate assay kit was used in the main study. 
3.5.3 Oxaliplatin and oxalate change in plasma during the 
incubation at 37℃ 
The main experiment of ‘oxalate study in human plasma with oxaliplatin’ was 
designed with 4 groups of oxaliplatin in different diluents which were incubated 
at 37℃ in order to simulate the degradation process of oxaliplatin in patient 
bodies. A group of blank plasma was also tested in this study to provide the 
oxalate data in blank plasma after treatment and storage under the same 
conditions as the other sample groups.  
3.5.3.1 Oxaliplatin degradation in plasma samples 
According to the result of this experiment (Table 3-7), oxaliplatin prepared in 
plasma – Groups B and C – degraded at a high reaction rate within the first day 
of the experiment and then entered a period of steady-state concentration. The 
degradation process of oxaliplatin in PUF, obtained from Group D, was similar 
to those results from plasma groups, which has also been reported in a 
previous study carried by Jerremalm, Elin. (124) The degradation process of 
oxaliplatin within the first day could not be indicated in detail by the results 
achieved from this study due to the low temporal resolution achievable. But this 
experiment could at least confirm the very short half-life (t1/2) of oxaliplatin in the 
initial degradation after administration. With the extensive non-enzymatic 
chemical transformation in human blood, the half-life of oxaliplatin in vivo has 
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been estimated at around 15 minutes in published literature. (124) (131) The 
half-life of oxaliplatin in human plasma could be approximately calculated as 12 
minutes with results from this experiment, which was close to the reference 
value of 15 minutes. (131)  
In this study, Group B was prepared with 0.2 mg/mL oxaliplatin in human 
plasma and intended to investigate the total amount of oxaliplatin 
concentrations (including free and protein-bound oxaliplatin) in plasma samples. 
Group C was assayed for the concentration of un-bound (free) oxaliplatin in 
plasma. Thus, concentrations of oxaliplatin bound with proteins in plasma could 
be calculated following the equation, 
 𝐶𝑜𝑛𝑐. (𝑏𝑜𝑢𝑛𝑑) = 𝐶𝑜𝑛𝑐. (𝑡𝑜𝑡𝑎𝑙) − 𝐶𝑜𝑛𝑐. (𝑢𝑛𝑏𝑜𝑢𝑛𝑑) [Conc.: concentration]. 
Samples from Group B were treated with acetonitrile to break down bonds 
between oxaliplatin and plasma proteins. This acetonitrile deproteinisation 
process was validated with the recovery rate of 108.32% and the oxaliplatin 
concentration found in plasma without acetonitrile treatment was about 54.04% 
of the total amount of oxaliplatin. As for oxaliplatin results from Group B and 
Group C, shown in Figure 3-13 below, the total oxaliplatin was approximately 
twice the amount of the un-bound oxaliplatin on average. 
 As shown in Figure 3-13, the total amount of oxaliplatin was degraded 
significantly in the first day, and so was the un-bound (free) oxaliplatin. 
However, throughout the experiment the observed concentration of protein-
bound oxaliplatin remained unchanged with few small fluctuations. It 
demonstrated that only un-bound or “free” oxaliplatin could undergo 
degradation. This significant result suggested that it is likely that only the free 
drug would contribute to therapeutic and adverse effects. In terms of drug 
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degradation and possible liberation of oxalate, the focus should be on the un-
bound fraction (free) of oxaliplatin. 
 
Figure 3-13, Concentrations of total, bound and un-bound (free) oxaliplatin calculated 
from result of Group B and Group C at each sample day.  
Figure 3-14 showed concentrations of oxaliplatin in samples from Group C and 
Group D, which represented the different degradation process of oxaliplatin in 
plasma and PUF. As shown in the figure, oxaliplatin in PUF started with a 
higher concentration but degraded down to the same value as the un-bound 
oxaliplatin in plasma. The PUF used in this study was prepared by subjecting a 
certain amount of human plasma to ultra-filter centrifuge. From previous 
literature, it was believed that within the PUF chloride ion (Cl-) was more 
concentrated than the plasma that PUF was prepared from. (209) Moreover, it 
has been proved that oxaliplatin can be ‘bio-transformed’ essentially by water 
and nucleophiles, such as Cl-. (127) However, Cl- concentrations in both plasma 
and PUF were not measured in this study. It cannot be indicated that the 
different Cl- concentrations contained in plasma and PUF were the reason for 
different oxaliplatin concentrations examined in plasma and PUF samples. 
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Figure 3-14, Concentrations of un-bound (free) oxaliplatin in plasma from Group C and 
oxaliplatin in PUF (plasma ultra-filtrate) from Group D at each sample day. 
3.5.3.2 Oxalate growth in plasma samples 
Since only un-bound (free) oxaliplatin could degrade in plasma samples (as 
discussed above), there should be the same amount of oxaliplatin degraded in 
these two plasma groups of Group B and Group C. Because the majority of 
oxalate in plasma was produced from oxaliplatin degradation, oxalate 
concentration values and variation tendency were highly similar for Group B and 
C as shown in Figure 3-15. These results also suggested it was less possible 
that protein bonds occurred between oxalate and plasma proteins, since the 
acetonitrile treatment operated on Group B samples did not affect the similarity 
of oxalate result from these two groups. After storage at 37℃ for 5 days, the 
oxalate result from Group B and C could both represent the growth of oxalate 
concentration in human plasma after administration with oxaliplatin.  
The variation tendency of oxalate concentrations in PUF samples of Group D 
was similar to the other two plasma groups (Group B and C) with slightly lower 
values in each sample. This concentration difference between oxalate in plasma 
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and in PUF samples could possibly be explained by the endogenous oxalate 
existing in human plasma. 
In Figure 3-15, oxalate concentrations in plasma samples of Group B and C 
were corrected with the endogenous oxalate detected in blank plasma control. 
The average oxalate concentration in blank plasma control was 0.0475 mmol/L, 
which was close to the average value (0.0317 mmol/L) of the concentration 
difference between plasma and PUF samples. According to Figure 3-15, 
oxalate concentrations detected in plasma samples (Group B and C) were close 
to those results from PUF samples (Group D) after correction with the 
endogenous value of oxalate in blank plasma.  
 
Figure 3-15, Oxalate concentrations for Group B and Group C after correction with the 
endogenous oxalate value from blank plasma control; and oxalate concentrations for 
Group D. [Group B: oxaliplatin samples prepared in plasma and treated with acetonitrile to detect the 
total amount of oxaliplatin including protein-bound and un-bound (free) oxaliplatin; Group C: 
oxaliplatin samples prepared in plasma to detect the un-bound (free) oxaliplatin; Group D: oxaliplatin 
samples prepared in PUF (plasma ultra-filtrate)] 
3.5.3.3 Reconciliation of oxalate production and oxaliplatin degradation 
3.5.3.3.1 In oxaliplatin infusions (with 5% glucose) when stored at 
37℃ 
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In this study, the control group (Group A) was prepared with 0.2 mg/mL 
oxaliplatin in 5% glucose, in order to show the change of oxaliplatin and oxalate 
in glucose infusions after incubation at 37℃ for 5 days. As shown in Figure 3-7 
and Figure 3-9 above (in Section 3.4.3), concentration changes of both 
oxaliplatin and oxalate from Group A were both almost linear. In samples of 
Group A, oxaliplatin concentrations increased with the regression equation 
of 𝑦 =  −16.789𝑥 + 155.2 (𝑅2 = 0.9811), while the concentration of oxalate was 
with the reduction plot of 𝑦 = 4.6149𝑥 + 0.4139 (𝑅2 = 0.9361). Considering the 
stability of oxaliplatin in infusions that stored in refrigerated conditions at 2 - 8℃, 
this result indicated that oxaliplatin degradation in 5% glucose infusions was 
influenced by temperature (37℃). Therefore, in clinical practice the storage 
conditions (especially temperature) for oxaliplatin infusions should be under 
strict control to prevent the potential risk of increased oxaliplatin degradation at 
higher temperature.  
In oxaliplatin infusions, oxalate was produced from oxaliplatin degradation, and 
theoretically its concentration increase should be in proportion to the 
concentration loss of oxaliplatin. As shown in Figure 3-16 below, the 
concentration increasing trends were at similar rates for oxaliplatin loss and 
oxalate gain. However, these concentration changes for oxaliplatin and oxalate 
were not equal in Group A.  
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Figure 3-16, Concentrations of oxaliplatin loss and oxalate gain in oxaliplatin infusions 
with 5% glucose from Group A tested at Day 1 – Day 5. [Conc. = Concentration in 
oxaliplatin infusions prepared with 5% glucose.] 
Infusion samples from Group A were prepared with only oxaliplatin and 5% 
glucose, thereby the potential interference to oxalate production could be from 
glucose, oxaliplatin and oxaliplatin degradation products, such as [Pt(DACH)]2+ 
(1,2-diaminocyclohexyl-platinum) complexes. Because the oxalate assay used 
in this study was operated with a spectrophotometer at 590 nm, neither glucose 
nor [Pt(DACH)]2+ complexes can be absorbed and determined at this 
wavelength according to European Pharmacopoeia. (164) In this case, 
concentration differences between oxaliplatin loss and oxalate gain at each 
sample time were not caused by interference from other components in 
oxaliplatin infusions. 
One potential reason for the concentration gap between oxaliplatin loss and 
oxalate gain could be the pH adjustment to the samples used for oxalate 
determination during the experiment. As mentioned in Section 3.3.2.3, diluted 
samples were adjusted to pH 5.0 – 7.0 with 1 N hydrochloric acid (HCl) for the 
oxalate assay, while samples for oxaliplatin determination were injected into the 
HPLC system without pH adjustment. It has been demonstrated in previous 
studies that oxaliplatin decay in aqueous media can be affected by the chloride 
concentration and pH of the solution. (127) As a result, during the sample 
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preparation procedure oxaliplatin might be further degraded and consequently 
produced more oxalate in those samples for oxalate determination. This 
hypothesis was not verified in this study, in which case the concentration 
difference between oxaliplatin and oxalate change in infusions cannot be fully 
explained. However, these concentration differences obtained in Group A could 
be used as reference to other plasma/PUF groups, in which samples were 
prepared following the same schedule. The average value of the concentration 
difference calculated at each sample time was approximate 0.0571 mmol/L, and 
results of other plasma/PUF groups were corrected with this value and 
discussed in the following section.  
3.5.3.3.2 In plasma/PUF samples when stored at 37℃ 
As discussed above, oxalate has been implicated in neurotoxicity associated 
with oxaliplatin chemotherapy and it could also be nephro-toxic when the 
plasma oxalate concentration increased to a certain level. (12) (188) Therefore, 
the relationship between oxalate concentration change and oxaliplatin 
degradation in plasma and PUF (plasma ultra-filtrate) was the focus of this 
study. 
Figure 3-17 and Figure 3-18 showed the relationship between concentrations of 
oxaliplatin loss and oxalate gain in plasma samples from Group B and Group C. 
Oxalate concentration gains shown in these two figures were corrected by three 
factors, which were 1) the endogenous oxalate tested in plasma control at each 
sample time; 2) the concentration gap between oxaliplatin loss and oxalate gain 
observed from the control group, Group A (refer to the above Section 3.5.3.3.1); 
3) the increase of endogenous oxalate in blank plasma samples when stored at 
37℃ for 5 days, which will be discussed in the following paragraph. 
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Figure 3-17, The relationship between concentrations of oxaliplatin loss and oxalate 
gain in Group B. [Oxalate concentrations have been corrected by three factors.] 
 
Figure 3-18, The relationship between concentrations of oxaliplatin loss and oxalate 
gain in Group C. [Oxalate concentrations have been corrected by three factors.] 
According to those figures above, the oxalate concentration gained in plasma 
samples was higher than the oxalate that can be explained by oxaliplatin 
degradation. It could indicated that after oxaliplatin administration the change of 
oxalate in human plasma was mainly related to non-enzymic transformation of 
oxaliplatin but partially affected by other factors, such as the endogenous 
oxalate that originally existed in human plasma. 
A group of blank plasma was tested to investigate concentration variations of 
the endogenous oxalate when incubated at 37℃ for the period of this 
experiment. All samples in this control group were blank plasma without any 
additional substances. Table 3-11 presented results of this plasma control 
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group, and mean values of oxalate concentrations from three tests were shown 
in Figure 3-19.  
Table 3-11, Mean values of oxalate concentrations from the blank plasma group after 
incubated at 37℃ for 5 days. 
Test Identifier 
Oxalate Concentration (mmol/L) 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Plasma Control 0.0064 0.0038 0.005 0.0212 0.0118 0.004 
Plasma Test 1 0.0085 0.011 0.016 0.028 0.0353 0.0272 
Plasma Test 2 0.0043 0.019 0.021 0.024 0.0332 0.0252 
Plasma Test 3 0.0021 0.02 0.02 0.025 0.0353 0.0291 
The mean oxalate Conc. 
among three samples 
-0.0014 0.0129 0.014 0.0045 0.0228 0.0232 
Conc. = Concentration; the mean oxalate Conc. was the average value calculated from three plasma 
tests at each sample day, which has been corrected by the oxalate concentrations in plasma control. 
 
Figure 3-19, Oxalate concentrations in blank plasma tests after incubation at 37℃ for 5 
days. [All concentrations were corrected by plasma control at each day.] 
To simplify the analysis, data from Group C will be referenced in the discussion 
below, since it could represent the oxaliplatin and oxalate status in plasma as 
discussed in above sections (Section 3.5.3.1 and Section 3.5.3.2). 
Assuming that the concentration of oxalate produced from oxaliplatin 
degradation was equal to the loss of oxaliplatin which was 0.1448 mmol/L at the 
first day in Group C. The total increased oxalate in plasma samples observed 
was 0.3568 mmol/L which suggested the extra oxalate generated from 
somewhere unknown was 0.2237 mmol/L. As shown in Table 3-11, after 
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storage under the same conditions at 37℃, oxalate concentrations in blank 
plasma were increased, and within the first day 0.0143 mmol/L oxalate was 
gained. Subtracting the endogenous oxalate increased by plasma itself, there 
was still 0.2094 mmol/L more oxalate that could not be traced back to the 
source.  
However, after excluding the effect of temperature on plasma, it could at least 
be confirmed that the unexplained concentration change of oxalate was related 
to oxaliplatin that was administered to plasma samples. Except for the 
degradation reaction, oxaliplatin might have other influences on human plasma, 
which could promote the oxalate production in plasma. Within the first day after 
administration 0.2 mg/mL oxaliplatin could cause an increase of oxalate in 
human plasma of approximate 0.3542 mmol/L. As described above, oxaliplatin 
concentrations were stabilized around 0.0138 mmol/L in plasma after the first 
day, while oxalate was still increasing in a gentle slope. (Shown in Figure 3-18) 
Therefore, those hypothetical effects from oxaliplatin might also interfere in the 
second phase of this experiment (Day 2 – Day 5). Although it was not 
investigated in this study, the potential relationship between oxaliplatin and 
endogenous oxalate in human plasma could be of interest for further studies on 
related subjects in the future. 
Those hypothetical effects of oxaliplatin on plasma could be related to a number 
of issues, such as 1) the sudden increase of oxalate after oxaliplatin 
administration might influence the endogenous oxalate in plasma; 2) oxaliplatin 
might have triggered some reactions between substances contained in plasma; 
3) other degradation products from oxaliplatin might be involved.  
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Figure 3-20, The relationship between concentrations of oxaliplatin loss and oxalate 
gain in Group D. 
The relationship between concentrations of oxaliplatin loss and oxalate gain in 
PUF (Group D) was shown in Figure 3-20. As discussed in the above sections, 
changes of oxaliplatin and oxalate in PUF were similar to those results in 
plasma, with the exception that the decay of oxaliplatin in PUF occurring at a 
higher degradation rate. More oxaliplatin was degraded and consequently more 
oxalate should be produced compared to plasma samples. However, when 
compared to the results from plasma groups, the difference between oxaliplatin 
loss and oxalate gain was slightly smaller in PUF. This meant the extra oxalate 
produced from plasma by the hypothetical effects from oxaliplatin was less in 
PUF than in plasma. In this case, the potential mechanism for the oxaliplatin 
influence on plasma might be more related with the substances which exist in 
human plasma but are not included in PUF. 
3.5.3.4 pH variation 
pH measurements of samples from each group were subject to no interference 
from other potential factors since those samples were all measured directly from 
the blood container. During 5 days incubation at 37℃, pH variations of samples 
from Group A, B, C and D were all relatively small.  
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Figure 3-10 presented in Section 3.4.3.3 (page 189) showed the reducing trend 
of pH values from oxaliplatin infusion samples in the control group of Group A. 
Two potential causes for pH reduction were considered: oxaliplatin degradation 
and change of glucose solvent. This pH reduction trend did not appear in other 
oxaliplatin groups that were prepared with plasma and PUF, in which case pH 
reduction should not be attributed by oxaliplatin degradation. Thus the result 
suggested that after incubation at 37℃, the glucose related reaction might be 
triggered which influenced the pH value of the solution.  
A previous study on glucose degradation was conducted by Per Kjellstrand 
(210), which indicated that temperature was the most important factor affecting 
the degradation of glucose among all storage conditions. Furthermore, pH 
reduced concurrently with glucose degradation under the storage temperature 
of 40℃ and the decrease rate for pH variation was higher with higher storage 
temperature. (210)  
Therefore, the pH reduction trend occurred with samples from Group A in this 
experiment could be explained by the degradation of glucose after storage at 
37℃ for 5 days. 
3.5.4 Clinical significance 
In the preliminary study, as discussed above, oxaliplatin infusions prepared with 
5% glucose were tested for both oxaliplatin and oxalate determination. After 
being stored at 2 – 8 ℃ for a long period of 577 days, the maximum amount of 
oxalate detected from 0.7 mg/mL oxaliplatin infusions (250 mL) was 1.24 mg, 
which was relatively small compared with the level of endogenous plasma 
oxalate. Therefore, the amount of oxalate produced in oxaliplatin infusions was 
acceptable and safe to human bodies. Consequently, in clinical practice 
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oxaliplatin infusions freshly prepared or with short-term storage at 2 - 8℃ before 
the drug administration should be free from any potential toxicity related 
to/caused by oxalate. It could even be speculated that after being stored for 3 
months (the proven stability period for oxaliplatin infusions from the previous 
stability study described in Chapter 2, page 136), the amount of oxalate 
generated in oxaliplatin infusions should be too small to cause any potential 
toxic effects to patients. 
In the main experiment, oxalate was detected within plasma/PUF samples after 
administration with oxaliplatin. However, the concentration of oxaliplatin (0.2 
mg/mL) applied in this study was 100 times higher than the Cmax value quoted in 
studies in the published literature. (11) Therefore, oxaliplatin and oxalate 
concentrations obtained from this study were reduced by 100 times to simulate 
the in vivo situation of plasma in patients. The highest concentration of oxalate 
obtained in plasma samples was 4.997 µmol/L after scaling down by 100 times 
and corrected by the plasma control test. This oxalate concentration value could 
be used to represent the highest oxalate concentration in the plasma of a 
patient’s body within 5 days after the administration of oxaliplatin. According to 
the previous literature, the concentration of plasma oxalate in healthy bodies 
was generally considered in 1 – 3 µmol/L, while in some cases it could be as 
high as 10 µmol/L but without any toxicity or potential damage to human bodies. 
(191) (207) Therefore, after oxaliplatin administration the amount of oxalate 
increased in plasma samples in this study was highly unlikely to cause 
significant toxic effects on patients. 
As mentioned in above sections, oxalate was the most likely suspect for 
causing the neurotoxicity associated with oxaliplatin therapies. Some previous 
published studies have excluded several potential factors that may cause the 
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neurotoxicity, and suggested that oxalate could be involved since it is the main 
degradation product of oxaliplatin. (12) (183)  
Regardless of the unknown mechanism of the acute neurotoxicity associated 
with oxaliplatin treatments, in order to cause any toxicity or damage, the amount 
of oxalate in blood circulation of human bodies had to be in the abnormal 
conditions or reach the toxic concentration level. (145) (146) However, results 
from this study proved that the amount of oxalate did not increase to abnormal 
level neither in oxaliplatin infusions nor in human plasma after administration of 
oxaliplatin infusions.  
The experiment on plasma/PUF samples was only conducted for 5 days after 
drug administration. As shown in result tables (Section 3.4.3.2, page 187), 
oxalate concentrations were possessed a slight increasing trend at the end of 
the experiment, and were likely to increase further after these 5 days. 
Nevertheless, the acute neurotoxicity reported in the literature normally 
appeared very quickly after the oxaliplatin administration. In this case, results of 
this study should be sufficient to analyse this type of neurotoxicity associated 
with oxaliplatin therapies.  
In summary, according to this study the amount of oxalate in both oxaliplatin 
infusions and in plasma (after oxaliplatin administration) was within the safe 
level for patients. Oxalate might not be the relative factor to the acute 
neurotoxicity which has been observed with oxaliplatin treatment. 
This study also showed that storage temperature conditions could have a 
significant influence on oxaliplatin infusions. In the preliminary study, more 
oxalate was detected in infusions with higher prepared oxaliplatin concentration 
(0.7 mg/mL). Therefore, with the concern of individual dosage for patients 
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oxaliplatin infusions prepared in clinical practice should be better calculated and 
prepared in lower concentration to reduce the risk for producing more oxalate. 
In addition, it was proven that oxaliplatin degraded faster in 5% glucose when 
stored at high temperature (37℃) (Section 3.4.3.1). Thus, the storage condition 
for oxaliplatin infusions in 5% glucose should be strictly controlled without 
exposure to high temperature even for a short time period. In clinical practice, 
the storage of oxaliplatin infusions should take extra concern in order to prevent 
any potential risk for patients. 
3.5.5 Limitations 
In the preliminary study (refer to Section 3.5.1), oxaliplatin infusions in 5% 
glucose from the previous stability study (described in Chapter 2, page 97) were 
used for oxalate and oxaliplatin determinations after a long-term storage at 2 – 
8℃. Results from the preliminary study suggested that the amount of oxalate 
produced in oxaliplatin infusions was speculated to be safe for patients. 
However, results could be more convincing if the oxalate determination would 
have been carried out concurrently with the oxaliplatin assay for all groups at 
each sample time during the stability study presented in Chapter 2.  
In clinical practice and dose-banding schemes, oxaliplatin infusions would not 
be used after a long-term storage, such as 500 days. The amount of oxalate 
detected in this preliminary study could not directly indicate the safety level of 
oxalate existing in oxaliplatin infusions that normally administered to patients. In 
addition, the increase tendency of oxalate in oxaliplatin infusions was not fully 
analysed in this preliminary study because of the lack of data from the great 
time gap during the long storage period. 
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3.6 Conclusion 
The amount of oxalate produced in oxaliplatin infusions (in 5% glucose) after 
long-term storage at 2 – 8℃ was relatively small and should not be considered 
harmful or toxic to human bodies. 
The concentration of oxalate increased in plasma after oxaliplatin administration 
when stored at 37℃ for 5 days. However, the total amount of increased plasma 
oxalate was relatively low, which suggested that oxalate might not be the cause 
of the acute neurotoxicity associated with oxaliplatin therapies. 
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Chapter 4: An ex vivo pharmacokinetics (PK) 
simulation study of oxaliplatin administered with 
different dosing schemes 
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4.1 Introduction 
4.1.1 Pharmacokinetics (PK) 
4.1.1.1 Introduction to PK 
Pharmacokinetics, as a branch of pharmacology, is the attempt to discover what 
happens to a drug from its administration to the complete elimination from the 
body. (211) (212) Generally, after oral administration a drug will be subjected to 
four processes in the body, which are absorption (A), distribution (D), 
metabolism (M) and excretion (E). (212) In the case of intravenous 
administration, the absorption phase is effectively instantaneous.  
Pharmacokinetics is the study of the time course of these four processes for 
drugs and the relationships between drug dose, plasma concentration and 
pharmacological (therapeutic and toxic) effect within the ADME processes. (211) 
(213) Key pharmacokinetic parameters related to the ADME processes include 
bioavailability (bioequivalence), apparent volume of distribution, 
biotransformation and clearance. (211) (213) 
Bioavailability is normally used to describe the rate and extent of drug 
absorption (A), which could be defined as the fraction of the administered drug 
dose that reaches systemic circulation. (211) According to this definition, 
different administration routes of drugs result in different bioavailability (the 
bioavailability for a drug administered intravenously can be defined as 100%). 
(211) (214) Thus, bioavailability is an important tool to determine the differences 
in drug absorption rates between non-intravenous forms of drug administration 
such as oral and percutaneous drug-delivery. (211) (213)  
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For a given drug distribution (D) process, the apparent volume of distribution (Vd) 
represents the relationship between the drug concentration in blood/plasma and 
the amount of drug in the whole body. (211) (215) However, there is no obvious 
relationship between the apparent and real volumes of drug distribution in 
patients’ bodies. (211) (215) The real volume of drug distribution is related to 
the different parts of the body fluid, including vascular fluid or blood, 
extracellular fluid and intracellular fluid. (211) (213) In general, for drugs bound 
to plasma proteins, the apparent volume of distribution is smaller than the real 
distribution volume; for drugs bound to extravascular tissues, the apparent 
volume of distribution is larger than the real volume of distribution. (211) (213) 
The apparent volume of drug distribution can be used to estimate the theoretical 
distribution volume and facilitate the production of the desired drug 
concentration in blood circulation. (211) 
Total clearance is another important pharmacokinetic parameter, which is used 
to characterize drug elimination (containing elements of both metabolism and 
excretion). (211) (216) Clearance indicates the volume of plasma (or blood) 
from which the drug is completely removed or cleared in a certain time period. 
(216) Drugs can be cleared from the body through various organs with different 
mechanisms, including renal filtration and secretion, hepatic biotransformation, 
biliary excretion, gastrointestinal tract clearance and pulmonary clearance. (211) 
(216) Total/systemic clearance is the sum of all individual clearance that 
contribute to the overall elimination of a drug, as shown in the equation: 
𝐶𝐿𝑡 = 𝐶𝐿𝑟 + 𝐶𝐿ℎ + 𝐶𝐿𝑏 + 𝐶𝐿𝑜𝑡ℎ𝑒𝑟 . [CLt: total body clearance; CLr: renal 
clearance; CLh: hepatic clearance; CLb: biliary clearance; CLother: clearance by 
all other routes.] (211) (216) 
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To conceptualize the interactions between the drug and organisms, a number of 
models have been developed. (216) The most commonly applied approach in 
pharmacokinetic studies is the compartmental model, which represents the 
body as a system of compartments to simplify complicated physiological 
systems. (211) (217) These compartments obviously are not physiologic or 
anatomically related, but this modelling system gives the best approximation to 
reality. (216) In compartmental models, the rates of transfer/elimination 
between/from compartments are assumed to follow first-order or linear kinetics. 
(211) (217) There are some drugs with nonlinear absorption, distribution or 
elimination characteristics, for such cases the ‘population’ model is preferred 
with additional consideration of random effects. (211) (217) Among the 
compartmental models, the one-compartment model is the simplest and most-
frequently used model for drugs that distribute throughout the body relatively 
rapidly or instantaneously in some cases. (211) (217) Multi-compartment 
models can be applied to those drugs that have different distribution rates to 
different tissues. (211) In multi-compartment models, the highly perfused 
organs/tissues and blood may be treated as the central compartment, while the 
poorly perfused organs/tissues may be considered as peripheral compartments. 
(211)  
Another modelling method used commonly is the non-compartment model, 
which can be applied to any compartmental model with fewer restrictive 
assumptions than other approaches. (130) (211) (217) In addition, based on the 
estimation of total drug exposure (refer to AUC), a non-compartment model can 
be used to estimate the drug’s associated pharmacokinetic parameters, such as 
bioavailability, clearance, apparent volume of distribution, half-life (t1/2), Tmax, 
Cmax and the fraction of a drug dose converted to a specific metabolite. (211) 
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(130) A non-compartment model can also be used to predict the average 
steady-state concentration (Css) and the time required to reach a certain fraction 
of the steady-state concentration of a drug. (211) Therefore, a non-
compartment model was selected for this study to obtain required 
pharmacokinetic parameters which would indicate the pharmacologic effects of 
oxaliplatin with different dosing and administration schemes. 
4.1.1.2 The importance of PK 
Pharmacokinetics is one of the fundamental scientific disciplines for the design 
and development of new drugs and for the reassessment of old drugs. (211) 
(218)  
The general drug design comprises several steps, including: 1) setting up a 
valid hypothesis of the target enzyme/receptor for the disease; 2) testing the 
biological activities with suitable models (or surrogate markers); 3) screening 
the ex vivo and in vivo biological activities of the new drug molecules. (218) 
Several compounds will be tested for their ex vivo activities as drug candidates 
during the screening stage. (216) (218) However, the result from ex vivo and 
animal experiment could be misleading without considering their 
pharmacokinetic characteristics, for example a promising compound could be 
excluded from the experiment with an inappropriate animal species or poor 
experimental design. (218) Early and rapid pharmacokinetic information from 
estimations are essential to select the optimal drug candidates with good 
bioavailability, desired half-life (t1/2) and suitable first-pass metabolism. (211) 
(218) In the development stage, minimal toxicity and maximum efficacy of 
selected drug candidates are the focus, which requires the most available 
pharmacokinetic data for the drug on absorption, distribution, metabolism and 
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excretion processes. (211) (218) In addition, pharmacokinetics could explain the 
underlying mechanisms of other important issues in drug development, such as 
drug-drug interaction, inter-individual variability of the drug efficacy and the 
relevant safety/risk assessment for inter-relationships between animal and 
human experiments or between ex vivo and in vivo studies. (211) (218) (219) 
In order to achieve the efficacy and safety of drug treatments, clinical 
pharmacokinetics, based on the knowledge of drug pharmacokinetics, is directly 
applied to therapeutic situations during the clinical practice of pharmaceutical 
care. (218) (219) Clinical pharmacokinetics can be applied to optimise the drug 
regimen, with relation to the dosage adjustment, drug formulation selection and 
optimal drug administration route. (213) (219) Besides this, the therapeutic drug 
monitoring (TDM) for drugs with narrow therapeutic window or high toxicity also 
requires the application of clinical pharmacokinetics, where plasma drug 
concentrations are determined during treatments and compared with defined, 
clinically-acceptable limits. (211) (213) (219)  
4.1.1.3 PK parameters 
A graphic profile of drug pharmacokinetics is the curve of plasma drug 
concentration versus time, represented as a typical time course in Figure 4-1 
below. Within this typical curve, there are four primary parameters used to 
characterise the PK of a drug substance: AUC, Cmax, Tmax and T1/2. After the 
drug is administered, the highest concentration in blood/plasma (Cmax) will be 
achieved at a certain time point (Tmax), which should be compared to the 
effective level of drug Cmax required to provide good therapeutic efficacy for 
patients. (212) (219) Cmax and Tmax exhibit larger variability due to the 
administration route than drug dosage. (212) (220) The hierarchical order of 
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different levels of Cmax and Tmax achieved with different drug administration 
routes is shown below: (212) (220) 
Cmax: Intravenous bolus>Intravenous infusion>Oral medicine>Intramuscular 
injection 
Tmax: Intravenous bolus<Intravenous infusion<Oral medicine<Intramuscular 
injection.  
T1/2 is one of the main pharmacokinetic parameters of a drug, which represents 
the time for the drug concentration to be reduced by half. (211) T1/2 is normally 
used to estimate the drug elimination and the time period of body exposure to a 
drug. (212) (216) In multiple-dosing methods, T1/2 has value in determining of 
the frequency of drug dosing in order to obtain the desired blood/plasma drug 
concentration in a patient’s body. (211) (220) 
 
Figure 4-1, A typical pharmacokinetic drug concentration-time curve. [Cmax: the highest 
drug concentration after administration; Tmax: the time point when Cmax is achieved; T1/2: 
the half-life of drug (using the decay from Cmax as example); AUC: the area under the 
drug concentration-time curve.] 
AUC, short for area under the drug concentration-time curve, is mathematically 
expressed as the integral of the plasma drug concentration over an interval of 
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definite time. (212) (219) In clinical practice, the commonly used method to 
estimate a drug  pharmacokinetic profile is to plot time and the plasma drug 
concentration measured at a number of discrete time points. (211) (212) (213) 
More sample measurements of plasma concentrations would be expected to 
increase the precision of the drug AUC value. (212) As shown in Figure 4-1, the 
AUC is dependent upon the achieved/maintained drug concentration and the 
length of the drug elimination time, which contributes to the drug exposure to 
the body’s tissues and organs. (216) The efficacy and toxicity of a drug, as 
discussed above, are related to the degree of drug exposure in the systemic 
compartment of the patient body. (211) (212) As a result, AUC  can be used as 
a surrogate for the total drug exposure over time and this information can 
facilitate various methods to increase the drug efficacy or reduce the toxicity, 
such as dosage adjustment, administration scheduling and formulation selection. 
(212) (219) In this study, five different administration schedules were evaluated 
and the AUC values were used in the data analysis as the key index to estimate 
and compare the therapeutic effect that these dosing methods would have on 
clinical outcomes. 
4.1.2 Background to this study 
4.1.2.1 PK characteristics for dosing methods selection 
An ex vivo PK simulation model under laboratory conditions was designed and 
applied in this study to compare the  key PK parameters from five different 
dosing methods, including Individual dosing, dose-banding with 5% and 10% 
deviation in each band, Logarithmic dose-banding and Flat-fixed dosing. These 
drug administration methods are all related to intravenous infusion but with 
different dose calculations and infusion administration systems.  
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In order to obtain a reliable comparison, drug infusions were prepared in similar 
volumes. Drug concentrations in the ‘central compartment’ were measured at 
22 time points, to produce a drug concentration-time curve for each ‘patient’ 
with each administration method. The simulated PK parameters used for 
comparisons between the 5 different dosing methods were Cmax and AUC. Cmax 
indicates the highest drug concentration achieved in the central compartment 
(blood circulation), which, ideally would remain within the threshold 
concentrations for the drug efficacy and toxicity if a therapeutic window could be 
defined. AUC represents the total drug exposure in a ‘patient’s body’, which is a 
key PK surrogate to estimate the drug efficacy and toxicity. As with Cmax, AUC 
can be calculated from the drug concentration-time curve by using specialist PK 
curve-fitting software. 
In clinical practice, the individual dosing scheme preparation according to 
patient’s BSA (body surface area), is used for the routine administration of 
oxaliplatin in chemotherapy. This traditional BSA-based dosing method is 
believed to provide the safest and most effective dose algorithms for patients 
when receiving cytotoxic drugs with a narrow therapeutic window. (8) However, 
the individualized BSA-based dosing is not optimal in many cases, and 
alternative dosing methods should be considered to provide more effective 
chemotherapy administrations to patients. (221) Therefore, this study will 
compare the new drug dosing approaches, such as different dose-banding 
schemes and flat-fixed dosing, with the conventional individualised dosing 
method. To identify any differences in the availability of drug to the tissues in a 
patient’s body between these different dosing systems, the comparison will 
focus on oxaliplatin PK parameters of AUC and Cmax. 
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4.1.2.2 PK data from previous studies of oxaliplatin 
Pharmacokinetic evaluation of oxaliplatin is a key part for the drug clinical 
development. Previously published PK studies on oxaliplatin are summarised in 
Table 4-1 with key data for oxaliplatin pharmacokinetic parameters.  
Since all these PK studies of oxaliplatin have been conducted under different 
laboratory conditions, there was a large variability between key PK parameters 
obtained by different studies. To ensure the referenced studies were of 
comparable quality, only the more robust studies were considered in this study, 
which met the following conditions: 
 Samples from at least 10 patients were taken, regardless of whether they 
received oxaliplatin in combination chemotherapy or as a single agent. 
 The oxaliplatin dosage used in the study was within the range of 70 – 90 
mg/m2, which was closer to the licenced dose of 85 mg/m2 used in this study. 
 Blood samples were taken at a minimum of 10 time points within 24 hours. 
Generally, it was considered that the higher sampling frequency would reduce 
the influence of any experimental errors and would add to the robustness of the 
concentration-time curve data obtained. 
Differences among previous PK studies of oxaliplatin included different drug 
administration systems (e.g. pumps, giving sets), assay methods and different 
PK curve-fitting models used for data analysis. In addition to the use of 
oxaliplatin in different combination chemotherapy regimens, the lengths of 
intravenous infusion of oxaliplatin also varied between studies (such as 2 hours, 
3 hours or 4 hours). Oxaliplatin assays in blood samples were different, but 
there were some common methods used in these studies including inductively 
coupled plasma mass spectrometer, flameless atomic absorption 
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spectrophotometry and liquid chromatography with post-column derivatization. 
The most common PK model used to analyse oxaliplatin PK data was the non-
compartmental PK model, while 2-compartment and 3-compartment models 
were occasionally reported.  
To assemble the ex vivo PK simulation model, the reference values of Vd and 
CLtotal are required, which should be selected from previous PK studies on 
oxaliplatin. However, analysis of the available data identified significant 
differences between previous studies in key pharmacokinetic parameters, such 
as Vd and CL, (see Table 4-1 below). Aside from the issues discussed above, 
these variations might also be attributed to the preparation and treatment of 
patient samples. In some studies patient samples were assayed directly as 
blood samples, whereas plasma and PUF samples were detected in other 
studies (shown in Table 4-1). To represent the distribution volume of total 
oxaliplatin in blood samples, Vd data demonstrated in three previous studies 
were selected for analysis, including Takimoto (2007) (129), Ehrsson (2002) 
(131) and Delord (2002) (222).  Thus, the average value of Vd = 12.41 L/m
2 was 
used for model assembly in this ex vivo PK study. The total clearance (CLtotal) of 
oxaliplatin referred in ex vivo simulations (2.88 L/h/m2) was selected as the 
mean value of general oxaliplatin clearance obtained in previous studies listed 
in Table 4-1 below with major outliers excluded. 
For practical and financial purposes, it was necessary to scale down the 
distribution volume used in the ex vivo model from the normal range of 
physiological volumes of human patients. The scale-down system applied in this 
study is described in detail in the experimental section. (Section 4.3.1.1) 
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Table 4-1, Summary of published literature on oxaliplatin pharmacokinetics. 
Resource 
Dose 
(mg/m
2
) 
No. of 
Patients 
Sample 
Type 
AUC0-t (µg*h/mL) CLtotal (L/h) Cmax (µg/mL) Vd (L) 
T1/2 
(h) 
Vd (L/m
2
) in 
whole blood 
CL (L/h/m
2
) 
Claudia Burz, 2009 
(3) 
85 4 
Plasma 51.4 (t=24h) 2.77 1.61 108 26.1 15.08 1.55 
UFT 4.8 (t=24h) 30.17 0.38 567 12.1 16.67 16.85 
130 4 
Plasma 54.81 (t=24h) 3.81 2.35 132.6 24.2 18.52 2.47 
UFT 5.87 (t=24h) 35.24 0.86 469.25 9.32 13.8 19.69 
Chris H. Takimoto, 
2007 (129) 
130 11 
Plasma 
89.5 (t=48h) 313 
(t=Infinity) 
0.214 (*1.73) 3.94 38.9 (*1.73) - 9.73 0.214 
UFT 9.14 (t=48h) 4.2 (*1.73) 1.31 361 (*1.73) - 19 4.2 
Kuniaki Shirao, 2006 
(223) 
90 3 
Plasma 244.3 0.37 (*1.73) 2.26 110.3 (*1.73) 7.6 27.58 0.37 
UFT 7.9 11.6 (*1.73) 0.96 1433.4 (*1.73) 0.18 75.44 11.6 
130 6 
Plasma 258.3 0.52 (*1.73) 3.22 127.2 (*1.73) 7.8 31.8 0.52 
UFT 11.3 11.7 (*1.73) 1.45 1612.7 (*1.73) 0.17 84.88 11.7 
Wolfgang Kern, 1999 
(133) 
130 12 
Plasma 1593 1.56 3.11 179 1 25 0.87 
UFT 20.17 13.32 1.61 349 0.09 10.26 7.44 
SPC from Aventis 
Pharma Limited, 
2011 (122) 
85 
- 
UFT 4.19 (t=48h) 17.4 0.814 440 0.43 12.94 9.72 
130 UFT 8.20 (t=48h) 10.1 1.21 582 0.28 17.11 5.64 
Margaret E. Macy, 
2013 (224) 
85 4 UFT 6.29 12.02 0.288 - 116.7  - 6.72 
100 4 UFT 8.17 - 0.294 - -  - -  
Paul L Mitchell, 2011 
(143) 
70 43 Plasma 87 (t=168h) 1.107 1.97 117.534 90 16.42 0.62 
H. Ehrsson, 2002 
(131) 
85 
4 
UFT 2.83 32.1 (*1.73) 1.44 0.26 (L/kg) 0.235 10.28 32.1 
6 
J.P. Delord, 2002 
(222) 
130; 80; 
100 
40 
UFT  - 18.7 - 40.8 - 
10 
10.45 
Blood - 0.127 - 17.9 - 0.071 
Claire Massari, 2000 
(225) 
130 13 
Plasma 49.02 2.51 2.59 69.72 0.45 9.74 1.4 
UFT 5.21 25.7 1.09 338.38 0.42 9.95 14.36 
Continued       
Resource 
Dose 
(mg/m
2
) 
No. of 
Patients 
Drug Administration 
Sample 
points 
Assay Method PK model 
Claudia Burz, 2009 
85 4 
2-hour intravenous infusion in 
FOLFOX4 12 in 24 
hours 
Inductively Coupled Plasma Mass 
Spectrometer (ICP-MS) 
non-compartment (WinNonLin, 
USA) 
130 4 
4-hour intravenous infusion in 
XELOX 
Chris H. Takimoto, 
2007 
130 11 
2-hour intravenous infusion with 
prophylactic antiemetic regimen 
13 in 504 
hours 
Inductively Coupled Plasma Mass 
Spectrometer (ICP-MS) 
non-compartment (WinNonLin 
3.1, USA) 
Kuniaki Shirao, 2006 
90 3 
2-hour intravenous infusion with 
5-fluorouracil and leucovorin 
13 in 338 
hours 
Inductively Coupled Plasma Mass 
Spectrometer (ICP-MS) 
non-compartment (WinNonLin 
3.1, USA) 
130 6 
Wolfgang Kern, 1999 130 12 
4-hour intravenous infusion with 
5-fluorouracil 
13 in 8 hours 
Flameless Atomic Absorption 
Spectrometry (GBC 904 AA, Maassen, 
Germany) 
3-compartment (TOPFIT) 
SPC from Aventis 
Pharma Limited, 
2011 
85 
- 2-hour intravenous infusion - - non-compartment 
130 
Margaret E. Macy, 
2013 
85 4 2-hour intravenous infusion in 
FOLFOX 
4 in 48 hours 
Flameless Atomic Absorption 
Spectrophotometry 
non-compartment (SAAM II 2.0, 
The Epsilon Group, VA) 100 4 
Paul L Mitchell, 2011 70 43 
2-hour intravenous infusion with 
gemcitabine 
10 in 24 
hours 
- - 
H. Ehrsson, 2002 85 
4 
2-hour intravenous infusion 9 in 12 hours 
Liquid Chromatography with postcolumn 
derivatization 
2-compartment 
6 
non-compartment (WIN 
NONLIN 1.5 SCI) 
J.-P. Delord, 2002 
130; 80; 
100 
40 
3-hour intravenous infusion with 
5FU and FA 
9 in 24 hours 
Flameless Atomic Absorption 
Spectrophotometry 
3-compartment (NONMEM) 
Claire Massari, 2000 130 13 2-hour intravenous infusion 
12 in 24 
hours 
Flameless Atomic Absorption 
Spectrophotometry (FAAS) 
- 
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4.1.3 PK simulation under laboratory conditions 
Although PK parameters are a potential surrogate for estimating the clinical 
effects and therapeutic outcomes obtained by switching from individual dosing 
to dose-banding (216), there is a problem in conducting PK studies with 
cytotoxic drugs. The acute and chronic toxicity, genotoxicity, potential 
mutagenic and carcinogenic effects of cytotoxic drugs, precludes the 
administration of this class of drugs to healthy volunteers who would normally 
provide subjects for PK studies. (3) This study explored the use of an ex vivo 
simulation model for the pharmacokinetic study on oxaliplatin in five different 
dosing strategies. Since oxaliplatin has a simple distribution procedure within 
the central blood circulation, only a single compartment needed to be simulated 
in the model. (109)  (225) Additionally, because of the 100% renal excretion of 
oxaliplatin, the simulated elimination rate used in this system could be simply 
adjusted with the renal clearance rate. (11) (225) Therefore, a simply structured 
ex vivo simulation model could be constructed for oxaliplatin PK studies. 
In this model, an infusion bag with 5% glucose was used to simulate the central 
compartment of the body, in which the volume represented the volume of 
distribution selected by the review of data from previous oxaliplatin PK studies. 
The renal drug elimination was replicated by the continuous outlet flow from the 
infusion bag (central compartment), the flow rate of which was scaled down 
from the total clearance (CLtotal) of oxaliplatin. Moreover, to balance the loss of 
glucose solution from the infusion bag caused by simulated renal excretion, a 
compensation bag with 5% glucose was used to replace this loss and maintain 
a constant volume for the ‘central compartment’. To apply the result from this 
study to general estimation of the oxaliplatin pharmacokinetics, the CLtotal 
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values, referred for the outlet flowrate in this simulation system, were selected 
from previous PK studies on patients with normal renal and hepatic functions.  
The main advantage of the ex vivo PK simulation approach was that it could 
avoid the need to request cancer patients to participate in a PK study. Generally, 
the clinical PK study would require up to 24 hours hospital stay of patients from 
post-infusion and blood samples would be taken invasively at many time points. 
Except for those inconveniences for patients, the clinical study involved with 
cancer patients would always require ethics approval and informed consent 
from patients and their oncologist. 
Other advantages of the ex vivo PK simulation method also included: 
 The simulation model was easy to build up and operate in laboratory 
conditions; 
 This simulation model can also be adjusted to simulate the PK process for 
different drugs; 
 The ex vivo PK simulation approach was cheaper and easier to obtain the PK 
data for cytotoxic drugs compared with in vivo clinical trials. 
 This ex vivo PK simulation model could be used in pre-clinical studies for the 
novel drug development, such as to facilitate a drug bioactivity study and/or 
animal experiments.  
However, there were certainly limitations of this ex vivo PK simulation system. 
As described above, only the central compartment of the body was simulated, 
thus the system cannot be applied to those drugs with more complicated 
distribution and elimination processes. Since this model simulated the human 
body with an infusion bag, the whole system with drug dose, distribution volume 
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and total body clearance must be scaled down to  a practical, laboratory-friendly 
volume which might affect the accuracy of the PK result.  
Considering all advantages and drawbacks, the ex vivo PK simulation model 
could be considered for future PK studies as an alternative approach to a study 
with real patients. 
4.1.4 Dosing administration strategies 
Since the 1950s, traditional dosing of chemotherapeutic drugs has normally 
been calculated from the body surface area (BSA). (226) (227) This approach 
results mainly from the use of BSA to scale doses between species to estimate 
the dose in different animals (mouse, dog) and thus determine a dose for phase 
I clinical studies in humans. (226) (227) As most cytotoxic agents have a 
relatively narrow therapeutic window this approach was considered the 
standard means of determining a “safe” dose close to the maximum tolerated 
dose (MTD) to provide optimal dose intensity of the drug. (221) (228) 
Meanwhile, patients with extreme body weight, such as the obese and children, 
can receive a suitably adjusted dosage to ensure the efficient and safe level of 
drug concentration in vivo. (226) The licenced dose for oxaliplatin was 85 
mg/m2 , with the body surface calculated from the BSA formula: (229) 
𝐵𝑆𝐴(𝑚2) = 0.007184 × ℎ𝑒𝑖𝑔ℎ𝑡(𝑐𝑚)0.725 ×𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)0.425. 
However, there are several problems associated with the BSA-based individual 
dosing of chemotherapeutic drugs, including the increased waiting time for 
patients, drug calculation errors and working stress for pharmacists and nursing 
staff involved. (8) (9) Therefore, dose-banding schedules have been introduced 
as a new approach for chemotherapy administration, which could provide the 
pre-prepared standard doses in batch-scale aseptic infusions (in bags or 
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syringes). (8) Additionally, these standard doses are calculated based on 
patients’ BSA. (8) (10) The dose-banding method is currently used for several 
chemotherapeutic drugs in the UK. (148) Compared to the individualized 
therapy, the dose-banding schemes allow the prospective quality control for 
pre-made infusions in the manufactory and prevent errors in dose calculation 
and drug administration. (8) (148) The dose-banding method could also reduce 
the waiting time for patients since the drug infusions are all pre-made and ready 
for administrations. (10) Therefore, a proper dose-banding scheme should be 
developed for the administration of oxaliplatin in cancer chemotherapies.  
In this study, three different dose-banding schemes were tested on 10 ‘patients’ 
which were a dose-banding scheme with the maximum 5% deviation in each 
band (5%DB), a dose-banding scheme with the maximum 10% deviation in 
each band (10%DB) and a logarithmic dose-banding scheme (LDB). Dose-
banding with 5% deviation (5%DB) was the most acceptable dose-banding 
scheme for physicians, which has been applied to different chemotherapeutic 
drugs in clinical practice. (152)  
Generally, the drug dose variations can be effected be several factors, such as 
the potential variation in drug stock vials; calculation errors on patients’ BSA; 
administration errors by pharmacists or nurses; the drug infusion waste in 
infusion bags and tubes during the injection to patients. (221) Therefore, the 
normal administration of individualized dosing could possibly cause more than 
10% drug dose errors in total, and 10% difference in the drug dosage should be 
theoretically acceptable. (9) Therefore, 10%DB with the dose variation of no 
more than 10% from the prescribed dose to the standard dose in each band 
should be considered as an optional dose-banding scheme for oxaliplatin 
administrations. Compared to 5%DB, 10%DB can be designed and operated 
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with less dose bands, which requires a lower number of pre-preparation infusion 
bags for standard doses in each band.  
In general, dose-banding schemes are designed with a linear relationship in 
band ranges, such as 5%DB and 10%DB. (230) As a result, the dose variation 
in bands with higher doses is smaller than in those bands with lower doses. 
(230) To improve the accuracy and safety in use of dose-banding schemes, a 
logarithmic dose-banding (LDB) scheme has been introduced with logarithmic 
relationships in doses to give even dose variations (≤ 6%) between concurrent 
dose bands. (230) (231) With the LDB scheme, patients prescribed with lower 
doses could be treated with less potential risk on dose errors. (231) In addition, 
a single sequence of LDB could cover doses from 1 mg to 100000mg, which 
can be applied to all systematically delivered cytotoxic drugs for patients of all 
sizes. (230) (231) To compare the logarithmic dose-banding (LDB) with other 
dose-banding schemes and individual dosing method, the dosing system of 
LDB referred from Geoff Hall (232) was also tested in this study.  
Previous literature discussed the flat-fixed dosing method and suggested to 
replace the current BSA-based dosing administration for some anticancer drugs, 
because of the weak relation found between BSA and the inter-individual PK 
variations. (221) (226) (233) However, the question of whether the analysis of 
such limited data can prove the safety and superiority of the flat-fixed dosing 
method has been controversial. (227) 
In this study, the ex vivo PK simulation model was set up to determine the PK 
parameters with these five different dosing schedules (IND, 5%DB, 10%DB, 
LDB and FFD). In order to find the preferred dosing administration strategy for 
oxaliplatin infusions, the simulated AUC and Cmax values and their inter-
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individual variabilities were analysed and compared for different dosing 
schemes in this ex vivo study. 
4.1.5 Purpose and objectives 
 To discover the optimal dosing method for oxaliplatin administration in 
chemotherapies by comparing the AUC and Cmax values simulated from the 
ex vivo PK model; 
 To determine the differences in simulated PK parameters from various drug 
administration methods, including individual dosing method (IND), dose-
banding scheme with the maximum 5% variation in each band (5%DB), 
dose-banding scheme with the maximum 10% variation in each band 
(10%DB), logarithmic dose-banding scheme (LDB) and flat-fixed dosing 
method (FFD); 
 To evaluate the inter-individual variability of AUC and Cmax for each patient 
group (n = 10) with different dosing schemes including IND, 5%DB, 10%DB, 
LDB and FFD. 
 To validate the reliability and accuracy of the ex vivo PK simulation system. 
4.2 Materials and methodology 
4.2.1 Materials 
4.2.1.1 Chemicals and reagents 
Oxaliplatin concentrate solution 5 mg/mL, batch no. PP02066; expiry 10/2015 
(Accord Healthcare Limited, UK) 
Glucose 5% w/v Macoflex, Lot. 899914122H, expiry 09/2016 (Macopharma, UK) 
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Sodium phosphate monobasic monohydrate (ACS reagent, 98.0 - 102.0%) 
(Sigma-Aldrich, Japan) 
Sodium phosphate dibasic (HPLC grade) (Sigma, USA) 
Sodium hydroxide 1M; Acid ortho-phosphoric; Methanol; Hydrochloric acid 1M 
(HPLC grade, Fisher Scientific, UK) 
Multifunction peroxide solution 3% (Specsavers, UK) 
pH electrode storage solution; pH 4.01 Buffer solution; pH 7.00 Buffer solution 
(Thermo Fisher Scientific, USA) 
Sterile water for irrigation and dilution, batch 12E22B28, expiry 04/2015 
(distilled and de-ionised) (Baxter, UK) 
4.2.1.2 Consumables 
Luer-lock syringes in 2 mL and 5 mL (B. Braun Medical Ltd, UK) 
Luer-lock syringes in 10 mL and 20 mL (Codan Medical ApS, UK) 
0.8 mm × 40 mm needles, 21G × 11/2’’, LOT 120507, expiry 04-2017 (BD 
Microlence, UK) 
1.1 mm × 40 mm needles, 19G × 11/2’’, LOT 120411, expiry 03-2017 (BD 
Microlance, UK) 
Screw-cap polypropylene tubes 20 mL (Gosselin SAS, UK) 
HPLC auto-sampler crew-cap vials 2 mL and caps (Chromacol Ltd., UK) 
Cellulose acetate filters (pore size 0.45 μm) (Sartorius Stedium Biotech, 
Germany) 
Disposable polypropylene pipettes 3 mL (Fisher Scientific, UK) 
Micropipette tips 1000 μL (Gilson SAS, France) 
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Prep Pad, 70% Isopropyl Alcohol BP (A CliniMed Group Company, UK) 
Colleague pump/gravity solution administration sets (Baxter, UK) 
4.2.1.3 Equipment and instrumentation 
Analytical balance: Sartorius Basic 100g - 0.0001g 4-figure balance (Sartorious 
Ltd., UK) 
Balance: SG-601(600g ×0.1g) 3-figure (S/N: 8335436123, Ohaus Corporation, 
USA) 
Colleague Volumetric Infusion Pump No. 1 – 4 (SN 9030134CK; SN 
9030221CK; SN 9030207CK; SN 99BC2129AA, Baxter, UK) 
Refrigerator at 2 – 8℃ (Fisher Scientific, UK) 
Incubator at 25 ± 1℃  (Gallenkamp, Japan) 
Digital thermometers (Fisher Scientific, UK) 
Micropipette: Proline Plus 100 – 1000 μL (Biohit Limited, UK) 
Micropipette: Proline Plus 10 – 100 µL (Biohit Limited, UK) 
pH meter : Orion 5 Star Benchtop with glass combination electrode (Thermo 
Scientific, UK) 
Magnetic stirrer : HI 190M (Hanna Instruments, UK) 
Glass filter holder and flask (Emil company, UK) 
Filter vacuum pump: FB 70155 (Fisher Scientific, UK) 
Class Ⅱsafety cabinet: Biological Class Ⅱ containment (Bigneat Ltd., UK) 
Gyro-rotatory shaker: Certomat M, Type 886008/4 (B. Braun Melsungen, AG, 
Germany) 
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Glassware: Grade A flasks, measuring cylinders and beakers (Fisher Scientific, 
UK) 
HPLC Column: Water Spherisorb® (CNRP) 4.6 mm×250 mm stainless steel, 
packed with 5.0 μm bonded phase cyano CNRP Column (Waters Limited, UK) 
HPLC System: (Jasco UK, Essex UK) 
Intelligent Column Thermostat, CO-2060 plus 
Intelligent Auto-sampler, AS 2057 plus 
Quaternary Gradient Pump, PU-2089 plus 
Multiwavelength Detector, FP 2020 
LE-Net Ⅱ/ADC 
Chrompass Software version 1.8.6.1 
4.2.2 HPLC assay for oxaliplatin 
A bonded-phase cyano column of Waters Spherisorb® (CNRP), 5.0 μm particle 
size and 4.6 mm × 250 mm, was used to separate oxaliplatin in the HPLC assay 
which was adapted and developed from the European Pharmacopoeia. (164) 
Separation was achieved under isocratic conditions with a mobile phase of 5 
mM phosphate buffer in pH 6.5. The detector was UV diode-array detector 
using 210 nm wave length, and Jasco ChromPass version 1.8.6.1 was used to 
collect and analyse the chromatographic data. HPLC conditions were shown 
below: 
Flow rate = 1.0 mL/min  
Injection volume = 20 µL 
Run time = 10 mins 
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Detection wave length = 210 nm 
Temperature of column oven = 35℃ 
Column maintenance: The HPLC column was conditioned every 14 days with 
the following cycle of solvents run through the column at a flow rate of 1 mL/min: 
HPLC grade water for 20 minutes; methanol and water with 50 : 50 (v/v) for 20 
minutes; 100% methanol for 20 minutes; methanol and water 50 : 50 (v/v) for 20 
minutes; HPLC grade water for 20 minutes. In addition, daily storage of the 
column required flushing with HPLC grade water for 20 minutes followed by 
50:50 methanol : water (v/v) for 20 minutes prior to shut down. 
Details of validation tests for this oxaliplatin assay in HPLC system have been 
described in the previous stability study of oxaliplatin infusions in Chapter 2 
(Section 2.2.2, page 110). 
4.2.3 The ex vivo PK simulation model 
This ex vivo system was designed for simulating the main pharmacokinetics 
behaviour of oxaliplatin in the central compartment of a human body. 
4.2.3.1 Four main components 
Reservoir A (central compartment) represented the central compartment of the 
patient’s body by using a 5% glucose infusion bag in 500 mL/1000 mL size. The 
volume of these bags referred to the volume of drug distribution (Vd) in the 
patient’s body which depended on the individual patient’s BSA (body surface 
area). (Refer to Section 4.3.1) 
Reservoir B (Compensation solution) was used to compensate the solution 
loss of the Reservoir A, in order to balance the volume of the simulated ‘central 
compartment’ of a patient’s body. During the experiment, the solution in 
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Reservoir A continuously flowed out in the flowrate scaled down from CLtotal to 
simulate the elimination process in the body. To maintain the ‘body weight’, 
different volumes of 5% glucose solution was infused to Reservoir A in different 
flowrate as the compensation for an individual ‘patient’, which volume (VB) could 
be calculated following the equation: VB = R1 × T1 + R1’ × T2. [R1: flow rate of 
pump 1(Reservoir A – Reservoir B) during infusion time; R1’: flow rate of pump 
1 after infusion time; T1: infusion time, 2 hours; T2: experimental time of post-
infusion, 6 hours.]. Considering various BSA values of the 10 ‘patients’ selected 
in this study, 5% glucose bags in 1000 mL were used as single or the 
combination of two bags for different patients. 
Reservoir C (Waste) was an empty bag used for collecting waste solutions 
from the ‘central compartment’, Reservoir A. This bag can be safely sealed and 
was in a large volume which could handle all waste solution produced from the 
‘patient’ during the 8-hour experiment. The volume of waste solution can be 
approximately calculated from the following equation: Vwaste = CL × Ttotal. [CL: 
the total clearance of oxaliplatin for individual ‘patient’; Ttotal: the total 
experimental time for each runs, 8 hours.] 
Drug infusions (diluted with 5% glucose) were prepared in different size 
syringes following different schedules according to the dosing administration 
systems (individual dosing, dose-banding schemes and flat-fixed dosing). 
Preparation and administration schedules for different dosing methods are 
described in the experimental section (Section 4.3.2). 
4.2.3.2 Pump function 
To ensure the accuracy of the infusion flowrates in this study, three Baxter 
Colleague volumetric pumps were validated and used to connect Reservoir B, 
232 
 
Reservoir C and oxaliplatin infusions to Reservoir A with the chemotherapeutic 
drug administration sets. The flowrates of inlet/outlet solutions to/from Reservoir 
A were controlled by these pumps and were adjusted respectively to balance 
the volume of the ‘central compartment” during each experimental run.  
Since these pumps are specially designed for intravenous infusion in clinical 
practice, they could provide lower flowrates within the range of 1 – 1200 mL/hr 
to meet the requirements for this study. To determine the accuracy and 
precision of each pump, validation tests for four Colleague pumps were 
conducted and as described in the experimental section (Section 4.3.1.3.1). 
The positions of each pump in the ex vivo simulation model are shown below: 
 Pump 1: set up on the transfer tubing between Reservoir B and Y-set 
tubing to pump 5% glucose solutions into Reservoir A for compensation. 
 Pump 2: set up on the transfer tubing between drug infusion syringes and 
Y-set tubing to pump oxaliplatin infusions into Reservoir A.  
 Pump 3: set up on the transfer tubing between Y-set and Reservoir C to 
pump the waste solution from Reservoir A to Reservoir C. 
Flowrates of these pumps needed to be re-set in different time periods: infusion 
time and post-infusion time.  
 F1: The flowrate of Pump 1 (F1) to compensate the ‘central compartment” 
with 5% glucose was adjusted to keep the constant weight/volume of 
Reservoir A.  
 F2: The flowrate of Pump 2 (F2) was the drug infusion rate which 
depended on the dosage (drug concentration and volume) of oxaliplatin 
infusions.  
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 F3: The flowrate of Pump 3 (F3) was the drug elimination rate which was 
calculated from the statistical value of the total clearance (CLtotal) for 
oxaliplatin published in previous literature. This flowrate was kept constant 
through the whole experiment period (including infusion time and post-
infusion time).  
As a result, these three flowrates were related as F1 + F2 = F3 during the 
infusion time (when Pump 1, 2, 3 were working at the same time). After the 
oxaliplatin infusion was complete, Pump 2 was immediately stopped and the 
relation for the other two pump flowrates was F1 = F3. The adjustment schedule 
of pump flowrates for different dosing administration is described in detail in the 
experiment section below (Section 4.3.1.3.2). 
4.2.3.3 System connections 
Several different connecting components were involved in this simulation 
system (shown in Figure 4-2), including connection ports, Y-set extension line, 
needles, spikes, syringes and the solution administration sets specifically 
designed for the Colleague volumetric pumps.  
Between main reservoirs, the Colleague pump/gravity solution administration 
sets were used where pumps were required. A Y-set extension line was used to 
connect each of the pump administration sets from Reservoir B and the drug 
infusions, and then combine the inlet flow into Reservoir A through a fine needle.  
To control the outlet flow from Reservoir A, another Y-set extension line was 
used to connect Reservoir A to the waste bag (Reservoir C). One branch of the 
Y-set line was connected to a pump administration set leading to Reservoir C. 
The other branch of the Y-set line with a luer-lock end was used as a sample 
port and connected to a sampling syringe at each time point.  
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Oxaliplatin infusions were prepared in different size syringes following different 
schedules of each dosing method (Section 4.3.2). Since more than one syringe 
was used for each patient, manifold sets, allowing at least 4 syringes to be used 
in combination, were applied in this system to connect drug infusion syringes 
and the pump administration set.  
Some solution transfer lines were adapted and remade to produce bespoke 
connections for the administration lines loaded into the pumping chambers of 
Pump 2 and Pump 3. For example, the administration set for Pump 2 
(connecting drug infusions to Reservoir A) required replacing a spike connector 
with a male luer-lock connector. The connection sets used are shown in Figure 
4-2. 
 
Figure 4-2, Connection components and tubing for the ex vivo PK simulation model, 
including pump administration set, special remade pump administration set, Y-set 
extension line and manifold set with 3 female luer-lock ports. 
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4.2.3.4 Whole system assembly 
The ex vivo pharmacokinetic (PK) simulation system is shown in Figure 4-3 
below. 
Reservoir A was located onto a tared analytical balance for monitoring the 
‘central compartment’ bag weight. Meanwhile, to ensure the complete mixing of 
the drug infusion, compensation 5% glucose and the solutions in Reservoir A, 
the Reservoir A and balance assembly were placed on a gyro-rotatory shaker at 
the adjusted speed (130 oscillations per minute).  
Reservoir B was hung up by an infusion bag holder higher than the table top 
level to give unrestricted input of 5% glucose solutions into the transfer line. 
Reservoir C was sealed safely with the connected solution transfer line to avoid 
any leaking of cytotoxic solutions. 
The transfer lines and connections between the oxaliplatin infusion syringes and 
Reservoir A were primed with the drug infusion to avoid any dead volume and 
ensure the accurate drug dose was delivered. Also when drug infusions were 
complete, the drug delivery line was flushed with 5% glucose to ensure all drug 
infusions could reach Reservoir A. 
Samples were withdrawn from the Y-set line connecting Reservoir A and 
Reservoir C. Before 8 mL of samples was collected from Reservoir A using a 
luer-lock syringe, a blank volume of solution (2 mL) was withdraw and 
abandoned to remove the dead volume in the Y-set connection line. It could 
prevent the effect on determination of oxaliplatin concentrations from the dead 
volume in solution transferring lines. 
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Before each simulation, all lines and connections were checked carefully to 
make sure the whole system was sealed properly without any risk of cytotoxic 
leakage or contamination. 
 
Figure 4-3, Whole system of the ex vivo PK simulation model. Reservoir A simulated 
the central compartment of the human body; Reservoir B was used to maintain the 
constant weight of Reservoir A by compensation with 5% glucose solution; Reservoir C 
was to collect waste solutions from Reservoir A. All connection components are as 
described in Figure 4-2. Line a: pump administration set; Line b: special pump 
administration set; all syringes used in this system are luer-lock, including drug infusion 
syringes and sample syringes. 
4.2.4 pH and weight monitor 
In the whole process of PK modelling, the solution volume of the infusion bag, 
representing the central compartment, was changed frequently with the 
withdrawal of samples for analysis, which could affect the oxaliplatin 
concentration in the infusion bag solution and in subsequent samples. Also, the 
change in composition could modify the pH in the solution and influence the 
chemical degradation of oxaliplatin. Therefore, the pH and weight of the ‘central 
compartment’ were monitored regularly throughout each simulation run. 
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An Orion 5 Star pH meter with glass electrode and automatic temperature 
compensation was used to measure the pH of samples at each time point for 
each patient. Triplicate measurements were used to gain the average pH value 
for the final pH for each sample. The pH meter was calibrated with reference 
buffer solutions at pH 4.01 and pH 7.00 each time before sampling. Between 
samples, distilled water was used to rinse the glass electrode. 
A 5-figure analytical balance was placed under the Reservoir A (simulated 
central compartment) to assess the volume change for each patient at each 
sample point. Weight of the ‘central compartment’ was calculated and adjusted 
in the beginning of the process according to the Vd of patient. After the infusion 
was started, the weight of Reservoir A before and after sampling was recorded 
to monitor the volume change during the experiment for each patient. As there 
was a gyro-rotatory stirrer under the balance, the balance reading might vary; 
so before recording the weight the stirrer was stopped for a few seconds to 
allow the balance reading to become stabilized. 
4.3 Experimental 
4.3.1 The ex vivo PK simulation model 
4.3.1.1 Scale-down schedule for the simulation model 
To enable the practical working of the PK simulation model with realistic 
volumes and to ensure simulated pharmacokinetic parameters of oxaliplatin 
were representative for the in vivo situation, the ex vivo simulation model in this 
study was scaled down proportionately in accordance with published 
pharmacokinetic data from previous oxaliplatin studies.  
The system characteristics were based on the following equations: 
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Ratein = Rateout Equation 1 
Ratein =
Dose × BSA
T
 
Equation 2 
Rateout = CL × BSA × Css Equation 3 
Css =
Dose
CL × T
 
Equation 4 
AUC =
Dose
CL
 
Equation 5 
K =
CL
Vd
 
Equation 6 
(Ratein: the rate of drug passing into the system; Rateout: the rate of drug running out of the 
system; dose: drug dose in infusions; BSA: the body surface area of ‘patient’; T: infusion time; 
CL: total clearance of the drug; Css: the drug steady state concentration (equal with Cmax); AUC: 
the area under drug concentration-time curve; K: elimination rate constant; Vd: the volume of 
drug distribution.) 
AUC (area under the drug concentration-time curve) is one of the key 
pharmacokinetic parameters, which could represent the exposure of tissues 
(normal and cancerous) to the drug in each patient. Therefore, to achieve AUC 
and K values that are physiologically and pharmacokinetic representative in 
different patients, the drug dose, Vd and CL must be reduced by the same factor 
in the scaling process for this simulation study. 
Selection of the scaling factor was dependent on various practical 
considerations such as the practical administration drug dose, the limited 
volume of available containers for the reservoirs that simulate the central 
compartment of the human body and the working flowrate range of the infusion 
pumps. For example, the reduced Vd (used as the ‘body volume’ for Reservoir A 
in this simulation system) must be small enough to be provided by a 
commercially – available IV bag; and the infusion outlet flowrate of the pump 
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that determined by the scaled down CL (total clearance) must be within the 
working range of these Colleague volumetric pump [1 – 1200 mL/hr (± 1 mL/hr)]. 
Similarly, the drug dose of oxaliplatin simulated in this model had to reflect the 
acceptable infusion concentration. Meanwhile, the volume of those drug 
infusions must be workable at a flowrate within the working range of the 
Colleague pumps. Finally, the oxaliplatin concentration in the samples from 
Reservoir A must be within the analytical range validated for the HPLC assay. 
Considering all potentially influential factors in this ex vivo study, three 
characteristics were scaled down by a factor of 40 as follows for each individual 
simulation. 
Dose = 85 mg m2⁄ × BSA 40⁄  Equation 7 
Vd = 12.41 L m
2⁄ × BSA 40⁄  Equation 8 
CL = 2.88 L h m2⁄⁄ × BSA 40⁄  Equation 9 
[The mean values of Vd (12.41 L/m
2
) and CL(2.88 L/h/m
2
) were selected from previous 
literatures as described in Section 4.1.2.2] 
Ten nominal patients were randomly selected from actual patients with the BSA 
range of 1.12 m2 - 2.70 m2 by using Microsoft Excel 2010 software (Microsoft 
Corporation, USA). This BSA (body surface area) range included typical values 
of BSA for cancer patients, and the random selection produced patients in BSA 
values of: 2.70 m2, 1.82 m2, 1.29 m2, 1.55 m2, 2.20 m2, 1.33 m2, 1.99 m2, 1.72 
m2, 2.52 m2 and 2.04m2. 
The summarised information of these ‘patients’ selected for this simulation 
study is shown below in Table 4-2. The individual dosage, Vd (volume of drug 
distribution) and CL (the total clearance) were calculated based on the patients’ 
BSA and scaled down by a factor of 40 in accordance with equations 7, 8 and 9 
shown above. 
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Table 4-2, Information of 10 ‘patients’ selected for this PK simulation study and their 
PK characteristics (Dose, Vd and CL) of calculated values and scaled-down (factor of 40) 
values. 
Patient BSA (m
2
) Dose (mg) Dose (mg)* Vd (L) Vd (L)* CL (L/hr) CL (L/hr)* 
Patient 1 2.70 229.50 5.74 33.51 0.8377 7.78 0.1944 
Patient 2 1.82 154.70 3.87 22.59 0.5647 5.24 0.1310 
Patient 3 1.29 109.65 2.74 16.01 0.4002 3.72 0.0929 
Patient 4 1.55 131.75 3.29 19.24 0.4809 4.46 0.1116 
Patient 5 2.20 187.00 4.68 27.30 0.6826 6.34 0.1584 
Patient 6 1.33 113.05 2.83 16.51 0.4126 3.83 0.0958 
Patient 7 1.99 169.15 4.23 24.70 0.6174 5.73 0.1433 
Patient 8 1.72 146.20 3.66 21.35 0.5336 4.95 0.1238 
Patient 9 2.52 214.20 5.36 31.27 0.7818 7.26 0.1814 
Patient 10 2.04 173.40 4.34 25.32 0.6329 5.88 0.1469 
The PK characteristics were calculated based on equations 7, 8 and 9 shown above. Dose: calculated 
with 85 mg/m
2
 dose of oxaliplatin; Vd: volume of drug distribution in patient body; CL: the total 
clearance of oxaliplatin. [ * ] indicates scaled down values of PK characteristics. 
The scaled-down factor of 40 times was applied to all scenarios running on the 
ex vivo simulation including individual dosing, dose-banding schedules (5%DB, 
10%DB and LDB) and flat-fixed dosing. The scaled-down dosing schemes are 
shown in Section 4.3.2. 
4.3.1.2 Model assembly 
Before the simulation system was assembled, three reservoirs were prepared in 
different ways referring to the ‘patient’ information shown in Table 4-2. 
 Reservoir A: To represent the ‘central compartment’ of the patient’s body, 
a 1000 mL or 500 mL 5% glucose IV infusion bag was adjusted into the 
volume of Vd required for the individual patient. For ‘patients’ with Vd 
values lower than 600 mL, a 500 mL glucose bag was used as Reservoir 
A. While the 1000 mL glucose bag was used for ‘patients’ with Vd greater 
than 600 mL. 
 Reservoir B: For Reservoir B, 5% glucose solution was used to maintain 
the constant volume of Reservoir A in order to balance the elimination 
from the simulated ‘central compartment’. The volume of 5% glucose 
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required for Reservoir B can be calculated as described in Section 4.2.3.1, 
which mostly depended on the flowrate of Pump 1. The relationship 
between flowrates of Pump 1, Pump 2 and Pump 3 is described in Section 
4.3.1.3.2 below. For the selected ‘patients’, the largest volume of 
Reservoir B required was approximately 1500 mL which required two 1000 
mL glucose bags, and the lowest volume required was about 700 mL for 
which only one 1000 mL glucose IV infusion bag was used. 
 Reservoir C: An empty infusion bag in the size of 3 L was used as the 
waste container for the outlet flow from Reservoir A, the ‘central 
compartment’ of the patient’s body. This size bag had the capacity to 
handle all waste solution from the range of 800 mL to 1600 mL (calculated 
from CL multiplied by the total experiment time of 8 hours). As the empty 
bag had three ports for connection but only one of them was used in this 
study, the other connection ports were also checked carefully before the 
experiments to ensure they were properly sealed to prevent cytotoxic 
containment.  
An analytical balance reading to 0.1 mg was validated and adjusted on the 
gyro-rotatory shaker. For the 1000 mL glucose bag of Reservoir A, the balance 
top-plate was not big enough to hold the whole bag and so a small laboratory 
tray was placed on top of the balance. The shaker underneath was set at 130 
oscillations/min speed during the experiment in order to mix the solution in 
Reservoir A. 
After all main pieces were set, the connection components (shown in Section 
4.2.1.3) were used to connect the whole system in accordance to the model 
design in Figure 4-3. To secure the insertion points to the Reservoir A bag, a 
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needle and a separated spike both with luer-lock ends were connected 
respectively to the inlet and outlet Y-set extension lines. 
4.3.1.3 Pump adjustment 
4.3.1.3.1 Validation of four volumetric pumps 
To ensure the accuracy of the infusion flowrates, four Baxter Colleague 
volumetric infusion pumps were prepared in this study: one pump was for spare 
and the other three were used according to Figure 4-3 (Section 4.2.3.4). Since 
these pumps were specially designed for intravenous infusion in clinical practice, 
they were expected to provide accurate volume delivery at lower flowrates to 
meet the requirements of this study. 
Validation tests were implemented before starting the experiment to determine 
the accuracy and precision of each pump. To include all flowrates applied in the 
study, the flowrates inside the broad range of 1 – 1200 mL/hr were tested over 
14 different values: 1, 2, 5, 8, 10, 15, 20, 50, 100, 200, 500, 800, 1000 and 1200 
mL/hr. Deionized water was used to be pumped at these flowrates and 
collected at the following time intervals.  
 For lower flowrates (1, 2, 5, 8, 10, 15, 20 mL/hr), the eluent was weighed 
every 30 minutes.  
 For higher flowrates (20, 50, 100, 200, 500, 800 and 1000 mL/hr), the eluent 
weights were measured every 5 minutes.  
Flowrates for each pump were calculated with the equation shown below: 
Flowrate (mL/hr) =  
weight (mg)
D (mg/mL) × time (h)
 
[D: density of water, ≈ 1g/m
3
.] 
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For each pump, all flowrates were tested in triplicate and the average results 
were used for precision and accuracy analysis with the respective criteria of 
standard deviation ≤ 2.0% and ≤ 5%. (234) The validation results for these four 
pumps are shown with the mean values of each flowrate and standard deviation 
(%) of triplicate data in Table 4-8 in Section 4.4.1.1. 
4.3.1.3.2 Flowrate calculation and adjustment for different patient 
simulations 
50 models in total with various pump flowrate settings were tested for 10 
‘patients’ with 5 different dosing methods. Before the experiment of each model, 
some extra time was required to test and set up three working pumps, and the 
spare pump to be used when failure result occurred in any of these pumps. 
Pump flowrates were adjusted following the operation steps described below: 
1) Pump 3 (between Reservoir A and Reservoir C) used the scaled-down 
value of the total clearance (CLtotal) of oxaliplatin for each ‘patient’ as the 
flowrate (F3) during the whole experiment period of 8 hours; 
2) The flowrate in Pump 2 (between Drug infusions and Reservoir A) 
depended on the oxaliplatin infusion volume, which was different for 
individual ‘patients’ with different dosing methods. The flowrate of Pump 2 
(F2) was only used during the infusion time of 2 hours and can be calculated 
with the equation:  
F2 = 
VS
T1
 
[F2 (mL/hr): flowrate of Pump 2; VS (mL): volume of oxaliplatin infusion syringe combination; 
T1 (hr): infusion time, 2 hours.] 
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3) The flowrate of Pump 1 (between Reservoir B and Reservoir A) during the 
infusion time (2 hours) can be calculated as: 
F1 = F3 − F2 
[F1 (mL/hr): the flowrate of Pump 1 during 2-hour infusion time; F2 (mL/hr): flowrate of Pump 
2 during infusion time; F3 (mL/hr): flowrate of Pump 3.] 
For the post-infusion time of 6 hours, the flowrate of Pump 1 should be 
changed and adjusted again as showing below: 
F1
′ = F3 
[F1’ (mL/h): the flowrate of Pump 1 during 6-hour post-infusion time; F3 (mL/h): flowrate of 
Pump 3.] 
The pump administration set used for transferring drug infusions was primed 
with oxaliplatin infusions before the pump adjustment and experiment started. 
Even though flowrates for the three working pumps were calculated theoretically, 
they still needed to be slightly adjusted during the experiment in order to 
balance the weight of Reservoir A. Variations of the ‘central compartment’ 
weight were controlled within ± 2% in this study. 
4.3.1.4 Solution preparation 
For different dosing methods, two oxaliplatin stock solutions at concentrations 
of 1 mg/mL and 5 mg/mL were used to prepare the drug infusion syringes. 
Oxaliplatin (5 mg/mL) was from the manufacturer original vial and stored in a 
refrigerator at 2 – 8℃. Oxaliplatin stock solution in 1 mg/mL was prepared by 
diluting 5 mg/mL oxaliplatin (2 mL) to 10 mL with 5% glucose in a 10 mL grade 
A volumetric flask.  
The 1 mg/mL stock solution was used for the preparation of oxaliplatin infusion 
syringes for the individual dosing method. Oxaliplatin syringes for other dosing 
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methods were prepared from 5 mg/mL oxaliplatin solution following schedules 
presented in Section 4.3.2.2. 
The standard oxaliplatin solution for HPLC assay was at the 10 µg/mL 
concentration, which was prepared by diluting 5 mg/mL oxaliplatin (0.01 mL) in 
a 5 mL volumetric flask with deionized water (HPLC grade). This concentration 
of 10 µg/mL has been selected especially considering the concentrations of all 
samples which were expected to be in the range of 2.0 µg/mL – 20.0 µg/mL. 
4.3.2 Drug dosing administration 
Five different dosing methods were tested in this study, including individual 
dosing method (IND), dose-banding scheme with 5% deviation (5%DB), dose-
banding scheme with 10% deviation (10%DB), flat-fixed dosing method (FFD) 
and Logarithmic dose-banding scheme (LDB). Individual dosing is the most 
widely used dosing administration method for anticancer drugs, in which the 
drug dose is calculated based on the BSA value of individual patient. (8) It must 
be noted that the BSA-based individual dose is not necessarily the optimal dose 
for the patient. (8) (13) (235) As an alternative dosing approach, dose-banding 
has been introduced into clinical practice for over 15 years and is increasingly 
adopted for a number of anticancer drugs. (10) (152) To compare the efficacy of 
different dosing methods, dose-banding schemes with a ± 5% and/or 10% 
maximum deviation from the BSA-individualised dose were simulated in this 
study along with the individual dosing method. In addition, logarithmic dose-
banding (LDB) has been introduced in some cancer centres. (230) The potential 
advantage of LDB is that it reduces the wide error bands at low doses seen in 
conventional dose-banding schemes. (230) (231) In recent years, the 
controversy about the application of flat-fixed dosing (FFD) to cytotoxic drugs, 
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which was recommended to replace the BSA-based dosing method, has been 
discussed in some related literatures. (13) (226) Therefore, the flat-fixed dosing 
was also included as a dosing scheme for oxaliplatin in this study. 
According to the previous stability study (Chapter 2, page 101), the stability 
concentration range of oxaliplatin infusions in 5% glucose was 0.2 mg/mL – 0.7 
mg/mL. Thus, in this simulation study oxaliplatin infusion syringes were 
prepared within this stability concentration range using 5% glucose. The 
preparation and administration of drug infusions are following the different 
dosing schedules listed in sections below. 
4.3.2.1 Individual dosing method (IND) 
Individual doses were calculated respectively by multiplying the licenced 
oxaliplatin dose of 85 mg/m2 by each patient’s BSA, and recording to 2 decimal 
places. (5) (174) To ensure comparisons between different dosing methods 
were realistic, drug infusions for different methods were prepared in similar 
volume by diluting oxaliplatin working stock with 5% glucose.  
In this ex vivo simulation study, all oxaliplatin infusions for IND and FFD were 
freshly prepared on the day of the experiment and were produced according to 
the principles of GMP (Good Manufacturing Practice) for aseptically prepared 
infusions. (236) The schedule of individual dosing for each ‘patient’ is described 
in Table 4-7 in Section 4.3.2.4 with other dosing methods. 
4.3.2.2 Dose-banding schemes 
With the BSA range of 1.12 m2 – 2.70 m2, different dose-banding schemes of 
oxaliplatin are shown in tables below based on the licenced dose of 85 mg/m2. 
(5) Three different dose-banding schemes were designed and applied in this 
study, including dose-banding scheme with ≤5% maximum deviation (5%DB), 
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dose-banding scheme with ≤10% maximum deviation (10%DB) and logarithmic 
dose-banding scheme with ≤6% maximum deviation (LDB).  
As discussed above, these dose-banding schemes were administered using the 
scaled-down standard dose that was prepared within the concentration range of 
0.2 mg/mL – 0.7 mg/mL for each band. Therefore, all pre-made oxaliplatin 
syringes for dose-banding schemes were prepared in different infusion volumes 
to keep drug concentrations in the required range (Shown in Table 4-3). 
Oxaliplatin syringes required for each dose-banding scheme were freshly 
prepared before model simulations and were used within the defined shelf-life 
(refer to the extended stability study in Chapter 2).  
Table 4-3, Preparation of oxaliplatin pre-made infusion syringes for dose-banding 
schemes (including 5%DB, 10%DB and LDB) in the ex vivo PK simulation study. 
Oxaliplatin dose 
of pre-made 
infusion (mg) 
Infusion 
syringe size 
(mL) 
Volume of 5 mg/mL 
oxaliplatin used for 
dilution (µL) 
Oxaliplatin concentration 
in the syringe after dilution 
with 5% glucose (mg/mL) 
0.24 1.0 48 0.24 
0.25 1.0 50 0.25 
0.30 1.0 60 0.30 
0.37 1.0 74 0.37 
0.38 1.0 76 0.38 
0.41 2.0 82 0.21 
0.46 2.0 92 0.23 
0.50 2.0 100 0.25 
1.13 5.0 226 0.23 
2.00 10.0 400 0.20 
3.00 15.0 600 0.20 
With the scaled-down drug doses, volumes of pre-made oxaliplatin infusions 
were too small to be prepared in infusion bags. Therefore, luer-lock syringes (in 
size of 1 mL, 2 mL, 5 mL, 10 mL and 15 mL) were used as containers for pre-
made drug infusions that were prepared from 5 mg/mL oxaliplatin stock solution. 
The preparation schedule of pre-made infusion syringes for three dose-banding 
schemes is shown together in Table 4-3. 
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4.3.2.2.1 Dose-banding scheme with 5% deviation in each band 
(5%DB) 
There were 12 dose bands in this dose-banding scheme covering oxaliplatin 
doses from 95 mg to 230 mg. The maximum deviation of the standard dose 
from the individual prescribed dose in each dose band was 5%. Standard doses 
were scaled down by a factor of 40 in each dose band. Pre-made syringes were 
prepared and used singly or in combinations at the following doses: 0.25 mg (1 
mL), 0.5 mg (2 mL), 2.0 mg (10 mL) and 3.0 mg (15 mL). 
The scaled-down dose-banding scheme with ≤5% deviation is shown in Table 
4-4. 
Table 4-4, Dose-banding scheme with ≤5% maximum deviation (5%DB) for oxaliplatin 
administration after scaled down by a factor of 40 for the ex vivo PK simulation study. 
Dose 
band 
(mg) 
Standard 
dose 
(mg) 
Standard 
dose scaled 
down by 40 
times (mg) 
Max 
deviation 
(%) 
Pre-made infusion 
syringes combination to 
deliver banded dose 
No. of 
syringes
*
 
Total volume 
of pre-made 
drug infusion 
(mL) 
95-105 100 2.50 5.00 2mg+0.5mg 2 12.00 
105-115 110 2.75 4.55 2mg+0.5mg+0.25mg 3 13.00 
115-125 120 3.00 4.17 3mg 1 15.00 
125-135 130 3.25 3.85 3mg+0.25mg 2 16.00 
135-145 140 3.50 3.57 3mg+0.5mg 2 17.00 
145-155 150 3.75 3.33 3mg+0.5mg+0.25mg 3 18.00 
155-165 160 4.00 3.13 2mg+2mg 2 20.00 
165-175 170 4.25 2.94 2mg+2mg+0.25mg 3 21.00 
175-185 180 4.50 2.78 2mg+2mg+0.5mg 3 22.00 
185-195 190 4.75 2.63 2mg+2mg+0.5mg+0.25mg 4 23.00 
195-210 200 5.00 5.00 3mg+2mg 2 25.00 
210-230 220 5.50 4.55 3mg+2mg+0.5mg 3 27.00 
[*]: the syringes used for 5%DB scheme were those pre-made syringes prepared with the schedule shown 
in Table 4-3. 
4.3.2.2.2 Dose-banding scheme with 10% deviation in each band 
(10%DB) 
Seven dose bands were designed, which covered doses from 95 mg to 230 mg 
of oxaliplatin. The deviation of a standard dose from a prescribed dose was less 
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than 10% among all bands in this scheme. Pre-made syringes used in this 
scheme were in the same dose and concentration as those syringes used in the 
5%DB scheme above. 
For some ‘patients’ from the selected BSA range there would be an overlap of 
the 10%DB and 5% DB doses as their dose bands were close. Thus, the 10 
‘patients’ used in this study were screened out to make sure the same standard 
dose would not be applied to the same ‘patient’ from these two different dose-
banding schemes. 
The scaled-down dose-banding scheme with ≤10% deviation is shown in Table 
4-5. 
Table 4-5, Dose-banding scheme with ≤10% deviation (10%DB) for oxaliplatin 
administration after scaled down by a factor of 40 for the ex vivo PK simulation study. 
Dose 
band 
(mg) 
Standard 
dose 
(mg) 
Standard 
dose scaled 
down by 40 
times (mg) 
Max 
Deviation 
(%) 
Pre-made infusion syringes 
combination to deliver 
banded dose 
No. of 
syringes
* 
Total volume 
of pre-made 
drug infusion 
(mL) 
90-110 100 2.50 10.00 2mg+0.5mg 2 12.00 
110-130 120 3.00 8.33 3mg 1 15.00 
130-150 140 3.50 7.14 3mg+0.5mg 2 17.00 
150-170 160 4.00 6.25 2mg+2mg 2 20.00 
170-190 180 4.50 5.56 2mg+2mg+0.5mg 3 22.00 
190-210 200 5.00 5.00 3mg+2mg 2 25.00 
210-250 230 5.75 9.52 3mg+2mg+0.5mg+0.25mg 3 28.00 
[*]: the syringes used for 5%DB scheme were those pre-made syringes prepared with the schedule shown 
in Table 4-3. 
4.3.2.2.3 Logarithmic dose-banding scheme (LDB) 
The logarithmic dose-banding scheme applied in this study is shown in Table 4-
6 with 9 bands covering from 84.6 mg to 230.9 mg of oxaliplatin dose and the 
maximum dose variation was ≤6% for each band. The pre-made syringes for 
LDB contained some different doses from 5%DB and 10%DB syringes, 
including 0.24 mg (1 mL), 0.30 mg (1 mL), 0.37 mg (1 mL), 0.38 mg (1mL), 0.41 
mg (2 mL), 0.46 mg (2 mL) and 1.13 mg (5 mL). Pre-made syringes in various 
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doses of LDB are shown in Table 4-3 together with the infusion syringes 
prepared for 5%DB and 10%DB. 
Table 4-6, Logarithmic dose-banding scheme (LDB) for oxaliplatin administration after 
scaled down by a factor of 40 for the ex vivo PK simulation study. 
Dose band 
(mg) 
Standard 
dose 
(mg) 
Standard 
dose scaled 
down by 40 
times (mg) 
Max 
deviation 
(%) 
Pre-made infusion 
syringes combination to 
deliver banded dose 
No. of 
syringes 
Total volume 
of pre-made 
drug infusion 
(mL) 
84.6-94.6 89.4 2.24 5.82 2mg+0.24mg 2 11.00 
94.6-105.7 100.0 2.50 5.70 2mg+0.5mg 2 12.00 
105.7-118.2 111.8 2.80 5.72 2mg+0.5mg+0.3mg 3 13.00 
118.2-132.2 125.0 3.13 5.76 2mg+1.13mg 2 15.00 
132.2-147.8 139.8 3.50 5.72 3mg+0.5mg 2 17.00 
147.8-165.2 156.3 3.91 5.69 3mg+0.5mg+0.41mg 3 19.00 
165.2-184.7 174.7 4.37 5.72 2mg+2mg+0.37mg 3 21.00 
184.7-206.5 195.3 4.88 5.73 2mg+2mg+0.5mg+0.38mg 4 23.00 
206.5-230.9 218.4 5.46 5.72 3mg+2mg+0.46mg 4 27.00 
[*]: the syringes used for 5%DB scheme were those pre-made syringes prepared with the schedule shown 
in Table 4-3. 
4.3.2.3 Flat-fixed dosing schedule (FFD) 
In the flat-fixed dosing method, a standardized dose was applied and used for 
all patients with different BSA. This fixed dose was 152.15 mg which was 
calculated by dose (mg) = 85mg/m2 ×BSA (m2) with the mean value of BSA 
1.79 m2. (157) To adjust to the scale-down system, the fixed dose was reduced 
by a factor of 40, which became approximately 4.00 mg. The flat-fixed dose can 
be prepared in the same size syringes (20 mL) for all ‘patients’. The oxaliplatin 
concentration in these syringes was 0.2 mg/mL, which was within the stability-
assessed concentration range (0.2 mg/mL – 0.7 mg/mL). 
The flat-fixed dosing scheme for 10 selected ‘patients’ is shown together with 
the individual dosing schedule in Table 4-7 in the following section. 
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4.3.2.4 Oxaliplatin administration for ‘patients’ with different dosing 
method 
The oxaliplatin administration for each ‘patient’ is shown in Table 4-7 with five 
different dosing methods after the appropriate scale-down procedure. BSA 
values of ten selected ‘patients’ are listed in this table, and for each dosing 
method three parts of information are included: 
 Drug dose used for each ‘patient’ is provided, and for the same patient 
drug dose might be different with different dosing method; 
 Syringe operations are described variously for different dosing methods. 
For individual dosing and flat-fixed dosing, the preparation of drug infusion 
syringes is shown in detail, including the required volume and 
concentration of oxaliplatin stock solution. For dose-banding schemes 
(5%DB, 10%DB and LDB), combinations of pre-made infusion syringes 
are described. 
 Total volume of oxaliplatin infusion presented in this table can be used 
to calculate the flowrate of oxaliplatin infusion operated in the experiment.
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Table 4-7, Doses and infusion combinations for each ‘patient’ with different dosing methods: individual dosing, flat-fixed dosing, dose-banding schemes [with maximum 5% (5%DB) and 10% (10%DB) deviation in each 
band] and logarithmic dose-banding. 
Patient 
BSA 
(m
2
) 
Individual dosing (IND) Dose-Banding with ≤ 5% deviation (5%DB) Dose-Banding with ≤ 10% deviation  (10%DB) Flat-fixed Dosing (FFD) Logarithmic dose-Banding )LDB) 
Dose 
(mg) 
Drug 
Volume of 
Stock 
Solution 
Infusion 
Volume 
(mL) 
Dose 
(mg) 
Syringe Combination 
Pre-made 
Infusion 
Volume 
(mL) 
Dose 
(mg) 
Syringe Combination 
Pre-made 
Infusion 
Volume 
(mL) 
Dose 
(mg) 
Drug 
Volume of 
Stock 
Solution 
Infusion 
Volume 
(mL) 
Dose 
(mg) 
Syringe Combination 
Pre-made 
Infusion 
Volume 
(mL) 
Patient 1 2.70 5.74 
5.74mL, 
1mg/mL 
20 5.50 3mg+2mg+0.5mg 27 5.75 3mg+2mg+0.5mg+0.25mg 28 4 
0.8mL, 
5mg/mL 
20 5.46 3mg+2mg+0.46mg 27 
Patient 2 1.82 3.87 
3.87mL, 
1mg/mL 
20 3.75 3mg+0.5mg+0.25mg 18 4.00 2mg+2mg 20 4 
0.8mL, 
5mg/mL 
20 3.91 3mg+0.5mg+0.41mg 19 
Patient 3 1.29 2.74 
2.74mL, 
1mg/mL 
20 2.75 2mg+0.5mg+0.25mg 13 2.50 2mg+0.5mg 12 4 
0.8mL, 
5mg/mL 
20 2.80 2mg+0.5mg+0.3mg 13 
Patient 4 1.55 3.29 
3.29mL, 
1mg/mL 
20 3.25 3mg+0.25mg 16 3.50 3mg+0.5mg 17 4 
0.8mL, 
5mg/mL 
20 3.13 2mg+1.13mg 15 
Patient 5 2.20 4.68 
4.68mL, 
1mg/mL 
20 4.75 2mg+2mg+0.5mg+0.25mg 23 4.50 2mg+2mg+0.5mg 22 4 
0.8mL, 
5mg/mL 
20 4.88 2mg+2mg+0.5mg+0.38mg 23 
Patient 6 1.33 2.83 
2.83mL, 
1mg/mL 
20 2.75 2mg+0.5mg+0.25mg 13 3.00 3mg 15 4 
0.8mL, 
5mg/mL 
20 2.80 2mg+0.5mg+0.3mg 13 
Patient 7 1.99 4.23 
4.23mL, 
1mg/mL 
20 4.25 2mg+2mg+0.25mg 21 4.00 2mg+2mg 20 4 
0.8mL, 
5mg/mL 
20 4.37 2mg+2mg+0.37mg 21 
Patient 8 1.72 3.66 
3.66mL, 
1mg/mL 
20 3.75 3mg+0.5mg+0.25mg 18 3.50 3mg+0.5mg 17 4 
0.8mL, 
5mg/mL 
20 3.50 3mg+0.5mg 17 
Patient 9 2.52 5.36 
5.36mL, 
1mg/mL 
20 5.50 3mg+2mg+0.5mg 27 5.75 3mg+2mg+0.5mg+0.25mg 28 4 
0.8mL, 
5mg/mL 
20 5.46 3mg+2mg+0.46mg 27 
Patient 10 2.04 4.34 
4.34mL, 
1mg/mL 
20 4.25 2mg+2mg+0.25mg 21 4.50 2mg+2mg+0.5mg 22 4 
0.8mL, 
5mg/mL 
20 4.37 2mg+2mg+0.37mg 21 
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4.3.3 Study procedure 
4.3.3.1 Study period 
According to the SPC (Summary of Product Characteristics), oxaliplatin infusion 
is generally used as 2-hour to 6-hour intravenous infusion in clinical practice. 
(122) However, as a part of the chemotherapy, oxaliplatin infusions are normally 
used to combine with other chemotherapeutic drugs. (237) In this case, the 
infusion time of oxaliplatin should be compromised with the chemotherapeutic 
procedure in clinical studies. (237) However, this ex vivo pharmacokinetics (PK) 
study was to simulate the oxaliplatin PK process in a ‘patient’ as a single agent 
without other anticancer drug combinations. Therefore 2-hour intravenous 
infusion time was applied to closely replicate the clinical situation in the 
simulation. 
Most previous pharmacokinetics studies of oxaliplatin were operated with the 
total study period of 24 hours, while 12 hours and 48 hours were rarely used as 
the whole study time in a few studies. (11) However, these studies suggested 
that the key pharmacokinetic data of oxaliplatin can be collected within 6 hours 
from the beginning of infusion. (11) (133) A 6-hour trial run before this study 
was implemented, and on the basis of this the total study period was adjusted 
into 8 hours to obtain the valid pharmacokinetics data of oxaliplatin infusions. 
During the 8-hour study, flowrates of all three pumps were adjusted following 
the schedule described in Section 4.3.1.3.2 above to ensure the constant 
weight of the body reservoir (Reservoir A). At the end of the infusion time (after 
2 hours), the flowrate of Pump 1 was changed manually to balance the system 
for the post-infusion period. Meanwhile samples were taken at pre-defined time 
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points through the whole study period including 2-hour infusion time and a post-
infusion time of 6 hours as shown below. 
4.3.3.2 Sample schedule 
In previous literature, samples were withdrawn in different schedules, among 
which an average of 11 samples were taken during the whole experiment period. 
(11) (223) To increase the accuracy and reliability of this study, 22 samples 
were taken and tested throughout the experiment. The sampling time schedules 
respectively for infusion and post-infusion periods are: 
 Sampling time points during infusion time:  
0.0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75 and 2.0 (hour) 
 Sampling time points during post-infusion period: 
2.25, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0 (hour) 
Samples were withdrawn from one branch of the Y-set extension line connected 
with Reservoir A by using 20 mL syringes with luer-lock. Before each test 
sample was taken, 2 mL of blank solution from the connecting line was 
withdrawn to avoid the dead volume effect on sample tests. 8 mL of sample was 
taken and stored in a 20 mL pre-labelled polypropylene container. 1 – 2 mL 
samples were pipetted from the container for HPLC assay, and the remaining 
sample solution was used for pH measurement. Samples for HPLC assay and 
pH measurement were analysed undiluted. 
4.3.3.3 Data analysis 
Oxaliplatin concentrations in samples were detected by the validated HPLC 
assay as described in Chapter 2 (Section 2.2.2, page 108), and then used for 
PK analysis with a software package (PK Solutions, version 2.0, Summit 
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Research Services, Colorado, USA). As there were 5 different dosing methods 
applied in this study, the total 50 pharmacokinetic models were built in PK 
Solutions with the oxaliplatin data from each simulation, including scaled down 
oxaliplatin dose (µg), the weight of Reservoir A (kg) and oxaliplatin 
concentrations (µg/mL) of 22 samples at all sampling time points. Values of 
AUC (area under the drug concentration-time curve) and Cmax were calculated 
from these pharmacokinetic models for each ‘patient’ with different dosing 
administration systems. Results of the PK parameters were then compared 
between the different dosing systems for oxaliplatin. 
4.4 Results 
4.4.1 System validation 
4.4.1.1 Pump validation 
Three Baxter Colleague volumetric infusion pumps were used in this study with 
one spare pump held in reserve. Each pump was tested at 14 different flowrates 
to obtain precision of volume delivery over the working range of 1 mL/hr – 1200 
mL/hr. The validation was carried out in triplicate from which the standard 
deviation (%) was calculated for each flowrate. Mean values of calculated 
flowrates are shown in Table 4-8 with the standard deviation.  
Differences between the nominal flowrates and the mean values of flowrate 
from each test were within the range of 0.00% - 2.52%, which were in the 
acceptance criteria of ≤ 5%. (234) The relative standard deviation (RSD) values 
of triplicate runs for each flowrate were generally ≤ 2.85%, while higher RSD 
values appeared at low flowrate of 1 mL/hr and 2 mL/hr in Pump A as 
respectively 10% and 20%. The working range of the flowrate required in this 
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study was 5 mL/hr – 200 mL/hr. Within this working range, flowrate precisions 
for all four pumps were under 2.47%.  
For all four pumps, the calibration plots of the nominal flowrate and test flowrate 
were linear over the flowrate range of 1.0 – 1200 mL/hr (n=14) in Figure 4-4. R2 
of 1.0000, 0.9999, 0.9999 and 1.0000 were respectively determined from the 
least-squares regression analysis of the plots and an even distribution of 
flowrates about the regression line can be inspected visually with all regression 
lines passed through the origin. Error bars of RSD from triplicate values for 
each flowrate are shown in these plots, which are not obvious since the RSD 
values were relatively small. Because the flowrate variations between test 
flowrate and the set flowrate were ≤ 2.52% in all four pumps, while the RSD 
values for triplicate tests in different flowrates were within 2.47%, the accuracy 
and precision of these pumps was considered acceptable for this study. 
 
Figure 4-4, Flowrate linearity plot for Pump A, B, C and D, with actual flowrate (test) plotted 
against nominal or “set” flowrate for each pump. (n = 14) 
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Table 4-8, Validation results of four pumps (Pump A, B, C and D) at different flowrates with mean values and relative standard deviation (RSD) of 
triplicate tests for precision and accuracy tests. 
Set or 
nominal 
flowrate 
(mL/hr)  
Pump A Pump B Pump C Pump D 
Calculated 
flowrate [RSD%] 
(mL/hr) 
Difference to 
set or nominal 
flowrate (%) 
Calculated 
flowrate [RSD%] 
(mL/hr) 
Difference to 
set or nominal 
flowrate (%) 
Calculated 
flowrate [RSD%] 
(mL/hr) 
Difference to 
set or nominal 
flowrate (%) 
Calculated 
flowrate [RSD%] 
(mL/hr) 
Difference to 
set or nominal 
flowrate (%) 
1200 1192.4 [2.85] 0.63 1194.4 [0.15] 0.47 1193.6 [0.91] 0.53 1196.0 [0.21] 0.33 
1000 1001.6 [1.02] 0.16 986.0 [0.19] 1.40 981.2 [0.46] 1.88 998.8 [1.08] 0.12 
800 799.2 [0.65] 0.10 786.8 [0.92] 1.65 793.32 [1.56] 0.84 802.4 [1.73] 0.30 
500 497.2 [0.91] 0.56 502.66 [1.64] 0.53 490.4 [0.51] 1.92 501.6 [0.24] 0.32 
200 204.87 [1.98] 2.44 200.0 [0.35] 0.00 197.2 [0.93] 1.40 202.0 [2.47] 1.00 
100 101.2 [0.68] 1.20 100.4 [1.83] 0.40 98.60 [0.93] 1.40 101.6 [2.46] 1.60 
50 49.6 [1.40] 0.80 48.74 [1.05] 2.52 50.13 [1.61] 0.26 49.6 [1.40] 0.80 
20 19.9 [2.10] 0.67 19.75 [1.27] 1.27 19.73 [0.59] 1.33 20.0 [0.00] 0.00 
15 15.07 [0.77] 0.44 15.0 [1.33] 0.00 14.73 [1.57] 1.78 15.03 [2.06] 2.00 
10 10.0 [0.00] 0.00 9.87 [1.17] 1.33 9.81 [1.84] 1.87 9.87 [2.34] 1.33 
8 8.11 [0.62] 1.38 7.87 [1.47] 1.67 7.97 [1.92] 0.42 8.11 [1.92] 1.38 
5 5.0 [0.00] 0.00 4.93 [2.34] 1.33 5.0 [0.00] 0.00 4.93 [2.34] 1.33 
2 2.0 [10.00] 0.00 2.0 [0.00] 0.00 2.0 [0.00] 0.00 2.0 [0.00] 0.00 
1 1.0 [20.00] 0.00 1.0 [0.00] 0.00 1.0 [0.00] 0.00 1.0 [0.00] 0.00 
RSD, relative standard deviation; calculated flowrates are all in mean values of triplicate results (n=3). 
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4.4.1.2 Model precision 
To validate the precision of this ex vivo pharmacokinetic simulation system, 5 
test runs of a ‘simulated patient’ under identical conditions were undertaken 
over 5 successive days. The ‘patient’ simulated in this precision test was 
selected from the BSA range of 1.12 m2 – 2.70 m2 and other parameters were 
calculated by the equations described in the experimental section (Section 
4.3.1.1). Information of the selected patient was: BSA = 1.84 m2, dose = 3.91 
mg, Vd = 570.9 mL, CLtotal = 132 mL/h. The individual dosage, Vd and CLtotal of 
oxaliplatin were scaled down according to the schedule described in Section 
4.3.1.1 above. 
Because the BSA-individualised dosing method (IND) is currently used in 
clinical practice as the routine administration method of oxaliplatin infusions, 
IND method was considered as a control group in this study. Thus, the precision 
of this PK simulation system was tested with the IND method. The precision 
tests were carried out under exactly the experimental conditions to be used, 
including model assembly, experiment time period and sampling schedule. 
The concentration-time curves of oxaliplatin for this ‘patient’ in the series of 5 
tests were all similar, as shown in Figure 4-5 below. The values of Cmax, Tmax 
and AUC were calculated using the ‘PK Solutions’ software package and 
compared in Table 4-9, which also includes the relative standard deviation 
(RSD) of these 5 tests. As shown in Table 4-9, Cmax of oxaliplatin were within 
the range of 4.5118 – 4.6875 µg/mL, and AUC values from 5 tests were 
between 19.6 – 22.1 µg-hr/mL. Tmax of oxaliplatin in this model was 2 h, which 
mostly depended on the 2-hour intravenous infusion simulation. Meanwhile, 
values of RSD for Cmax, Tmax and AUC were 1.5625%, 0.00% and 4.8401%, 
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respectively, which indicated that the sensitivity and reproducibility of this ex 
vivo PK simulation system was satisfactory.  
 
Figure 4-5, Concentration-time curves of 5 oxaliplatin PK tests on a ‘simulated patient’ 
with the BSA value of 1.84m
2
 in the precision test. 
Table 4-9, Cmax, Tmax and AUC∞ of oxaliplatin in precision test of 5 simulations on the 
selected ‘patient’ (BSA=1.84 m2) with the relative standard deviation (RSD). 
Test  Cmax (µg/mL) Tmax (hour) AUC∞ (µg-hr/mL) 
Test 1 4.6826 2 21.1 
Test 2 4.5996 2 22.1 
Test 3 4.5118 2 19.6 
Test 4 4.6875 2 20.5 
Test 5 4.6038 2 19.9 
RSD (%) 1.5625 0 4.8401 
4.4.1.3 Oxaliplatin assay validation 
Oxaliplatin concentrations were detected by the HPLC assay validated and 
used in the previous stability study in Chapter 2. Validation details of this assay 
were described in Chapter 2 (Section 2.2.2.2, page 110). However, the 
expected oxaliplatin concentrations in samples from PK simulations were in the 
range of 1 – 20 µg/mL, which were lower than those concentrations tested in 
the previous stability study. Therefore, a linearity validation test on oxaliplatin 
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solutions (in 5% glucose) was conducted in this PK study with concentrations of 
0.5, 1.0, 2.0, 5.0, 10.0, 15.0 and 20 µg/mL. 
The calibration plot was shown to be linear over the concentration range 0.5 – 
20.0 μg/mL (n=7), with the equation of y = 1.0512x - 0.035 (R2 = 0.9999) 
derived from the least-squares regression analysis, and an even distribution of 
the data on the regression line can be inspected visually as shown in Figure 4-6. 
 
Figure 4-6, Oxaliplatin linearity of response plot with analytic concentrations and peak 
heights obtained with the HPLC assay in the concentration range of 0.5 – 20.0 µg/mL 
(n= 7). 
4.4.2 The ex vivo PK simulation results for each ‘patient’ 
4.4.2.1 pH monitor 
Table 4-10 shows pH measurements for ten patients in different dosing 
methods with the relative standard deviations (RSD) of all 22 samples in each 
simulation experiment. The mean pH value for each ‘patient’ was within the 
range of 4.10 – 4.32, and the relative standard deviation values shown in Table 
4-10 were between 0.61% - 4.68%. pH change in samples can reflect the fluid 
composition in the system, which might influence oxaliplatin concentrations in 
the ‘central compartment’ of the patient’s body (Reservoir A) and then result in 
the incorrect pharmacokinetic simulation of oxaliplatin. pH variation among the 
samples for each ‘patient’ simulation was less than 0.23 unit, which indicated no 
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significant chemical and/or physical change in the ex vivo PK simulation system 
throughout this study. 
Table 4-10, Mean values of pH for ten ‘patients’ in different dosing methods (IND, 
5%DB, 10%DB, FFD and LDB) with the relative standard deviations (RSD) from 22 
measured pH values for each simulation. 
Patient  
Individual 
Dosing 
[RSD%] 
Dose-banding 
with 5% deviation 
[RSD%] 
Dose-banding 
with 10% 
deviation [RSD%] 
Flat-fixed 
dosing [RSD%] 
Log dose-
banding 
[RSD%] 
Patient 1 4.16 [3.94] 4.16 [2.37] 4.25 [2.45] 4.21 [0.61] 4.17 [1.08] 
Patient 2 4.18 [1.27] 4.22 [2.80] 4.27 [2.80] 4.24 [1.05] 4.18 [1.56] 
Patient 3 4.14 [1.29] 4.25 [1.18] 4.21 [3.40] 4.21 [1.82] 4.17 [1.42] 
Patient 4 4.31 [2.56] 4.10 [4.50] 4.23 [2.46] 4.21 [0.89] 4.28 [2.66] 
Patient 5 4.20 [1.30] 4.23 [4.68] 4.20 [0.99] 4.31 [2.20] 4.41 [1.25] 
Patient 6 4.21 [2.37] 4.24 [1.16] 4.28 [2.46] 4.24 [3.38] 4.29 [0.79] 
Patient 7 4.13 [4.57] 4.16 [3.10] 4.25 [1.47] 4.18 [1.33] 4.31 [1.71] 
Patient 8 4.12 [3.05] 4.21 [4.17] 4.21 [1.19] 4.11 [1.65] 4.15 [1.09] 
Patient 9 4.22 [1.87] 4.29 [2.20] 4.32 [1.96] 4.20 [1.91] 4.44 [2.74] 
Patient 10 4.19 [3.20] 4.15 [1.98] 4.17 [0.66] 4.23 [2.05] 4.26 [1.47] 
RSD: relative standard deviation. 
4.4.2.2 Weight monitor 
The weight of Reservoir A (‘central compartment’ of the patient’s body) were 
measured and recorded before and after each sample time to monitor the 
change of ‘body’ weight and volume. Although flowrates of inlet and outlet 
solutions to/from Reservoir A were adjusted to balance the ‘body’ weight, the 
gain and/or loss of Reservoir A weight could be caused by other factors, such 
as reservoir bag position moved by the gyro-rotatory shaker, solution loss 
during sample withdrawal, dead volume in solution transfer tubing. Therefore, 
the weight monitoring applied in this study throughout the experiment was to 
ensure these potential effects on the weight change of Reservoir A would not 
artificially affect the determination of oxaliplatin concentrations. 
Weight change within/between sample times of each ‘patient’ administered with 
different dosing methods were analysed and are shown in Table 4-11. Weight 
changes between/within sampling were compared to the weight of Reservoir A 
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at the end of each experiment, which gave the maximum percentage of weight 
gain/loss to Reservoir A weight.  
 Weight change within sampling: At each sample time, the weight of 
Reservoir A was recorded before and after sample withdrawal, which 
were used to calculate the weight change during the sampling operation. 
 Weight change between sampling: There were different time gaps 
between each sample point. To monitor the weight change occurred in 
those time gaps, the weight of Reservoir A measured before sample 
withdrawal was compared with the weight recorded after the last 
sampling time. 
Any potential effect of weight change to the whole system, thereby, could be 
indicated by these percentage values. As shown in Table 4-11, the weight 
changes between/within sampling were all less than 1.0%, in the range of 
0.0681% - 0.9968%. According to this result, the weight change of Reservoir A 
would not significantly influence the oxaliplatin concentration in the samples 
from the pharmacokinetic simulations. 
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Table 4-11, Weight changes of Reservoir A (‘central compartment of patient body’) between/within each sample time for ten simulated ‘patients’ in 
different dosing methods. 
Patient  
Individual dosing 
Dose-banding with 5% 
deviation 
Dose-banding with 10% 
deviation 
Flat-fixed dosing Log dose-banding 
Weight 
change 
between 
sampling 
(%) 
Weight 
change 
within 
sampling 
(%) 
Weight 
change 
between 
sampling 
(%) 
Weight 
change 
within 
sampling 
(%) 
Weight 
change 
between 
sampling 
(%) 
Weight 
change 
within 
sampling 
(%) 
Weight 
change 
between 
sampling 
(%) 
Weight 
change 
within 
sampling 
(%) 
Weight 
change 
between 
sampling 
(%) 
Weight 
change 
within 
sampling 
(%) 
Patient 1 0.5008 0.1713 0.5105 0.1873 0.2300 0.1313 0.5951 0.2317 0.6661 0.3702 
Patient 2 0.3655 0.2230 0.5465 0.1437 0.6139 0.3242 0.8275 0.1718 0.5951 0.1631 
Patient 3 0.8441 0.4573 0.4923 0.2249 0.9499 0.1485 0.8071 0.2067 0.8966 0.3427 
Patient 4 0.6183 0.3990 0.2381 0.1628 0.2379 0.1208 0.9078 0.1569 0.6442 0.1831 
Patient 5 0.7815 0.1462 0.5961 0.2384 0.8711 0.2433 0.6944 0.3432 0.5753 0.1661 
Patient 6 0.4540 0.6609 0.4886 0.1361 0.9087 0.1775 0.9968 0.1458 0.8878 0.2311 
Patient 7 0.4790 0.1204 0.6891 0.1356 0.6970 0.3587 0.5693 0.0681 0.7974 0.1777 
Patient 8 0.6033 0.3605 0.6049 0.2093 0.8628 0.6036 0.6246 0.1171 0.7283 0.1860 
Patient 9 0.4121 0.1334 0.3016 0.2552 0.3718 0.1151 0.4572 0.1787 0.0455 0.4930 
Patient 10 0.4460 0.1588 0.8407 0.3493 0.8098 0.1977 0.6084 0.1264 0.7799 0.0808 
Weights of sample volumes (10 mL) withdrawn from Reservoir A were excluded from the ‘weight change within sampling’. 
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4.4.2.3 Results of oxaliplatin PK simulations   
At each sample time, concentrations of oxaliplatin were determined by the 
validated HPLC assay. Oxaliplatin concentrations calculated from 
chromatographic peak height were input to the PK Solutions software to create 
oxaliplatin concentration-time curves. From the concentration-time curve, the 
main oxaliplatin PK parameters were estimated by the ‘PK Solutions’ software 
package, including Cmax, Tmax and AUC. The estimated values of these PK 
parameters for each patient with different dosing methods are shown in Table 4-
12. 
Table 4-12, Oxaliplatin PK results from the ex vivo PK simulations, including Cmax, 
Tmax and AUC, for each patient in different dosing methods. 
Patient 1 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.5521 3.8042 3.7242 2.509 3.9544 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.8 17.6 17.4 12.9 18.1 
      Patient 2 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.9723 4.5272 4.3002 4.4275 4.2346 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 20.7 18.0 18.4 17.0 17.9 
      Patient 3 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 5.52584 4.2217 4.7359 6.9103 4.5646 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.4 15.8 18.0 26.5 18.3 
      Patient 4 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 5.3099 4.6301 4.3712 5.3974 4.4593 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 20.5 18.1 18.4 22.5 17.3 
      Patient 5 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.472 4.2776 4.0688 3.9859 4.4491 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.5 18.9 17.2 19.0 20.7 
  
 
le 4-12,  
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Continued      
Patient 6 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 5.2413 4.2497 4.5942 6.1034 4.3727 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 18.9 15.3 17.9 24.1 16.7 
      Patient 7 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.7062 3.9707 4.2534 4.2387 4.3543 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.8 17.3 16.4 18.7 19.5 
      Patient 8 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.7477 4.3622 4.1917 3.348 3.8551 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.0 17.7 16.9 13.8 15.5 
      Patient 9 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.2402 4.2977 4.1917 3.348 3.8551 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.1 19.7 17.9 14.1 20.2 
      Patient 10 IND 5%DB 10%DB FFD LDB 
Cmax (µg/mL) 4.6187 3.9431 3.8633 3.9268 3.8919 
Tmax (hr) 2.0 2.0 2.0 2.0 2.0 
AUC (µg-hr/mL) 19.8 17.4 17.7 17.8 17.0 
IND = Individual dosing; 5%DB = dose-banding scheme with 5% deviation; 10%DB = dose-banding 
scheme with 10% deviation; FFD = Flat-fixed dosing; LDB = Logarithmic dose-banding scheme; Cmax = 
the maximum oxaliplatin concentration in ‘body’ after dose administration; Tmax = the time of maximum 
oxaliplatin concentration; AUC = area under the oxaliplatin concentration-time curve. 
4.4.3 Summary and comparisons of PK results 
4.4.3.1 AUC distribution 
To achieve the required therapeutic efficacy, AUC values for patients of 
different BSA should ideally cluster around a constant value, which can provide 
the safe (non-toxic) and effective drug exposure in the patient. 
AUC values of each patient for different dosing methods are shown in Figure 4-
7, in which the distributions of patients’ AUC values are visualized. As shown in 
Figure 4-7, AUC values have a more compact distribution for individual dosing 
(IND) and the dose-banding scheme with 10% deviation (10%DB). While in the 
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dose-banding scheme with 5% deviation (5%DB) and logarithmic dose-banding 
scheme (LDB), the variation between patients is larger. AUC values for flat-fixed 
dosing (FFD) are distributed across the widest range compared to the other 
dosing methods. 
Mean values of AUC for 10 patients in each dosing scheme are shown with 
standard deviations in Figure 4-8. Relative standard deviation (RSD) values for 
Individual dosing, 5% dose-banding scheme, 10% dose-banding scheme and 
Log dose-banding scheme are 0.6023%, 1.2985%, 0.6460% and 1.6254%, 
respectively. However, with the Flat-fixed dosing method, AUC values show 
more variations between patients with different BSA, giving an higher RSD of 
4.5583%. 
 
Figure 4-7, Distribution of ‘patients’ AUC values for five different dosing methods: 
Individual dosing (IND), dose-banding scheme with 5% deviation (5%DB), dose-
banding scheme with 10% deviation (10%DB), Flat-fixed dosing (FFD) and Log dose-
banding scheme (LDB). 
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Figure 4-8, Mean values of 10 ‘patients’ AUC with relative standard deviations (error 
bars)  for five different dosing methods: Individual dosing (IND), dose-banding scheme 
with 5% deviation (5%DB), dose-banding scheme with 10% deviation (10%DB), Flat-
fixed dosing (FFD) and Log dose-banding scheme (LDB). 
4.4.3.2 Relationships between patient’s BSA and AUC values for different 
dosing methods 
Ten ‘patients’ with randomly selected BSA were included in this simulation 
study to estimate the inter-patient variability of oxaliplatin AUC values gained 
with different dosing administration methods.  
The relationship between patients’ BSA and the AUC, calculated from PK 
simulations, are shown in Figures 4-9 to 4-13: Figure 4-9 represents the 
Individual dosing method (IND); Figure 4-10 represents the dose-banding 
scheme with 5% deviation (5%DB); Figure 4-11 represents the dose-banding 
scheme with 10% deviation (10%DB); Figure 4-12 represents the Logarithmic 
dose-banding scheme (LDB) and Figure 4-13 represents the Flat-fixed dosing 
(FFD).  
With the IND dosing method, AUC values are all around the same level of 20.0 
µg-hr/mL for ten ‘patients’ with different BSA and the rough trend line is flat as 
shown in Figure 4-9. Figure 4-11 for 10%DB shows similar AUC-BSA 
relationship as IND. For dose-banding scheme with 5% deviation (5%DB), AUC 
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values slightly increase in patients with higher BSA. As shown in Figure 4-12, 
AUC values are more variable in Log dose-banding scheme (LDB), and also 
increase when BSA grows higher. The most dispersive AUC distribution for 
different BSA is presented in Figure 4-13 with Flat-fixed dosing method (FFD). 
However, there is an obvious variation tendency in FFD plot which indicates 
AUC values reduce with BSA’s increase.  
Regardless of FFD, the inter-patient variabilities of AUC with IND and three 
dosing-banding schemes were relatively small.  
 
Figure 4-9, Relationship between patients’ BSA and AUC from the ex vivo PK 
simulations in Individual dosing (IND). 
 
Figure 4-10, Relationship between patients’ BSA and AUC from the ex vivo PK 
simulations in dose-banding scheme with 5% deviation (5%DB). 
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Figure 4-11, Relationship between patients’ BSA and AUC from the ex vivo PK 
simulations in dose-banding scheme with 10% deviation (10%DB). 
 
Figure 4-12, Relationship between patients’ BSA and AUC from the ex vivo PK 
simulations in Logarithmic dose-banding scheme (LDB). 
 
Figure 4-13, Relationship between patients’ BSA and AUC from the ex vivo PK 
simulations in Flat-fixed dosing method (FFD). 
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4.4.3.3 Comparisons between different dosing strategies 
Individual dosing calculated with BSA represents the current practice and was 
used as the control group for comparisons with other dosing schemes. As 
mentioned in the above sections, Cmax and AUC are two important 
pharmacokinetic parameters, which could be surrogate measurements for the 
drug’s efficacy and toxicity. In this section, Cmax and AUC of IND (control) were 
compared to those results of other dosing methods as shown in Table 4-13 and 
Table 4-14. 
Cmax values for each ‘patient’ with different dosing methods are shown in Table 
4-13, which also contains Cmax variations of each dosing scheme compared to 
IND. The mean value of Cmax from 10 ‘patients’ in IND is 4.8119 µg/mL (± 
0.3682). With respect to the IND, the mean percentage of Cmax values from 
simulations with 5%DB, 10%DB, LDB and FFD are respectively 12.13%, 
12.26%, 11.13% and 8.53%. Although the Cmax variation between FFD and IND 
is smaller than other dosing methods, the inter-patient difference of Cmax values 
in FFD is much higher with the relative standard deviation (RSD) of 31.06% 
among 10 ‘simulated patients’. 
Table 4-14 shows AUC values for ten ‘patients’ with each dosing method and 
the variations of AUC from 5%DB, 10%DB, FFD and LDB compared to IND. 
These AUC variations are visualized in Figure 4-14 which presents the 
distribution of AUC variations (compared to IND) separately for each dosing 
scheme. For an individual ‘patient’ the AUC values simulated from dose-
banding schemes (5%DB, 10%DB and LDB) are generally within 20% 
difference to the IND result. Compared with other dosing methods, the inter-
patient variation of AUC in FFD is the largest with the RSD of 24.45%.  
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Table 4-13, Cmax values for ten ‘patients’ with different dosing administration methods and comparisons of Cmax between dosing schemes of 5%DB, 
10%DB, FFD, LDB and the IND. 
Patient 
Cmax (µg/mL) 
Individual 
dosing 
(IND) 
Dose-banding scheme 
with 5% deviation 
(5%DB) 
Dose-banding scheme 
with 10% deviation 
(10%DB) 
Flat-fixed dosing (FFD) 
Logarithmic dose-
banding scheme (LDB) 
Conc. 
(µg/mL) 
Compare to 
IND (%) 
Conc. 
(µg/mL) 
Compare to 
IND (%) 
Conc. 
(µg/mL) 
Compare to 
IND (%) 
Conc. 
(µg/mL) 
Compare to 
IND (%) 
Patient 1 4.5521 3.8042 83.57 3.7242 81.81 2.5090 55.12 3.9544 86.87 
Patient 2 4.9723 4.5272 91.05 4.3002 86.48 4.4275 89.04 4.2346 85.16 
Patient 3 5.2584 4.2217 80.28 4.7359 90.06 6.9103 131.41 4.5646 86.81 
Patient 4 5.3099 4.6301 87.20 4.3712 82.32 5.3974 101.65 4.4593 83.98 
Patient 5 4.4720 4.2776 95.65 4.0688 90.98 3.9859 87.12 4.4491 99.49 
Patient 6 5.2413 4.2497 81.81 4.5942 87.65 6.1034 116.45 4.3727 83.43 
Patient 7 4.7062 3.9707 84.37 4.2534 90.38 4.2387 90.07 4.3543 92.52 
Patient 8 4.7477 4.3622 91.88 4.1917 88.29 3.3480 70.52 3.8551 81.20 
Patient 9 4.2402 4.2977 101.36 4.1182 97.12 3.1679 74.71 4.6267 109.12 
Patient 10 4.6187 3.9431 85.37 3.8633 83.64 3.9268 85.02 3.8919 84.26 
Mean values 
of Cmax (SD) 
4.8119 
(0.37) 
4.2284 
(0.26) 
88.25 (6.66) 
4.2221 
(0.31) 
87.87 (4.64) 
4.4015 
(1.37) 
90.11 (22.15) 
4.2763 
(0.28) 
89.28 (8.76) 
RSD (%) 7.65 6.13 7.55 7.25 5.28 31.06 24.58 6.59 9.81 
Conc. = Concentration; Compare to IND (%): the percentage of Cmax from one dosing scheme compared to Cmax from Individual dosing for the same patient; RSD: relative standard 
deviation of Cmax values among 10 ‘patients’ in each dosing method. 
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Table 4-14, AUC data for ten ‘patients’ with different dosing administration methods and comparisons of AUC between dosing schemes of 5%DB, 
10%DB, FFD, LDB and the IND. 
Patient 
AUC∞ (µg-hr/mL) 
Individual 
dosing 
(IND) 
Dose-banding scheme 
with 5% deviation 
(5%DB) 
Dose-banding scheme 
with 10% deviation 
(10%DB) 
Flat-fixed dosing (FFD) 
Logarithm dose-
banding (LDB) 
AUC∞      
(µg-hr/mL) 
Compare 
to IND (%) 
AUC∞      
(µg-hr/mL) 
Compare 
to IND (%) 
AUC∞      
(µg-hr/mL) 
Compare 
to IND (%) 
AUC∞      
(µg-hr/mL) 
Compare 
to IND (%) 
Patient 1 19.8 17.6 88.89 17.4 87.88 12.9 65.15 18.1 91.41 
Patient 2 20.7 18.0 86.96 18.4 88.89 17.0 82.13 17.9 86.47 
Patient 3 19.4 15.8 81.44 18.0 92.78 26.5 136.60 18.3 94.33 
Patient 4 20.5 18.1 88.29 18.4 89.76 22.5 109.76 17.3 84.39 
Patient 5 19.5 18.9 96.92 17.2 88.21 19.0 97.44 20.7 106.20 
Patient 6 18.9 15.3 80.95 17.9 94.71 24.1 127.51 16.7 88.36 
Patient 7 19.8 17.3 87.37 16.4 82.83 18.7 94.44 19.5 98.48 
Patient 8 19.0 17.7 93.16 16.9 88.95 13.8 72.63 15.5 81.58 
Patient 9 19.1 19.7 103.14 17.9 93.72 14.1 73.82 20.2 105.76 
Patient 10 19.8 17.4 87.88 17.7 89.40 17.8 89.90 17.0 85.86 
Mean values 
of AUC (SD) 
19.7 (0.60) 17.6 (1.30) 
89.50 
(6.73) 
17.6 (0.65) 
89.71 
(3.41) 
18.6 (4.56) 
94.94 
(23.67) 
18.1 (1.63) 
92.28 
(8.73) 
RSD (%) 3.07 7.39 7.52 3.67 3.80 24.45 24.93 8.97 9.46 
AUC∞: the area under oxaliplatin concentration-time curve; Compare to IND (%): the percentage of AUC value from one dosing scheme compared to AUC from Individual dosing 
(IND) for the same patient; RSD: relative standard deviation of AUC values among 10 ‘patients’ in each dosing method. 
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Figure 4-14, Distribution of AUC variations as % (compared to the AUC from IND for 
the same patient) for ten ‘patients’ with 5%DB, 10%DB, FFD and LDB dosing schemes, 
respectively. 
In Table 4-15, AUC variations for the four alternative dosing schemes compared 
with the IND method have been divided into five bands which are ≤ ±5%, ≤ 
±10%, ≤ ±15%, ≤ ±20% and > ±20%. For 5%DB, 10%DB and LDB, all 10 
‘patients’ exhibit AUC variations of less than 20% from IND, while for FFD only 
5 ‘patients’ are within 20% AUC deviation. Simulations with 5%DB, 10%DB and 
LDB produced AUC variation ≤ ±15%, with respect to IND, for which ‘patient’ 
numbers were respectively 8, 9 and 8. As the AUC variations in ‘patients’ with 
FFD exhibited a wide range, only 4 ‘patients’ are within the ≤ ±15% AUC 
variations. Therefore, for most patients the dose-banding schemes provide AUC 
values closer to IND than the FFD scheme. 
Table 4-15, Number of ‘patients’ with different AUC variations (compared to IND) for 
each dosing method. 
Dosing methods 
AUC variation compared to Individual Dosing (IND) 
≤ ±5% ≤ ±10% ≤ ±15% ≤ ±20% > ±20% 
Dose-banding scheme with 
5% deviation (5%DB) 
2 3 8 10 0 
Dose-banding scheme with 
10% deviation (10%DB) 
0 3 9 10 0 
Logarithmic dose-banding 
scheme (LDB) 
1 5 8 10 0 
Flat-fixed dosing (FFD) 1 3 4 5 5 
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4.5 Discussion 
4.5.1 Functionality of the ex vivo PK simulation model 
4.5.1.1 Model design 
The pharmacokinetic simulation model created in this study has been described 
in detail in the methodology and experimental sections above. Some 
modifications were made to this model specific for oxaliplatin simulations. 
I. 5% Glucose was used to simulate the ‘body fluid’ in Reservoir A and 
Reservoir B, which respectively represented the ‘central compartment’ of 
the patient’s body and the compensation solution. Generally, 0.9% saline 
solution is the most commonly used solution for medical purposes, such as 
wound flush cleaning and intravenous injections. In this case, 0.9% saline 
solution was once considered for use in this PK simulation model. However, 
oxaliplatin is not stable in acid environment and will undergo nucleophilic 
substitution reactions with chloride ions in 0.9% saline solution. (127) As a 
result, in clinical practice oxaliplatin infusions are administered in 5% 
glucose solution instead of 0.9% saline solution. (124) (127) To prevent the 
un-necessary degradation of oxaliplatin during the experiment and balance 
the mixture of drug infusions (in 5% glucose) and solutions in other 
reservoirs, 5% glucose solution was selected to be used as the ‘body fluid’ 
in this study. 
II. The high distribution volume of oxaliplatin after drug administration required 
the use of a 1 litre solution bag as the ‘central compartment’ of the patient’s 
body in the scaled model. (11) (109) Due to the nature of the DACH (1,2-
diaminocyclohexane) platinum complexes are lipophilic, oxaliplatin in 
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plasma ultra-filtrate (PUF) can widely distribute in the central blood system. 
(11) (131) In addition, oxaliplatin derivatives will irreversibly bind to proteins, 
DNA and/or other cellular macromolecules, which increases the apparent 
distribution volume of oxaliplatin. (11) (109) According to the literature, the 
high distribution volume of oxaliplatin is normally calculated from the 
determination of oxaliplatin in plasma ultra-filtrate rather than in plasma. (11) 
(129) (238) This may be because the analysis of filterable platinum is more 
straightforward than analysis of intake oxaliplatin in plasma.  Since the 
Reservoir A in this model represents the centre blood system of a ‘patient 
body’, the distribution volume of oxaliplatin in plasma was modelled in this 
study. Following the scale-down schedule in the experiment section, the 
stated distribution volumes for the 10 selected ‘patients’ were within the 
range of 400.2 mL – 837.7 mL. 
The infusion and clearance processes simulated in this PK model 
represented the addition of the drug to, and the removal of drug from, the 
central compartment of the patient’s body. Since oxaliplatin has a simple 
distribution procedure without special preference for tissues or organs, (11) 
this ex vivo PK simulation system was assembled based on a single 
reservoir representing the whole ‘body’ compartment. Otherwise, more 
reservoirs might be adjusted and combined to represent the ‘patient body’ in 
order to simulate different distribution rates for diffusion to different 
tissues/organs in a human body. 
III. Because the elimination of oxaliplatin from the human body is almost 
entirely via the kidney, the simulation system could be simplified by using 
single outlet tubing to replicate drug clearance. (11) (225) Only 2% of the 
administration oxaliplatin dose is excreted by faeces. (11) (109) The total 
276 
 
amount of oxaliplatin in plasma includes bound and un-bound platinum 
complexes, which can be cleared from plasma by binding to proteins or 
NDA and renal elimination. (11) (223) (225) The un-bound (free) platinum 
from oxaliplatin is rapidly excreted through urine after drug administration, 
with a half-life of approximate14 minutes. (109) (225) While total oxaliplatin 
in plasma normally is characterized by tri-phasic elimination, which has a 
short half-life Tα following a long terminal half-life Tγ (can be as much as 
300 hours). (3) (11) (109) (129) In this study, there was no real plasma in 
Reservoir A and subsequently oxaliplatin in the simulated ‘patient body’ is 
all in un-bound form.  Therefore, the total clearance of oxaliplatin in this 
study could be considered as the renal clearance: CLtotal ≈ CLrenal.  
The single compartment PK model used in this study enables different dose 
systems to be compared but could not provide meaningful comparisons of key 
pharmacokinetic values, such as AUC and Cmax, with the data obtained from the 
in vivo studies, see Section 4.5.1.2 below.  
4.5.1.2 Simulation results of PK parameters 
As described above, the PK simulation model for oxaliplatin was designed as a 
one-compartment system in 5% glucose solutions which cannot replicate the 
actual change of oxaliplatin in human plasma, such as protein binding and non-
enzymic degradation/metabolism due to the nucleophilic attack by plasma 
electrolytes. (4) (124) Therefore, the simulated results of AUC and Cmax from 
this study could not reflect the in vivo PK process of oxaliplatin. 
However, the in vivo PK data of oxaliplatin obtained from previous clinical 
studies varied greatly. (11) (131) The in vivo studies on patients with cytotoxic 
drugs were always affected by difficulties, such as the subject patient non-
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homogeneity; various chemotherapy combinations were administered to 
patients with oxaliplatin in different doses (mainly of 85 mg/m2 and 130 mg/m2); 
un-predictable patient numbers (not all enrolled patients would go through the 
whole study) in each study; oxaliplatin was administered in different infusion 
time length. (3) (11) (123) In addition, different types of sample were examined 
for oxaliplatin determination in these clinical studies, including whole blood, 
plasma, plasma ultra-filtrate (PUF) and urine samples. (131) (225)  
With the limitation of having no comparability to in vivo studies, this PK 
simulation model, however, still allows the comparisons between the different 
dosing systems used for oxaliplatin administration in this ex vivo study. 
4.5.2 Optimal dosing administration for oxaliplatin infusions 
4.5.2.1 Traditional dosing method 
When compared with regular medicines, cytotoxic drugs normally have a 
narrower therapeutic window, and thus it is believed that, the drug dose of 
cytotoxic agents need to be prepared and administered with more precision, as 
its precise dosing is related to drug therapeutic effect and toxicity. (239) 
Therefore, the individualized dosing method was applied to cytotoxic drugs to 
replace the initial dosing method of fixed dose in grams or milligrams. (36) The 
first introduction of BSA-based dosing method to clinical oncology was in 1958 
by Pinkel (228), which was based on the theory that patient’s elimination 
capacity is dependent on the body surface area (BSA) rather than the body 
weight. (13) (228) Since then, the BSA-based dosing is always considered as 
the standard drug administration method for most cytotoxic drugs. (226) (227) 
Pharmacokinetic investigations were constantly conducted in order to improve 
the therapeutic index of cytotoxic agents by using new-modified detection 
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methods and technics. (227) In recent studies, BSA-based dosing has been 
proven with no significant contribution to the reduction in variability of AUC. (227) 
(233) In addition, it has been indicated that the BSA value of patient was either 
poorly or not related to the PK characteristics of the drug, and generally could 
not affect the drug efficacy and toxicity. (13) As shown in Figure 4-15, the key 
PK parameter of AUC (area under the drug concentration-time curve) is 
significantly correlated with the elimination CL (total clearance). (211) But 
patient’s BSA is not correlated with the CL for most cytotoxic drugs. (226) This 
resulted in the large inter-individual variability that has been observed with the 
BSA-based dosing administration in current clinical practice, which could be 
improved by using alternative dosing methods to patients, such as flat-fixed 
dosing (FFD). (13)  (221)  
 
Figure 4-15, Effective factors to the therapeutic efficacy and toxicity of most cytotoxic 
drugs. 
For most cytotoxic drugs currently under use, the knowledge of their 
metabolism mechanism is not clearly known, especially the characteristics that 
could affect drug clearance and AUC. (13) (221) If a relationship between BSA 
and drug exposure and/or clearance was established for a cytotoxic drug, the 
BSA-based dosing method could be the most appropriate dosing scheme for 
the administration of that drug. (221)  
Dose-banding is a novel dosing administration strategy based on standardized 
dosages calculated with BSA in each band. (Refer to Section 1.4 in Chapter 1, 
page 88) Unlike the traditional BSA-based individual dosing method (IND), 
dose-banding schemes are operated with several pre-defined dose bands and 
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the patient can receive the standard dose from one of these bands which 
covers his/her prescribed dosage (calculated with BSA value). (8) Since the 
dose-banding scheme is also based on BSA calculations, it would not be 
expected to largely improve the drug efficacy compared with the IND. (13) 
Therefore, the primary concern for dose-banding studies should be proving that 
dose-banding schemes are not worse than IND in terms of drug exposure in the 
patient’s body. (13) (152)  
4.5.2.2 Comparisons of simulated AUC and Cmax values for different 
dosing methods  
In this study, the AUC and Cmax values were simulated from the ex vivo PK 
model to investigate the difference between drug exposures in a ‘central 
compartment’ of the patient’s body administered with different dosing schemes. 
The percentage difference between the simulated AUC values of each dosing 
scheme and IND method are presented in Table 4-16 below, which was 
calculated using the equation:  
Relative Difference(%) =  
AUC′ − AUCIND
AUCIND
 × 100 
[AUC’: AUC value from the simulation with one of the dosing methods among 5%DB, 10%DB, 
FFD and LDB; AUCIND: AUC value from simulations with the individual dosing method].  
In addition, the absolute value of AUC difference between dose-banding 
schemes or FFD and the IND was compared using the paired Student’s t-tests, 
from which the calculated P (n = 10) values are also shown in Table 4-16.  
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Table 4-16, Differences of AUC values and the associated standard deviation (SD) from 
dosing schemes of 5%DB, 10%DB, FFD and LDB compared to IND. 
Patient 
AUC difference 
of 5%DB to IND 
(%) 
AUC difference 
of 10%DB to IND 
(%) 
AUC difference 
of LDB to IND 
(%) 
AUC difference 
of FFD to IND 
(%) 
Patient 1 -11.11 -12.12 -8.59 -34.85 
Patient 2 -13.04 -11.11 -13.53 -17.87 
Patient 3 -18.56 -7.22 -5.67 36.6 
Patient 4 -11.71 -10.24 -15.61 9.76 
Patient 5 -3.08 -11.79 6.2 -2.56 
Patient 6 -19.05 -5.29 -11.64 27.51 
Patient 7 -12.63 -17.17 -1.52 -5.56 
Patient 8 -6.84 -11.05 -18.42 -27.37 
Patient 9 3.14 -6.28 5.76 -26.18 
Patient 10 -12.12 -10.6 -14.14 -10.1 
Mean values of 
AUC difference 
(SD) 
-10.50 (6.73) -10.29 (3.41) -7.72 (8.73) -5.06 (23.67) 
P (n = 10) ˂ 0.05 ˂ 0.05 ˂ 0.05 ˂ 0.05 
AUC difference to IND (%): the percentage of the AUC difference between each dosing scheme and 
individual dosing for the same patient; SD: standard deviation; RSD: relative standard deviation; IND = 
Individual dosing; 5%DB = dose-banding scheme with 5% deviation; 10%DB = dose-banding scheme 
with 10% deviation; FFD = Flat-fixed dosing; LDB = Logarithmic dose-banding scheme; P (n = 10): 
calculated from absolute values of AUC differences by the paired Student’s t-tests. 
Even though AUC (area under the drug concentration-time curve) can surrogate 
the drug exposure in the body, it could not represent the drug characteristics 
alone without considering other pharmacokinetic parameters, especially Cmax. 
(13) Generally AUC values depend on the drug concentration-time curve; 
however it is possible for two different concentration-time curves to share the 
same AUC value as shown in Figure 4-16. There are two different 
concentration-time curves in this figure, named as curve A and curve B, of 
which AUC values are the same (AUC = AUC’) but Cmax values are significantly  
different (Cmax > Cmax’). Even though the drug exposures in a patient’s body are 
identical for curve A and curve B, the therapeutic effect could be totally different. 
If the drug in question has a defined “therapeutic window”, then there is a risk 
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that a low Cmax value will not provide a therapeutic effect and, conversely, that a 
high Cmax value would produce unacceptable toxicity. 
 
Figure 4-16, Example of two concentration-time curves for a theoretical drug with the 
same AUC value and different Cmax for each curve. [Cmax and AUC are for Curve A; Cmax’ and 
AUC’ are for Curve B] 
The Cmax variations between simulation results of different dosing schemes and 
the IND are shown in Table 4-17 below. Furthermore, absolute values of Cmax 
differences in each dosing method were compared using the Student’s t-test, for 
which p values are also shown in the table. 
Among three different dose-banding schemes, the LDB exhibit the smallest 
AUC and Cmax variation of -7.72% and -10.72% compared to IND. AUC and 
Cmax variations for 5%DB are respectively similar to those values obtained from 
10%DB (-10.29% and -12.13%), which are -10.50% and -11.75%. In this study, 
oxaliplatin concentration-time curves from simulations administered with 
different dosing methods were all of similar curve shapes with Cmax obtained at 
2.0 hour time point (Tmax). (Shown in Appendix C) Furthermore, Cmax differences 
between dose-banding schemes and the IND are within the range of -19.72% – 
+9.12%, which is similar to their AUC variation range (-19.05% – +5.76%). 
Therefore, the AUC values and differences (compared to the IND) could be 
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used to compare the simulated oxaliplatin PK characteristics for dose-banding 
schemes. 
Table 4-17, Differences of Cmax values and the associated standard deviation (SD) from 
dosing schemes of 5%DB, 10%DB, FFD and LDB compared to IND. 
Patient 
Cmax difference 
of 5%DB to IND 
(%) 
Cmax difference of 
10%DB to IND 
(%) 
Cmax difference 
of LDB to IND 
(%) 
Cmax difference 
of FFD to IND 
(%) 
Patient 1 -16.43 -18.19 -13.13 -44.88 
Patient 2 -8.95 -13.52 -14.84 -10.96 
Patient 3 -19.72 -9.94 -13.19 31.41 
Patient 4 -12.8 -17.68 -16.02 1.65 
Patient 5 -4.35 -9.02 -0.51 -12.88 
Patient 6 -18.19 -12.35 -16.57 16.45 
Patient 7 -15.63 -9.62 -7.48 -9.93 
Patient 8 -8.12 -11.71 -18.8 -29.48 
Patient 9 1.36 -2.88 9.12 -25.29 
Patient 10 -14.63 -16.36 -15.74 -14.98 
Mean values of 
Cmax difference 
(SD) 
-11.75 (6.66) -12.13 (4.64) -10.72 (8.76) -9.89 (22.15) 
P (n = 10) ˂ 0.05 ˂ 0.05 ˂ 0.05 ˂ 0.05 
Cmax difference to IND (%): the percentage of the Cmax difference between one dosing scheme and 
individual dosing for the same patient; SD: standard deviation; RSD: relative standard deviation; IND = 
Individual dosing; 5%DB = dose-banding scheme with 5% deviation; 10%DB = dose-banding scheme 
with 10% deviation; FFD = Flat-fixed dosing; LDB = Logarithmic dose-banding scheme; P (n = 10): 
calculated from absolute values of Cmax differences by the paired Student’s t-tests. 
As shown in Table 4-18 below, the oxaliplatin doses administered with dose-
banding schemes are mostly within 5% difference to the IND, while some of the 
doses used in 10%DB are within the 10% difference compared to IND. But 
these small variations on drug doses could not explain the larger differences 
found in simulated AUC values observed between dose-banding schemes and 
the IND.  
For example, in 10%DB Patient 3 (1.29 m2) was administered with 2.50 mg 
oxaliplatin, which was 8.76% (the largest dose difference among all dose-
banding schemes) lower than the dose calculated for the IND. However, the 
AUC variation between 10%BD and IND for this patient was only -7.22% which 
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was even lower than the average value of AUC variations between 10%DB and 
IND. The highest AUC variation to the IND (-19.05%) was observed from the 
simulation of Patient 6 (1.33 m2) administered with 5%DB using the dose of 
2.75 mg, which was only 2.47% lower than individualized dosage. Therefore, 
the AUC variation simulated between dose-banding schemes and the IND did 
not directly correspond to the dose differences in drug administration. Hence, 
other effective factors should be considered for these AUC variations, including 
the technical difficulties with the administration of dose-banding schemes.   
In this simulation study, as described in the experimental sections, pre-made 
drug infusions for dose-banding schemes (including 5%DB, 10%DB and LDB) 
were prepared in syringes with multiple sizes. The dose-banding schemes were 
administered with combinations of infusion syringes, which required more 
complex drug infusion administration sets to ensure all syringes were infused to 
‘patients’ within the 2-hour infusion time. Compared with the single infusion 
syringe used in the IND method, the intricate administration of dose-banding 
schemes could result in a larger amount of drug loss in combination syringes 
(especially 2 mL and 5 mL syringes) and/or infusion tubing sets. Because all 
dosing schemes were scaled down by a factor of 40 in this simulation model, 
the small loss of drug infusions would cause effective changes in drug doses 
used in dose-banding schemes. This potential drug loss could also explain the 
lower values of simulated AUC and Cmax in dose-banding schemes compared to 
the result from the IND method. 
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Table 4-18, Different doses administered to each simulated ‘patient’ with different dosing methods and the percentage difference of ‘administered’ 
dose to the individualized dosage (used in IND). 
Patient 
BSA 
(m2) 
Dose in 
IND (mg) 
5%DB scheme 10%DB scheme LDB scheme FFD scheme 
Dose 
(mg) 
Dose 
Difference 
(%) 
Dose 
(mg) 
Dose 
Difference 
(%) 
Dose 
(mg) 
Dose 
Difference 
(%) 
Dose 
(mg) 
Dose 
Difference 
(%) 
Patient 1 2.70 5.74 5.50 4.18 5.75 0.17 5.46 4.88 4.00 30.31 
Patient 2 1.82 3.87 3.75 3.10 4.00 3.36 3.91 1.03 4.00 3.36 
Patient 3 1.29 2.74 2.75 0.36 2.50 8.76 2.80 2.19 4.00 45.99 
Patient 4 1.55 3.29 3.25 1.22 3.50 6.38 3.13 5.17 4.00 21.58 
Patient 5 2.20 4.68 4.75 1.50 4.50 3.85 4.88 4.27 4.00 14.53 
Patient 6 1.33 2.83 2.75 2.47 3.00 6.01 2.80 1.06 4.00 41.34 
Patient 7 1.99 4.23 4.25 0.47 4.00 5.44 4.37 3.31 4.00 5.44 
Patient 8 1.72 3.66 3.75 2.46 3.50 4.37 3.50 4.37 4.00 9.29 
Patient 9 2.52 5.36 5.50 2.61 5.75 7.28 5.46 1.87 4.00 25.37 
Patient 10 2.04 4.34 4.25 2.07 4.50 3.69 4.37 0.69 4.00 7.83 
BSA: body surface area; IND: individual dosing method; 5%DB: dose-banding scheme with 5% deviation; 10%DB: dose-banding scheme with 10% deviation; FFD: flat-fixed 
dosing; LDB: logarithmic dose-banding scheme; dose difference: the percentage of dose difference between one dosing scheme and IND for the same patient, 
𝐷𝑜𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (%) =  
|𝐷𝑜𝑠𝑒′−𝐷𝑜𝑠𝑒|
𝐷𝑜𝑠𝑒
× 100% [Dose’ = drug dose in different dosing method; dose = drug dose in IND]. 
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As shown in Table 4-16 and Table 4-17 above, results of p ˂ 0.05 from the 
paired Student’s t-tests (n = 10) indicated the statistically significance of the 
differences in those simulated AUC values between three dose-banding 
schemes and the IND method. This value calculated based on the ex vivo PK 
simulations might not fully reflect the clinical situations, considering that those 
paired t-tests were based on a small sample group of 10 ‘patients’. In addition, a 
recent study from Chatelut (13) has indicated that for most studied drugs there 
exists no statistically significant difference of AUC values between the dose-
banding scheme and the individual dosing method (IND). (13) In the Chatelut 
study, 6 drugs were studied in total on adult cancer patients and the significant 
difference (P ˂ 0.05) of mean values of AUC only occurred for Paclitaxel 
between the dose-banding scheme and the IND method. (13) Furthermore, the 
dose-banding scheme used in the Chatelut study featured larger dose 
variations (-14% to +22%) in wider bands, of which three dose bands were 
defined as BSA ˂ 1.7 m2; 1.7 m2 ≤ BSA ˂ 1.9 m2; BSA ≥ 1.9 m2. (13) The 
evidence then suggests that, dose-banding schemes with lower dose variations, 
such as the 5%DB, 10%DB and LDB simulated in the ex vivo PK model within 
this study, should be able to provide the effective AUC in patients close to the 
values gained from the IND method. 
In this simulation study, the flat-fixed dosing method (FFD) with the 
standardized 4 mg dose showed large variations on drug doses among all 10 
‘patients’ compared to the IND, which was within the range of 3.36% - 45.99% 
as shown in Table 4-18. Even though the mean values of AUC and Cmax 
variations between FFD and the IND were relatively small, the variation ranges 
were much wider than the dose-banding schemes, which were -34.85% to 
+36.6% and -44.88% to +31.41% respectively for AUC and Cmax variations. 
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According to these results, the administration of FFD could potentially over- or 
under-dose patients. However, the estimation of clearance in this ex vivo PK 
model was only based on the BSA value of each ‘patient’. Other factors that 
might influence the FFD dosing approach were not reflected in this simulation, 
such as renal function, liver function, plasma protein levels etc. (227)  
Since the BSA-based dosing method started to be questioned, the flat-fixed 
dosing scheme was recommended by some published literature sources. (226) 
For drugs established with a broad therapeutic window and small inter-
individual variability in limited toxicity, flat-fixed dosing is likely to be the best 
approach. (226) However, there is not enough evidence to support the 
application of FFD to cytotoxic drugs. (227) (233) A previous study on cisplatin 
has indicated that FFD could be used for cisplatin administration on well-defined 
homogenous patients without significant inter-individual variabilities. (240) But 
for patients with extreme BSA values, such as children and obese patients, the 
fixed dose has not been proven with acceptable efficacy and safety with 
cytotoxic drugs. (227) (241) In some clinical studies on actual patients, the flat-
fixed dosing has also shown greater inter-individual variability on PK 
characteristics, such as AUC values, compared with the BSA-based dosing 
scheme. (13) (233) Similar to the results from previous clinical studies, in this ex 
vivo simulation study the flat-fixed dosing scheme has been shown to be worse 
than other BSA-based dosing methods, including individual dosing and dose-
banding schemes. 
4.5.2.3 Inter-patient variability of AUC and Cmax from different dosing 
methods 
To obtain the therapeutic effectiveness on more patients, the inter-individual 
pharmaceutical variability is a key parameter to investigate in drug therapies, 
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especially for cytotoxic drugs with a narrow therapeutic window. (218) (221) The 
significant PK inter-individual variability could potentially lead to unpredictable 
variety in clinical response and adverse effects. (218) (226) Some studies 
showed that the BSA-based dosing method did not significantly reduce the 
inter-individual variability for some drugs. (221) (226) However, for most 
cytotoxic drugs, other available dosing scheme, such as flat-fixed dosing, has 
not shown better results of lower inter-individual variability compared with the 
BSA-based individual dosing method. (13) (227) (233)  
Therefore, the PK inter-individual variability from different dosing schemes was 
compared in this ex vivo simulation study. The inter-individual variability of AUC 
and Cmax for 10 selected ‘patients’ was expressed as coefficient of variation 
(CV%) shown in Table 4-19 below. These CV (%) values were calculated from 
the AUC and Cmax values observed from PK simulations administered with 
different dosing methods, including individual dosing (IND), dose-banding 
scheme with 5% deviation in each band (5%DB), dose-banding scheme with 10% 
deviation in each band (10%DB), logarithmic dose-banding scheme (LDB) and 
flat-fixed dosing (FFD).  
As shown in Table 4-19, the CV (%) values of Cmax for three dose-banding 
schemes were close to the IND all around 7%. In terms to AUC, the CV (%) 
gained from the IND and 10%DB were respectively 3.0652% and 3.6664%, 
while for 5%DB and LDB the CV (%) values were slightly higher of 7.3865% 
and 8.9699%. According to the available literature, the inter-individual variability 
for cytotoxic drugs is normally around 25% considering all dosing schemes 
(including BSA-based dosing). (226) In this case, drug administration with dose-
banding schemes has not significantly increased the inter-individual variability 
when compared with the IND method. While among all three dose-banding 
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schemes, 10%DB showed the lowest AUC variability in simulations among 10 
‘patients’. 
Table 4-19, Mean values of AUC and Cmax with coefficient of variation (CV) calculated 
from 10 simulated ‘patients’ with different dosing methods, including IND, 5%DB, 
10%DB, LDB and FFD. 
Dosing Methods 
AUC (Area under the 
concentration-time curve) 
Cmax (The maximum drug 
concentration) 
Mean values 
of AUC [SD] 
(µg-hr/mL) 
CV (%) 
Mean values 
of Cmax [SD] 
(µg/mL) 
CV (%) 
Individual dosing (IND) 19.7 [0.60] 3.0652 4.8119 [0.37] 7.6514 
Dose-banding scheme with 
5% deviation (5%DB) 
17.6 [1.30] 7.3865 4.2284 [0.26] 6.1267 
Dose-banding scheme with 
10% deviation (10%DB) 
17.6 [0.65] 3.6664 4.2221 [0.31] 7.2514 
Logarithmic dose-banding 
scheme (LDB) 
18.1 [1.63] 8.9699 4.2763 [0.28] 6.5919 
Flat-fixed dosing (FFD) 18.6 [4.56] 24.4545 4.4015 [1.37] 31.0601 
SD: standard deviation; CV (%): coefficient of variation. 
Compared with other dosing methods, PK simulations with flat-fixed dosing 
(FFD) resulted in the largest CV (%) values of 24.4545% and 31.0601% 
respectively for the AUC and Cmax. These high CV values could indicate that 
compared with other dosing schemes, the flat-fixed dosing is less optimal for 
oxaliplatin administration since it might cause a greater inter-individual 
variability of drug exposure in real patients. According to those simulation 
results, the flat-fixed dosing scheme is not recommended for clinical use. 
4.5.3 Clinical application 
4.5.3.1 Dose-banding schemes (including 5%DB, 10%DB and LDB) 
With a small number of clinical studies on cytotoxic drugs, there is only limited 
evidence to persuade oncologists to consider alternative dosing strategies 
which challenge the traditional individual dosing method (IND). (152) (227) At 
the present time, some clinicians, regulators and/or industrial drug developers 
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remain unconvinced by the arguments for change. (221) However, the dose-
banding scheme with less than 5% deviation from the prescribed dose in each 
band (5%DB) has gained wide acceptance and has been applied to several 
widely-used anticancer drugs in clinical practice. (10) (152) It may be more 
difficult for the 10%DB with higher dose deviation to gain acceptance from 
physicians without reliable pharmacological and pharmacokinetic data to 
support the efficacy and safety of this dosing scheme. (152) However, the 
greater variation of administered dose possible with 10%DB should be 
considered in context of the complexities of cytotoxic drug administration, and 
whether the individualised dose calculated from BSA is ever administered 
accurately in clinical practice anyway. (221) (226) In fact, intravenous infusion 
dosing errors with the individual dosing method (IND) during the drug 
preparation and administration are very common with a reported incidence of up 
to 50%. (79) (221) These errors are normally caused by systematic errors (fault 
calculation), inaccurate height and weight information from patient, initial 
variation from stock vial of the drug and inevitable residual infusion waste in 
infusion administration tubing. (149) (221)  
Therefore, 10% dose variation in the 10%DB scheme should not be considered 
excessive when compared with the high error incidence in current IND method 
for oxaliplatin. Moreover, 10%DB scheme can be operated with less dose 
bands compared with the other two dose-banding schemes. In this case fewer 
variants of standard dose, administered with the combination of pre-made 
infusions, would be required for each band, which is more practical and 
economical for both manufacturers and pharmacists (Table 4-20).  
The pre-filled syringes in this simulation study were scaled down from actual 
drug doses to represent the pre-prepared drug infusion bags in practice, which 
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are one of the main error causes in drug preparation. In practice, the pre-
prepared drug infusion bags could be prepared in more convenient doses for 
dose-banding schemes. As a result, 10%DB would only require 3 types of pre-
made infusion bags with various doses which is less than 4 infusion bags 
required by 5%DB (Shown in Table 4-20). 
Table 4-20, Comparison of pre-made infusions requirements for three dose-banding 
schemes of 5%DB, 10%DB and LDB in clinical practice. 
Dose-banding schemes 
designed for oxaliplatin 
administration 
Max dose 
deviation in 
each band 
Number of 
dose bands 
Number of 
pre-made 
infusions 
Max number of 
syringes in a 
combination 
Dose-banding scheme with 
5% deviation (5%DB) 
5% 12 4 4 
Dose-banding scheme with 
10% deviation (10%DB) 
10% 7 3 4 
Logarithmic dose-banding 
scheme (LDB) 
6% 9 10 4 
Max dose deviation: the maximum dose deviation between the standard dose and the prescribed dose in 
each band. Dose-banding schemes presented in this table are designed for oxaliplatin administrations to 
patients with BSA range from 1.12 m
2
 to 2.70 m
2
. 
For the logarithmic dose-banding scheme (LDB), 10 infusion bags in different 
doses are required to be prepared for drug administration as shown in Table 4-
20. In clinical practice, the more infusion bags produced and stored for the LBD 
scheme could result in greater potential waste of drug infusions compared with 
other dose-banding schemes. Furthermore, the standard dose in each band is 
more precise in the LDB, which raises the potential risk of calculation and 
preparation errors. Most importantly, few pharmacists and technicians are 
confident with their understanding or use of the LDB scheme in clinical practice. 
Even if administration doses of the LDB scheme are calculated by computers, 
serious medication errors could still occur since the pharmacist may not 
recognise potential errors caused by computer faults.  
In summary, simulation results from this study indicated that the 10%DB 
scheme provided comparable pharmacokinetic performance to IND and other 
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dose-banding schemes in terms of AUC and Cmax. Considering the advantages 
discussed above, the 10% DB scheme would be the preferred option for 
oxaliplatin administration compared to 5%DB and LDB. The low number of 
different pre-prepared drug infusions required with this scheme would make it 
more attractive for a pharmaceutical manufacturer to enter the market with a 
small range of licenced ready-to-use infusions, for which providing extended 
drug-stability periods of >12 months is achievable. 
4.5.3.2 Flat-fixed dosing 
As discussed in the above Section 4.5.2, the flat-fixed dosing scheme (FFD) 
was recommended to be applied for cytotoxic drug administration since the 
value of the BSA-based dosing method has been put into question. (226) (227)  
Flat-fixed dosing refers to simply application with one fixed dose for all patients 
regardless to their various BSA values or other pharmacological differences, 
which is a widely used dosing strategy for the majority of drugs. (226) The 
highlight benefits of FFD are the positive economic implications and the lower 
risk in terms of dosing errors caused by dose calculation, preparation and 
administration. (226) (227) However, patients with extreme conditions, such as 
children and obese patients, might be easily over- and/or under-dosed by 
administration with the fixed dose. (227) (241) The drugs that are suitable for 
FFD administrations would have: 1) a broad therapeutic window; 2) lower inter-
individual variability of PK parameters; 3) limited toxicity and adverse effects. 
(226)  
In this ex vivo PK study, as discussed above, the simulation results on 10 
‘patients’ (within the BSA range of 1.12 m2 – 2.70 m2) indicated the large 
variations of PK parameters (AUC and Cmax) between FFD and the individual 
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dosing method. With a relatively high inter-individual variability for AUC/Cmax, 
the flat-fixed dosing scheme is not recommended for oxaliplatin administration 
in clinical practice among the five dosing methods featured in this thesis. 
4.5.4 Limitations of this study 
Three main limitations of the ex vivo PK simulation model were identified during 
this study: 
First, lack of reliable pharmacokinetic data on oxaliplatin has given limited 
parameterisation of this ex vivo PK simulation model. The drug total clearance 
(CL), has been selected and calculated from previous PK studies of oxaliplatin. 
Therefore, the CL value applied to each simulated ‘patient’ might not accurately 
reflect the actual individual patient without consideration of patient-specific 
clinical factors such as renal function. This gives rise to the real-life possibility of 
patients with the same BSA having different CL values. In clinical studies, 
patients are subjected to rigorous clinical monitoring and drug concentrations 
are measured in blood/plasma/ultra-filtrate plasma (PUF) samples from patients 
to obtain an oxaliplatin concentration-time curve for PK analysis. (225) In these 
cases, the PK result is more specific and accurate for each individual patient. 
The variability of AUC/Cmax, compared to experiments on patients, was 
unavoidable in ex vivo simulations because those simulation settings relied on 
assumed values of patient parameters, such as CL and Vd. However, in clinical 
studies the intra-individual variability should be higher with real patients, as the 
patient’s medical conditions are not stabilized all the time and the PK values 
may change during the course of chemotherapy. 
Second, the scaled-down model required higher precision of drug preparation, 
model assembly and experiment processing. The purpose of the scaled-down 
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schedule in this study was to adjust this simulation model to suit the laboratory 
conditions. However, after the drug dose has been scaled down by a factor of 
40, the drug preparation required accuracy of measurements of small volumes 
ranging from 0.01 mL to 1 mL. For example, using the same stock solution of 1 
mg/mL, a patient with 2.20 m2 BSA requires 187 mL stock drug infusion for 
dilution. In the scaled-down simulation model, 4.68 mL stock has to be diluted in 
5% glucose and stored within a 20 mL volumetric syringe. A small inaccuracy 
with these low volumes can result in a high percentage error. For dose-banding 
schemes, the pre-filled oxaliplatin syringes were prepared 12 days in advance 
to simulate the practical situation. Some of those syringes were prepared in 
smaller volumes (the smallest syringe was in 2 mL) to ensure the oxaliplatin 
concentrations of infusions were within the stability range of 0.2 mg/mL – 0.7 
mg/mL (Chapter 2, page 97). The dose error could be relatively high in small 
volumes since a single drop of infusion might cause a large variation within the 
syringe. Furthermore, even a small dead volume in the scaled-down simulation 
system might make a difference in the determination of oxaliplatin 
concentrations at sample times. These errors caused by the scale-down 
schedule could not be totally eliminated despite all of the precautions taken:  
 Oxaliplatin stock solutions in different concentrations have been diluted 
in syringes to provide appropriate operable drug volumes;  
 Pipettes with two different working ranges and precisions were used for 
transferring drug infusions in different volumes;  
 All tubing in the simulation system was pre-filled with the correct 
solutions: tubing connected with drug syringes was pre-filled with 
oxaliplatin infusions from the syringe; tubing connected with 
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compensation reservoir (Reservoir B) and waste reservoir (Reservoir C) 
was pre-filled with 5% glucose. 
Third, ‘patients’ with extreme BSA values were not included in this study. The 
BSA range selected in this study was 1.12 m2 – 2.70 m2, which included slightly 
higher BSA values than the average BSA range from the other literature. (157) 
(242) In consideration of the increasing trend of body weight within cancer 
patients, larger BSA  values should be included in pre-clinical and clinical 
studies. However, extreme BSA values were not included in this simulation 
study because pharmacokinetic data could not have been validated on extreme 
ranges and these groups could also include patients with special conditions who 
would require specialised clinical evaluation prior to chemotherapy.  
4.6 Conclusion 
The ex vivo PK simulation model designed and used in this study was validated 
with acceptable accuracy and precision. Considering the difficulties surrounding 
clinical studies of cytotoxic drugs on real cancer patients, the ex vivo PK 
simulation is more economical and easier to operate, which should be 
considered as an alternative approach for PK studies of cytotoxic drugs.  
Simulations of flat-fixed dosing (FFD) showed results with relatively large AUC 
variability among patients, which was not even comparable to the individual 
dosing method. However, all three dose-banding schemes demonstrated 
acceptable inter-individual variability on AUC and Cmax values, including dose-
banding scheme with maximum 5% deviation (5%DB), dose-banding scheme 
with maximum 10% deviation (10%DB) and logarithmic dose-banding scheme 
(LDB). Among the different dose-banding schemes, 10%DB has been proven to 
have more advantages in practice.  
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Overall, the ex vivo PK simulations for oxaliplatin infusions demonstrated that 
dose-banding scheme with 10% deviation (10%DB) would be the preferred 
dosing scheme for oxaliplatin administration compared with other studied 
dosing methods.  
This simulation study could not fully reflect the clinical situations and PK 
characteristics of oxaliplatin when administered to real patients. But these 
simulation results confirmed the feasibility of future application of dose-banding 
schemes in clinical practice. Consequently, further clinical studies of dose-
banding with assessment of drug toxicity and efficacy could facilitate the 
implementation of dose-banding schemes for oxaliplatin administration. 
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Chapter 5: Conclusion and Recommendations  
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5.1 Contribution to knowledge on dose-banding of 
cancer chemotherapy 
The studies reported in this thesis have confirmed that implementation of dose-
banding for oxaliplatin chemotherapy into clinical practice is feasible. Three key 
issues for the development of dose-banding scheme for oxaliplatin 
administration were investigated in studies presented in Chapter 2, Chapter 3 
and Chapter 4 of this thesis.  
Chapter 2 focused on the preparation and stability of standard oxaliplatin 
infusions. Dose-banding schemes require long-term physical and chemical 
stability (28 – 84 days) (149) of the infusion to enable advance batch 
preparation of standard infusions by hospital pharmacy compounding units or 
pharmaceutical manufacturers. (8) (159) The stability study described in 
Chapter 2 indicated the effective stability period (84 days) for oxaliplatin 
infusions over a concentration range of 0.2 mg/mL – 0.7 mg/mL, which is a 
significant increase in the previous shelf-life of oxaliplatin infusions claimed in 
the SPC (Summary of Product Characteristics) and available literature. (5) (243) 
(168) After confirming the stability of oxaliplatin infusions is sufficient for 
advance preparation for dose-banding schemes, the potential for oxaliplatin 
infusions subjected to long-term storage to contribute to patient toxicity as a 
result of small quantities of drug degradation products was explored with 
studies on oxalate, a potential degradation product of oxaliplatin, conducted in 
Chapter 3. Oxalate has been implicated in previous reports (12) (147) as being 
associated with the oxaliplatin-related peripheral neuropathy. This study found 
that a relatively small increase in oxalate concentration occurred in oxaliplatin 
infusions after long-term storage and also in human plasma containing 
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oxaliplatin. However, comparisons of these oxalate sources against the levels of 
endogenous oxalate suggest that oxalate from oxaliplatin infusions is unlikely to 
be the main cause of neurotoxicity associated with oxaliplatin treatments. (147) 
The combination of these two studies thus demonstrated that oxaliplatin 
infusions within a standard concentration range prepared and stored for dose-
banding schemes are safe for patient administration. The final uncertainty which 
this thesis aimed to address was, whether or not the dose-banding scheme can 
provide acceptable drug efficacy and toxicity for patients compared with the 
individual dosing method based on BSA (Body Surface Area) that are currently 
used in routine practice. Clinical studies to answer this question were precluded 
on the basis of patient numbers, cost and the level of intervention necessary to 
accurately monitor disseminated disease. Therefore the AUC (area under the 
concentration-time curve) of plasma concentration-time curves for oxaliplatin 
was used as a surrogate for clinical measurement and the pharmacokinetic (PK) 
behaviour of oxaliplatin simulated in an ex vivo model was compared for dose-
banding schemes and the individual dosing method, as shown in Chapter 4. 
Different dose-banding schemes with 5% and 10% maximum deviation from the 
prescribed dose both demonstrated an acceptable inter-individual variability of 
AUC values, and the mean values of simulated AUC and their standard 
deviation values were comparable to the individualised dosing. Although the ex 
vivo simulation has a number of limitations which are discussed in Chapter 4, 
the results of the dose-banding approach were comparable to individual dosing 
when evaluated under the same conditions. In addition, the dose-banding 
scheme with 10% maximum deviation from prescribed dose was as acceptable 
as the 5% variation dose-banding scheme. The 10% variation scheme requires 
fewer standard infusions and was recommended in this thesis as the best 
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option for oxaliplatin administration among all three dose-banding schemes. In 
summary, the results from studies reported in this thesis support the dose-
banding of oxaliplatin administration in routine oncology practice using the 
scheme with 10% maximum deviation from the prescribed dose.   
5.2 Advancing knowledge on oxaliplatin stability 
The stability study on oxaliplatin infusions in Chapter 2 has set a benchmark for 
stability studies required by dose-banding schemes with the sequential 
temperature cycling design. It has not only extended the stability period of the 
drug up to 84 days, but also supports the storage and re-use of unused drug 
infusions that have been dispensed and returned from the clinic.  
In clinical practice, the drug waste caused by change and/or cancellation of the 
chemotherapy treatment is thought to cost about 1% of a hospital cancer drug 
budget. (244) Since the stability of the re-issued oxaliplatin infusions was 
simulated in the stability study, the standard infusion bags for dose-banding can 
be safely re-used within 7 days of further refrigerated storage after being 
exposed to room temperature for up to 24 hours. The temporary storage 
conditions during transportation and in clinical areas must be monitored to 
ensure the conditions used in the sequential temperature cycling study (25℃) 
are not exceeded. In terms of wastage reduction, dose-banding offers a further 
advantage over individualised dosing in that batches of standard infusions for 
dose-banding schemes can be prepared in numbers that use an integral 
number of manufacturer’s drug vials. This could reduce the drug wastage 
associated with part-used vials and circumvents the technical challenges of re-
using part-vial contents.  
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These savings, although significant with conventional cytotoxic chemotherapy, 
are even more significant if the concept of dose-banding can be applied to high-
cost targeted therapies with stability considerations permitting. 
Another key issue arising from the stability study was defining the acceptance 
limits for variation of the oxaliplatin concentration. For long-term stability studies, 
it is difficult to track all components that may be present in the drug infusion, 
which could include diluent components, potentially leachable chemicals from 
the container, the drug and drug degradation products. The latter could be 
present in very low concentrations, which makes the resolution and 
quantification of degradation products very difficult. Furthermore, the drug 
degradation products may be transient species that would degrade further 
during the term of the stability study. For cytotoxic drugs, such as oxaliplatin, 
the information and knowledge about their degradation products are currently 
limited with unclear/unknown therapeutic and toxic effects. Drug degradation 
products arising in the drug infusion are not always the same as the related 
substances or impurities described in the Pharmacopoeia (e.g. European 
Pharmacopoeia). In this case, it is very difficult to measure, isolate and identify 
those drug-related complexes from a dilute infusion. A pragmatic approach to 
prevent any potential risk from those compounds is required and one practical 
approach is to use more restrictive acceptance criteria for the drug assay. The 
stability study in Chapter 2 used the acceptance criteria of ± 5% (instead of the 
± 10% often used in previous studies) for concentration variations of oxaliplatin. 
With this ± 5% criteria for the drug change, concentrations of the drug 
degradation products or other drug-related complexes are limited, and so the 
risk of any potential toxicities to patients arising from these compounds would 
be reduced. (149) 
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In the UK, aseptic pharmaceuticals with shelf-life exceeding 7 days must be 
prepared in appropriately accredited hospital pharmacies or by manufacturers 
licenced by the Medicines and Healthcare products Regulatory Agency (MHRA). 
(159) The preparation procedure for those pharmaceuticals must be in 
compliance with the European guidelines on good pharmaceutical 
manufacturing practice (GMP). This ensures that pre-prepared drug infusions 
for dose-banding schemes will be manufactured with rigorous quality assurance 
and that extensive validation procedures will be carried out by appropriately 
qualified staff. (245) When compared with the traditional individualized dosing 
method that is normally prepared and administered in hospital/clinic, the 
industrial manufacture of drug infusions for dose-banding schemes, and the 
associated quality control (QC) procedures, should ensure that drug 
administration errors are minimised. 
5.3 Findings related to the neurotoxicity of oxaliplatin 
In Chapter 3, the knowledge of the potential contribution of oxalate to 
oxaliplatin-related neurotoxicity is enhanced, by the finding that the level of 
oxalate produced in oxaliplatin infusions after long-term storage and the amount 
of oxalate produced from oxaliplatin by non-enzymic transformation in human 
plasma (incubated at 37℃ to simulate the patient body) were within accepted 
safe levels in both cases. The study implies that it is highly unlikely that oxalate 
derived from administered doses of oxaliplatin is the main cause of neurotoxicity 
associated with oxaliplatin treatments.  
In previous studies, the neurotoxicity of oxalate has been demonstrated by 
exposing the neuron cells to a high dose of oxalate. (147) (246) According to 
the findings from this thesis, however, the plasma oxalate increase caused by 
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oxaliplatin administration would not reach the toxic levels indicated in these 
previous studies. (145) (246) The role of oxalate in oxaliplatin side-effects can 
therefore be drawn into question. This leaves several alternative hypotheses 
surrounding the role of oxalate in the neurotoxicity of oxaliplatin: 
1) Oxaliplatin might affect the neuro-sensitivity of the patient body to oxalate, 
meaning that oxalate can become neurotoxic at lower concentrations; 
2) Oxaliplatin might influence the rate of oxalate uptake in humans from 
normal dietary/metabolic sources; 
3) The oxaliplatin-related neurotoxicity might be due to other factors 
independent of oxalate. 
The first two hypotheses could have potential ramifications in clinical practice, in 
that there might be potential benefits in modifying the patients’ diet before and 
during oxaliplatin treatments to reduce the baseline concentration of plasma 
oxalate. Clearly further studies are required to clarify these hypotheses, 
including research into the effect of oxaliplatin on the absorption, transport and 
metabolism of oxalate.  Such work is beyond the scope of this thesis. 
5.4 An alternative approach to the understanding of PK 
characteristics of cytotoxic drugs 
With the notable exception of carboplatin, for most cytotoxic drugs there are no 
clear relationships between blood-concentration and therapeutic effect or 
toxicity. (119) As such, pharmacokinetic-guided chemotherapy has been of little 
benefit in clinical practice. However, PK studies are of value in drawing 
comparisons between different drug administration systems including oral 
versus intra-venous dosing (e.g. methotrexate) (247), liposomal formulations 
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versus solutions for injection (e.g. epirubicin) (248) and dose-banding versus 
individualised chemotherapy. (13) The latter example has been used as a 
surrogate for clinical studies in efforts to establish that dose banding is both 
safe and effective. There is, however, a paucity of reported PK information for 
cytotoxic drugs.  The limited oxaliplatin PK data in the published literature was 
identified in this thesis. Reasons for the limited PK experimentation and clinical 
studies on oxaliplatin are: 
1) Oxaliplatin is a relatively new drug that was recently launched in the 1990s 
(1), and most studies and investigations on oxaliplatin PK characteristics have 
only been conducted since it was approved for clinical use (129); 
2) There are unavoidable difficulties in general associated with clinical studies 
on cytotoxic drugs including oxaliplatin. These include the ethical barrier against 
administration of cytotoxic agents to healthy subjects, and the non-homogeneity 
of available test patients, which leads to significant differences of reported PK 
data between studies (11) (129).  
In addition, variations of PK characteristics between previous studies in similar 
conditions were mostly affected by the form of oxaliplatin measured in samples. 
(11) (129) For example, the volume of distribution (Vd) estimated for the total 
amount of oxaliplatin was 35 L, whereas the Vd value tested for the un-bound 
oxaliplatin was 440 L. (11) (249) Furthermore, in previous clinical studies the 
concentration of un-bound (free) oxaliplatin determined in plasma was generally 
overestimated because the inactive oxaliplatin bound to amino acids and other 
small biomolecules in blood was also included in the plasma oxaliplatin. (11) 
Another issue contributing to the incomplete PK data of oxaliplatin and other 
anticancer drugs is that no data are available for drug behaviours in the healthy 
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human body, for the reason mentioned above where administration of cytotoxic 
drugs to healthy volunteers is not permitted.  
The ex vivo PK simulation model developed in Chapter 4 is in need of further 
development and refinement (as discussed previously), but has potential value 
in comparing dose-banding, and the dose-banding variants against 
individualised dosing as it is possible to replicate the practical differences in the 
drug administration systems associated with these different schemes but 
without subjecting cancer patients to inconvenient and invasive clinical studies. 
This validated ex vivo model can be adjusted for different drugs to simulate their 
PK processes. Generally, drug PK models are built on specific simulation 
software parameterised on a large amount of available PK data. But this ex vivo 
PK model only requires the estimated values of CLtotal (total clearance) and Vd 
(distribution volume) to set up, and then the drug concentration-time curve can 
be obtained and analysed to give the key PK parameters of AUC (area under 
the drug concentration-time curve), Cmax (the maximum drug concentration) and 
Tmax (the time when Cmax is achieved). 
Even though the ex vivo simulations might not be able to fully replicate the 
actual physiological process experienced in vivo, it is of utility in comparing drug 
administration systems and schemes (as described above) and also to simulate 
the drug PK profile in ‘patients’ with different conditions, such as patients with 
impaired renal function and patients with extreme BSA (body surface area) 
values. 
The above considerations demonstrate that the ex vivo simulation model 
described in this thesis merits further development to facilitate ongoing research 
into dose-banding and other alternative dose-schemes. 
306 
 
5.5 Recommendations for the further implementation of 
dose-banding  
Dose-banding, as a relatively new dosing scheme for cytotoxic drug 
administration, has been described and explained in previous chapters in this 
thesis, together with the benefits that dose-banding would bring to the clinical 
practice of chemotherapy.  
This project on oxaliplatin, as described in each chapter, including extended 
stability studies, evaluation of potential toxicities that could be related to the 
drug, its degradation products or metabolites, and the use of a PK simulation, 
could all serve as a template for studies on the dose-banding of other cytotoxic 
drugs.  The question for clinicians is not just a simple choice between 
individualised dosing and dose-banding, but a more detailed scrutiny of the 
different variants of dose-banding schemes available (5% or 10% maximum 
deviation from prescribed dose, logarithmic dose-banding). Clinical studies on 
other cytotoxic drugs have demonstrated that there was no significant difference 
between dose-banding and individual dosing on drug administration to cancer 
patients. (13) (152) Replicating such studies with all cytotoxic agents currently 
used in cancer chemotherapy is unrealistic and the pragmatic approach 
described in this thesis offers a way forward. It is important that clinicians have 
at least some evidence available to support their decisions on whether to 
implement new ideas such as dose-banding into practice. A national survey of 
oncologists by Kaestner and Sewell (152), indicated strong support for dose-
banding but also the desire for further evidence, especially with new drugs. The 
work described in this thesis provides a means of securing evidence within a 
reasonable time-scale. 
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In principle, dose-banding schemes should enable the use of a limited range of 
defined standard infusions which, in turn, should support the development of 
licensed “ready-made/ready to administer” chemotherapy infusions by the 
pharmaceutical industry. Licensed pharmaceuticals produced by the 
pharmaceutical industry are generally accepted as the “gold-standard” for 
patient safety and drug efficacy. However, to encourage the pharmaceutical 
industry to launch a range of standard infusions for dose-banding of oxaliplatin, 
for example, one common standard dose-banding scheme would need to be 
adopted by all pharmacists for national or European use. The numbers of 
standard drug infusions required in this common schedule would then make it 
financially viable for the industry to launch the dose-banding product. Compared 
with 5%DB, fewer pre-made drug infusions would be required for 10%DB, which 
would be attractive for both the industry and pharmacists, from a manufacturing 
and storage perspective. In this context, the studies described in this thesis 
could have significant long-term impact. 
The very first licensed dose-banding product with a range of standard cytotoxic 
infusions has just been launched in spring 2016. This was the Gemcitabine 
ready-to-go infusion bag by Sun Pharma. (250) All users could benefit from the 
convenience, quality control and regulatory protection offered by this licenced 
product. With this Gemcitabine product, the pharmaceutical industry wishes to 
convince all users, including pharmacists and oncology physicians, to accept 
and conform to their proposed dose-banding scheme. Clearly, there needs to 
be a harmonised approach to dose-banding schemes, not only within a country 
but across countries. It is hereby recommended that the dose-banding scheme 
with 10% deviation constructed in this thesis should be considered for 
oxaliplatin administration by both the pharmaceutical industry and hospital 
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pharmacists, which could be used as the standard schedule to avoid difficulties 
of future approaches caused by different administration schedules used 
between industry and clinical practice. 
Furthermore, dose-banding schemes could also be adopted in non-oncological 
therapeutic areas for drugs that currently require individualized dosage (based 
on various rationales which include, but are not limited to, BSA) for patients, 
such as infectious diseases and IV antibiotics. To gain the quality and safety 
benefits from dose-banding, the drug used for non-cancer treatments and/or 
supportive therapies must be suitable for a dose-banding scheme in line with 
the approach outlined within this thesis for oxaliplatin. The drug must have an 
extended shelf-life (the minimum 28 days – 84 days) and should be assigned a 
harmonised scheme of standard infusions to support the pre-preparation 
procedure in either the pharmaceutical industry or hospital aseptic units. Clinical 
studies and/or PK studies of the target drug must indicate no significant 
difference on therapeutic effect and toxicity between the proposed dose-
banding scheme and its in-use individualized dosing method. 
In parallel with such developments, it is necessary to ensure that health-care 
professionals (pharmacists, physicians and nurses) receive continuing 
professional education on dose-banding from a reliable source. This is 
necessary to ensure the safe implementation of such schemes, and to ensure 
these new developments, with opportunities for improved patient experience 
and safety, are fully exploited in our healthcare systems. Considering the 
paucity of literature and studies on dose-banding schemes, the dose-banding 
section in the literature review of this thesis (Section 1.4, Chapter 1) could form 
the basis of two materials about dose-banding: 
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1) A review paper to update the current knowledge on dose-banding 
developments; 
2) An information and education package could be produced from Chapter 
1 (literature review) to introduce the dose-banding approach and its 
benefits for health professionals. 
It is acknowledged that such developments would require a multi-disciplinary 
input from all key stakeholders. 
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Appendix A: The stability data for oxaliplatin infusions  
In the extended stability study of oxaliplatin infusions in 5% glucose, each 
infusions group was stored and sampled following the sequential temperature 
cycling schedule mentioned in Chapter 2. Seven groups were included in this 
study, which were Group A, B, C, D, E, F and G. In each group, 6 oxaliplatin 
infusion bags were prepared in two concentrations, 3 bags were in 0.2 mg/mL 
and the other 3 bags were in 0.7 mg/mL. Each groups were sampled after 
preparation in the first day (T0) and then stored in the refrigerator at 2 - 8℃ for a 
certain period of time (which were 1, 3, 7, 14, 28, 56 and 84 days respectively 
for Group A to G). Samples were tested for chemical and physical stability from 
those infusions in each group after stored at 2 - 8℃  (T1), following which 
oxaliplatin infusions groups were kept at room temperature (25℃) for another 24 
hours (T2) and then sampled again. Afterwards, those infusion groups were 
stored back in the refrigerator at 2 - 8℃ for another 7 days (T3) and samples 
were tested in the end of this storage period for chemical and physical stability 
of oxaliplatin infusions. 
Results for all 6 oxaliplatin infusion bags in each group were shown below, 
including oxaliplatin concentrations in samples, pH measurements, weight 
monitor at each sample time, sub-visual particle counts (10 µm and 25 µm) and 
visual inspection. 
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Table A-1, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group A at different sample time. 
Sample time 
point 
Infusion bag 
identifier in 
Group A 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After 
Sampling 
10 µm 25 µm 
D0T0 
0.2A1 0.2 0.1855 4.44 273.8 264.6 6.0 0 clear, clean and colourless 
0.2A2 0.2 0.1848 4.35 275.0 266.0 2.5 0 clear, clean and colourless 
0.2A3 0.2 0.1817 4.36 274.8 265.6 2.5 0 clear, clean and colourless 
0.7A1 0.7 0.6499 4.41 274.2 265.0 6.0 0 clear, clean and colourless 
0.7A2 0.7 0.6499 4.41 273.8 264.7 15.0 0 clear, clean and colourless 
0.7A3 0.7 0.6471 4.41 273.9 264.6 7.0 0 clear, clean and colourless 
D1T1 (stored at 
2-8℃) 
0.2A1 0.2 0.1813 4.46 264.6 255.3 1.5 0 clear, clean and colourless 
0.2A2 0.2 0.1795 4.40 266.0 256.8 2.5 0 clear, clean and colourless 
0.2A3 0.2 0.1832 4.41 265.6 256.5 2.5 0 clear, clean and colourless 
0.7A1 0.7 0.6410 4.47 265.0 255.9 3.0 0 clear, clean and colourless 
0.7A2 0.7 0.6435 4.47 264.7 255.6 3.5 0 clear, clean and colourless 
0.7A3 0.7 0.6412 4.48 264.7 255.5 2.5 0 clear, clean and colourless 
D2T2 (stored at 
25℃) 
0.2A1 0.2 0.1804 4.44 255.3 246.1 4.5 0 clear, clean and colourless 
0.2A2 0.2 0.1814 4.37 256.8 247.6 7.5 0 clear, clean and colourless 
0.2A3 0.2 0.1812 4.37 256.5 247.4 3.5 0 clear, clean and colourless 
0.7A1 0.7 0.6396 4.43 255.9 246.6 0.5 0 clear, clean and colourless 
0.7A2 0.7 0.6347 4.44 255.5 246.4 3.0 0 clear, clean and colourless 
0.7A3 0.7 0.6331 4.43 255.5 246.3 0.0 0 clear, clean and colourless 
D9T3 (stored at 
2-8℃) 
0.2A1 0.2 0.1870 4.44 246.0 236.8 2.5 0 clear, clean and colourless 
0.2A2 0.2 0.1866 4.39 247.6 238.3 2.5 0 clear, clean and colourless 
0.2A3 0.2 0.1883 4.41 247.3 238.2 0.5 0 clear, clean and colourless 
0.7A1 0.7 0.6625 4.46 246.6 237.4 1.0 0 clear, clean and colourless 
0.7A2 0.7 0.6621 4.47 246.4 237.1 1.5 0 clear, clean and colourless 
0.7A3 0.7 0.6620 4.48 246.3 237.0 1.0 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D1T1 = after stored at 2 - 8℃ for 1 day; D2T2 = after stored at 25℃ for 24 hours; D9T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
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Table A-2, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group B at different sample time. 
Sample time 
point 
Infusion bag 
identifier in 
Group B 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After 
Sampling 
10 µm 25 µm 
D0T0 
0.2B1 0.2 0.1893 4.28 275.1 265.9 5.5 0 clear, clean and colourless 
0.2B2 0.2 0.1868 4.28 275.0 265.7 4.0 0 clear, clean and colourless 
0.2B3 0.2 0.1902 4.28 275.2 266.0 4.0 0 clear, clean and colourless 
0.7B1 0.7 0.6726 4.36 273.9 264.8 4.0 0 clear, clean and colourless 
0.7B2 0.7 0.6664 4.37 274.9 265.8 6.5 0 clear, clean and colourless 
0.7B3 0.7 0.6609 4.36 274.8 265.6 6.5 0 clear, clean and colourless 
D3T1 (stored at 
2-8℃) 
0.2B1 0.2 0.1911 4.37 266.0 256.8 6.5 0.5 clear, clean and colourless 
0.2B2 0.2 0.1862 4.37 265.7 256.5 2.0 0 clear, clean and colourless 
0.2B3 0.2 0.1894 4.35 266.0 256.8 1.0 0 clear, clean and colourless 
0.7B1 0.7 0.6720 4.45 264.9 255.6 1.0 0 clear, clean and colourless 
0.7B2 0.7 0.6631 4.45 265.9 256.6 0.0 0 clear, clean and colourless 
0.7B3 0.7 0.6651 4.45 265.7 256.4 2.0 0 clear, clean and colourless 
D4T2 (stored at 
25℃) 
0.2B1 0.2 0.1878 4.40 256.7 247.5 1.5 0 clear, clean and colourless 
0.2B2 0.2 0.1859 4.38 256.4 247.2 0.5 0 clear, clean and colourless 
0.2B3 0.2 0.1879 4.38 256.7 247.4 4.5 0 clear, clean and colourless 
0.7B1 0.7 0.6680 4.47 255.5 246.3 2.0 0 clear, clean and colourless 
0.7B2 0.7 0.6650 4.46 256.5 247.3 1.0 0 clear, clean and colourless 
0.7B3 0.7 0.6590 4.46 256.4 247.1 0.5 0 clear, clean and colourless 
D11T3 (stored at 
2-8℃) 
0.2B1 0.2 0.1886 4.39 247.5 238.3 1.5 0 clear, clean and colourless 
0.2B2 0.2 0.1895 4.38 247.3 238.1 3.0 0 clear, clean and colourless 
0.2B3 0.2 0.1861 4.38 247.5 238.2 2.5 0 clear, clean and colourless 
0.7B1 0.7 0.6752 4.46 246.3 237.1 1.0 0 clear, clean and colourless 
0.7B2 0.7 0.6617 4.46 247.3 238.1 1.0 0 clear, clean and colourless 
0.7B3 0.7 0.6646 4.46 247.1 237.9 1.5 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D3T1 = after stored at 2 - 8℃ for 3 day; D4T2 = after stored at 25℃ for 24 hours; D11T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
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Table A-3, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group C at different sample time. 
Sample time 
point 
Infusion bag 
identifier in 
Group C 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After 
Sampling 
10 µm 25 µm 
D0T0 
0.2C1 0.2 0.1915 4.28 274.9 265.6 1.5 0 clear, clean and colourless 
0.2C2 0.2 0.1893 4.28 274.6 265.3 2.0 0 clear, clean and colourless 
0.2C3 0.2 0.1899 4.25 275.1 265.9 3.0 0 clear, clean and colourless 
0.7C1 0.7 0.6609 4.33 273.7 264.5 5.5 0 clear, clean and colourless 
0.7C2 0.7 0.6647 4.34 273.9 264.8 9.0 0 clear, clean and colourless 
0.7C3 0.7 0.6669 4.32 274.4 265.2 4.0 0 clear, clean and colourless 
D7T1 (stored at 
2-8℃) 
0.2C1 0.2 0.1871 4.41 265.7 256.4 4.0 0 clear, clean and colourless 
0.2C2 0.2 0.1874 4.42 265.4 256.1 2.5 0 clear, clean and colourless 
0.2C3 0.2 0.1881 4.40 265.9 256.6 0.5 0 clear, clean and colourless 
0.7C1 0.7 0.6540 4.47 264.5 255.2 2.0 0 clear, clean and colourless 
0.7C2 0.7 0.6561 4.48 264.9 255.6 2.5 0.5 clear, clean and colourless 
0.7C3 0.7 0.6551 4.45 265.3 256.0 3.0 0 clear, clean and colourless 
D8T2 (stored at 
25℃) 
0.2C1 0.2 0.1885 4.43 256.4 247.0 3.0 0 clear, clean and colourless 
0.2C2 0.2 0.1856 4.43 256.1 246.8 1.0 0 clear, clean and colourless 
0.2C3 0.2 0.1857 4.42 256.6 247.5 1.0 0 clear, clean and colourless 
0.7C1 0.7 0.6595 4.48 255.2 245.9 2.0 0 clear, clean and colourless 
0.7C2 0.7 0.6543 4.49 255.6 246.3 2.5 0 clear, clean and colourless 
0.7C3 0.7 0.6546 4.48 256.0 246.7 0.5 0 clear, clean and colourless 
D15T3 (stored at 
2-8℃) 
0.2C1 0.2 0.1887 4.45 247.0 237.9 2.0 0 clear, clean and colourless 
0.2C2 0.2 0.1903 4.42 246.9 237.6 2.5 0 clear, clean and colourless 
0.2C3 0.2 0.1887 4.39 247.6 238.3 3.5 0 clear, clean and colourless 
0.7C1 0.7 0.6650 4.47 246.0 236.8 5.5 0 clear, clean and colourless 
0.7C2 0.7 0.6624 4.47 246.3 237.1 1.5 0 clear, clean and colourless 
0.7C3 0.7 0.6682 4.44 246.8 237.6 2.5 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D7T1 = after stored at 2 - 8℃ for 7 day; D8T2 = after stored at 25℃ for 24 hours; D15T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
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Table A-4, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group D at different sample time. 
Sample time 
point 
Infusion bag 
identifier in 
Group D 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After 
Sampling 
10 µm 25 µm 
D0T0 
0.2D1 0.2 0.1894 4.38 275.1 265.9 2.5 0 clear, clean and colourless 
0.2D2 0.2 0.1880 4.37 274.9 265.6 2.0 0 clear, clean and colourless 
0.2D3 0.2 0.1902 4.38 274.0 264.7 3.0 0.5 clear, clean and colourless 
0.7D1 0.7 0.6637 4.43 275.0 265.8 17.5 0 clear, clean and colourless 
0.7D2 0.7 0.6665 4.45 274.2 265.0 5.5 0 clear, clean and colourless 
0.7D3 0.7 0.6624 4.43 275.1 265.8 23.5 0 clear, clean and colourless 
D14T1 (stored at 
2-8℃) 
0.2D1 0.2 0.1894 4.35 265.9 256.6 3.5 0 clear, clean and colourless 
0.2D2 0.2 0.1905 4.36 265.6 256.5 1.0 0 clear, clean and colourless 
0.2D3 0.2 0.1908 4.38 264.7 255.5 2.0 0 clear, clean and colourless 
0.7D1 0.7 0.6625 4.43 265.8 256.5 0.5 0 clear, clean and colourless 
0.7D2 0.7 0.6657 4.44 264.9 255.8 1.0 0 clear, clean and colourless 
0.7D3 0.7 0.6651 4.43 265.8 256.6 1.5 0 clear, clean and colourless 
D15T2 (stored at 
25℃) 
0.2D1 0.2 0.1880 4.37 256.6 247.4 4.5 0.5 clear, clean and colourless 
0.2D2 0.2 0.1874 4.36 256.5 247.3 1.5 0 clear, clean and colourless 
0.2D3 0.2 0.1882 4.38 255.5 246.3 1.5 0 clear, clean and colourless 
0.7D1 0.7 0.6562 4.43 256.5 247.3 1.0 0 clear, clean and colourless 
0.7D2 0.7 0.6688 4.44 255.8 246.5 2.5 0 clear, clean and colourless 
0.7D3 0.7 0.6606 4.43 256.6 247.4 4.5 0 clear, clean and colourless 
D22T3 (stored at 
2-8℃) 
0.2D1 0.2 0.1837 4.38 247.3 238.1 3.5 0 clear, clean and colourless 
0.2D2 0.2 0.1855 4.38 247.2 238.0 3.0 0 clear, clean and colourless 
0.2D3 0.2 0.1848 4.40 246.2 237.0 5.0 0 clear, clean and colourless 
0.7D1 0.7 0.6527 4.45 247.3 238.1 3.0 0 clear, clean and colourless 
0.7D2 0.7 0.6565 4.48 246.5 237.2 4.5 0 clear, clean and colourless 
0.7D3 0.7 0.6500 4.46 247.3 238.1 2.5 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D14T1 = after stored at 2 - 8℃ for 14 day; D15T2 = after stored at 25℃ for 24 hours; D22T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
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Table A-5, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group E at different sample time. 
Sample time 
point 
Infusion bag 
identifier in 
Group E 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After 
Sampling 
10 µm 25 µm 
D0T0 
0.2 E1 0.2 0.1926 4.39 274.4 265.2 2.0 0 clear, clean and colourless 
0.2 E2 0.2 0.1910 4.42 274.4 265.2 7.5 0 clear, clean and colourless 
0.2 E3 0.2 0.1907 4.38 274.5 265.4 5.0 0 clear, clean and colourless 
0.7 E1 0.7 0.6744 4.43 274.6 265.3 5.0 0 clear, clean and colourless 
0.7 E2 0.7 0.6731 4.48 275.3 266.2 5.5 0 clear, clean and colourless 
0.7 E3 0.7 0.6761 4.45 275.1 265.9 5.0 0 clear, clean and colourless 
D28T1 (stored at 
2-8℃) 
0.2 E1 0.2 0.1990 4.43 265.1 255.8 5.0 0 clear, clean and colourless 
0.2 E2 0.2 0.1951 4.45 265.1 255.8 4.0 0 clear, clean and colourless 
0.2 E3 0.2 0.1924 4.42 265.3 256.1 3.5 0.5 clear, clean and colourless 
0.7 E1 0.7 0.6845 4.46 265.2 256.0 4.0 0.5 clear, clean and colourless 
0.7 E2 0.7 0.6848 4.51 266.1 256.9 7.5 0.5 clear, clean and colourless 
0.7 E3 0.7 0.6839 4.48 265.8 256.7 7.0 0.5 clear, clean and colourless 
D29T2 (stored at 
25℃) 
0.2 E1 0.2 0.1890 4.46 255.8 246.6 2.0 0 clear, clean and colourless 
0.2 E2 0.2 0.1869 4.45 255.7 246.6 9.0 0.5 clear, clean and colourless 
0.2 E3 0.2 0.1863 4.43 256.0 246.9 4.5 0 clear, clean and colourless 
0.7 E1 0.7 0.6565 4.48 255.9 246.7 5.0 0 clear, clean and colourless 
0.7 E2 0.7 0.6570 4.53 256.8 247.7 4.0 1.0 clear, clean and colourless 
0.7 E3 0.7 0.6564 4.49 256.6 247.5 6.5 0 clear, clean and colourless 
D36T3 (stored at 
2-8℃) 
0.2 E1 0.2 0.1918 4.43 246.7 237.5 5.0 0 clear, clean and colourless 
0.2 E2 0.2 0.1910 4.44 246.7 237.5 9.5 0 clear, clean and colourless 
0.2 E3 0.2 0.1927 4.39 247.0 237.9 5.5 0 clear, clean and colourless 
0.7 E1 0.7 0.6816 4.45 246.8 237.7 18.5 0 clear, clean and colourless 
0.7 E2 0.7 0.6842 4.50 247.8 238.6 7.0 0.5 clear, clean and colourless 
0.7 E3 0.7 0.6856 4.47 247.6 238.5 4.5 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D28T1 = after stored at 2 - 8℃ for 28 day; D29T2 = after stored at 25℃ for 24 hours; D36T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
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Table A-6, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group F at different sample time. 
Sample time point 
Infusion bag 
identifier in 
Group F 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After 
Sampling 
10 µm 25 µm 
D0T0 
0.2 F1 0.2 0.1922 4.45 274.7 265.5 4.5 0 clear, clean and colourless 
0.2 F2 0.2 0.1934 4.39 274.5 265.3 2.0 0 clear, clean and colourless 
0.2 F3 0.2 0.1911 4.36 275.1 265.9 3.0 0 clear, clean and colourless 
0.7 F1 0.7 0.6634 4.45 274.5 265.4 3.0 0 clear, clean and colourless 
0.7 F2 0.7 0.6637 4.44 273.9 264.7 3.0 0.5 clear, clean and colourless 
0.7 F3 0.7 0.6639 4.43 275.0 265.9 3.0 0 clear, clean and colourless 
D56T1 (stored at 
2-8℃) 
0.2 F1 0.2 0.1858 4.49 265.3 256.2 7.5 0 clear, clean and colourless 
0.2 F2 0.2 0.1860 4.33 265.1 256.0 5.5 0.5 clear, clean and colourless 
0.2 F3 0.2 0.1852 4.35 265.8 256.6 6.5 0 clear, clean and colourless 
0.7 F1 0.7 0.6467 4.40 265.3 256.0 2.5 0 clear, clean and colourless 
0.7 F2 0.7 0.6395 4.41 264.6 255.4 4.0 0 clear, clean and colourless 
0.7 F3 0.7 0.6496 4.44 265.7 256.6 3.0 0 clear, clean and colourless 
D57T2 (stored at 
25℃) 
0.2 F1 0.2 0.1905 4.51 256.1 247.0 4.0 0 clear, clean and colourless 
0.2 F2 0.2 0.1913 4.39 256.0 246.8 6.0 0 clear, clean and colourless 
0.2 F3 0.2 0.1890 4.37 256.5 247.3 4.5 0 clear, clean and colourless 
0.7 F1 0.7 0.6617 4.45 256.0 246.9 3.0 0.5 clear, clean and colourless 
0.7 F2 0.7 0.6593 4.45 255.4 246.1 5.0 0 clear, clean and colourless 
0.7 F3 0.7 0.6562 4.46 256.6 247.4 4.0 0 clear, clean and colourless 
D64T3 (stored at 
2-8℃) 
0.2 F1 0.2 0.1873 4.45 246.9 237.8 11.0 0.5 clear, clean and colourless 
0.2 F2 0.2 0.1903 4.37 246.7 237.5 3.0 0 clear, clean and colourless 
0.2 F3 0.2 0.1898 4.35 247.2 238.0 2.0 0 clear, clean and colourless 
0.7 F1 0.7 0.6578 4.43 246.9 237.7 3.5 0 clear, clean and colourless 
0.7 F2 0.7 0.6629 4.44 246.1 236.9 2.5 0 clear, clean and colourless 
0.7 F3 0.7 0.6729 4.43 247.3 238.1 4.5 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D56T1 = after stored at 2 - 8℃ for 56 day; D57T2 = after stored at 25℃ for 24 hours; D64T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
 
  
341 
 
Table A-7, Chemical and physical stability results in 6 oxaliplatin infusion bags from Group G at different sample time. 
Sample time 
point 
Infusion bag 
identifier in 
Group G 
Nominal 
Conc. 
(mg/mL) 
Oxaliplatin Conc. in 
samples (mg/mL) 
pH 
Bag Weight (g)  Particle Count 
Visual Inspection Before 
Sampling 
After Sampling 10 µm 25 µm 
D0T0 
0.2 G1 0.2 0.1862 4.45 275.1 265.9 5.0 0 clear, clean and colourless 
0.2 G2 0.2 0.1873 4.38 275.0 265.9 1.0 0 clear, clean and colourless 
0.2 G3 0.2 0.1868 4.36 274.9 265.7 4.5 0 clear, clean and colourless 
0.7 G1 0.7 0.6579 4.47 273.6 264.3 4.5 0 clear, clean and colourless 
0.7 G2 0.7 0.6561 4.42 274.8 265.7 5.0 0 clear, clean and colourless 
0.7 G3 0.7 0.6559 4.44 274.8 265.5 13.0 0 clear, clean and colourless 
D84T1 (stored at 
2-8℃) 
0.2 G1 0.2 0.1916 4.45 265.7 256.5 2.5 0 clear, clean and colourless 
0.2 G2 0.2 0.1944 4.36 265.7 256.5 8.5 0 clear, clean and colourless 
0.2 G3 0.2 0.1906 4.32 265.5 256.3 0.5 0 clear, clean and colourless 
0.7 G1 0.7 0.6760 4.41 264.1 254.9 0.5 0 clear, clean and colourless 
0.7 G2 0.7 0.6606 4.37 265.5 256.3 3.0 0 clear, clean and colourless 
0.7 G3 0.7 0.6619 4.39 265.4 256.2 2.0 0 clear, clean and colourless 
D85T2 (stored at 
25℃) 
0.2 G1 0.2 0.1832 4.44 256.5 247.3 3.5 0 clear, clean and colourless 
0.2 G2 0.2 0.1922 4.39 256.5 247.4 7.0 0 clear, clean and colourless 
0.2 G3 0.2 0.1834 4.36 256.3 247.1 2.5 0 clear, clean and colourless 
0.7 G1 0.7 0.6666 4.46 254.9 245.8 10.5 0 clear, clean and colourless 
0.7 G2 0.7 0.6440 4.41 256.3 247.3 1.5 0 clear, clean and colourless 
0.7 G3 0.7 0.6525 4.43 256.1 247.0 2.5 0 clear, clean and colourless 
D92T3 (stored at 
2-8℃) 
0.2 G1 0.2 0.1869 4.47 247.3 238.0 13.5 1.0 clear, clean and colourless 
0.2 G2 0.2 0.1850 4.38 247.3 238.1 6.5 0.5 clear, clean and colourless 
0.2 G3 0.2 0.1880 4.35 247.1 237.9 4.0 0 clear, clean and colourless 
0.7 G1 0.7 0.6531 4.44 245.7 236.6 4.0 0 clear, clean and colourless 
0.7 G2 0.7 0.6481 4.42 247.2 238.0 6.5 0 clear, clean and colourless 
0.7 G3 0.7 0.6419 4.42 246.9 237.8 4.5 0 clear, clean and colourless 
Conc. = concentration; D0T0 = time zero, right after the infusion preparation; D84T1 = after stored at 2 - 8℃ for 84 day; D85T2 = after stored at 25℃ for 24 hours; D92T3 = after stored at 2 - 8℃ for 7 days following the 24-hour storage at 25℃. 
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Appendix B: Data from the oxalate study in plasma 
The oxalate study described in Chapter 3 included the oxalate determination in 
human plasma after administration with oxaliplatin. Four groups of oxaliplatin 
solutions were prepared and detected for oxaliplatin and oxalate concentrations:  
Group A (Control group) was prepared in 5% glucose, and results from this 
group could be used as the benchmark comparison reference for other groups;  
Group B was prepared in human plasma and the total amount of 
oxaliplatin/oxalate (including fractions bound to plasma protein and un-bound 
fractions) in plasma was determined in this group. 
Group C was also prepared in human plasma, but only concentrations of the 
un-bound (free) oxaliplatin/oxalate were detected in this group.  
Group D was prepared in plasma ultra-filtrate (PUF) in order to test the 
concentration change of oxaliplatin/oxalate without interference from plasma 
proteins. 
In order to simulate the degradation process of oxaliplatin in blood circulation of 
human bodies, all four groups were stored at 37℃ for 5 days to simulate the 
physiological temperature. 
Results of oxaliplatin and oxalate concentrations for triplicate tests in Group A – 
D are shown in Table B-1 and Table B-2 below, together with the concentration 
variations relative to the result at time zero (first experiment day). 
pH values for triplicate tests of each group were measured at each sampling 
day, which results and changes throughout the experiment are shown in Table 
B-3 below. 
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Table B-1, Oxaliplatin concentrations in triplicate sample solutions from Group A – D at each sample time, together with the concentration variations 
of oxaliplatin with respect to the initial values at T0. 
Group 
Identifier 
Day0 
(T0) 
Day 1 Day 2 Day 3 Day 4 Day 5 
Conc. 
(µg/mL) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
Conc. 
(µg/mL) 
Conc. 
Relative 
to T0 (%) 
A 
(Control) 
A1 159.0030 142.2250 89.45 110.0380 69.20 106.9930 67.29 86.2220 54.23 74.5530 46.89 
A2 157.3870 133.2880 84.69 114.9010 73.01 105.7320 67.18 81.6440 51.87 76.3430 48.51 
A3 157.0970 146.3810 93.18 117.2760 74.65 107.0660 68.15 87.5690 55.74 74.3830 47.35 
B 
B1 68.2960 8.8280 12.93 10.5500 15.45 8.1600 11.95 8.1210 11.89 11.0840 16.23 
B2 65.6720 20.0050 30.46 22.1240 33.69 20.7410 31.58 18.4490 28.09 21.8180 33.22 
B3 66.5603 18.5930 27.93 22.3380 33.56 20.1750 30.31 16.6030 24.94 21.6120 32.47 
C 
C1 60.4530 4.2650 7.06 4.7920 7.93 6.4930 10.74 5.7510 9.51 6.4500 10.67 
C2 63.3940 4.4550 7.03 4.1660 5.92 6.4930 10.24 6.6490 10.49 5.7720 9.10 
C3 61.7920 4.3670 7.07 4.5500 7.36 5.1020 8.26 6.3740 10.32 6.5220 10.55 
D 
D1 111.5850 31.8480 28.54 9.1570 8.21 5.1020 4.57 6.0380 5.41 6.3890 5.73 
D2 119.0970 36.0450 30.27 9.6260 8.08 5.0150 4.21 5.4760 4.60 6.1230 5.14 
D3 118.2130 34.2120 28.94 9.8820 8.36 7.6960 6.51 5.9380 5.02 5.9290 5.02 
Conc. : Concentration; Conc. Relative to T0: the percentage of tested oxaliplatin concentration at each sample time compared with the initial values at time zero. 
  
344 
 
Table B-2, Oxalate concentrations in triplicate sample solutions from Group A – D, together with the variations of oxalate concentrations with respect 
to the initial values at T0. 
Group Identifier 
Day0 
(T0) 
Day 1 Day 2 Day 3 Day 4 Day 5 
Conc. 
(µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative to 
T0 (µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative to 
T0 (µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative to 
T0 (µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative to 
T0 (µg/mL) 
Conc. 
(µg/mL) 
Increased 
Conc. 
Relative to 
T0 (µg/mL) 
A 
(Control) 
A1 0.0000 4.2339 4.2339 12.8223 12.8223 12.1131 12.1131 15.7895 15.7895 25.1705 25.1705 
A2 -1.8417 4.8387 6.6804 12.8223 14.6640 15.1413 16.9830 15.1822 17.0239 24.5566 26.3983 
A3 -3.6835 10.8871 14.5706 12.2117 15.8952 13.3244 17.0079 17.6113 21.2948 23.9427 27.6262 
B 
B1 9.8226 43.5484 33.7258 42.7408 32.9182 37.5505 27.7279 32.1862 22.3636 46.6576 36.8350 
B2 9.2087 40.5242 31.3155 42.7408 33.5321 36.3392 27.1305 38.8664 29.6577 46.6576 37.4489 
B3 10.4366 42.3387 31.9021 37.8562 27.4196 38.7618 28.3252 46.7611 36.3245 47.2715 36.8349 
C 
C1 8.5948 43.5484 34.9536 43.9620 35.3672 49.6635 41.0687 49.1903 40.5955 52.1828 43.5880 
C2 8.5948 41.1290 32.5342 42.7408 34.1460 49.6635 41.0687 49.1903 40.5955 52.1828 43.5880 
C3 9.8226 40.5242 30.7016 42.1303 32.3077 38.1561 28.3335 50.4049 40.5823 51.5689 41.7463 
D 
D1 3.6835 33.2661 29.5826 40.9091 37.2256 50.8748 47.1913 42.5101 38.8266 44.8158 41.1323 
D2 5.5252 39.3145 33.7893 40.2985 34.7733 50.8748 45.3496 43.7247 38.1995 46.0437 40.5185 
D3 4.2974 36.8952 32.5978 39.0773 34.7799 50.2692 45.9718 44.9393 40.6419 46.6575 42.3601 
Conc. : Concentration. 
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Table B-3, pH measurements at each sample time for Group A – D with the variations compared to the initial value at T0. 
Group 
Identifier 
Day0 
(T0) 
Day 1 Day 2 Day 3 Day 4 Day 5 
pH pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
pH 
pH 
difference 
to T0 (%) 
A 
(Control) 
A1 5.30 4.95 -0.35 4.84 -0.46 4.73 -0.57 4.60 -0.70 4.59 -0.71 
A2 5.21 4.93 -0.28 4.84 -0.37 4.77 -0.44 4.65 -0.56 4.61 -0.60 
A3 5.25 4.88 -0.37 4.83 -0.42 4.73 -0.52 4.64 -0.61 4.61 -0.64 
B 
B1 7.10 6.91 -0.19 7.20 0.10 7.05 -0.05 7.18 0.08 7.14 0.04 
B2 7.12 6.94 -0.18 7.22 0.10 7.15 0.03 7.20 0.08 7.14 0.02 
B3 7.12 6.98 -0.14 7.26 0.14 7.09 -0.03 7.23 0.11 7.26 0.14 
C 
C1 7.08 7.07 -0.01 7.22 0.14 7.24 0.16 7.33 0.25 7.06 -0.02 
C2 7.04 7.07 0.03 7.19 0.15 7.23 0.19 7.31 0.27 7.08 0.04 
C3 7.05 6.93 -0.12 7.17 0.12 7.21 0.16 7.34 0.29 7.04 -0.01 
D 
D1 7.04 7.11 0.07 7.12 0.08 7.31 0.27 7.21 0.17 7.34 0.30 
D2 7.16 7.13 -0.03 7.12 -0.04 7.17 0.01 7.28 0.12 7.36 0.20 
D3 7.08 7.08 0.00 7.18 0.10 7.35 0.27 7.25 0.17 7.33 0.25 
pH difference to T0: the percentage of pH changes at each sample time compared with the initial values at time zero. 
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Appendix C: Pharmacokinetics (PK) simulation data  
In the ex vivo pharmacokinetic (PK) simulation study, 10 patients with different 
BSA (body surface area) values were selected and simulated with oxaliplatin 
administered with different dosing methods. 5 dosing methods were applied, 
including individual dosing scheme, dose-banding scheme with 5% deviation, 
dose-banding scheme with 10% deviation, logarithmic dose-banding scheme 
and flat-fixed dosing method. During the simulation, 22 samples were withdrawn 
from the ‘body reservoir’ following the study schedule and weight changes of 
the ‘body reservoir’ bag were monitored by recording the balance readings 
before and after sampling. Meanwhile, the concentration of oxaliplatin in each 
sample was detected by a validated HPLC assay. pH values for those 22 
samples were also measured at each sample time point. 
Drug doses applied for each dosing scheme were different: 
Individual dosing method: the drug dose was calculated by the patient’s BSA 
and 85 mg/m2 oxaliplatin. 
Dose-banding schemes (including all three schemes): the drug dose was used 
as the standard dose from the certain dose band that fitted the patient’s 
individual dose, which should following the scheme schedules described in 
Chapter 4. 
Flat-fixed dosing: the drug dose was selected to be fixed 4 mg for all patients. 
Results for the total 50 simulation tests (10 ‘patients’ × 5 dosing methods) are 
presented in tables below along with the illustration of oxaliplatin concentration 
– time curve for each patient in each dosing scheme. 
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C.1 Patient 1 
The basic setting information for Patient 1 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 2.70 m2; Vc = 837.7 mL; CLtotal = 194.4 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
Table C-1, Results of the simulation test on Patient 1 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 5.74 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
Concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.34 837.3 827.4 
S1T0.25 0.25 0.6113 4.27 829.1 817.7 
S2T0.5 0.50 1.2824 4.21 821.6 810.4 
S3T0.75 0.75 1.9043 4.22 811.5 801.9 
S4T1.0 1.00 2.4641 4.20 804.1 793.8 
S5T1.25 1.25 2.9902 4.19 796.9 786.1 
S6T1.5 1.50 3.5416 4.18 789.9 779.9 
S7T1.75 1.75 4.0069 4.17 781.7 771.5 
S8T2.0 2.00 4.5521 4.17 774.2 762.1 
S9T2.25 2.25 4.1682 4.16 762.7 755.5 
S10T2.5 2.50 3.9333 4.17 756.8 746.4 
S11T3.0 3.00 3.4238 4.18 742.9 731.1 
S12T3.5 3.50 2.9774 4.16 742.3 730.9 
S13T4.0 4.00 2.5811 4.14 738.7 726.4 
S14T4.5 4.50 2.2228 4.14 728.8 717.8 
S15T5.0 5.00 1.9366 4.14 725.9 714.5 
S16T5.5 5.50 1.6799 4.15 722.5 710.7 
S17T6.0 6.00 1.4349 4.13 718.2 706.2 
S18T6.5 6.50 1.2478 4.11 709.2 702.1 
S19T7.0 7.00 1.0719 4.11 707.6 698.3 
S20T7.5 7.50 0.9411 4.12 700.7 691.2 
S21T8.0 8.00 0.7724 4.13 696.8 688.9 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-1, Oxaliplatin concentration-time curve for Patient 1 with 2-hour infusions 
administered in Individual dosing scheme. 
Table C-2, Results of the simulation test on Patient 1 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the standard dose of 5.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 838.1 827.6 
S1T0.25 0.25 0.6986 4.19 833.8 820.9 
S2T0.5 0.50 1.2066 4.18 825.1 814.1 
S3T0.75 0.75 1.7703 4.18 818.2 805.9 
S4T1.0 1.00 2.2789 4.17 809.3 799.7 
S5T1.25 1.25 2.8054 4.17 804.1 795.3 
S6T1.5 1.50 3.3075 4.16 792.9 781.3 
S7T1.75 1.75 3.6074 4.16 785.7 776.3 
S8T2.0 2.00 3.8042 4.16 777.6 765.4 
S9T2.25 2.25 3.5746 4.15 768.3 759.4 
S10T2.5 2.50 3.3186 4.15 767.1 787.1 
S11T3.0 3.00 2.8990 4.15 759.1 751.5 
S12T3.5 3.50 2.5206 4.15 755.1 748.4 
S13T4.0 4.00 2.1787 4.14 750.1 740.9 
S14T4.5 4.50 1.9066 4.15 739.4 728.3 
S15T5.0 5.00 1.6197 4.14 738.0 728.9 
S16T5.5 5.50 1.4347 4.16 731.7 721.9 
S17T6.0 6.00 1.2522 4.14 728.9 718.0 
S18T6.5 6.50 1.1006 4.13 722.1 712.4 
S19T7.0 7.00 0.9507 4.13 709.1 697.3 
S20T7.5 7.50 0.8260 4.12 705.4 696.5 
S21T8.0 8.00 0.6994 4.12 698.2 688.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-2, Oxaliplatin concentration-time curve for Patient 1 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
Table C-3, Results of the simulation test on Patient 1 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the standard dose of 5.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.30 837.0 827.1 
S1T0.25 0.25 0.6028 4.26 828.6 818.0 
S2T0.5 0.50 1.1686 4.26 818.8 810.6 
S3T0.75 0.75 1.7129 4.25 812.7 803.4 
S4T1.0 1.00 2.0908 4.26 805.0 796.1 
S5T1.25 1.25 2.5483 4.26 795.9 786.3 
S6T1.5 1.50 3.0631 4.27 788.9 778.1 
S7T1.75 1.75 3.4551 4.26 781.4 770.5 
S8T2.0 2.00 3.7242 4.26 771.2 759.0 
S9T2.25 2.25 3.5191 4.26 762.6 753.1 
S10T2.5 2.50 3.2684 4.27 755.9 746.4 
S11T3.0 3.00 2.8681 4.27 749.2 738.5 
S12T3.5 3.50 2.5057 4.27 742.5 733.6 
S13T4.0 4.00 2.1224 4.27 736.5 727.8 
S14T4.5 4.50 1.8755 4.26 732.2 723.2 
S15T5.0 5.00 1.5979 4.24 727.6 717.7 
S16T5.5 5.50 1.3815 4.23 722.7 712.8 
S17T6.0 6.00 1.2052 4.22 714.3 705.2 
S18T6.5 6.50 1.0009 4.21 705.6 693.8 
S19T7.0 7.00 0.9076 4.22 686.8 677.9 
S20T7.5 7.50 0.7404 4.22 679.4 670.2 
S21T8.0 8.00 0.6475 4.20 664.1 654.3 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-3, Oxaliplatin concentration-time curve for Patient 1 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
Table C-4, Results of the simulation test on Patient 1 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the standard dose of 5.46 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.19 837.6 828.9 
S1T0.25 0.25 0.6016 4.17 830.7 820.0 
S2T0.5 0.50 1.1702 4.17 823.7 812.0 
S3T0.75 0.75 1.7391 4.16 820.9 809.5 
S4T1.0 1.00 2.2994 4.17 817.9 798.2 
S5T1.25 1.25 2.7880 4.16 804.3 786.7 
S6T1.5 1.50 3.2514 4.17 789.4 784.8 
S7T1.75 1.75 3.7309 4.17 791.7 777.8 
S8T2.0 2.00 3.9544 4.17 784.2 771.2 
S9T2.25 2.25 3.7020 4.18 774.5 766.5 
S10T2.5 2.50 3.4385 4.17 770.8 760.1 
S11T3.0 3.00 3.0273 4.17 762.8 758.1 
S12T3.5 3.50 2.6093 4.16 764.5 751.9 
S13T4.0 4.00 2.2592 4.16 758.5 745.0 
S14T4.5 4.50 1.9558 4.16 752.4 740.6 
S15T5.0 5.00 1.7237 4.17 735.3 722.9 
S16T5.5 5.50 1.5000 4.17 730.1 717.5 
S17T6.0 6.00 1.3006 4.18 721.8 707.2 
S18T6.5 6.50 1.1087 4.18 706.8 695.6 
S19T7.0 7.00 0.9576 4.19 699.7 692.4 
S20T7.5 7.50 0.8232 4.20 697.5 686.1 
S21T8.0 8.00 0.7007 4.18 682.8 671.3 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-4, Oxaliplatin concentration-time curve for Patient 1 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
Table C-5, Results of the simulation test on Patient 1 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 837.5 826.5 
S1T0.25 0.25 0.3607 4.21 829.4 818.9 
S2T0.5 0.50 0.7166 4.21 820.5 815.6 
S3T0.75 0.75 1.0538 4.21 818.4 802.8 
S4T1.0 1.00 1.3956 4.21 806.0 795.8 
S5T1.25 1.25 1.7406 4.21 793.2 782.6 
S6T1.5 1.50 2.0307 4.20 785.7 777.0 
S7T1.75 1.75 2.2393 4.20 779.6 770.4 
S8T2.0 2.00 2.5090 4.21 774.2 765.5 
S9T2.25 2.25 2.3914 4.21 768.0 757.3 
S10T2.5 2.50 2.3052 4.21 759.8 746.3 
S11T3.0 3.00 1.9806 4.21 754.8 745.5 
S12T3.5 3.50 1.7391 4.21 752.8 743.1 
S13T4.0 4.00 1.5180 4.21 747.7 738.5 
S14T4.5 4.50 1.3110 4.21 743.5 734.4 
S15T5.0 5.00 1.1651 4.21 739.4 729.8 
S16T5.5 5.50 1.0334 4.21 736.2 726.3 
S17T6.0 6.00 0.8860 4.21 734.6 721.8 
S18T6.5 6.50 0.7668 4.21 723.7 711.4 
S19T7.0 7.00 0.6884 4.20 716.7 709.1 
S20T7.5 7.50 0.5504 4.20 714.0 704.2 
S21T8.0 8.00 0.4987 4.19 712.3 700.2 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-5, Oxaliplatin concentration-time curve for Patient 1 with 2-hour infusions 
administered in Flat-fixed dosing method. 
C.2 Patient 2 
The basic setting information for Patient 2 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 1.82 m2; Vc = 564.7 mL; CLtotal = 131.0 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
Figure C-6, Oxaliplatin concentration-time curve for Patient 2 with 2-hour infusions 
administered in Individual dosing scheme. 
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Table C-6, Results of the simulation test on Patient 2 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 3.87 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 564.2 554.5 
S1T0.25 0.25 0.8351 4.19 553.3 544.6 
S2T0.5 0.50 1.4855 4.19 543.4 534.0 
S3T0.75 0.75 2.2115 4.19 536.1 525.8 
S4T1.0 1.00 2.8460 4.19 526.1 516.9 
S5T1.25 1.25 3.4865 4.19 518.0 507.6 
S6T1.5 1.50 4.1378 4.19 507.5 497.6 
S7T1.75 1.75 4.7249 4.18 504.7 495.5 
S8T2.0 2.00 4.9723 4.18 488.6 478.7 
S9T2.25 2.25 4.6924 4.18 481.4 471.9 
S10T2.5 2.50 4.3415 4.18 472.6 462.8 
S11T3.0 3.00 3.7106 4.18 464.8 458.2 
S12T3.5 3.50 3.1772 4.17 451.6 439.3 
S13T4.0 4.00 2.7216 4.17 446.8 438.5 
S14T4.5 4.50 2.3234 4.17 439.9 430.0 
S15T5.0 5.00 1.9243 4.18 430.8 420.8 
S16T5.5 5.50 1.6231 4.17 422.6 411.1 
S17T6.0 6.00 1.3705 4.17 420.0 408.6 
S18T6.5 6.50 0.9302 4.17 411.1 402.0 
S19T7.0 7.00 0.7588 4.17 405.5 395.4 
S20T7.5 7.50 0.6369 4.17 398.8 388.4 
S21T8.0 8.00 0.5558 4.16 387.7 379.1 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-7, Oxaliplatin concentration-time curve for Patient 2 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
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Table C-7, Results of the simulation test on Patient 2 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 3.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.29 566.3 556.1 
S1T0.25 0.25 0.7207 4.27 558.5 547.6 
S2T0.5 0.50 1.3854 4.24 544.8 535.5 
S3T0.75 0.75 1.9967 4.22 535.7 527.2 
S4T1.0 1.00 2.5540 4.23 528.4 518.5 
S5T1.25 1.25 3.1436 4.22 519.3 510.6 
S6T1.5 1.50 3.6471 4.22 513.4 503.7 
S7T1.75 1.75 4.1373 4.21 504.4 495.6 
S8T2.0 2.00 4.5272 4.20 497.8 487.1 
S9T2.25 2.25 4.2069 4.21 489.0 478.9 
S10T2.5 2.50 3.8650 4.21 480.5 470.5 
S11T3.0 3.00 3.2915 4.22 473.5 464.2 
S12T3.5 3.50 2.7978 4.22 467.5 456.4 
S13T4.0 4.00 2.3590 4.22 459.7 450.2 
S14T4.5 4.50 2.0335 4.23 452.8 442.6 
S15T5.0 5.00 1.6769 4.22 445.8 435.5 
S16T5.5 5.50 1.3887 4.21 439.3 429.2 
S17T6.0 6.00 1.1461 4.22 432.4 422.8 
S18T6.5 6.50 0.9398 4.22 426.1 415.4 
S19T7.0 7.00 0.8321 4.22 417.1 406.9 
S20T7.5 7.50 0.7163 4.21 409.5 399.9 
S21T8.0 8.00 0.5732 4.20 402.9 392.1 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-8, Oxaliplatin concentration-time curve for Patient 2 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
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Table C-8, Results of the simulation test on Patient 2 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 546.9 554.2 
S1T0.25 0.25 0.9396 4.19 553.2 544.1 
S2T0.5 0.50 1.4874 4.20 543.6 535.4 
S3T0.75 0.75 2.0788 4.18 535.2 525.1 
S4T1.0 1.00 2.5306 4.18 526.0 517.2 
S5T1.25 1.25 2.9704 4.18 517.7 508.4 
S6T1.5 1.50 3.3186 4.18 508.6 499.2 
S7T1.75 1.75 3.9880 4.18 499.6 490.7 
S8T2.0 2.00 4.3002 4.18 486.0 479.6 
S9T2.25 2.25 3.9640 4.19 485.5 475.9 
S10T2.5 2.50 3.8004 4.17 476.6 466.7 
S11T3.0 3.00 3.2105 4.17 472.6 464.3 
S12T3.5 3.50 2.6822 4.17 470.9 458.6 
S13T4.0 4.00 2.2979 4.16 461.2 451.2 
S14T4.5 4.50 2.0098 4.16 455.3 445.3 
S15T5.0 5.00 1.7741 4.16 447.7 436.3 
S16T5.5 5.50 1.4259 4.14 443.2 429.8 
S17T6.0 6.00 1.1977 4.14 437.7 424.6 
S18T6.5 6.50 1.0852 4.13 431.0 420.3 
S19T7.0 7.00 0.9306 4.13 424.2 414.6 
S20T7.5 7.50 0.7265 4.11 416.7 409.2 
S21T8.0 8.00 0.6094 4.11 408.3 399.5 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-9, Oxaliplatin concentration-time curve for Patient 2 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
0.00 2.00 4.00 6.00 8.00 10.00
O
xa
lip
la
ti
n
 c
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
L)
 
Time (hour) 
356 
 
Table C-9, Results of the simulation test on Patient 2 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 3.91 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 564.7 553.6 
S1T0.25 0.25 0.5426 4.20 557.6 547.5 
S2T0.5 0.50 1.1643 4.19 549.0 539.8 
S3T0.75 0.75 1.7035 4.17 540.9 530.2 
S4T1.0 1.00 2.2898 4.18 533.3 523.8 
S5T1.25 1.25 2.8439 4.18 525.2 515.8 
S6T1.5 1.50 3.3016 4.18 517.1 507.5 
S7T1.75 1.75 3.8028 4.18 508.6 499.0 
S8T2.0 2.00 4.2346 4.18 501.0 492.0 
S9T2.25 2.25 3.9741 4.18 493.0 483.7 
S10T2.5 2.50 3.6533 4.17 484.9 475.9 
S11T3.0 3.00 3.2140 4.17 478.1 468.7 
S12T3.5 3.50 2.7328 4.17 471.8 462.2 
S13T4.0 4.00 2.3821 4.17 465.3 455.8 
S14T4.5 4.50 2.0350 4.16 459.2 449.6 
S15T5.0 5.00 1.7503 4.17 453.3 444.4 
S16T5.5 5.50 1.5067 4.18 446.1 436.7 
S17T6.0 6.00 1.2940 4.19 439.5 429.5 
S18T6.5 6.50 1.0756 4.19 433.3 424.3 
S19T7.0 7.00 0.9147 4.19 427.2 417.6 
S20T7.5 7.50 0.7743 4.20 420.9 412.2 
S21T8.0 8.00 0.6346 4.22 415.0 404.1 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-10, Oxaliplatin concentration-time curve for Patient 2 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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Table C-10, Results of the simulation test on Patient 2 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.27 564.5 553.8 
S1T0.25 0.25 0.6807 4.22 552.6 540.8 
S2T0.5 0.50 1.2613 4.24 543.3 532.6 
S3T0.75 0.75 1.9050 4.23 538.2 529.5 
S4T1.0 1.00 2.4101 4.23 530.6 521.9 
S5T1.25 1.25 2.9575 4.24 523.5 513.7 
S6T1.5 1.50 3.5851 4.23 516.6 505.8 
S7T1.75 1.75 3.8515 4.24 507.6 497.0 
S8T2.0 2.00 4.4275 4.24 499.6 483.4 
S9T2.25 2.25 4.1103 4.24 491.9 479.8 
S10T2.5 2.50 3.8269 4.24 482.6 473.8 
S11T3.0 3.00 3.2294 4.24 477.8 467.7 
S12T3.5 3.50 2.8382 4.23 470.9 460.2 
S13T4.0 4.00 2.3577 4.24 462.8 453.3 
S14T4.5 4.50 2.0451 4.25 457.2 447.0 
S15T5.0 5.00 1.7833 4.23 449.9 441.2 
S16T5.5 5.50 1.4645 4.24 444.0 434.1 
S17T6.0 6.00 0.9717 4.24 435.3 425.8 
S18T6.5 6.50 0.7484 4.23 430.0 420.1 
S19T7.0 7.00 0.6453 4.22 425.9 415.5 
S20T7.5 7.50 0.5236 4.23 420.9 410.8 
S21T8.0 8.00 0.4158 4.23 417.4 407.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
C.3 Patient 3 
The basic setting information for Patient 3 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 1.29 m2; Vc = 400.2 mL; CLtotal = 92.9 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
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Table C-11, Results of the simulation test on Patient 3 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 2.74 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.18 400.6 391.7 
S1T0.25 0.25 0.6975 4.15 392.5 383.3 
S2T0.5 0.50 1.4649 4.15 383.7 373.4 
S3T0.75 0.75 2.1951 4.16 374.9 365.5 
S4T1.0 1.00 2.9157 4.14 366.4 357.1 
S5T1.25 1.25 3.5895 4.15 357.8 349.1 
S6T1.5 1.50 4.2533 4.16 350.1 340.0 
S7T1.75 1.75 4.8382 4.15 340.5 331.5 
S8T2.0 2.00 5.2584 4.15 333.0 323.1 
S9T2.25 2.25 4.8554 4.15 321.8 314.4 
S10T2.5 2.50 4.4369 4.14 310.8 293.3 
S11T3.0 3.00 3.7699 4.14 300.2 292.4 
S12T3.5 3.50 3.1757 4.14 292.4 283.8 
S13T4.0 4.00 2.6474 4.14 295.5 284.2 
S14T4.5 4.50 2.2173 4.14 288.0 280.2 
S15T5.0 5.00 1.7775 4.13 281.8 272.4 
S16T5.5 5.50 1.4676 4.13 274.6 264.5 
S17T6.0 6.00 1.1898 4.13 265.9 257.6 
S18T6.5 6.50 0.9702 4.13 259.2 250.6 
S19T7.0 7.00 0.8021 4.13 253.7 244.3 
S20T7.5 7.50 0.6554 4.13 247.5 237.9 
S21T8.0 8.00 0.4812 4.13 240.7 229.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-11, Oxaliplatin concentration-time curve for Patient 3 with 2-hour infusions 
administered in Individual dosing scheme. 
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Table C-12, Results of the simulation test on Patient 3 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 2.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.29 401.5 392.2 
S1T0.25 0.25 0.9373 4.27 393.0 384.8 
S2T0.5 0.50 1.4646 4.26 385.0 374.9 
S3T0.75 0.75 2.0083 4.25 375.8 365.5 
S4T1.0 1.00 2.5576 4.24 366.0 355.7 
S5T1.25 1.25 3.0355 4.26 356.1 347.0 
S6T1.5 1.50 3.5308 4.24 346.7 337.3 
S7T1.75 1.75 3.9402 4.24 337.9 327.5 
S8T2.0 2.00 4.2217 4.24 328.4 318.5 
S9T2.25 2.25 3.8772 4.24 318.6 308.4 
S10T2.5 2.50 3.5229 4.25 310.0 299.5 
S11T3.0 3.00 2.9904 4.25 301.9 292.8 
S12T3.5 3.50 2.5029 4.25 294.5 284.3 
S13T4.0 4.00 2.0239 4.25 286.2 275.7 
S14T4.5 4.50 1.7083 4.25 277.8 267.1 
S15T5.0 5.00 1.4001 4.24 268.3 257.6 
S16T5.5 5.50 1.0974 4.25 259.7 249.6 
S17T6.0 6.00 0.9163 4.25 251.4 241.7 
S18T6.5 6.50 0.7509 4.25 243.0 233.4 
S19T7.0 7.00 0.5933 4.26 234.7 224.4 
S20T7.5 7.50 0.4533 4.26 226.2 216.3 
S21T8.0 8.00 0.3555 4.25 214.1 204.1 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-12, Oxaliplatin concentration-time curve for Patient 3 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
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Table C-13, Results of the simulation test on Patient 3 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 2.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.21 400.4 390.2 
S1T0.25 0.25 1.0742 4.18 392.2 382.9 
S2T0.5 0.50 1.8013 4.18 384.4 374.6 
S3T0.75 0.75 2.0669 4.17 376.4 366.6 
S4T1.0 1.00 2.8496 4.18 368.3 358.6 
S5T1.25 1.25 3.5472 4.18 360.2 350.6 
S6T1.5 1.50 4.0096 4.19 352.0 342.4 
S7T1.75 1.75 4.7330 4.18 343.6 333.9 
S8T2.0 2.00 4.7359 4.17 334.8 325.0 
S9T2.25 2.25 4.3373 4.20 325.4 315.7 
S10T2.5 2.50 4.0075 4.19 317.0 307.4 
S11T3.0 3.00 3.5190 4.20 310.6 300.7 
S12T3.5 3.50 2.9033 4.21 304.3 294.6 
S13T4.0 4.00 2.4871 4.22 298.3 288.6 
S14T4.5 4.50 2.1012 4.23 292.3 282.5 
S15T5.0 5.00 1.7298 4.24 285.7 276.3 
S16T5.5 5.50 1.4387 4.25 278.8 269.8 
S17T6.0 6.00 1.1580 4.25 272.8 263.1 
S18T6.5 6.50 0.7416 4.26 266.6 257.1 
S19T7.0 7.00 0.5156 4.26 260.5 251.1 
S20T7.5 7.50 0.4015 4.27 254.5 245.0 
S21T8.0 8.00 0.3121 4.26 248.5 238.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-13, Oxaliplatin concentration-time curve for Patient 3 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
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Table C-14, Results of the simulation test on Patient 3 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 2.8 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.18 401.2 388.9 
S1T0.25 0.25 0.7747 4.14 391.2 382.9 
S2T0.5 0.50 1.5022 4.16 384.4 375.2 
S3T0.75 0.75 2.0260 4.17 376.9 367.2 
S4T1.0 1.00 2.7284 4.15 368.0 359.0 
S5T1.25 1.25 3.2128 4.17 360.3 350.9 
S6T1.5 1.50 3.7788 4.17 351.6 341.2 
S7T1.75 1.75 4.2394 4.18 342.8 334.4 
S8T2.0 2.00 4.5646 4.17 336.1 326.4 
S9T2.25 2.25 4.1454 4.18 328.3 318.6 
S10T2.5 2.50 3.8481 4.17 320.5 309.8 
S11T3.0 3.00 3.2690 4.17 312.3 304.0 
S12T3.5 3.50 2.8535 4.16 307.8 297.0 
S13T4.0 4.00 2.3393 4.18 300.5 291.9 
S14T4.5 4.50 1.8966 4.18 294.6 284.7 
S15T5.0 5.00 1.6218 4.17 288.4 279.5 
S16T5.5 5.50 1.3478 4.16 281.2 271.6 
S17T6.0 6.00 1.1075 4.14 274.1 265.0 
S18T6.5 6.50 0.9187 4.14 267.5 257.6 
S19T7.0 7.00 0.7720 4.17 261.7 251.8 
S20T7.5 7.50 0.6019 4.19 253.5 244.8 
S21T8.0 8.00 0.5152 4.18 247.4 237.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-14, Oxaliplatin concentration-time curve for Patient 3 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
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Table C-15, Results of the simulation test on Patient 3 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.23 400.3 390.4 
S1T0.25 0.25 0.8864 4.18 391.8 381.6 
S2T0.5 0.50 1.8380 4.19 382.8 372.2 
S3T0.75 0.75 2.7590 4.19 373.5 363.3 
S4T1.0 1.00 3.6580 4.20 365.0 354.5 
S5T1.25 1.25 4.6133 4.20 356.4 346.9 
S6T1.5 1.50 5.4098 4.19 348.3 339.3 
S7T1.75 1.75 6.2397 4.20 340.8 329.0 
S8T2.0 2.00 6.9103 4.21 330.5 319.8 
S9T2.25 2.25 6.4137 4.21 320.8 312.2 
S10T2.5 2.50 5.9227 4.21 312.7 302.9 
S11T3.0 3.00 5.0283 4.21 305.6 295.8 
S12T3.5 3.50 4.3090 4.21 298.4 287.5 
S13T4.0 4.00 3.5343 4.22 290.1 280.2 
S14T4.5 4.50 2.9951 4.23 282.6 272.4 
S15T5.0 5.00 2.4782 4.23 275.0 265.1 
S16T5.5 5.50 2.0646 4.23 266.9 256.8 
S17T6.0 6.00 1.7106 4.24 258.4 248.5 
S18T6.5 6.50 1.3939 4.22 250.8 241.2 
S19T7.0 7.00 1.1777 4.24 243.1 233.3 
S20T7.5 7.50 0.9553 4.23 235.5 225.9 
S21T8.0 8.00 0.7521 4.24 227.7 217.7 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-15, Oxaliplatin concentration-time curve for Patient 3 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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C.4 Patient 4 
The basic setting information for Patient 4 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 1.55 m2; Vc = 480.9 mL; CLtotal = 111.6 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
Table C-16, Results of the simulation test on Patient 4 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 3.29 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.36 481.0 471.6 
S1T0.25 0.25 0.7600 4.32 472.2 462.4 
S2T0.5 0.50 1.5478 4.31 463.8 455.2 
S3T0.75 0.75 2.2017 4.31 456.4 447.4 
S4T1.0 1.00 2.9174 4.31 448.1 439.5 
S5T1.25 1.25 3.5806 4.27 441.0 432.1 
S6T1.5 1.50 4.2536 4.27 431.5 416.5 
S7T1.75 1.75 4.7211 4.27 417.9 408.8 
S8T2.0 2.00 5.3099 4.27 409.3 399.2 
S9T2.25 2.25 4.9380 4.27 397.1 391.7 
S10T2.5 2.50 4.5386 4.29 394.5 383.8 
S11T3.0 3.00 3.8509 4.29 389.2 377.2 
S12T3.5 3.50 3.2051 4.30 379.8 368.3 
S13T4.0 4.00 2.6733 4.31 372.1 360.6 
S14T4.5 4.50 2.2650 4.31 364.6 355.5 
S15T5.0 5.00 1.8885 4.32 358.2 347.2 
S16T5.5 5.50 1.5272 4.33 351.0 340.8 
S17T6.0 6.00 1.2829 4.33 344.2 333.9 
S18T6.5 6.50 1.0795 4.35 332.2 322.4 
S19T7.0 7.00 0.8414 4.32 325.2 315.4 
S20T7.5 7.50 0.7142 4.31 318.1 307.4 
S21T8.0 8.00 0.5847 4.30 310.4 299.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-16, Oxaliplatin concentration-time curve for Patient 4 with 2-hour infusions 
administered in Individual dosing scheme. 
Table C-17, Results of the simulation test on Patient 4 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 3.25 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.12 481.2 470.6 
S1T0.25 0.25 0.5385 4.07 469.5 460.1 
S2T0.5 0.50 1.3128 4.04 459.7 449.9 
S3T0.75 0.75 2.2207 4.06 449.8 440.3 
S4T1.0 1.00 2.6911 4.06 440.5 431.0 
S5T1.25 1.25 3.2784 4.06 431.1 421.0 
S6T1.5 1.50 3.6568 4.06 421.3 411.5 
S7T1.75 1.75 4.2633 4.07 412.0 402.9 
S8T2.0 2.00 4.6301 4.06 403.0 393.5 
S9T2.25 2.25 4.0541 4.07 393.6 384.4 
S10T2.5 2.50 3.9544 4.10 385.3 374.8 
S11T3.0 3.00 3.3231 4.10 375.2 366.4 
S12T3.5 3.50 2.8103 4.10 366.5 356.8 
S13T4.0 4.00 2.4234 4.11 358.6 349.0 
S14T4.5 4.50 2.0745 4.13 350.0 340.2 
S15T5.0 5.00 1.6942 4.13 341.8 332.2 
S16T5.5 5.50 1.4345 4.15 333.6 323.3 
S17T6.0 6.00 1.1683 4.17 325.6 316.4 
S18T6.5 6.50 0.9380 4.18 317.6 307.5 
S19T7.0 7.00 0.7640 4.19 308.7 299.4 
S20T7.5 7.50 0.6570 4.20 300.2 290.4 
S21T8.0 8.00 0.5258 4.20 292.1 282.0 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-17, Oxaliplatin concentration-time curve for Patient 4 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
Table C-18, Results of the simulation test on Patient 4 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 3.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.25 481.0 471.2 
S1T0.25 0.25 0.3102 4.20 469.9 459.8 
S2T0.5 0.50 1.2048 4.21 459.9 450.4 
S3T0.75 0.75 1.6559 4.20 450.4 440.4 
S4T1.0 1.00 2.2944 4.21 440.4 431.0 
S5T1.25 1.25 3.0272 4.21 430.8 421.3 
S6T1.5 1.50 3.4285 4.21 421.2 411.6 
S7T1.75 1.75 4.1582 4.21 411.6 402.3 
S8T2.0 2.00 4.3712 4.21 402.4 392.9 
S9T2.25 2.25 3.9714 4.22 393.6 384.0 
S10T2.5 2.50 3.8049 4.22 384.6 374.8 
S11T3.0 3.00 3.1619 4.23 376.4 366.9 
S12T3.5 3.50 2.7623 4.23 368.0 358.4 
S13T4.0 4.00 2.2899 4.25 360.2 350.5 
S14T4.5 4.50 2.0102 4.25 352.7 343.1 
S15T5.0 5.00 1.6454 4.25 344.8 335.0 
S16T5.5 5.50 1.3693 4.25 336.4 326.7 
S17T6.0 6.00 1.2402 4.26 328.4 318.8 
S18T6.5 6.50 1.0253 4.26 319.4 309.8 
S19T7.0 7.00 0.8958 4.27 310.3 300.2 
S20T7.5 7.50 0.7229 4.27 301.8 291.9 
S21T8.0 8.00 0.6257 4.27 291.9 282.2 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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 Figure C-18, Oxaliplatin concentration-time curve for Patient 4 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
Table C-19, Results of the simulation test on Patient 4 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 3.13 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.25 480.8 467.0 
S1T0.25 0.25 0.3220 4.24 466.9 457.3 
S2T0.5 0.50 1.0807 4.24 457.3 447.9 
S3T0.75 0.75 1.6900 4.25 448.2 438.8 
S4T1.0 1.00 2.3577 4.26 438.9 429.0 
S5T1.25 1.25 2.7305 4.26 430.2 420.3 
S6T1.5 1.50 3.4348 4.26 421.3 411.7 
S7T1.75 1.75 4.2809 4.28 412.8 403.0 
S8T2.0 2.00 4.4593 4.27 404.5 395.1 
S9T2.25 2.25 3.9447 4.27 395.9 386.1 
S10T2.5 2.50 3.6214 4.28 387.7 378.3 
S11T3.0 3.00 3.0886 4.29 380.7 370.3 
S12T3.5 3.50 2.7041 4.30 373.5 364.0 
S13T4.0 4.00 2.2616 4.30 367.3 357.8 
S14T4.5 4.50 1.9097 4.31 361.1 351.4 
S15T5.0 5.00 1.4999 4.31 354.3 344.7 
S16T5.5 5.50 1.4153 4.32 347.8 338.7 
S17T6.0 6.00 1.1612 4.31 341.6 332.4 
S18T6.5 6.50 0.9377 4.31 335.8 326.0 
S19T7.0 7.00 0.8220 4.31 330.0 320.3 
S20T7.5 7.50 0.6705 4.31 323.6 313.5 
S21T8.0 8.00 0.5589 4.31 315.6 305.3 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-19, Oxaliplatin concentration-time curve for Patient 4 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
Table C-20, Results of the simulation test on Patient 4 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 480.9 471.1 
S1T0.25 0.25 0.5836 4.20 473.0 462.7 
S2T0.5 0.50 1.5475 4.21 464.8 454.5 
S3T0.75 0.75 2.2670 4.21 456.6 446.5 
S4T1.0 1.00 3.0404 4.20 450.1 440.9 
S5T1.25 1.25 3.6745 4.21 443.7 432.6 
S6T1.5 1.50 4.4418 4.21 434.8 425.0 
S7T1.75 1.75 4.8977 4.22 426.1 415.4 
S8T2.0 2.00 5.3974 4.24 417.0 406.7 
S9T2.25 2.25 4.8952 4.22 408.9 398.4 
S10T2.5 2.50 4.6380 4.21 400.1 389.7 
S11T3.0 3.00 4.0212 4.21 394.0 383.7 
S12T3.5 3.50 3.4345 4.21 387.3 378.0 
S13T4.0 4.00 2.9324 4.21 380.2 370.8 
S14T4.5 4.50 2.5078 4.21 375.0 364.8 
S15T5.0 5.00 2.1380 4.22 368.0 357.4 
S16T5.5 5.50 1.7980 4.22 362.2 352.1 
S17T6.0 6.00 1.5165 4.22 351.4 340.3 
S18T6.5 6.50 1.2643 4.21 346.7 334.6 
S19T7.0 7.00 1.0686 4.20 337.3 327.1 
S20T7.5 7.50 0.8857 4.21 331.4 321.5 
S21T8.0 8.00 0.7444 4.22 325.8 315.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-20, Oxaliplatin concentration-time curve for Patient 4 with 2-hour infusions 
administered in Flat-fixed dosing method. 
C.5 Patient 5 
The basic setting information for Patient 5 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 2.20 m2; Vc = 682.6 mL; CLtotal = 158.4 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
 
 
Figure C-21, Oxaliplatin concentration-time curve for Patient 5 with 2-hour infusions 
administered in Individual dosing scheme. 
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Table C-21, Results of the simulation test on Patient 5 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 4.68 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.24 682.5 672.2 
S1T0.25 0.25 0.6216 4.20 674.8 665.0 
S2T0.5 0.50 1.2251 4.21 669.2 658.4 
S3T0.75 0.75 1.9427 4.20 658.4 648.4 
S4T1.0 1.00 2.4086 4.20 651.3 641.0 
S5T1.25 1.25 3.0705 4.20 644.1 635.5 
S6T1.5 1.50 3.5557 4.19 640.8 627.3 
S7T1.75 1.75 4.0128 4.20 629.8 619.7 
S8T2.0 2.00 4.4720 4.19 624.8 615.6 
S9T2.25 2.25 4.1414 4.20 621.9 609.3 
S10T2.5 2.50 3.8399 4.18 613.4 603.6 
S11T3.0 3.00 3.3201 4.18 608.4 597.7 
S12T3.5 3.50 2.8215 4.19 603.8 594.0 
S13T4.0 4.00 2.4850 4.19 600.5 589.1 
S14T4.5 4.50 2.2362 4.20 595.8 586.3 
S15T5.0 5.00 1.8813 4.19 593.0 582.9 
S16T5.5 5.50 1.5892 4.18 586.9 576.8 
S17T6.0 6.00 1.3982 4.19 581.1 571.3 
S18T6.5 6.50 1.2179 4.18 575.4 563.4 
S19T7.0 7.00 1.0113 4.20 566.3 556.8 
S20T7.5 7.50 0.8750 4.20 560.2 551.7 
S21T8.0 8.00 0.7338 4.20 557.0 547.2 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-22, Oxaliplatin concentration-time curve for Patient 5 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
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Table C-22, Results of the simulation test on Patient 5 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 4.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.37 682.9 671.3 
S1T0.25 0.25 0.8564 4.34 673.9 663.2 
S2T0.5 0.50 1.4846 4.32 663.6 654.7 
S3T0.75 0.75 2.1310 4.30 657.5 648.9 
S4T1.0 1.00 2.5713 4.27 650.8 639.6 
S5T1.25 1.25 3.1217 4.27 641.3 628.6 
S6T1.5 1.50 3.4765 4.25 638.0 627.2 
S7T1.75 1.75 3.8962 4.22 629.9 620.5 
S8T2.0 2.00 4.2776 4.22 621.7 613.5 
S9T2.25 2.25 3.9349 4.21 616.8 605.7 
S10T2.5 2.50 3.6891 4.21 609.5 600.4 
S11T3.0 3.00 3.1431 4.20 605.7 595.7 
S12T3.5 3.50 2.7201 4.18 601.4 590.8 
S13T4.0 4.00 2.3943 4.18 594.2 583.9 
S14T4.5 4.50 2.0542 4.19 591.3 582.2 
S15T5.0 5.00 1.7669 4.21 588.7 580.0 
S16T5.5 5.50 1.5392 4.21 585.3 575.2 
S17T6.0 6.00 1.3291 4.22 573.8 559.6 
S18T6.5 6.50 1.1408 4.21 567.8 554.7 
S19T7.0 7.00 0.9798 4.21 557.5 548.5 
S20T7.5 7.50 0.8505 4.18 547.3 537.6 
S21T8.0 8.00 0.7102 4.18 530.3 522.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-23, Oxaliplatin concentration-time curve for Patient 5 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
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Table C-23, Results of the simulation test on Patient 5 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 4.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.23 682.2 671.7 
S1T0.25 0.25 0.5860 4.20 674.3 661.9 
S2T0.5 0.50 1.1525 4.19 666.3 655.9 
S3T0.75 0.75 1.7453 4.19 658.6 649.5 
S4T1.0 1.00 2.1658 4.20 652.1 639.6 
S5T1.25 1.25 2.6700 4.19 643.4 634.2 
S6T1.5 1.50 3.1512 4.20 636.7 625.5 
S7T1.75 1.75 3.6356 4.20 628.2 618.6 
S8T2.0 2.00 4.0688 4.18 622.3 610.6 
S9T2.25 2.25 3.8367 4.19 614.6 604.3 
S10T2.5 2.50 3.5652 4.20 607.9 597.6 
S11T3.0 3.00 2.9002 4.19 603.7 592.2 
S12T3.5 3.50 2.5029 4.19 598.6 585.5 
S13T4.0 4.00 2.1778 4.20 592.1 581.3 
S14T4.5 4.50 1.9018 4.19 587.9 571.5 
S15T5.0 5.00 1.6710 4.19 578.3 568.2 
S16T5.5 5.50 1.4379 4.20 575.1 565.0 
S17T6.0 6.00 1.2527 4.20 569.9 561.3 
S18T6.5 6.50 1.0607 4.20 566.7 554.7 
S19T7.0 7.00 0.8863 4.20 560.2 551.4 
S20T7.5 7.50 0.7815 4.19 556.7 546.0 
S21T8.0 8.00 0.6458 4.21 552.0 541.7 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-24, Oxaliplatin concentration-time curve for Patient 5 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
0.00 2.00 4.00 6.00 8.00 10.00
O
xa
lip
la
ti
n
 c
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
L)
 
Time (hour) 
372 
 
Table C-24, Results of the simulation test on Patient 5 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 4.88 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.44 682.5 671.5 
S1T0.25 0.25 0.6930 4.42 674.9 662.9 
S2T0.5 0.50 1.3549 4.41 665.2 652.7 
S3T0.75 0.75 1.9360 4.42 654.0 643.4 
S4T1.0 1.00 2.5026 4.42 646.3 634.7 
S5T1.25 1.25 3.1445 4.41 638.3 625.4 
S6T1.5 1.50 3.7744 4.40 629.7 620.4 
S7T1.75 1.75 4.1370 4.42 623.3 613.2 
S8T2.0 2.00 4.4491 4.42 612.8 603.8 
S9T2.25 2.25 4.1403 4.41 605.5 596.7 
S10T2.5 2.50 3.8499 4.41 597.0 587.3 
S11T3.0 3.00 3.2140 4.41 590.3 579.2 
S12T3.5 3.50 2.8707 4.41 583.4 573.7 
S13T4.0 4.00 2.4749 4.40 577.5 567.9 
S14T4.5 4.50 2.1183 4.41 572.2 560.9 
S15T5.0 5.00 1.8579 4.41 564.7 554.6 
S16T5.5 5.50 1.5779 4.40 559.1 550.0 
S17T6.0 6.00 1.4114 4.40 552.6 543.2 
S18T6.5 6.50 1.2051 4.39 548.8 538.7 
S19T7.0 7.00 1.0175 4.40 541.6 531.7 
S20T7.5 7.50 0.8519 4.40 535.8 525.8 
S21T8.0 8.00 0.7579 4.38 527.2 517.3 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-25, Oxaliplatin concentration-time curve for Patient 5 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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Table C-25, Results of the simulation test on Patient 5 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.35 682.0 667.7 
S1T0.25 0.25 0.5432 4.28 674.2 661.8 
S2T0.5 0.50 1.0926 4.27 666.5 653.3 
S3T0.75 0.75 1.6200 4.29 656.9 644.6 
S4T1.0 1.00 2.1388 4.28 647.3 636.5 
S5T1.25 1.25 2.6651 4.27 639.0 626.2 
S6T1.5 1.50 3.1622 4.29 629.1 618.4 
S7T1.75 1.75 3.6315 4.30 619.9 608.6 
S8T2.0 2.00 3.9859 4.31 614.6 601.6 
S9T2.25 2.25 3.7723 4.30 602.8 591.0 
S10T2.5 2.50 3.4866 4.30 593.9 583.8 
S11T3.0 3.00 3.0977 4.31 594.4 581.0 
S12T3.5 3.50 2.6466 4.32 587.9 575.9 
S13T4.0 4.00 2.4036 4.31 581.5 568.9 
S14T4.5 4.50 2.0979 4.31 574.4 562.2 
S15T5.0 5.00 1.8229 4.32 570.4 560.6 
S16T5.5 5.50 1.5473 4.32 562.7 553.2 
S17T6.0 6.00 1.3307 4.32 554.2 543.1 
S18T6.5 6.50 1.1873 4.32 543.5 532.7 
S19T7.0 7.00 1.0148 4.35 537.3 526.3 
S20T7.5 7.50 0.8695 4.33 526.5 517.5 
S21T8.0 8.00 0.7614 4.32 510.9 500.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
C.6 Patient 6 
The basic setting information for Patient 6 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 1.33 m2; Vc = 412.6 mL; CLtotal = 95.8 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
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Table C-26, Results of the simulation test on Patient 6 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 2.83 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.28 412.6 403.3 
S1T0.25 0.25 0.7300 4.19 400.8 392.5 
S2T0.5 0.50 1.5026 4.18 390.5 381.1 
S3T0.75 0.75 2.2440 4.19 380.6 370.8 
S4T1.0 1.00 2.9795 4.19 374.6 366.0 
S5T1.25 1.25 3.5859 4.20 365.0 354.6 
S6T1.5 1.50 4.2538 4.19 357.0 346.1 
S7T1.75 1.75 4.9113 4.20 345.1 335.6 
S8T2.0 2.00 5.2413 4.21 343.0 334.1 
S9T2.25 2.25 4.8283 4.21 334.8 323.1 
S10T2.5 2.50 4.4176 4.21 321.8 313.1 
S11T3.0 3.00 3.6283 4.21 316.5 306.5 
S12T3.5 3.50 3.0294 4.22 306.5 299.5 
S13T4.0 4.00 2.5511 4.23 300.6 292.1 
S14T4.5 4.50 2.0594 4.22 292.2 284.2 
S15T5.0 5.00 1.6769 4.22 283.4 275.3 
S16T5.5 5.50 1.3672 4.23 276.4 268.4 
S17T6.0 6.00 1.0893 4.24 271.5 267.9 
S18T6.5 6.50 0.8702 4.23 269.5 256.8 
S19T7.0 7.00 0.6884 4.20 261.8 251.5 
S20T7.5 7.50 0.5591 4.20 250.2 238.5 
S21T8.0 8.00 0.4333 4.17 241.1 229.7 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-26, Oxaliplatin concentration-time curve for Patient 6 with 2-hour infusions 
administered in Individual dosing scheme. 
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Table C-27, Results of the simulation test on Patient 6 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 2.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.27 411.6 401.6 
S1T0.25 0.25 0.1229 4.25 402.2 392.3 
S2T0.5 0.50 0.5001 4.24 393.3 383.3 
S3T0.75 0.75 0.9866 4.24 384.3 374.3 
S4T1.0 1.00 1.9954 4.24 374.5 364.7 
S5T1.25 1.25 2.7944 4.25 365.0 354.3 
S6T1.5 1.50 3.6776 4.25 355.9 346.0 
S7T1.75 1.75 4.0790 4.26 346.5 336.7 
S8T2.0 2.00 4.2497 4.25 337.4 327.3 
S9T2.25 2.25 3.8239 4.26 328.2 317.3 
S10T2.5 2.50 3.5370 4.25 319.0 309.0 
S11T3.0 3.00 2.9876 4.25 310.8 300.6 
S12T3.5 3.50 2.5183 4.24 302.5 292.2 
S13T4.0 4.00 2.1029 4.23 294.3 283.4 
S14T4.5 4.50 1.7502 4.23 285.6 275.8 
S15T5.0 5.00 1.3904 4.23 277.5 267.4 
S16T5.5 5.50 1.1853 4.23 269.4 258.6 
S17T6.0 6.00 0.9440 4.23 260.9 250.8 
S18T6.5 6.50 0.7359 4.24 252.4 242.6 
S19T7.0 7.00 0.6228 4.23 242.9 233.5 
S20T7.5 7.50 0.4881 4.24 234.4 224.0 
S21T8.0 8.00 0.3981 4.23 220.3 210.5 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-27, Oxaliplatin concentration-time curve for Patient 6 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
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Table C-28, Results of the simulation test on Patient 6 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 3.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.29 412.7 402.7 
S1T0.25 0.25 0.2472 4.24 403.1 395.1 
S2T0.5 0.50 0.8506 4.25 394.7 384.5 
S3T0.75 0.75 1.5381 4.25 386.2 376.5 
S4T1.0 1.00 2.4892 4.24 377.7 368.1 
S5T1.25 1.25 3.0885 4.26 369.4 359.4 
S6T1.5 1.50 3.6707 4.25 360.7 351.1 
S7T1.75 1.75 4.3343 4.26 352.5 342.5 
S8T2.0 2.00 4.5942 4.27 343.8 333.8 
S9T2.25 2.25 4.2131 4.28 335.4 325.7 
S10T2.5 2.50 3.8791 4.28 326.9 317.3 
S11T3.0 3.00 3.3145 4.28 320.3 310.0 
S12T3.5 3.50 2.8266 4.30 313.6 304.4 
S13T4.0 4.00 2.4358 4.30 307.6 297.4 
S14T4.5 4.50 2.0531 4.31 301.2 291.5 
S15T5.0 5.00 1.7425 4.32 294.5 285.2 
S16T5.5 5.50 1.4730 4.31 289.2 279.9 
S17T6.0 6.00 1.2145 4.31 283.3 274.2 
S18T6.5 6.50 1.0152 4.29 277.7 268.4 
S19T7.0 7.00 0.8455 4.29 271.6 261.6 
S20T7.5 7.50 0.7324 4.29 264.5 255.4 
S21T8.0 8.00 0.5782 4.30 258.2 248.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-28, Oxaliplatin concentration-time curve for Patient 6 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
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Table C-29, Results of the simulation test on Patient 6 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 2.8 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.28 412.4 402.1 
S1T0.25 0.25 0.6180 4.29 403.9 394.8 
S2T0.5 0.50 1.4927 4.30 395.2 385.1 
S3T0.75 0.75 2.0839 4.30 386.4 378.8 
S4T1.0 1.00 2.7181 4.30 380.6 370.5 
S5T1.25 1.25 2.8951 4.30 371.0 360.6 
S6T1.5 1.50 3.5291 4.30 362.4 353.5 
S7T1.75 1.75 3.9844 4.30 353.6 344.2 
S8T2.0 2.00 4.3727 4.29 346.7 336.6 
S9T2.25 2.25 3.9826 4.28 338.9 329.6 
S10T2.5 2.50 3.6199 4.28 331.2 321.2 
S11T3.0 3.00 3.0437 4.29 323.6 314.8 
S12T3.5 3.50 2.5720 4.29 317.9 308.3 
S13T4.0 4.00 2.1189 4.29 311.1 301.9 
S14T4.5 4.50 1.7608 4.29 304.8 295.4 
S15T5.0 5.00 1.4670 4.30 298.9 289.5 
S16T5.5 5.50 1.0680 4.29 292.3 281.6 
S17T6.0 6.00 0.8080 4.29 283.6 274.0 
S18T6.5 6.50 0.6870 4.28 276.7 267.1 
S19T7.0 7.00 0.5593 4.28 270.2 260.4 
S20T7.5 7.50 0.4429 4.28 264.2 254.6 
S21T8.0 8.00 0.3921 4.29 257.6 247.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-29, Oxaliplatin concentration-time curve for Patient 6 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
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Table C-30, Results of the simulation test on Patient 6 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.37 412.4 403.2 
S1T0.25 0.25 0.8850 4.26 405.6 396.3 
S2T0.5 0.50 1.6466 4.26 398.6 388.4 
S3T0.75 0.75 2.5550 4.26 392.3 382.2 
S4T1.0 1.00 3.6221 4.24 385.0 375.3 
S5T1.25 1.25 4.5456 4.24 378.3 368.8 
S6T1.5 1.50 4.7759 4.24 371.2 361.2 
S7T1.75 1.75 5.5781 4.23 363.8 353.2 
S8T2.0 2.00 6.1034 4.25 356.8 346.3 
S9T2.25 2.25 5.3578 4.24 347.6 336.9 
S10T2.5 2.50 5.1012 4.23 337.5 328.0 
S11T3.0 3.00 4.3757 4.23 329.9 319.4 
S12T3.5 3.50 3.7766 4.23 322.7 313.0 
S13T4.0 4.00 3.2118 4.23 316.2 306.0 
S14T4.5 4.50 2.7327 4.22 309.1 299.6 
S15T5.0 5.00 2.3058 4.22 301.6 291.9 
S16T5.5 5.50 1.9232 4.22 294.1 284.2 
S17T6.0 6.00 1.6365 4.21 286.7 276.6 
S18T6.5 6.50 1.3360 4.22 279.2 268.8 
S19T7.0 7.00 1.1001 4.22 271.3 261.5 
S20T7.5 7.50 0.9233 4.20 264.4 254.6 
S21T8.0 8.00 0.7314 4.21 256.5 246.3 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-30, Oxaliplatin concentration-time curve for Patient 6 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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C.7 Patient 7 
The basic setting information for Patient 7 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 1.99 m2; Vc = 617.4 mL; CLtotal = 143.3 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
Table C-31, Results of the simulation test on Patient 7 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 4.23 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.29 617.6 607.3 
S1T0.25 0.25 0.7784 4.12 607.8 597.5 
S2T0.5 0.50 1.4378 4.11 598.2 588.6 
S3T0.75 0.75 2.1934 4.10 589.5 578.8 
S4T1.0 1.00 2.9226 4.11 579.9 569.7 
S5T1.25 1.25 3.4829 4.10 571.4 561.4 
S6T1.5 1.50 3.9512 4.10 562.8 553.1 
S7T1.75 1.75 4.3470 4.10 554.6 545.6 
S8T2.0 2.00 4.7062 4.10 547.0 537.2 
S9T2.25 2.25 4.3651 4.10 538.5 528.1 
S10T2.5 2.50 4.0904 4.10 530.6 520.6 
S11T3.0 3.00 3.5074 4.11 524.4 515.2 
S12T3.5 3.50 3.0378 4.08 518.5 507.5 
S13T4.0 4.00 2.5863 4.10 510.1 500.2 
S14T4.5 4.50 2.1912 4.12 502.1 492.2 
S15T5.0 5.00 1.8681 4.13 494.1 484.3 
S16T5.5 5.50 1.5671 4.14 487.3 476.5 
S17T6.0 6.00 1.3192 4.16 480.0 469.3 
S18T6.5 6.50 1.1092 4.20 473.2 465.2 
S19T7.0 7.00 0.9278 4.16 470.2 460.1 
S20T7.5 7.50 0.7758 4.15 462.9 454.7 
S21T8.0 8.00 0.6373 4.13 455.8 445.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-31, Oxaliplatin concentration-time curve for Patient 7 with 2-hour infusions 
administered in Individual dosing scheme. 
Table C-32, Results of the simulation test on Patient 7 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 4.25 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.22 616.1 596.0 
S1T0.25 0.25 0.8018 4.19 599.1 589.0 
S2T0.5 0.50 1.2091 4.19 585.9 573.8 
S3T0.75 0.75 1.8157 4.19 577.1 566.1 
S4T1.0 1.00 2.3655 4.19 569.6 559.9 
S5T1.25 1.25 2.7377 4.19 562.3 551.6 
S6T1.5 1.50 3.2164 4.17 553.8 543.9 
S7T1.75 1.75 3.5326 4.16 545.4 536.6 
S8T2.0 2.00 3.9707 4.17 538.6 527.7 
S9T2.25 2.25 3.6321 4.14 531.4 520.9 
S10T2.5 2.50 3.3792 4.14 522.6 512.7 
S11T3.0 3.00 2.9084 4.13 516.9 506.2 
S12T3.5 3.50 2.5079 4.13 510.1 500.6 
S13T4.0 4.00 2.1261 4.13 505.1 494.5 
S14T4.5 4.50 1.8102 4.16 499.0 489.0 
S15T5.0 5.00 1.5502 4.15 492.9 483.6 
S16T5.5 5.50 1.2883 4.16 487.8 477.1 
S17T6.0 6.00 1.1032 4.15 480.8 470.3 
S18T6.5 6.50 0.9485 4.13 474.4 463.8 
S19T7.0 7.00 0.7642 4.11 468.1 457.9 
S20T7.5 7.50 0.6460 4.12 461.7 452.3 
S21T8.0 8.00 0.5682 4.10 455.4 445.7 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-32, Oxaliplatin concentration-time curve for Patient 7 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
Table C-33, Results of the simulation test on Patient 7 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.26 617.3 603.8 
S1T0.25 0.25 0.7673 4.23 604.3 594.0 
S2T0.5 0.50 1.4682 4.24 596.8 586.7 
S3T0.75 0.75 2.1427 4.24 589.4 578.5 
S4T1.0 1.00 2.6998 4.24 584.0 570.2 
S5T1.25 1.25 3.1525 4.25 572.8 563.8 
S6T1.5 1.50 3.5631 4.24 567.1 554.4 
S7T1.75 1.75 3.9610 4.24 558.3 546.5 
S8T2.0 2.00 4.2534 4.24 547.6 539.7 
S9T2.25 2.25 3.7479 4.25 540.7 531.9 
S10T2.5 2.50 3.2385 4.25 535.2 525.5 
S11T3.0 3.00 2.7715 4.25 529.5 520.9 
S12T3.5 3.50 2.2821 4.25 524.3 516.3 
S13T4.0 4.00 1.7486 4.26 519.9 510.6 
S14T4.5 4.50 1.5623 4.28 514.4 505.7 
S15T5.0 5.00 1.2628 4.28 510.7 501.6 
S16T5.5 5.50 1.1056 4.26 507.5 498.9 
S17T6.0 6.00 0.9329 4.26 502.1 493.8 
S18T6.5 6.50 0.8365 4.27 497.0 489.4 
S19T7.0 7.00 0.7337 4.26 492.8 484.9 
S20T7.5 7.50 0.7044 4.27 487.4 480.0 
S21T8.0 8.00 0.5907 4.28 484.4 471.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-33, Oxaliplatin concentration-time curve for Patient 7 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
Table C-34, Results of the simulation test on Patient 7 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 4.37 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.35 617.1 605.7 
S1T0.25 0.25 0.7039 4.31 610.9 598.4 
S2T0.5 0.50 1.3603 4.31 601.6 589.4 
S3T0.75 0.75 1.9712 4.31 591.4 580.9 
S4T1.0 1.00 2.5512 4.31 582.4 571.6 
S5T1.25 1.25 3.0873 4.32 574.0 562.2 
S6T1.5 1.50 3.5903 4.31 564.3 554.9 
S7T1.75 1.75 4.1263 4.31 555.8 546.2 
S8T2.0 2.00 4.3543 4.31 548.3 536.7 
S9T2.25 2.25 4.0318 4.29 538.8 528.4 
S10T2.5 2.50 3.6842 4.35 531.5 520.6 
S11T3.0 3.00 3.2184 4.31 525.2 514.9 
S12T3.5 3.50 2.7930 4.30 520.9 510.3 
S13T4.0 4.00 2.3838 4.30 514.7 504.5 
S14T4.5 4.50 2.0977 4.30 509.4 499.2 
S15T5.0 5.00 1.8067 4.31 504.1 493.8 
S16T5.5 5.50 1.5584 4.28 498.8 488.8 
S17T6.0 6.00 1.3270 4.29 494.3 484.0 
S18T6.5 6.50 1.0794 4.29 489.8 480.9 
S19T7.0 7.00 0.9672 4.30 483.0 472.1 
S20T7.5 7.50 0.8175 4.30 476.7 466.6 
S21T8.0 8.00 0.7073 4.31 471.3 460.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-34, Oxaliplatin concentration-time curve for Patient 7 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
Table C-35, Results of the simulation test on Patient 7 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.19 616.3 604.9 
S1T0.25 0.25 0.5969 4.18 614.8 604.3 
S2T0.5 0.50 1.1297 4.17 606.7 596.8 
S3T0.75 0.75 1.7327 4.18 598.4 588.3 
S4T1.0 1.00 2.2981 4.15 590.2 579.7 
S5T1.25 1.25 2.9056 4.16 582.1 571.8 
S6T1.5 1.50 3.3126 4.17 573.7 564.0 
S7T1.75 1.75 3.8159 4.18 565.3 555.3 
S8T2.0 2.00 4.2387 4.18 555.0 544.5 
S9T2.25 2.25 3.9624 4.18 546.8 536.6 
S10T2.5 2.50 3.6992 4.22 538.9 528.8 
S11T3.0 3.00 3.2139 4.19 532.7 522.7 
S12T3.5 3.50 2.8027 4.19 526.6 516.1 
S13T4.0 4.00 2.4539 4.19 519.8 509.8 
S14T4.5 4.50 2.1229 4.19 512.6 502.8 
S15T5.0 5.00 1.7855 4.18 505.9 495.7 
S16T5.5 5.50 1.5725 4.18 498.6 488.7 
S17T6.0 6.00 1.3863 4.18 491.6 481.9 
S18T6.5 6.50 1.1564 4.18 484.3 474.4 
S19T7.0 7.00 1.0155 4.18 477.6 468.0 
S20T7.5 7.50 0.8764 4.19 472.3 462.2 
S21T8.0 8.00 0.7287 4.19 465.0 454.1 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-35, Oxaliplatin concentration-time curve for Patient 7 with 2-hour infusions 
administered in Flat-fixed dosing method. 
C.8 Patient 8 
The basic setting information for Patient 8 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 1.72 m2; Vc = 533.6 mL; CLtotal = 124.0 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
Figure C-36, Oxaliplatin concentration-time curve for Patient 8 with 2-hour infusions 
administered in Individual dosing scheme. 
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Table C-36, Results of the simulation test on Patient 8 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 3.66 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.21 533.6 524.4 
S1T0.25 0.25 0.6364 4.15 528.8 514.4 
S2T0.5 0.50 1.4302 4.15 516.1 505.7 
S3T0.75 0.75 2.1922 4.13 507.7 498.1 
S4T1.0 1.00 2.8343 4.13 499.4 489.8 
S5T1.25 1.25 3.5461 4.12 492.0 482.8 
S6T1.5 1.50 4.1577 4.13 484.5 474.5 
S7T1.75 1.75 4.7059 4.12 466.9 458.3 
S8T2.0 2.00 4.7477 4.10 456.0 445.0 
S9T2.25 2.25 4.3648 4.09 452.1 440.9 
S10T2.5 2.50 4.0303 4.08 442.4 432.6 
S11T3.0 3.00 3.4042 4.08 437.1 424.6 
S12T3.5 3.50 2.8763 4.08 431.2 421.6 
S13T4.0 4.00 2.4096 4.09 424.7 414.8 
S14T4.5 4.50 2.0347 4.10 421.1 410.1 
S15T5.0 5.00 1.7269 4.12 411.6 404.7 
S16T5.5 5.50 1.4240 4.13 406.4 397.7 
S17T6.0 6.00 1.1590 4.13 397.7 387.6 
S18T6.5 6.50 0.9965 4.14 386.3 377.2 
S19T7.0 7.00 0.8169 4.15 377.8 368.9 
S20T7.5 7.50 0.6878 4.12 371.7 361.4 
S21T8.0 8.00 0.5656 4.10 371.3 356.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-37, Oxaliplatin concentration-time curve for Patient 8 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
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Table C-37, Results of the simulation test on Patient 8 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 3.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.30 533.4 523.4 
S1T0.25 0.25 0.7656 4.27 524.5 514.7 
S2T0.5 0.50 1.4817 4.26 515.3 506.3 
S3T0.75 0.75 2.1458 4.25 507.3 499.3 
S4T1.0 1.00 2.7018 4.24 501.8 489.8 
S5T1.25 1.25 3.2299 4.24 494.2 481.5 
S6T1.5 1.50 3.4368 4.23 485.1 475.5 
S7T1.75 1.75 3.8551 4.22 477.9 468.0 
S8T2.0 2.00 4.3622 4.22 470.2 458.7 
S9T2.25 2.25 4.0461 4.21 459.1 448.2 
S10T2.5 2.50 3.7019 4.21 450.2 438.7 
S11T3.0 3.00 3.2070 4.20 443.3 433.3 
S12T3.5 3.50 2.6661 4.19 437.5 428.6 
S13T4.0 4.00 2.2457 4.18 430.9 420.2 
S14T4.5 4.50 1.9014 4.18 422.9 413.1 
S15T5.0 5.00 1.5854 4.18 415.3 405.2 
S16T5.5 5.50 1.3961 4.17 407.5 396.7 
S17T6.0 6.00 1.1510 4.17 399.4 389.4 
S18T6.5 6.50 0.9713 4.16 392.3 382.3 
S19T7.0 7.00 0.8001 4.16 384.8 374.8 
S20T7.5 7.50 0.6558 4.15 370.5 359.5 
S21T8.0 8.00 0.5386 4.15 361.9 351.9 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-38, Oxaliplatin concentration-time curve for Patient 8 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
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Table C-38, Results of the simulation test on Patient 8 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 3.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.25 533.7 520.0 
S1T0.25 0.25 0.6081 4.22 524.0 510.0 
S2T0.5 0.50 1.3431 4.22 514.3 502.9 
S3T0.75 0.75 1.8641 4.20 506.0 494.6 
S4T1.0 1.00 2.4562 4.21 496.3 486.3 
S5T1.25 1.25 2.9645 4.22 487.8 478.0 
S6T1.5 1.50 3.3913 4.22 482.1 469.2 
S7T1.75 1.75 3.8597 4.21 473.0 458.3 
S8T2.0 2.00 4.1917 4.21 463.5 440.0 
S9T2.25 2.25 3.7883 4.20 453.5 440.0 
S10T2.5 2.50 3.5542 4.21 443.9 427.9 
S11T3.0 3.00 2.9227 4.20 431.6 421.4 
S12T3.5 3.50 2.5527 4.20 425.2 417.0 
S13T4.0 4.00 2.0489 4.21 420.5 410.5 
S14T4.5 4.50 1.7487 4.20 413.4 403.2 
S15T5.0 5.00 1.4459 4.21 406.4 397.4 
S16T5.5 5.50 1.1831 4.19 399.3 390.4 
S17T6.0 6.00 0.9740 4.22 391.2 382.8 
S18T6.5 6.50 0.7934 4.21 384.8 375.2 
S19T7.0 7.00 0.6581 4.21 375.0 369.5 
S20T7.5 7.50 0.5437 4.21 372.6 360.6 
S21T8.0 8.00 0.4795 4.21 365.7 355.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-39, Oxaliplatin concentration-time curve for Patient 8 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
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Table C-39, Results of the simulation test on Patient 8 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 3.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.19 533.6 523.9 
S1T0.25 0.25 0.6810 4.16 524.3 514.8 
S2T0.5 0.50 1.2028 4.15 515.0 505.4 
S3T0.75 0.75 1.7627 4.16 506.1 496.5 
S4T1.0 1.00 2.2370 4.15 497.2 487.1 
S5T1.25 1.25 2.5712 4.14 488.1 478.1 
S6T1.5 1.50 2.8169 4.15 478.6 469.7 
S7T1.75 1.75 3.3099 4.15 470.2 460.5 
S8T2.0 2.00 3.8551 4.15 461.0 449.8 
S9T2.25 2.25 3.5048 4.15 450.6 440.4 
S10T2.5 2.50 3.2443 4.14 441.2 432.0 
S11T3.0 3.00 2.7910 4.14 434.7 425.2 
S12T3.5 3.50 2.3636 4.15 430.1 420.6 
S13T4.0 4.00 2.0098 4.15 426.4 416.9 
S14T4.5 4.50 1.7884 4.15 422.5 406.9 
S15T5.0 5.00 1.4646 4.15 410.6 401.0 
S16T5.5 5.50 1.2332 4.15 405.3 395.5 
S17T6.0 6.00 1.0625 4.15 400.7 391.0 
S18T6.5 6.50 0.8953 4.15 396.3 387.1 
S19T7.0 7.00 0.7512 4.16 391.9 382.2 
S20T7.5 7.50 0.6116 4.17 386.9 377.5 
S21T8.0 8.00 0.4973 4.16 381.2 371.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-40, Oxaliplatin concentration-time curve for Patient 8 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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Table C-40, Results of the simulation test on Patient 8 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.16 533.8 524.0 
S1T0.25 0.25 0.6040 4.09 525.1 514.8 
S2T0.5 0.50 1.0877 4.10 515.9 506.5 
S3T0.75 0.75 1.5074 4.09 507.9 497.9 
S4T1.0 1.00 1.9049 4.09 498.3 488.9 
S5T1.25 1.25 2.4305 4.09 489.8 479.8 
S6T1.5 1.50 2.7557 4.10 481.2 471.2 
S7T1.75 1.75 3.2408 4.10 472.6 463.0 
S8T2.0 2.00 3.3480 4.09 464.5 454.5 
S9T2.25 2.25 3.2247 4.10 456.0 446.3 
S10T2.5 2.50 3.0543 4.10 447.8 438.0 
S11T3.0 3.00 2.7588 4.11 439.5 429.6 
S12T3.5 3.50 2.3827 4.11 432.7 424.1 
S13T4.0 4.00 1.6947 4.10 428.5 418.9 
S14T4.5 4.50 1.5297 4.10 422.2 412.8 
S15T5.0 5.00 1.4981 4.10 416.5 406.5 
S16T5.5 5.50 1.0347 4.12 409.9 400.7 
S17T6.0 6.00 0.9754 4.12 404.9 395.2 
S18T6.5 6.50 0.7408 4.10 399.0 388.9 
S19T7.0 7.00 0.6414 4.13 393.4 384.6 
S20T7.5 7.50 0.4779 4.12 389.1 380.6 
S21T8.0 8.00 0.3667 4.11 383.2 372.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
C.9 Patient 9 
The basic setting information for Patient 9 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 2.52 m2; Vc = 781.8 mL; CLtotal = 181.4 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
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Table C-41, Results of the simulation test on Patient 9 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 5.36 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.26 781.2 773.2 
S1T0.25 0.25 0.7069 4.24 793.2 784.0 
S2T0.5 0.50 1.2968 4.24 785.8 774.9 
S3T0.75 0.75 1.8192 4.23 777.8 768.0 
S4T1.0 1.00 2.4378 4.22 770.4 761.1 
S5T1.25 1.25 2.9138 4.22 763.2 753.5 
S6T1.5 1.50 3.4722 4.22 756.2 746.9 
S7T1.75 1.75 4.0254 4.22 749.6 740.4 
S8T2.0 2.00 4.2402 4.22 742.2 732.2 
S9T2.25 2.25 3.9252 4.23 734.4 723.8 
S10T2.5 2.50 3.6784 4.23 727.5 717.9 
S11T3.0 3.00 3.1830 4.23 723.6 714.3 
S12T3.5 3.50 2.7402 4.24 719.4 709.7 
S13T4.0 4.00 2.4111 4.24 711.5 702.0 
S14T4.5 4.50 2.1093 4.24 707.5 697.8 
S15T5.0 5.00 1.8276 4.24 703.9 694.1 
S16T5.5 5.50 1.6008 4.22 696.1 687.6 
S17T6.0 6.00 1.3749 4.21 691.6 682.5 
S18T6.5 6.50 1.1602 4.19 688.7 679.5 
S19T7.0 7.00 1.0147 4.19 682.7 674.4 
S20T7.5 7.50 0.8667 4.20 677.6 667.8 
S21T8.0 8.00 0.7351 4.19 658.3 654.0 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-41, Oxaliplatin concentration-time curve for Patient 9 with 2-hour infusions 
administered in Individual dosing scheme. 
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Table C-42, Results of the simulation test on Patient 9 with oxaliplatin administered in 
Dose-banding with 5% deviation with the drug dose of 5.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.36 781.9 774.0 
S1T0.25 0.25 0.8305 4.32 779.0 768.2 
S2T0.5 0.50 1.2594 4.31 768.8 756.5 
S3T0.75 0.75 1.8844 4.30 758.8 748.5 
S4T1.0 1.00 2.3579 4.30 751.6 743.1 
S5T1.25 1.25 2.9216 4.29 743.3 733.8 
S6T1.5 1.50 3.4738 4.29 737.4 728.8 
S7T1.75 1.75 3.9538 4.29 733.1 721.3 
S8T2.0 2.00 4.2977 4.28 723.2 714.5 
S9T2.25 2.25 3.9954 4.29 713.1 703.3 
S10T2.5 2.50 3.7361 4.29 705.4 695.3 
S11T3.0 3.00 3.2235 4.27 702.5 694.8 
S12T3.5 3.50 2.8351 4.28 697.2 688.8 
S13T4.0 4.00 2.4524 4.28 689.7 678.7 
S14T4.5 4.50 2.1317 4.29 685.7 681.4 
S15T5.0 5.00 1.8245 4.29 678.2 669.6 
S16T5.5 5.50 1.5576 4.29 675.2 671.8 
S17T6.0 6.00 1.3570 4.28 669.3 658.2 
S18T6.5 6.50 1.2071 4.28 663.6 658.2 
S19T7.0 7.00 1.0383 4.27 656.7 648.0 
S20T7.5 7.50 0.8841 4.25 652.0 642.9 
S21T8.0 8.00 0.7619 4.26 635.5 625.2 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-42, Oxaliplatin concentration-time curve for Patient 9 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
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Table C-43, Results of the simulation test on Patient 9 with oxaliplatin administered in 
Dose-banding with 10% deviation with the drug dose of 5.75 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.32 782.5 771.3 
S1T0.25 0.25 0.6183 4.30 774.3 765.6 
S2T0.5 0.50 1.3274 4.29 766.6 755.8 
S3T0.75 0.75 1.9448 4.29 757.5 748.6 
S4T1.0 1.00 2.6048 4.29 749.2 738.6 
S5T1.25 1.25 3.0321 4.30 739.4 729.3 
S6T1.5 1.50 3.4235 4.30 731.5 721.4 
S7T1.75 1.75 3.9454 4.30 722.3 711.4 
S8T2.0 2.00 4.1182 4.30 710.7 699.5 
S9T2.25 2.25 3.7884 4.31 699.5 689.7 
S10T2.5 2.50 3.5208 4.32 693.5 681.3 
S11T3.0 3.00 3.0417 4.32 688.5 678.6 
S12T3.5 3.50 2.6919 4.33 681.4 670.6 
S13T4.0 4.00 2.3302 4.33 674.1 664.0 
S14T4.5 4.50 2.0068 4.34 667.0 657.0 
S15T5.0 5.00 1.7429 4.34 659.1 650.2 
S16T5.5 5.50 1.4667 4.34 652.4 641.7 
S17T6.0 6.00 1.2787 4.35 645.0 636.0 
S18T6.5 6.50 1.0683 4.34 638.7 629.4 
S19T7.0 7.00 0.8898 4.34 631.6 621.6 
S20T7.5 7.50 0.8163 4.33 624.3 615.5 
S21T8.0 8.00 0.6580 4.33 618.4 608.4 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-43, Oxaliplatin concentration-time curve for Patient 9 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
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Table C-44, Results of the simulation test on Patient 9 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 5.46 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.50 778.5 767.3 
S1T0.25 0.25 1.0263 4.46 762.8 753.2 
S2T0.5 0.50 1.3962 4.45 754.8 740.7 
S3T0.75 0.75 2.0020 4.46 741.0 724.8 
S4T1.0 1.00 2.6081 4.47 724.9 719.4 
S5T1.25 1.25 3.1317 4.45 718.5 707.2 
S6T1.5 1.50 3.6732 4.46 707.3 692.8 
S7T1.75 1.75 4.1828 4.47 698.1 684.2 
S8T2.0 2.00 4.6267 4.46 686.3 674.5 
S9T2.25 2.25 4.3297 4.47 676.8 662.6 
S10T2.5 2.50 3.9930 4.45 662.3 653.2 
S11T3.0 3.00 3.4816 4.45 654.6 643.0 
S12T3.5 3.50 3.0309 4.43 644.5 631.1 
S13T4.0 4.00 2.6473 4.43 631.0 623.3 
S14T4.5 4.50 2.2570 4.42 619.6 610.3 
S15T5.0 5.00 1.9208 4.41 609.5 598.8 
S16T5.5 5.50 1.6462 4.40 597.2 585.4 
S17T6.0 6.00 1.4144 4.41 583.7 572.6 
S18T6.5 6.50 1.1908 4.41 571.1 553.7 
S19T7.0 7.00 1.0453 4.43 550.7 538.5 
S20T7.5 7.50 0.8483 4.40 535.0 524.4 
S21T8.0 8.00 0.7114 4.41 521.8 512.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-44, Oxaliplatin concentration-time curve for Patient 9 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
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Table C-45, Results of the simulation test on Patient 9 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.25 781.8 774.6 
S1T0.25 0.25 0.5839 4.21 776.0 764.6 
S2T0.5 0.50 0.8787 4.22 764.8 756.2 
S3T0.75 0.75 1.3952 4.20 758.7 748.6 
S4T1.0 1.00 1.8009 4.20 748.8 739.7 
S5T1.25 1.25 2.2217 4.20 739.2 728.5 
S6T1.5 1.50 2.5466 4.20 730.9 720.4 
S7T1.75 1.75 2.9371 4.20 721.1 707.3 
S8T2.0 2.00 3.1679 4.26 708.9 698.4 
S9T2.25 2.25 3.0612 4.20 701.3 690.8 
S10T2.5 2.50 2.8221 4.21 691.5 684.2 
S11T3.0 3.00 2.4955 4.19 688.3 678.7 
S12T3.5 3.50 2.1252 4.19 680.5 668.9 
S13T4.0 4.00 1.8300 4.19 678.7 669.4 
S14T4.5 4.50 1.6029 4.19 673.3 663.6 
S15T5.0 5.00 1.3401 4.20 668.3 657.7 
S16T5.5 5.50 1.1392 4.20 663.1 654.8 
S17T6.0 6.00 1.0048 4.20 656.9 643.8 
S18T6.5 6.50 0.8473 4.19 648.2 638.1 
S19T7.0 7.00 0.7367 4.19 643.8 633.7 
S20T7.5 7.50 0.6104 4.19 636.1 626.9 
S21T8.0 8.00 0.5093 4.18 630.1 620.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
 
Figure C-45, Oxaliplatin concentration-time curve for Patient 9 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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C.10 Patient 10 
The basic setting information for Patient 10 was calculated based on the study 
schedule mentioned in Chapter 4, which was listed below: 
BSA = 2.04 m2; Vc = 632.9 mL; CLtotal = 146.9 mL/h. 
[Vc: distribution volume of oxaliplatin; CLtotal: the total clearance of oxaliplatin.] 
 
 
Table C-46, Results of the simulation test on Patient 10 with oxaliplatin administered in 
Individual dosing scheme with the drug dose of 4.34 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.29 631.7 622.3 
S1T0.25 0.25 0.8716 4.23 624.0 613.9 
S2T0.5 0.50 1.5275 4.22 614.5 606.4 
S3T0.75 0.75 2.1684 4.21 608.4 596.8 
S4T1.0 1.00 2.8103 4.21 597.8 588.0 
S5T1.25 1.25 3.4091 4.20 589.0 578.8 
S6T1.5 1.50 3.9923 4.20 580.7 570.1 
S7T1.75 1.75 4.2616 4.18 571.5 561.5 
S8T2.0 2.00 4.6187 4.19 559.1 547.7 
S9T2.25 2.25 4.3476 4.18 553.6 545.1 
S10T2.5 2.50 4.0392 4.16 544.7 538.7 
S11T3.0 3.00 3.4737 4.18 540.7 531.4 
S12T3.5 3.50 3.0115 4.17 536.5 526.9 
S13T4.0 4.00 2.5495 4.18 532.2 522.3 
S14T4.5 4.50 2.1599 4.19 527.6 518.4 
S15T5.0 5.00 1.8208 4.21 522.5 512.6 
S16T5.5 5.50 1.5756 4.22 516.9 506.7 
S17T6.0 6.00 1.3321 4.20 511.7 501.4 
S18T6.5 6.50 1.1400 4.18 498.7 487.9 
S19T7.0 7.00 0.9483 4.16 493.4 484.3 
S20T7.5 7.50 0.8349 4.14 479.0 469.6 
S21T8.0 8.00 0.6845 4.15 476.3 466.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-46, Oxaliplatin concentration-time curve for Patient 10 with 2-hour infusions 
administered in Individual dosing scheme. 
Table C-47, Results of the simulation test on Patient 10 with oxaliplatin administered in 
Dose-banding scheme with 5% deviation with the drug dose of 4.25 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.21 633.2 621.1 
S1T0.25 0.25 0.6325 4.17 620.6 609.0 
S2T0.5 0.50 1.2130 4.16 614.1 603.5 
S3T0.75 0.75 1.8145 4.16 606.9 594.9 
S4T1.0 1.00 2.3507 4.16 599.6 590.8 
S5T1.25 1.25 2.8517 4.15 594.4 584.8 
S6T1.5 1.50 3.2702 4.15 589.2 577.2 
S7T1.75 1.75 3.7176 4.15 582.3 570.2 
S8T2.0 2.00 3.9431 4.15 572.7 560.2 
S9T2.25 2.25 3.6723 4.16 567.1 550.0 
S10T2.5 2.50 3.4298 4.14 555.8 546.5 
S11T3.0 3.00 2.8992 4.13 556.7 548.0 
S12T3.5 3.50 2.4980 4.12 552.3 543.4 
S13T4.0 4.00 2.1743 4.12 547.3 532.4 
S14T4.5 4.50 1.8015 4.12 538.1 527.9 
S15T5.0 5.00 1.6052 4.13 533.1 522.3 
S16T5.5 5.50 1.3721 4.14 521.8 510.8 
S17T6.0 6.00 1.1648 4.15 514.4 504.5 
S18T6.5 6.50 0.9749 4.16 507.3 496.3 
S19T7.0 7.00 0.8396 4.15 500.5 489.6 
S20T7.5 7.50 0.7286 4.15 493.1 479.5 
S21T8.0 8.00 0.6274 4.14 488.1 477.6 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-47, Oxaliplatin concentration-time curve for Patient 10 with 2-hour infusions 
administered in Dose-banding scheme with 5% deviation. 
Table C-48, Results of the simulation test on Patient 10 with oxaliplatin administered in 
Dose-banding scheme with 10% deviation with the drug dose of 4.5 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.19 632.7 622.4 
S1T0.25 0.25 0.6617 4.17 623.9 614.5 
S2T0.5 0.50 1.2355 4.18 617.8 609.0 
S3T0.75 0.75 1.8200 4.18 610.2 598.4 
S4T1.0 1.00 2.1583 4.18 602.8 591.0 
S5T1.25 1.25 2.7784 4.18 594.3 584.9 
S6T1.5 1.50 3.2296 4.17 592.2 579.8 
S7T1.75 1.75 3.7441 4.18 580.6 569.5 
S8T2.0 2.00 3.8633 4.18 570.4 560.9 
S9T2.25 2.25 3.5348 4.17 564.6 553.6 
S10T2.5 2.50 3.4114 4.17 556.9 545.9 
S11T3.0 3.00 2.9851 4.17 551.5 540.6 
S12T3.5 3.50 2.6670 4.18 544.8 534.0 
S13T4.0 4.00 2.3217 4.17 538.5 527.3 
S14T4.5 4.50 1.8731 4.16 532.4 521.7 
S15T5.0 5.00 1.6386 4.17 526.8 515.2 
S16T5.5 5.50 1.5034 4.17 520.2 510.7 
S17T6.0 6.00 1.2890 4.17 514.3 504.3 
S18T6.5 6.50 1.0909 4.17 508.8 499.5 
S19T7.0 7.00 0.9467 4.17 504.8 493.3 
S20T7.5 7.50 0.7833 4.17 497.6 487.9 
S21T8.0 8.00 0.6594 4.17 493.1 482.8 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-48, Oxaliplatin concentration-time curve for Patient 10 with 2-hour infusions 
administered in Dose-banding scheme with 10% deviation. 
Table C-49, Results of the simulation test on Patient 10 with oxaliplatin administered in 
Logarithmic Dose-banding scheme with the drug dose of 4.37 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.25 632.9 622.7 
S1T0.25 0.25 0.6118 4.24 625.8 616.2 
S2T0.5 0.50 1.2108 4.25 618.6 608.8 
S3T0.75 0.75 1.7186 4.25 612.1 600.9 
S4T1.0 1.00 2.1818 4.25 603.0 593.6 
S5T1.25 1.25 2.5384 4.25 595.5 585.6 
S6T1.5 1.50 2.9547 4.25 587.0 577.5 
S7T1.75 1.75 3.4216 4.24 579.8 570.0 
S8T2.0 2.00 3.8919 4.25 572.3 561.2 
S9T2.25 2.25 3.5188 4.26 564.7 554.3 
S10T2.5 2.50 3.2979 4.25 557.4 547.2 
S11T3.0 3.00 2.8366 4.26 552.9 543.4 
S12T3.5 3.50 2.4848 4.27 549.8 539.9 
S13T4.0 4.00 2.1763 4.26 544.7 535.0 
S14T4.5 4.50 1.9002 4.28 539.3 529.5 
S15T5.0 5.00 1.6230 4.27 534.5 524.4 
S16T5.5 5.50 1.4129 4.28 530.0 520.3 
S17T6.0 6.00 1.2108 4.28 525.2 515.8 
S18T6.5 6.50 1.0608 4.28 521.8 511.9 
S19T7.0 7.00 0.8988 4.28 516.6 507.0 
S20T7.5 7.50 0.7801 4.28 511.5 502.0 
S21T8.0 8.00 0.6557 4.28 505.8 495.2 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-49, Oxaliplatin concentration-time curve for Patient 10 with 2-hour infusions 
administered in Logarithmic Dose-banding scheme. 
Table C-50, Results of the simulation test on Patient 10 with oxaliplatin administered in 
Flat-fixed dosing method with the drug dose of 4.0 mg. 
Sample 
Identifier 
Sample 
Time 
(hour) 
Oxaliplatin 
concentration 
(µg/mL) 
pH 
Weight (g) 
Before 
sampling 
After 
sampling 
S0T0 0.00 0.0000 4.28 632.6 621.2 
S1T0.25 0.25 0.4876 4.25 624.0 613.8 
S2T0.5 0.50 1.0135 4.27 615.1 604.8 
S3T0.75 0.75 1.5849 4.25 606.3 596.4 
S4T1.0 1.00 2.1352 4.25 598.0 587.4 
S5T1.25 1.25 2.6707 4.24 588.9 578.7 
S6T1.5 1.50 3.1345 4.24 580.2 569.6 
S7T1.75 1.75 3.5536 4.25 573.7 564.8 
S8T2.0 2.00 3.9268 4.24 565.1 552.8 
S9T2.25 2.25 3.7328 4.24 555.3 545.6 
S10T2.5 2.50 3.5011 4.23 547.6 536.7 
S11T3.0 3.00 2.9587 4.22 540.8 530.4 
S12T3.5 3.50 2.6339 4.22 535.2 524.6 
S13T4.0 4.00 2.2793 4.22 529.3 519.6 
S14T4.5 4.50 1.9462 4.22 523.5 514.0 
S15T5.0 5.00 1.6847 4.22 517.5 507.4 
S16T5.5 5.50 1.4326 4.22 511.0 500.6 
S17T6.0 6.00 1.2506 4.21 504.9 494.5 
S18T6.5 6.50 1.0719 4.22 498.4 488.1 
S19T7.0 7.00 0.9196 4.21 490.8 480.6 
S20T7.5 7.50 0.7777 4.20 483.8 474.0 
S21T8.0 8.00 0.6708 4.21 475.6 464.1 
Sample identifier: presented as the sample number and time points in hour; for example, S9T2.25 means 
the number 9 sample which was withdrawn at the 2.25 hour (2 hours and 15 minutes) after the start of the 
infusion. Weight: weight monitor of Reservoir A, the ‘body reservoir’. 
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Figure C-50, Oxaliplatin concentration-time curve for Patient 10 with 2-hour infusions 
administered in Flat-fixed dosing method. 
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